<SEC-DOCUMENT>0001493152-23-040115.txt : 20231109
<SEC-HEADER>0001493152-23-040115.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109171622
ACCESSION NUMBER:		0001493152-23-040115
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		231393770

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:LIXT="http://lixte.com/20230930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2023%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_033_LIXT_lixte.com_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230101_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" id="xdx2ixbrl0823" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" id="xdx2ixbrl0825" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" id="xdx2ixbrl0827" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" id="xdx2ixbrl0829" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_NonRelatedPartiesMember" id="xdx2ixbrl1274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_NonRelatedPartiesMember" id="xdx2ixbrl1275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_NonRelatedPartiesMember" id="xdx2ixbrl1276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_NonRelatedPartiesMember" id="xdx2ixbrl1277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember" id="xdx2ixbrl1328" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20230930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-02</xbrli:startDate>
        <xbrli:endDate>2023-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorOneMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorTwoMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-03-162023-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-03-16</xbrli:startDate>
        <xbrli:endDate>2023-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-11</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_NewIndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-06</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-26</xbrli:startDate>
        <xbrli:endDate>2023-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-07_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-10</xbrli:startDate>
        <xbrli:endDate>2021-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_NonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-282022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-28</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_srt_DirectorMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-292023-06-30_custom_FourNonOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-29</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_FourNonOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_FourNonOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_FourNonOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-302023-09-30_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_OtherClinicalAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:OtherClinicalAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-04</xbrli:startDate>
        <xbrli:endDate>2021-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_WorkOrderAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-18</xbrli:startDate>
        <xbrli:endDate>2018-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:Dr.JamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BastiaanVanDerBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-042023-10-05_srt_OfficerMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-04</xbrli:startDate>
        <xbrli:endDate>2023-10-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-23</xbrli:startDate>
        <xbrli:endDate>2013-12-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-12</xbrli:startDate>
        <xbrli:endDate>2015-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-09</xbrli:startDate>
        <xbrli:endDate>2022-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-15</xbrli:startDate>
        <xbrli:endDate>2023-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1b2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>LIXT:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20230101__20230930_zgLVQOv85wx6"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentQuarterlyReport_c20230101__20230930_zHxpvZNdRNjc"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20230101__20230930_z8sjneLwzlza"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20230101__20230930_zYghjgtdZft3"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentTransitionReport_c20230101__20230930_zmQQ6QTWX6p6"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span id="xdx_909_edei--EntityFileNumber_c20230101__20230930_zZEVoycFJ6Pi"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20230101__20230930_zrevYMmHTPtk"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20230101__20230930_ztrFeFQf1qEa"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230101__20230930_zBspTN4eD3sf"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20230101__20230930_zvoUlzCVPVpd"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine1">680
East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20230101__20230930_zg2vOz4IIK4i"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine2">Suite 180</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20230101__20230930_zJmEIt71o7qd"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressCityOrTown">Pasadena</ix:nonNumeric></span>,
<span id="xdx_90C_edei--EntityAddressStateOrProvince_c20230101__20230930_zimsxdqeNCnc"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20230930_zT4SASLBZYBg"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressPostalZipCode">91101</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--CityAreaCode_c20230101__20230930_zbMMX3EH1yQ4"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_905_edei--LocalPhoneNumber_c20230101__20230930_ziLUdx5aIblj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_za5bhKUAXbBl"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zyo3hnOcFWZk"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_907_edei--SecurityExchangeName_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zHgMFXylRPp4"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zRAx08RML07i"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zMdwFoi7PBEd"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_908_edei--SecurityExchangeName_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zD8e9zAexcv9"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityCurrentReportingStatus_c20230101__20230930_zb9B3oMe5MPd"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityInteractiveDataCurrent_c20230101__20230930_ziTSP7JEHRzj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20230101__20230930_z60JtgblFw42"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_908_edei--EntitySmallBusiness_c20230101__20230930_zfX3WjIJ7R73"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20230101__20230930_z37MGfRYkUSf"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_90F_edei--EntityShellCompany_c20230101__20230930_zslWKiTvWNH7"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 6, 2023, the Company had <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20231106_z91BNzNZyrYh" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-11-06" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span> shares of common stock, $0.0001 par value, issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Su_001">PART I - FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_002">Item 1. Condensed Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_003">Condensed Consolidated Balance Sheets &#8211; September 30, 2023 (Unaudited) and December 31, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_004">Condensed Consolidated Statements of Operations (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_005">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_006">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_007">Notes to Condensed Consolidated Financial Statements (Unaudited) &#8211; Three Months and Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">52</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II - OTHER INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A. Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Defaults Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_001"></span>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_002"></span>ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_003"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zxjYWSKhS6R1" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230930_zfeItmNquVJ4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_znRObtsGegAi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzxow_zYJ21YKOxZ8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,105,611</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,353,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AdvancesOnResearchAndDevelopmentContractServices_i02I_pp0p0_maACzxow_zivVEOSOeyj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">147,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_i02I_pp0p0_maACzxow_zqqmvPrmW1qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzxow_zYGlmiuxpxq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzxow_maAz09H_zSU6bqlgDqqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,234,696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_pp0p0_mtAz09H_zkt5NfQtGt0g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,234,696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0_maLCzlt7_zMRPQRyFxxz1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses, including $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCB1JiSdTLXb" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,895</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AccountsPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSpcIoO8QlE4" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,982</ix:nonFraction></span> to related parties at September 30, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">221,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,764</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ResearchAndDevelopmentContractLiabilitiesCurrent_i02I_pp0p0_maLCzlt7_zztzaVqz7F5f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzlt7_maLASEzriC_zhSIau2eZp22" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">394,786</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzriC_z4BaUsQR2S8c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_maSEzNet_zaheGdHXcLJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred Stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zkFQIUc5jJt9" title="Preferred stock, par value"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zghL7cK2QhTi" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930_ztgqXrewhx9k" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_z69yi9UGgahd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zn8xTd5P4Ope" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5yIdMFEu147" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zsyKCTX4zrG9" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ziidGKIsfZ52" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series A Convertible Preferred Stock, $<span id="xdx_902_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwNwZ2TUCmKj" title="Preferred stock liquidation preference per share"><span id="xdx_90C_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVxTjjL3y0Ke" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></ix:nonFraction></span></span> per share stated value, liquidation preference based on assumed conversion into common shares &#8211; <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zPJOYdxIZkE2" title="Preferred stock, issuable upon conversion"><span id="xdx_90C_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zPSVtvUjD1Ge" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzNet_zD8N3OSbFjGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zAN4SqsN4yJ4" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zihY5CXNt3xi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20230930_zJ8aFCYTrI7a" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zbJ3jIMXNeVb" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20230930_zV7VotmycES8" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20230930_zqkLsvrBS7gj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20221231_zG9zpaAiUhn6" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zf7yxB41bXij" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,706</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzNet_z6ujO5yDrOJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,872,208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,059,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzNet_zKyXzU1jWijl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">47,449,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">43,394,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzriC_mtSEzNet_zev2QwZABRp7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,922,960</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,165,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzriC_z8CBdodz2nJf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,234,696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_004"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zl2sBHLO0bOg" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20230930_zx05LbNFKnIg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220701__20220930_ziXepydy9VR2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230930_zUhqcDSXTuic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zZcFh8jKB3Yl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzyvZ_zQ1LePItECG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zi9WNvwdB3gd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zkMiCzKpM1I8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i02_maOEz0wM_zKwR5dHl7P1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Compensation to related parties, including stock-based compensation expense of $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_zrE2RzwTNk2a" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_zHo46RdNzWYi" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_zKR1jcd962ll" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_zOFdBlbJZCSc" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022, respectively</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,957</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,398,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963,409</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LegalFees_i02_pp0p0_maOEz0wM_zlUYSXNcCCG3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">835,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">944,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherCostAndExpenseOperating_i02_pp0p0_maOEz0wM_zIv1Z2CcRDd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">357,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290,993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,081,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">875,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEz0wM_zkYYXti2RBe9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,487</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">272,388</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">895,649</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEz0wM_msOILzyvZ_z3lEwnfFMkhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total costs and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,024,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,478,501</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,064,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,678,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzyvZ_maNILzp6v_z4EWYq1sZOXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,024,181</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,478,501</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,064,326</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,678,863</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InvestmentIncomeNonoperating_maNILzp6v_zGQOD5qTPend" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_iN_pp0p0_di_msNILzp6v_zIAYEU0bxAii" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,240</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNILzp6v_z61DFvbl7Mqh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzp6v_zCvmV0f1ZL1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,018,760</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,478,009</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,054,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,681,231</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zC5L69DjSuy1" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" title="Net loss per common share basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_z8smmYhE68Ce" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.49</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zVg6btYCOxc6" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" title="Net loss per common share basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_z9d9JmTsEKMf" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.89</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zTtKGLDHD4A3" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" title="Net loss per common share basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zn2tuZYU6eBf" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.25</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_zhmDFvZA8aQl" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" title="Net loss per common share basic"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zL2mhDNkIbqi" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zpQ6zFGFbOm3" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_z1nrkirUyLZk" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,074,938</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930_zzvZq5Qigks7" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930_zRJnDfTT06Al" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,659</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zvDbYYQO02Wk" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zkV4VYbcYUN" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,803,466</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930_zt5fsyIu3bo6" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930_zWG3Phhpqune" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,554,183</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_005"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zqlzJjDZN9Pe" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_zR3rZ6Gegcua" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zv9EtVVVgVi7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zdInNsENn7oa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTiloqTZvu2b" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_zTHX1C2ML8ji" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-in</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2"><b>Accumulated</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Three months ended September 30, 2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zQ4hHeRESUCa" style="vertical-align: bottom; background-color: White">
    <td style="width: 23%">Balance, June 30, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQEksds7l2th" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zznRK0hrpdOh" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,665,956</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,623,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,430,713</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,692,534</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zOR1UWYRreqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIeEnnFhXJv2" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zlevyWaHo6L8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zurfYSdrG2" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z2Mseq2BpZU3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_z8RL3DhLVpCa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,018,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,018,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20230701__20230930_eus-gaap--StockholdersEquity_iE_z78Uh0ipftOb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zcAAwEuG9JQ9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV6X9jvMs8Tj" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,872,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,449,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,922,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nine months ended September 30, 2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20230101__20230930_eus-gaap--StockholdersEquity_iS_zV3geLu8rl5" style="vertical-align: bottom; background-color: White">
    <td>Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4AEUASQwjdh" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zULUVOxmy12" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,059,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,394,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,165,227</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z7e3K9I6rCFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7lz1pOo8Ph" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zskTAZfHaQ4a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs83jYZb7vgc" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zy5IhBY4md4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5plsRr8hRvg" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zmR4hnOe9aga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zlN1THbg19t9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,054,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,054,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20230101__20230930_eus-gaap--StockholdersEquity_iE_zpytel0602g4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zh5sv1v180Hb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCa7rzE7E4xa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,872,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,449,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,922,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-in</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2"><b>Accumulated</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Three months ended September 30, 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zQn5v9TOzYPg" style="vertical-align: bottom; background-color: White">
    <td style="width: 23%">Balance, June 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNXFLiIZ2qN8" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUtji4wt0e8a" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,593</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,277,486</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,285,386</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,492,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z7IQE5GRox9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_z9OB7hADn3wh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,478,009</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,478,009</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20220701__20220930_eus-gaap--StockholdersEquity_iE_zusYirykxBt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znC0GPVVudT4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbzdZ5U5uYh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,674,369</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,763,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,411,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nine months ended September 30, 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20220101__20220930_eus-gaap--StockholdersEquity_iS_zz594WSiw124" style="vertical-align: bottom; background-color: White">
    <td>Balance, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zoqEwt2Vduxf" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqUzu9leGkgb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,372,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,082,164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220101__20220930_eus-gaap--StockholdersEquity_iS_zlFFqAxbJ7w" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z47cIiR1bonk" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkbRlKaq7J3g" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,372,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,082,164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHB8xKw5Ovob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCAHvil9G17b" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zGWf0ElU3Qja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zekINnXGBAFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,681,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,681,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20220101__20220930_eus-gaap--StockholdersEquity_iE_zcTGUZNCFSKh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWzblF7PmUG5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEtWNs7GlCV5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,674,369</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,763,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,411,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20220101__20220930_eus-gaap--StockholdersEquity_iE_z0kw0F40MLZk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z68Flen4Tw28" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKTFJRBn42ui" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,674,369</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,763,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,411,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_006"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zSvGASmhCHwh" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20230930_zZ6o24tDfDH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220930_zsv86fH7taZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z9T3BEjlTBPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maNCPBUzpk3_zvaUMJDpRBP1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,054,774</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,681,231</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zCDUEsbv7Dtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationAbstract_i02B_zy4NuCC95jO2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense included in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_i03_maNCPBUzpk3_zQKt5bqVLq98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ShareBasedCompensationIncludedInResearchAndDevelopmentCost_i03_maNCPBUzpk3_zTQIMLPyy0W4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i03B_zJAbLWQ0duL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zoWUNno8CAh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Increase) decrease in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_i05N_di_msNCPBUzpk3_z7Dm96YUAxg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidInsurance_i05N_di_msNCPBUzpk3_zXUG2TAr9lQ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i05N_di_msNCPBUzpk3_zenNvzALx1fg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Other prepaid expenses and current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,460</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,708</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zXFhwB3tWYZ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase (decrease) in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i05_maNCPBUzpk3_zG9hAduLg7Wf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,593</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_i05_maNCPBUzpk3_z7eLiCCCItZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,969</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzpk3_maCCERCzmWo_zn457BLNGyph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,391,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,403,289</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_znBbY3fOI9la" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzQGd_zWtwIUSfas2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzQGd_zvoYn5LiYLui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzQGd_zt1bgVFAPjEc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzQGd_maCCERCzmWo_z2WlOwAYyNF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,143,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_zO2aqJsaK2Ci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_mtCCERCzmWo_zhdRqYCWZPud" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,738,095</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zxX6BhYW7l08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,353,392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,823,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_z64hcWW6UWc6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,105,611</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,561,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zMlcVoYLPcn2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationRelatedText_i01_za7sHD1pL762" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaidNet_i01_zw7V9uomff79" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,088</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesPaidNet_i01_zESxtPxLyM31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_007"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months and Nine Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zoUNYkcAGija" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_827_zYhBMmcl4Du5">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at September 30, 2023, and for the three months
and nine months ended September 30, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2023, and the results of its operations for the three months and nine months ended September 30, 2023 and 2022, and its cash flows
for the nine months ended September 30, 2023 and 2022. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#8217;s
audited consolidated financial statements at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>President
and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan was appointed as the Company&#8217;s President and Chief Executive Officer, at which time he replaced
Dr. John S. Kovach as the Company&#8217;s President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE1TzfK1NL9i" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market, the Company held a special
meeting of stockholders on May 26, 2023 to seek approval for an amendment to the Company&#8217;s Certificate of Incorporation to effect
a reverse stock split of its issued and outstanding shares of common stock. As a result of the approval of this amendment, the Company
effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z02S4g9t2jY3" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. Commencing with
the opening of trading on the Nasdaq Capital Market on Monday, June 5, 2023, the Company&#8217;s common stock began trading on a post-split
basis under the same symbol LIXT. The Company subsequently received confirmation from Nasdaq that it had regained compliance with the
minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria
for continued listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum bid price requirement over time,
or that it will be successful in maintaining compliance with any of the other Nasdaq continued listing requirements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_80B_eus-gaap--NatureOfOperations_z9OGZ05Ow1c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82E_zyfvEivLRqCd">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug research company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
reflected in the accompanying financial statements, for the nine months ended September 30, 2023, the Company recorded a net loss of
$<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930_zp7FFVQsogdk"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,054,774</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
used cash in operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230930_zbOVMBwcis9"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,391,142</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
At September 30, 2023, the Company had cash of $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230930_zcCr2UZflSJk"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,105,611</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available to fund its operations. Because the
Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time and
resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2023, the Company&#8217;s
remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated
approximately $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pp0p0_c20230930_zsauRVl4oQ5g"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,262,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see
Note 9), which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through at least September 30, 2024. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able
to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating
plans may change as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional
funds may be needed sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zhCCLzEw3wsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_ztDvgeDNAQcd">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_z2eti3b7lHA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z1cYKXmAmo18">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zsUiVAlVqDP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zgeelSlJlfZc">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense denominated in a foreign currency. Such cost or expense is converted into United States
dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company
purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase
of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations. As of September 30,
2023 and December 31, 2022, the Company did not hold any currencies other than the United States dollar in its bank account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWzwfpwvFc43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zGhku7413rFf">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84B_eus-gaap--UseOfEstimates_zYGhTCfb0Tx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zL3s4xHNvmGj">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSoAG8Iwlnka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmYUevFxr3g8">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230930_zzVrO5ZoyS68" title="Cash FDIC insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230930_zs0T6H0X5Owg" title="Cash SIPC insurance"><ix:nonFraction name="LIXT:CashSIPCInsuredAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2WDGaqCYUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zqpONPVFXKPi">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="LIXT:PrepaidInsurancePolicyTextBlock"><p id="xdx_843_ecustom--PrepaidInsurancePolicyTextBlock_zI8WxieDP9T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_znLMoh1EJMVc">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zajv7XUxgz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwxMXWdWwNmf">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230701__20230930_zLzVVea1Id54"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,012</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220701__20220930_zzVJ8sD3ciy8"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,163</ix:nonFraction></span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20230101__20230930_zwRoGlqq5qKg"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">835,362</ix:nonFraction> </span>and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20220101__20220930_zGZuG1zKNcy8"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">944,789</ix:nonFraction></span>
for the nine months ended September 30, 2023 and 2022, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6qs5gImq235" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zwN75KICZ743">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zSIu73Xo3yge" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgxsksCwncR2" title="Concentration of risk, percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE1JebAMNyQ7" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztsybRVNETe3" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>% or more of general and administrative costs or research and development costs for the three months and nine months
ended September 30, 2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2023 and 2022 included charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWabCorlhdT6" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.0</ix:nonFraction></span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEz1rVlkt6z1" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.5</ix:nonFraction></span>% of
total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2023
and 2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z5BMLGPUFem" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.6</ix:nonFraction></span>% and
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zpVWgiFEylqb" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.9</ix:nonFraction></span>%, respectively, of total general and administrative costs. General and administrative costs for the three months ended September
30, 2023 also included charges from two vendors representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zVWHsjU8QUo8" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorOneMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.9</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zWLC2BdhvGA2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorTwoMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.6</ix:nonFraction></span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2023 included charges from four vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLh24gMc58ta" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">38.9</ix:nonFraction></span>%,
<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgPU1rru6XKc" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24.9</ix:nonFraction></span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zovs1r0vOTTh" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.9</ix:nonFraction></span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zbeSvniRKGf2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.9</ix:nonFraction></span>%, respectively, of total research and development costs. Research and development costs for the three months ended
September 30, 2022 include charges from four vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4FV76f6LBx3" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.0</ix:nonFraction></span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5NlA7ZRYwlb" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.2</ix:nonFraction></span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze6F9qyZMwA6" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.9</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7foDi94gOH2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.0</ix:nonFraction></span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2023 and 2022 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsFHITlsxmP7" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25.2</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJhUDYmnON21" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25.0</ix:nonFraction></span>% of
total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2023 and
2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zxaPfYTaCZ2g" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.2</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zh85uOaSUJHc" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.7</ix:nonFraction></span>%,
respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zANX9VkcZwbc" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35.9</ix:nonFraction></span>%,
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1oh68qZT2Pj" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z90sPG8XIzll" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.4</ix:nonFraction></span>%, respectively, of total research and development costs. Research and development costs for the nine months ended September
30, 2022 include charges from three vendors and consultants representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz5Uc8IabDkj" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31.0</ix:nonFraction></span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zidbKL6e9gZh" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.7</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zMKkchs4NhHf" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span>%, respectively, of total research and
development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zziQ71bS1YUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaEsmGGKefQ1">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of September 30, 2023 or
December 31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2023 or December
31, 2022. Subsequent to September 30, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7FnXFc6LX6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_znKG4J2eNzWl">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash
for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="LIXT:WarrantsPolicyTextBlock"><p id="xdx_841_ecustom--WarrantsPolicyTextBlock_zkM34u8aIrf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5AI7k5nQ0qb">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480,
Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 5)
meet the requirements for equity classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zK6hNr4oWbFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_ztxdQ1PgXS5g">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2XT2q3Vedm7" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">340,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">332,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,556,178</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">745,448</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z2KMGOqhgLY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zUuzLaadsK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z9fPxBAs9CCa">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zruReJoFaQ4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zOp60YNQ3pK">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting
Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212;
Stock Compensation (Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB
Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC
Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280
&#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new
guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03
immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial
statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

</ix:nonNumeric><p id="xdx_85E_zAgxAESh4uPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_80E_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zav7OskLkOUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_823_zuqL31HSGgy8">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="LIXT:ResearchDevelopmentTableTextBlock"><p id="xdx_894_ecustom--ResearchDevelopmentTableTextBlock_zrcsjMtV2fXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated
with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical
regions where such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zqLHcZFdzSM1" style="display: none">Schedule
of Research and Development Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20230930_zDf90xcyndd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220701__20220930_zyM03hvMlOoh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zgJohYyjc56h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220930_zZzDEHQsVGT9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_z4XvV3CYrPli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,744</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,846</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,565</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_z26fC9u1fpM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,246</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zCxObD6nrZf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zsPXl1vtkSM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Netherlands</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zglxOoL5IBL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,487</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,388</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">895,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_z3zd7m1rEQN8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expense</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,487</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,388</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">895,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_zXuSXx688aw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFi765UO65il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_823_zfu8SkSLRn2a">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930_zVOvVYqk9H17" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zdgCSf0uwmi8" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLf9Y3SMfuIa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_90F_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpVwzFi0nyj5" title="Principal cash obligations and commitments"><ix:nonFraction name="LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20230317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNljoFshXUYb" title="Preferred stock dividend, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2015-03-162023-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% of the annual net revenue of the Company divided by <span id="xdx_908_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpUeHq1XHSdb" title="Annual net revenue"><ix:nonFraction name="LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span>, until converted or redeemed. As of September 30, 2023 and December
31, 2022, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zlNIZJ2fGsNl" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_z86k5TX1qdDj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,650,000</ix:nonFraction></ix:nonFraction></span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board
of Directors may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PreferredStockConversionBasis_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPuSIA5glSH8" title="Preferred stock, conversion description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" name="us-gaap:PreferredStockConversionBasis">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY3kHZF7Q5ah" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.20833</ix:nonFraction></span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOilYgJeMsxh" title="Gross proceeds from sale of transaction"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,875,000</ix:nonFraction></span>.</ix:nonNumeric></span> The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znbcJ1IsMZx9" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAgGmKMPaGpa" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></span></span> outstanding shares
of Series A Convertible Preferred Stock would convert into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zZx7AkhOApz7" title="Preferred stock convertible into common stock"><span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zx8mj8rfHaZh" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></ix:nonFraction></span></span> shares of common stock at September 30, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zDMiMyDvqmck" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zmTuNU4F7F2k" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zje6so0n6zP4" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zXAmlxuUq3ta" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of September 30, 2023 and
December 31, 2022, the Company had <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_zNQcDkJi7dWe" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_z1HVGKzPq8T" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zhRNheIEPIl7" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zSc4285ahqmd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,706</ix:nonFraction></ix:nonFraction></span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBCKEusXGYIk" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share. All share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock
split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOCcJDLGXmI6" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwUEtA7CkeOi" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> shares exercisable at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxIBCYzLaWv9" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT0IowCaph3f" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">April
12, 2022 Sale of Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDeecwPVTVb" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztBLVJqBgMdk" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share in a registered direct
offering, generating gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjHFMs0JNXX8" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,800,000</ix:nonFraction></span>. The total cash costs of this offering were $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaZIGzFEQDS8" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">658,616</ix:nonFraction></span>, resulting in net proceeds of
$<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9XzJ6DEShb" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,141,384</ix:nonFraction></span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zsT3UBdm5KOb" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-12_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,000</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zpmApYfQ69k9" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-12_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July
20, 2023 Sale of Common Stock and Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM5B4ifsL0x4" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znlNev8VOTVh" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share and pre-funded warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zohoH8AhPbh7" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span>
shares of common stock at a price of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeNMvMvR4K81" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.9999</ix:nonFraction></span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ2sH5F1OJLd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full. As of August 7, 2023, all pre-funded warrants had been exercised in full. The pre-funded
warrants were determined to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLRTMyMZnBp6" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYY2Ha97JPo4" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_dc_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zompdFE1Cmci" title="Warrant expires term"><ix:nonNumeric contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt-sec:durwordsen" name="LIXT:ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable">five years</ix:nonNumeric></span>
thereafter on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zl3jqtrpUpC8" title="Warrant expires date"><ix:nonNumeric contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 20, 2028</ix:nonNumeric></span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zW72K4rRfD7e" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,499,964</ix:nonFraction></span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCUYrMqlYixg" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">362,925</ix:nonFraction></span>, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIO5Kc5WkjRf" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,137,039</ix:nonFraction></span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zTP1n2U2wBcg" title="Warrants to purchase shares"> <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">35,000</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zLZ2nMjb2Yvj" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.60</ix:nonFraction></span> per share and
expiring on <span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zRn4KhYvCkd3" title="Warrant expires date"><ix:nonNumeric contextRef="From2023-07-192023-07-20_custom_PlacementAgentsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 20, 2028</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8C2hmOT7cYb" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> pre-funded warrants, exercisable at $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGvERjmtHQ8" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per common share, were
exercised for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5YPkzyOgLjb" title="Exercise of common stock options"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfmliIOR7mej" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_znoHxzeoS0f" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-07_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>
per share) and to the placement agent (exercisable at $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3qc6XEbZfh8" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-07_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></span>
per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications,
reorganizations or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional
investor contain a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction (a sale or
transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control, the holder
of the unexercised common stock warrants will be entitled to receive cash consideration equal to a Black-Scholes valuation, as
defined in the warrant agreement. If such fundamental transaction is not within the Company&#8217;s control, the warrant holder
would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#8217;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash
payment for a warrant redemption as a distribution from stockholders&#8217; equity, as and when such cash payment is
made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhHFKCNEJo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the nine months ended September 30, 2023, excluding the <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6kO1BxglUn3" title="Warrants to purchase shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> pre-funded warrants,
exercisable at $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePO4syuM9ra" title="Common stock, par or stated value per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per common share, to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTPSlCjBRr9" title="Warrants to purchase shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> shares of common stock described above, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zC8PkhwyBa0i" style="display: none">Schedule of Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTWGXOVzX9ja" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb805odK5IS2" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.161</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0ZP2vMYjG3j" title="Number of Shares, Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">618,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKfJ7FaYHen8" title="Weighted Average Exercise Price, Issued" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLlRcrdfaY9h" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztbqlLNImt76" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5mOK4pPyyS1" title="Number of Shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0kqxgwjAGn3" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0829">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwpfFTAA1YE9" title="Number of Shares, Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK3fWOMCO5ha" title="Weighted Average Exercise Price, Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN2ejtbtuaL8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">4.24</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7uclRtbEc5b" title="Number of Shares, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,031</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBrpG9xzXPT3" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhcNZbWrYLk" title="Number of Shares, Warrants exercisable, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcHvkMxTNhee" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgTYyU7QM2G9" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">4.24</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z1K878rCBUD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zztBqUPLK7rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaLZorDpdJu5" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zltTwPRuv1ok" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhuVdovBn5B2" title="Warrants Outstanding Shares" style="width: 47%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z55dmao6Mka" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.600</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZLhk6etfMUg" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWDwDBwvcVfk" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zj7d2Ceu95nb" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqTRr9U7PTbc" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXl7zLlzOVyl" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHAi6xf6gxG" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdJKWyt0dQk" title="Warrants Outstanding Shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930_zmjOH53BqWod" title="Warrants Outstanding Shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zGyYbeFI2Gsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z489484kBsG5" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.00</ix:nonFraction></span> per share at September 30, 2023 consist of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBkrEpVs81be" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,497,000</ix:nonFraction></span> publicly-traded warrants pre-split <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbVyz21f5lj" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> that
were issued as part of the Company&#8217;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPSAPv0i5jQb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span> per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWPaUfIh7hyi" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span>, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVUsnkyJqHq3" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57.00</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPRmAu3PPXRb" title="Fair market value of stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.45</ix:nonFraction></span> per share on September 30, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcG6o54ltZs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82E_znXlPUB0QMfj">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_900_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zDbAcHtPNI17" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_900_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zXPqF7A1AdE5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z8iBPG9CIJAc" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span>, respectively, to Dr. Kovach under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zPfT1WTQPjpg" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,500</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zbNLroryDWSe" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,500</ix:nonFraction></span>, respectively,
to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated
statements of operations for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zdaKYI1PoY31" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90D_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zuvyMKcbPCgl" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the three months ended September
30, 2023 and 2022, the Company paid $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zxN7fTSCiw14" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zSoz4hzJ0UA4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Dr. Miser under this employment agreement, and during the nine
months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z9b6JLkv58kj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zuKSZw1hpzj7" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span>, respectively, to Dr. Miser under this employment agreement,
which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_909_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zqdi1K38Ksyg" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_908_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zibRcudpDW5f" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zXML71QFoZF4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zaEe2AYaTLxg" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-07-012023-09-30_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zy3QgP87tR43" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-09-30_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,436</ix:nonFraction></span>, respectively, for the three months and nine months ended September 30, 2023.
During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zRSlvxlNg0Wk" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z0SAHQ7szDY6" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Mr. Forman under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_905_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zVJIRQaq9cA6" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zX8fpg3NeB1f" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span>, respectively,
to Mr. Forman under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated
statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_90D_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zyaTma7f9U9g" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_906_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zQAIqIBugYI5" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zp2rOuZc1U8i" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zLwH0TPHehtl" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Mr. Weingarten
under this employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zuckifzBeIjk" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIWsFe724u93" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,250</ix:nonFraction></span>,
respectively, to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the
Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023, to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_906_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zjTva8f2dUoi" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors. During the three months and nine months ended
September 30, 2023, the Company paid $<span id="xdx_909_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zuozEEqOTYTb" title="Compensation"><span id="xdx_90C_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zwyeBzjuv9Pc" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,667</ix:nonFraction></ix:nonFraction></span></span> to Mr. van der Baan under this employment agreement, which costs are included in general
and administrative costs in the Company&#8217;s consolidated statements of operations for such periods. Mr. Van der Baan was appointed
as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20220615_zcxdOmneoQV" title="Cash board fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2022-06-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_90C_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zYGctzdEc7Gg" title="Cash board fee payable quarterly"><ix:nonFraction name="LIXT:ManagementFeePayableQuarterly" contextRef="AsOf2022-06-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
9).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for independent directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z0XMbmfM4Duj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_za0jGC4FmPf5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zymV2IUuxYLa" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zKGJG4vm0YCj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zsGg1KTU8C26" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for independent directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new independent directors &#8211; The Company grants options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zVk9HehVzio1" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zDtHCdx6uZQk" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% on the grant date and the remaining <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z2P8VxCZH03" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% vesting <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930_zmggabJEsw7a" title="Award vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $<span id="xdx_90B_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVtl8SY3syMe" title="One time cash"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to independent directors &#8211; Effective on the last business day of the month of June, the Company grants options
to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zqqPa04kbGn4" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant,
vesting <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zzOMgNl9Xqvi" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully
vested, subject to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount
of such stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors,
for a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_90F_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzuA9jzcekqg" title="Annual cash fee"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to independent directors was $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zOFzv8FZiSX7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,228</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zuD6DvrC7yxj" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,324</ix:nonFraction></span>, respectively, for the three months ended September 30, 2023
and 2022. Total cash compensation paid to independent directors was $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zw3ZSfGYx9c" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,229</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zWEzLdl52pE" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,510</ix:nonFraction></span>, respectively, for the nine months ended September
30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zkNzOsV5Ft1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zCumS3XlPEW4" style="display: none">Summary of Related Party Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230701__20230930_zXtPzbawr8W4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_zlkUFkvHMQc9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zF5Qrmn4YUg9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20220930_zhOyWuLBgWH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdTYXtsXSyPe" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,895</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,074</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-09-30_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">802,760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockBasedMember_zHoTcCa8zH34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-09-30_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zzkQX8iRRvwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,957</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,398,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963,409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_zlpCe759Ssqb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related
    party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,957</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,398,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963,409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_z3eXZDt8Ten1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zMLTkSRADci2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_828_z1SR3qly2M88">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zafFpZ06Xlu5" title="Number of restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,333</ix:nonFraction></span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWW3D6bRNBYa" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvuD35rd3Xy8" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,333</ix:nonFraction></span> shares.
The Company has scheduled a meeting of stockholders for November 27, 2023 to consider and vote on, among other matters, a proposal to
increase the number of common shares issuable under the 2020 Plan by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBueXCOBE8k1" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,667</ix:nonFraction></span> shares, to a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRur1AcrIv0d" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, there was a deficiency of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zQqh9H1LgZHe" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,980</ix:nonFraction> </span>shares with respect to stock options issuable under the 2020 Plan. However,
subject to approval of the proposal to increase the number of common shares issuable under the 2020 Plan at the meeting of stockholders
scheduled for November 27, 2023, there will be unexpired stock options for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrb5AS9VMbk5" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,313</ix:nonFraction></span> shares issued and outstanding under the 2020 Plan
and <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHwTsWEGS8O4" title="Shares were available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">199,687</ix:nonFraction> </span>shares available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXtUFyzGcPW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zfgpbDyRkv44" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930_zUwF11wlHIdl" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.843</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930_zlhGen2z87db" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930_zFXJ0JmdW6xf" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">138.05</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zFiz9nGu1nl2" title="Expected life"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2022, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220930_zDSXZcdldCtg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.03</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220930_zJe73ve7yIY1" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20220930_zNEfvh7lXCuk" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">198.79</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zisZAepBOJa3" title="Expected life"><ix:nonNumeric contextRef="From2022-01-012022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.6</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zmiAA6LFZr85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZdd8D2RIovg" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zntCbzqgH4c" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zHVYt9PZNwJe" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $71.40 per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6BYEEFZCfil" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsyxzJ7KZZ0f" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEDe3qWKDIVc" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsSySPcPQJhj" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,806</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zak2DAJIjElg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,259</ix:nonFraction></span> for the three
months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z03N3qDbpWxi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,501</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ9AngHtEaxe" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,954</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVXDDGVQoN09" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zayzoJefj7s2" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,333</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC8wwUoS4id3" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-302020-08-07_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z32ckApiKyZ4" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5azDtUzV1b" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">572,650</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz6fIZ5IXi01" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z604TJC65id2" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,163</ix:nonFraction></span> was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPKT2w5qb1wb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,551</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zijr9z2osFZ7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,085</ix:nonFraction></span> for the three
months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zwstCNam4NX3" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,544</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg44xJV09jQ9" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,078</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVtfYn5Ftfjb" title="Stock options description"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_z2ZAFYofQWF7" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zULixY6fCiia" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrfqqs0IJ7og" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">71.40</ix:nonFraction> </span>per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg6sI8Zaw78d" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfRi0iQ7jO59" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc6YtvRxSS5e" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy9OQPYGJck3" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,806</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUQZ65pjCb2g" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,259</ix:nonFraction></span> for the three months ended September 30,
2023 and 2022, respectively, and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb7pHndyTBz3" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,501</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpDnbGd2cENg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,954</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022, respectively, with respect
to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zE4CB3NANqbb" title="Stock options description"><ix:nonNumeric contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zf3UrKskq6jb" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6hceGbq9JX9" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zxUrm8idk1i9" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">32.00</ix:nonFraction></span> per share (the closing market price on the grant
date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zebnferywMOg" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">753,611</ix:nonFraction></span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGphqam0SPLj" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">30.144</ix:nonFraction></span> per share), of which $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zS8DhB78F499" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">376,800</ix:nonFraction></span> was attributable to the portion of the stock options fully
vested on April 9, 2021 and was therefore charged to operations on that date. Although the remaining unvested portion of the fair value
of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options
terminated on October 30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zL15gULMTJdi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,692</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_z55LmLvPPoU2" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,684</ix:nonFraction></span> for the three months and nine months ended September
30, 2022, respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zF2Sg0krn8kk" title="Stock options description"><ix:nonNumeric contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z8CDWItMgfCk" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzQgvlo0x3ab" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span>
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zc7usJl0J6md" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">28.00</ix:nonFraction> </span>per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zpdP8ZgvtVBd" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">658,363</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zLMnU1NtXnAe" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">26.335</ix:nonFraction></span> per
share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zgoEsRRGDSi9" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">329,188</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. The Company recorded charges to general and administrative costs in the consolidated statement of
operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RjHoJIXps1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3YHv9mP58Be" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,827</ix:nonFraction></span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zi6LEXwFAGj8" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,388</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6yu8ria5Kxa" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,215</ix:nonFraction></span> for the nine
months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z63CABwuq9qd" title="Stock options description"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the
Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of
Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zZAd6xHreXB6" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>
shares (a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zLpF5EH1f5c5" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zIUqEijouci8" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zoGHl33ELSIk" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.30</ix:nonFraction></span> per share (the
closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z1uJR4AbWvVc" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,421,095</ix:nonFraction></span>
($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOLEuSc8F2vc" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">28.423</ix:nonFraction></span>
per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zGVrOIk5WOvc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zLHY2ksXlIZ2" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">179,100</ix:nonFraction></span>
for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zSTAKXjTrGCd" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">211,412</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zQMGyxVE3e42" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">531,455</ix:nonFraction></span>
for the nine months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zF9o3zD8Xd4d" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z35yQNWzNBH" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zFB5DvmsXBdi" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-162022-06-17_srt_DirectorMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span>
at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zS7bUOlhE7y9" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.40</ix:nonFraction></span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zDGMa68H381" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,525</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zaNi0pl5i2Uj" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.341</ix:nonFraction></span> per share),
of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zu8FODcTNFV3" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,263</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zau6IIrvODac" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,801</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zm2C23awz7qh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,801</ix:nonFraction></span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zV6axkm8eEgg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,084</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zvjDjIncW6Z2" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,449</ix:nonFraction></span> for the nine months
ended September 30, 2023 and 2022, respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zJv439dY2ry6" title="Stock options description"><ix:nonNumeric contextRef="From2022-01-012022-06-30_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zxDmx7T0PB7f" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-06-012021-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuPBNQXbsxH9" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220628__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_za4hwzANisQi" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-282022-06-30_srt_DirectorMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zNnp58RRAcH4" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.40</ix:nonFraction></span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCa0QMcDoD61" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,700</ix:nonFraction></span> ($<span id="xdx_909_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuzadZHkiFfi" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">6.334</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzsxgBXB7W0l" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,916</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zke4roWdzh64" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,860</ix:nonFraction></span> for
the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zXWAAyOPZg8j" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,965</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zSbe8u11wsNi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,860</ix:nonFraction></span> for the nine months ended September 30, 2023
and 2022, respectively, with respect to these stock options.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPihBnic9Bo9" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_srt_DirectorMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zqjxrT3h4VTd" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zGrJzjPAm3uk" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>
per share, vesting <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziYgSbIWrhG8" title="Share based compensation vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on issuance and <span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhuANZxNViRk" title="Share based compensation issuance, percentage"><ix:nonFraction name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zbEf27pdSkF7" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjeBHLeFG0Ql" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">262,560</ix:nonFraction></span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znubjJrHRfJ4" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.282</ix:nonFraction></span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zO8QjNuxlJ9c" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,528</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zCeBwECz9GZ6" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,053</ix:nonFraction></span> for the
three months and nine months ended September 30, 2023, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zllxBBCI0gHa" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zkXsG0amN9t" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z4lUHoIe24Jg" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,264</ix:nonFraction></span> ($<span id="xdx_900_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCYTUjpjmx84" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">4.326</ix:nonFraction></span> per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zKRLVnat5Yv4" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230606__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmBtZoiDm0m5" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-06-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYgUXE994V9h" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.88</ix:nonFraction> </span>per share
(the closing market price on the grant date), vesting <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zWtNoow6xrVi" title="Share based compensation vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-06-292023-06-30_custom_FourNonOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zFpFXJXKdty1" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-06-292023-06-30_custom_FourNonOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,593</ix:nonFraction></span> ($<span id="xdx_907_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_ztyjuq4LEC81" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficersMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">4.8131</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zf0co99NOIAh" title="Stock based compensation"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zXNmV1tZ4C12" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_FourNonOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_FourNonOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,232</ix:nonFraction></ix:nonFraction></span></span> for the
three months and nine months ended September 30, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bastiaan van der Baan, Mr. van der Baan was granted
stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3CcsLS8JTRl" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc23SAZFWS9c" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3FsVuMj86Oa" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,066</ix:nonFraction></span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20230626__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBuY2A4lcYA8" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.612</ix:nonFraction></span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkIquRZ91PGl" title="Stock based compensation"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zXGG7paNdExg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,466</ix:nonFraction></ix:nonFraction></span> </span>for the three months and nine months ended September 30, 2023 with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each of such persons ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each of such persons are contractually scheduled to expire one year from the respective dates that their service to the Company
terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zauCGEf9gBz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zs8KYHunmwUi" style="display: none">Summmary of Stock-based Compensation Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_zKvXYW25Doji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20220930_zkWi7ODwOsjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230930_zihVRu0M1BH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_zEeAqz8dy69g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zUsTG6NOBHNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zIJ2IPZInf8k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zIGnguhXuLo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,106</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,146</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,649</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zKYjKEx00hJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuOnmgRxuN4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2023 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zmI7aGeU55G8" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230930_zdbiTnSA2AOa" title="Number of shares, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">389,479</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zv4loaOvqwRe" title="Weighted average exercise price, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.1826</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230930_ztQZycVN4PJi" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zEN3kaotjXE7" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zgMvMYCbSQwh" title="Number of shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zHiQcLuvFmxd" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.0250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20230930_z0fOeCCEjqId" title="Number of shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zeZmYLVRqwHc" title="Weighted average exercise price, expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230930_z5Cdd26ERkNk" title="Number of shares, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z8ZFkZGA4aMj" title="Weighted average exercise price, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.8197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zWo2Yt9dEkJ2" title="Weighted average remaining contractual life (in years), stock options outstanding"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.96</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCVOhAWDILi3" title="Number of shares, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">281,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_zRNdZtWFjbzj" title="Weighted average exercise price, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.8335</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230930_zQV7tfaxceda" title="Number of shares, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zCOZ3jvLSAq3" title="Weighted average exercise price, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.8997</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z02bkROQC2Yh" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.93</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zvPmWfj8TBi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_900_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230930_ztT1f0Sd3Et9" title="Total deferred compensation expense for outstanding value of unvested stock options"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">808,000</ix:nonFraction></span> at September 30, 2023, which
will be recognized subsequent to September 30, 2023 over a weighted-average period of approximately <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230930_zRMIk1w1bWRa" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">28</ix:nonNumeric></span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFHv7Nv5V2Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at September 30,
2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zc5BLjyk8Fm5" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BJvZTwvRMg" title="Exercise Prices" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.950</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z4S0dDRoDK1g" title="Options Outstanding (Shares)" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHlyPPzmVB49" title="Options Exercisable (Shares)" style="width: 30%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zW1Kv318YTAh" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znu0bafyQqw3" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1Y14Wvktsi9" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuOTbR14jGd9" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWArKZ3eUtzc" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFSENW3isqle" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z049sE32KZX2" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3EzQLjoLWOh" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zp4a3Cw0vm25" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,563</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTNu4lOz3Elb" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zXo88duZ95B7" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zznhSdtALEUa" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z2hJmRZJRvFj" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z5xoRZDMsLhb" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zG76ifye7pta" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zKangMbgi1x1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNye65ckqlFe" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxIdreuF6F5k" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPjBV5zSIX7a" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zUoaqshFf6ka" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNMHKGC96GY7" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBgF0BrNcB9a" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLWvZvmQN0x7" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEHI544hTjvc" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMDm870ZUGb" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zd9Wnw0jSHT4" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zg0WYkhCZHm2" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrOOC4yPft16" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKfJ7QtIVlt4" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRYHIY9mZlTl" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zEN0rhxarIyk" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z9XPMuwqGXS9" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zzEwYECZuTka" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zYYI4ksHWSob" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">66.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwiJF2VE8qVh" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRRzSGEUeHja" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zYWnEYkDJsS5" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">71.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zEjNksFoRbIf" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zragodmNuVIl" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zy9cC17TEx4i" title="Exercise Prices" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-09-30_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">120.000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgCKLz4dA9Xg" title="Options Outstanding (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zt5zKAuuQKVg" title="Options Exercisable (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930_zlYWcK0ee0pb" title="Options Outstanding (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930_z3NySbFeQmuf" title="Options Exercisable (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zW3lKq54bZdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230930_zqZG0J7gcEog" title="Fair market value, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">2.45</ix:nonFraction></span> per share on September 30, 2023, there was <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20230930_zGrCkwTuXzJ9" title="Intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> intrinsic value attributed to exercisable but unexercised
common stock options at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230930_zwwGYT2LDaC8" title="Outstanding stock options to acquire shares of common stock not vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,938</ix:nonFraction></span> shares of the Company&#8217;s common stock had not vested at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zu0TA8k3fzQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_824_zLNnUH0Vo63h">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2023 and 2022, the Company did not record any provision for income taxes, as the
Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ9Sw9RVjYUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82D_zver3TU4LCP">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2023 and
December 31, 2022, the Company was not subject to any pending or threatened legal claims or actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company&#8217;s remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements not yet incurred, as described below, aggregated $<span id="xdx_901_eus-gaap--ContractualObligation_iI_c20230930_zrb2O8bSHvak" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,262,000</ix:nonFraction></span>, which, based on current estimates, are currently scheduled to
be incurred through approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is
subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation
of such funds to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures
will be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration
are not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can
frequently involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified,
suspended or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein
should be considered as estimates only based on current clinical assumptions and conditions, and are typically subject to significant
modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzoVUGimRbHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_z1xWwPGQoxDa" style="display: none">Schedule
of Contractual Clinical Trials</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Institution</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
                                            Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            End Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
                                            Objective</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Update</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NCT
                                            No.</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zMweHho9w3cb" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember" name="LIXT:ClinicalTrialDescription">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Phase 1b</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: left">City of Hope and Sarah Cannon</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zkGYUKP3Zfqh" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember" name="LIXT:ContractualClinicalTrialPeriodStartDate">March 2021</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zbwDDMA9u5Z9" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember" name="LIXT:ContractualClinicalTrialPeriodEndDate">March 2026</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: center"><span id="xdx_90C_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zxabq7ZIrDjj" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">14</ix:nonFraction></span> to <span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zWO4jNr1shBd" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">36</ix:nonFraction></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Determine RP2D</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Three patients entered</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">NCT04560972</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90D_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z6UaZC3NQEje" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ClinicalTrialDescription">LB-100 combined with doxorubicin in sarcoma</ix:nonNumeric></span></td><td>&#160;</td>
    <td>Phase 1b</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zwtlNZQEM8ij" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ContractualClinicalTrialPeriodStartDate">June 2023</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zXCiV4a8eJff" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ContractualClinicalTrialPeriodEndDate">June 2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zq7hEVY7iX0k" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">9</ix:nonFraction></span> to <span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zYEZiX3WVhxf" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">18</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">Determine MTD and RP2D</td><td>&#160;</td>
    <td style="text-align: left">One patient entered</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zv0hojwaMeRj" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember" name="LIXT:ClinicalTrialDescription">Doxorubicin with or without LB-100 in sarcoma</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">Randomized Phase 2</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zXtpTMghuJG" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember" name="LIXT:ContractualClinicalTrialPeriodStartDate">July 2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zExmr02ZwFBj" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember" name="LIXT:ContractualClinicalTrialPeriodEndDate">June 2026</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zagZZ9zMCkSj" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">150</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">Determine efficacy: PFS</td><td>&#160;</td>
    <td style="text-align: left">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_908_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zzOUOeN7Pu8c" title="Description of Clinical Trial"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member" name="LIXT:ClinicalTrialDescription">LB-100 combined with dostarlimab in ovarian clear cell carcinoma</ix:nonNumeric></span></td><td>&#160;</td>
    <td>Phase 1b/2</td><td>&#160;</td>
    <td style="text-align: left">MD Anderson</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zJVMhpxLYtJ6" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member" name="LIXT:ContractualClinicalTrialPeriodStartDate">March 2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_z2sBINvnUAuc" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member" name="LIXT:ContractualClinicalTrialPeriodEndDate">December 2025</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zqj4ttmOLVN9" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">21</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">Determine the survival of patients with ovarian clear cell carcinoma</td><td>&#160;</td>
    <td style="text-align: left">No patients entered at September 30, 2023</td><td>&#160;</td>
    <td style="text-align: justify">NCT06065462</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z3IPntyM95le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a five-year Clinical Trial Research Agreement with the Moffitt Cancer Center
and Research Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;). Pursuant to the Clinical Trial Research Agreement, Moffitt
agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead
anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome
(MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2023, the Phase 1b/2 clinical trial at Moffitt evaluating LB-100 in patients with MDS was closed by the
principal investigator. In this clinical trial, single agent LB-100 was used on a new schedule of days 1, 3, and 5 every 3 weeks. The
Company is not employing this schedule in its other clinical trials. Although the Maximally Tolerated Dose (&#8220;MTD&#8221;) was not
achieved, there was no dose-limiting toxicity on this schedule at doses that were greater than the MTD in the Phase 1 clinical trial
of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zLlPogT4MNTj" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-07-012023-09-30_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zyVwgf4xm8Je" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-07-012022-09-30_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,218</ix:nonFraction></span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. During the nine
months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zDIIUiL8ZRU6" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-012023-09-30_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zC4xI4jGu5pb" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-01-012022-09-30_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,623</ix:nonFraction></span>, respectively, pursuant to this agreement, which
have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30,
2023, total costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230130__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjKf7nJJL9d9" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-302023-09-30_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,074</ix:nonFraction></span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(&#8220;PFS&#8221;, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative
median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zuRLIufGzrqj" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_OtherClinicalAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,000</ix:nonFraction></span>. Although the production of new inventory
has been completed, nominal trailing costs subsequent to September 30, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b section of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the
nine months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhpdwMTxcFak" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,829</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zu15nqUCyOx6" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, pursuant to this agreement.
Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of operations.
Through September 30, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_905_ecustom--AmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zpXK2C9wMoi6" title="Amount related to milestone payment"><ix:nonFraction name="LIXT:AmountRelatedToMilestonePayment" contextRef="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,652</ix:nonFraction></span> for work done under this agreement through the fourth
milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_909_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfp1NkeOYKQ9" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,423,000</ix:nonFraction></span>
as of September 30, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously
untreated ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm
the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free-survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early July 2023, the Company was notified that one of three centers accruing patients to its Phase 1b clinical trial in small cell lung
cancer had a shortage of carboplatin and as a result the clinical trial was placed on a temporary enrollment hold. This matter was resolved
and the temporary enrollment hold was lifted in late July 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the nine months
ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zuqvNcSPWNY8" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,001</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zP5pRYVBiWQl" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, pursuant to this agreement, which are
included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30, 2023, total
costs of $<span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zdwWmlSCt5za" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,512</ix:nonFraction></span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zSeiWOnS6D5e" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,000</ix:nonFraction></span>
as of September 30, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zVeUW4sPPOsc" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theradex.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to conduct a Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin
alone in first line of advanced soft tissue sarcomas. The study is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zFxPBycuLeg6" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z1AXKjoguBx8" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction></span>% to Theradex for services and approximately <span id="xdx_90A_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVAsDydlzcRa" title="Percentage of payment through software"><ix:nonFraction name="LIXT:ExpectedPaymentThroughSoftware" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>% for payments for pass-through software costs. During the three months and nine months
ended September 30, 2023, the Company incurred costs of $$<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSTHoEM8mpEj" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,750</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z3EdXnmm5Wne" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, respectively, pursuant to this work order. As of September
30, 2023, total costs of $<span id="xdx_906_eus-gaap--DeferredCosts_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLvm0N1ke9jl" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z5GGHCqJglzk" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></span> as of September 30, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain has not been determined. Many
drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Five patients were entered into this study and analysis of the blood and tissue has been conducted. If there is clinical
evidence in at least two of the patients of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results
of this study are currently being reviewed by the NCI and a report is pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Trial</b>. On September 20, 2023, the Company announced a Phase 1b/2 collaborative clinical trial to assess whether
adding LB-100 to the programmed death receptor-1 (&#8220;PD-1&#8221;)-blocking monoclonal antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab,
may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). The clinical trial
is sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and will be conducted at MD Anderson, and
will also be open at Northwestern University&#8217;s Robert H. Lurie Comprehensive Cancer Center. The Company will provide LB-100 and
GSK will provide dostarlimab and financial support for the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex (&#8220;CRO&#8221;), to monitor the Phase 1b/2
clinical trial being managed and conducted by Moffitt. The clinical trial began in April 2019 and the first patient was entered into
the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the three months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zamaK1pgiNqb" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566</ix:nonFraction></span> and
$<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zgmkdNclhHC4" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,953</ix:nonFraction></span>, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022, the Company incurred costs
of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zNpO5ArAhM6b" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,850</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zZT29UYWdHCb" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,792</ix:nonFraction></span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zblboL8TZ3O4" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,138</ix:nonFraction></span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the three months ended June 30,
2023 (see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to September 30,
2023 are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAbOe1yyahA5" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,000</ix:nonFraction></span>. During the three months ended September 30, 2023 and 2022, the Company
incurred costs of $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zZhDZv4Ngnp2" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-07-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGeb3CpCF6qc" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-07-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,731</ix:nonFraction></span>, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022,
the Company incurred costs of $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zF1EKsYPpeB9" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,740</ix:nonFraction></span> and $<span id="xdx_909_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zqVqxKeecYJ6" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,466</ix:nonFraction></span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of
$<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zXDTi6qcrZyg" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,181</ix:nonFraction></span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zRbqECELYYBc" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember_custom_CityOfHopeNationalMedicalCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,000</ix:nonFraction></span> as of September 30, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zAeIbBBkFJDf" title="Non refundable license issue fee"><ix:nonFraction name="LIXT:NonRefundableLicenseIssueFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction> </span>after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $<span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zApRbs2byUd6" title="Maintenance fee"><ix:nonFraction name="LIXT:AnnualLicenseMaintenanceFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $<span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsw53rxZnWC" title="Payment on non refundable milestone"><ix:nonFraction name="LIXT:PaymentsOnNonrefundableMilestone" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,897,000</ix:nonFraction></span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2023, the Company recorded credits to operations of $<span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20230701__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z1CxROS0EXG1" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-07-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,507</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zP6QYLuaYHFl" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,109</ix:nonFraction></span>, respectively,
representing the reversal of obligations previously recorded with respect to the Exclusive License Agreement. During the three months
and nine months ended September 30, 2022, the Company recorded charges to operations of $<span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20220701__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zud92GBcb3ca" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-07-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,301</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OperatingCostsAndExpenses_c20220101__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zoM6ohs9lD89" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,699</ix:nonFraction></span>, respectively, in connection
with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_z1iuid16g825" title="Salary and compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">640,000</ix:nonFraction></span>, payable monthly (see Note 6). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_z5wxTcgx982k" title="Annual compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">775,000</ix:nonFraction></span>, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zTmpyXfRFWP9" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. In addition,
Mr. Forman is being provided an office allowance of approximately $<span id="xdx_906_eus-gaap--PaymentsForRent_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zW91votLSB6g" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-11-052022-11-06_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></span> per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_90C_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_zvjgBCWu3xud" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual may be
increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors. Mr. Van der Baan was appointed as Chairman of the Board
of Directors upon the death of Dr. Kovach on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers increased to $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20230925__20230926__srt--TitleOfIndividualAxis__srt--OfficerMember_zFZep8FiVpz" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-09-252023-09-26_srt_OfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,000</ix:nonFraction></span>, effective September 26, 2023, which has continued through
September 30, 2023. As a result of Dr. Kovach&#8217;s death on October 5, 2023, aggregate annual compensation of all officers will decrease
to $<span id="xdx_903_eus-gaap--OfficersCompensation_c20231004__20231005__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ9d6d04Dmy" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-10-042023-10-05_srt_OfficerMember_srt_MinimumMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span> from that date forward.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOnWrw5qnBBj" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOh1FdiHtaK2" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2023-07-012023-09-30_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYjwLAVRMBZ5" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2022-07-012022-09-30_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> for the three months
ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYuWWjqVzzG" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2023-01-012023-09-30_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> and $<span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zPkFNR1YYQSb" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2022-01-012022-09-30_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022, which
were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_904_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zX0iWnt9r0Q5" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90F_ecustom--ReimbursementExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zElbb42jkqIj" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2023-07-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> and $<span id="xdx_901_ecustom--ReimbursementExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zFE5UtSib4Ph" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2022-07-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> for the three months ended September 30, 2023 and
2022, respectively, and $<span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zRzAEDgcIQ75" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2023-01-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zIzXnqSxRsCd" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2022-01-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022, respectively, which were included
in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 6), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zh6xad3tqnPj" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">391,000</ix:nonFraction></span> Euros and
provide a sufficient supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
<span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z15qYDfwSemf" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">250,000</ix:nonFraction></span> Euros (approximately $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxZ7PYRN9w49" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,000</ix:nonFraction></span> at October 3, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmXXu4Il4Az8" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-07-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,568</ix:nonFraction></span> and $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zA67BibNkONf" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-07-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,068</ix:nonFraction></span>, respectively,
with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements
of operations. During the nine months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_900_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zjSBsGbhW3qk" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,949</ix:nonFraction></span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYU2SzIExbQ5" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,184</ix:nonFraction></span>,
respectively, with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated
statements of operations. As of September 30, 2023, total costs of $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zyfriKm30zBf" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,356</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s
aggregate commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlVPND6Qjsql" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,000</ix:nonFraction></span> as
of September 30, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid
for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zOw1s53Hvd3b" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,980</ix:nonFraction></span> for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$<span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zfE3rkYMt2O9" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,274</ix:nonFraction></span> for services to be rendered through April 30, 2024. During the three months ended September 30, 2023 and 2022, the Company incurred
costs of $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z13A7he1ZCD9" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-07-012023-09-30_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,845</ix:nonFraction></span> and $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbUE2GqePu4b" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-07-012022-09-30_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,549</ix:nonFraction></span>, respectively, pursuant to this contract. During the nine months ended September 30, 2023 and 2022, the Company
incurred costs of $<span id="xdx_906_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zhW026YHpQrd" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-09-30_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,028</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zt2JVOP8CER5" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-09-30_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,902</ix:nonFraction></span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zQUxCCDjlkFf" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,841</ix:nonFraction></span> have
been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_c20230930_zTuGRcM6JdCd" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></span> as
of September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising efforts in the future is uncertain and
cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zXAWZTrsJx8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82E_zlSvuJduLuj7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements
with the SEC. Other than those matters described elsewhere in the footnotes, there were no material subsequent events which affected,
or could affect, the amounts or disclosures in the condensed consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_81D_zgghOv027i1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the &#8220;Company&#8221;) contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might
include statements regarding the Company&#8217;s financial position, business strategy and other plans and objectives for future operations,
and assumptions and predictions about future clinical trials and their timing and costs, product demand, supply, manufacturing costs,
marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as &#8220;intend&#8221;,
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;potential(ly)&#8221;, &#8220;continue&#8221;, &#8220;forecast&#8221;,
&#8220;predict&#8221;, &#8220;plan&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;,
&#8220;expect&#8221; or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations
reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company
cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action
that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties.
Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available
cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion
should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly
Report on Form 10-Q and the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, including the section
entitled &#8220;Item 1A. Risk Factors&#8221;. The Company does not intend to update or revise any forward-looking statements to reflect
new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug research company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>President
and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan was appointed as the Company&#8217;s President and Chief Executive Officer, at which time he replaced
Dr. John S. Kovach as the Company&#8217;s President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>News
Release</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, the Company announced a Phase 1b/2 collaborative clinical trial to assess whether adding LIXTE&#8217;s LB-100 to GSK&#8217;s
programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment
of ovarian clear cell carcinoma (OCCC). The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will
be conducted at MD Anderson, and will also be open at Northwestern University&#8217;s Robert H. Lurie Comprehensive Cancer Center. LIXTE
will provide LB-100 and GSK will provide dostarlimab and financial support for the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial is based on the observation of longer survival of patients with OCCC treated with immunotherapy whose cancer cells have
an acquired gene mutation resulting in a reduction in PP2A. This finding was reported by the lead clinical investigators of this new
clinical trial: Amir Jazaeri MD, Professor of Gynecologic Oncology at MD Anderson, and Emily Hinchcliff, MD, MPH, Assistant Professor
of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine. The observation by Drs. Jazaeri and Hinchcliff is
that a genetically acquired reduction in PP2A enhances sensitivity to immunotherapy and raises the possibility that reducing PP2A pharmacologically
with LB-100 will enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody dostarlimab in patients with OCCC lacking the
genetic reduction in PP2A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As reflected in the accompanying financial statements, for the nine months ended September 30, 2023, the Company recorded a net loss of
$4,054,774 and used cash in operations of $3,391,142. At
September 30, 2023, the Company had cash of $5,105,611 available to fund its operations. Because the Company is currently engaged in
various early-stage clinical trials, it is expected that it will take a significant amount of time and resources to develop any product
or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s business is unlikely to generate
any sustainable operating revenues in the next several years and may never do so. Even if the Company is able to generate revenues through
licensing its technology, product sales or other commercial activities, there can be no assurance that the Company will be able to achieve
and maintain positive earnings and operating cash flows. At September 30, 2023, the Company&#8217;s remaining contractual commitments
pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated approximately $6,262,000,
which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through at least September 30, 2024. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able
to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating
plans may change as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional
funds may be needed sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to recent accounting pronouncements is provided at Note 3 to the condensed consolidated financial statements for the three
months and nine months ended September 30, 2023 and 2022 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to concentration of risk is provided at Note 3 to the condensed consolidated financial statements for the three months and
nine months ended September 30, 2023 and 2022 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s consolidated financial statements in conformity with generally accepted accounting principles in the
United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments
can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions
or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable
in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates
the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly.
Actual results could differ from those estimates. Significant estimates include those related to assumptions used in the calculation
of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services, and the realization
of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company&#8217;s
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and Licensing Legal and Filing Fees and Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs are charged to operations
as incurred. Patent and licensing legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, patent and licensing legal and filing fees and costs related to the development and
protection of its intellectual property were $178,012 and $271,163, respectively, a decrease of $93,151, or 34.4% in 2023, as compared
to 2022. During the nine months ended September 30, 2023 and 2022, patent and licensing legal and filing fees and costs related to the
development and protection of its intellectual property were $835,362 and $944,789, respectively, a decrease of $109,427, or 11.6% in
2023, as compared to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
late 2021, the Company engaged a new patent law firm that is highly regarded for its expertise in biotechnology. This firm conducted
a comprehensive analysis of the Company&#8217;s extensive patent portfolio in order to implement a program to maximize intellectual property
protection, both domestically and internationally. As a result, several patents were filed in 2022, reflecting potential new uses of
the Company&#8217;s lead clinical compound LB-100 in cancer therapy. The Company expects that patent and licensing legal and filing fees
and costs will remain relatively stable for the remainder of 2023 as compared to 2022, as the Company continues to focus on efforts to
expand clinical programs to analyze various potential uses for LB-100 and to develop and expand its patent portfolio related to the clinical
development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
descriptive summary of the patent portfolio for the Company&#8217;s most important clinical programs involving the development of LB-100,
as well as a detailed listing of each domestic and international patent that has been issued, is presented at &#8220;ITEM 1. BUSINESS
&#8211; Intellectual Property&#8221; in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480,
Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing meet the
requirements for equity classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Business Activities and Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug research company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s product pipeline is primarily focused on inhibitors of
protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses
two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing its development activities on its LB-100 series of drugs. The Company believes that the mechanism by which compounds
of the LB-100 series affect cancer cell growth is different from cancer agents currently approved for clinical use. Lead compounds from
each series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, compounds
from both series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers
of neural tissue. Lead compounds of the LB-100 series also have activity against melanoma, breast cancer and sarcoma in animal models
and enhance the effectiveness of commonly used anti-cancer drugs in these animal models. The enhancement of anti-cancer activity of these
anti-cancer drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when
combined with standard anti-cancer regimens against many tumor types, the Company&#8217;s compounds will improve therapeutic benefit
without enhancing toxicity in humans. The Company is not currently planning to allocate resources to further develop its LB-200 series
of drugs,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LB-100 series consists of novel structures which have the potential to be first in their class and may be useful in the treatment of
not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which have the potential
to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher&#8217;s disease,
in addition to cancer and neurodegenerative diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has demonstrated that lead compounds of both the LB-100 series and the LB-200 are active against a broad spectrum of human cancers
in cell culture and against several types of human cancers in animal models. The research on these compounds was initiated in 2006 under
a Cooperative Research and Development Agreement, or CRADA, with the National Institute of Neurologic Disorders and Stroke, or NINDS,
of the National Institutes of Health, or NIH, dated March 22, 2006 that was subsequently extended through a series of amendments until
it terminated on April 1, 2013. As discussed below, the Company&#8217;s primary focus is on the clinical development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LB-200 series consists of histone deacetylase inhibitors (HDACi). Many pharmaceutical companies are also developing drugs of this type,
and at least two companies have HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this
significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, have neuroprotective
activity, and have anti-fungal activity. In addition, these compounds have low toxicity. LB-200 has not yet advanced to the clinical
stage and would require additional capital to fund further development. Accordingly, because of the Company&#8217;s focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, the Company has decided not to actively pursue
the pre-clinical development of the LB-200 series of compounds. At this time, the Company intends to only maintain composition and synthesis
patents on the LB-200 series of compounds in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with leading academic research centers in the United States, Europe and Asia have established the breadth of activity of LB-100 in pre-clinical
models of several major cancers. There is considerable scientific interest in LB-100 because it exerts its activity by a novel mechanism
and is the first of its type to be evaluated so broadly in multiple animal models of cancer and now in human beings. LB-100 is one of
a series of serine/threonine phosphatase (s/t ptase) inhibitors designed by the Company. The s/t ptases are ubiquitous enzymes that regulate
many cell signaling networks important to cell growth, division and death. The s/t ptases have long been appreciated as potentially important
targets for anti-cancer drugs. However, because of the multi- functionality of these enzymes, it had been widely held that pharmacologic
inhibitors of s/t ptases would be too toxic to allow their development as anti-cancer treatments, but the Company has shown that this
is not the case. LB-100 was well tolerated at doses associated with objective regression (significant tumor shrinkage) and/or the arresting
of tumor progression in patients with progressive cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies showed that LB-100 itself inhibits a spectrum of human cancers and that combined with standard cytotoxic drugs and/or radiation,
LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. Given at very low doses
in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely used new immunotherapy drugs.
This finding raises the possibility that LB-100 may further expand the value of the expanding field of cancer immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed a Phase 1 clinical trial of LB-100 to evaluate its safety that showed it is associated with antitumor activity in humans
at doses that are readily tolerable. Responses included objective regression (tumor shrinkage) lasting for 11 months of a pancreatic
cancer and cessation of growth (stabilization of disease) for 4 months or more of 9 other progressive solid tumors out of 20 patients
who had measurable disease. As Phase 1 clinical trials are fundamentally designed to determine safety of a new compound in humans, the
Company was encouraged by these results. The next step is to demonstrate in Phase 2 clinical trials the efficacy of LB-100 in one or
more specific tumor types, against which the compound has well documented activity in pre-clinical models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to expand the breadth and depth of its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead,
moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain
milestones are reached. The Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements
with pharmaceutical companies with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising efforts in the future is uncertain and
cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations,
and is dependent on its ability to raise equity capital to fund its operating requirements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s condensed consolidated statements of operations as discussed herein are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Compensation to related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">356,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">643,957</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,398,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,963,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">357,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,993</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,081,893</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">875,016</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132,487</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">272,388</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">749,029</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">895,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total costs and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,024,181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,478,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,064,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,678,863</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,024,181</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,478,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,326</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,678,863</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,211</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(279</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,119</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,088</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,240</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,339</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,018,760</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,478,009</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,054,774</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,681,231</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.49</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.89</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.25</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,074,938</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,664,659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,803,466</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,554,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the three months ended September 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the three months ended September 30, 2023, general and administrative costs were $891,694, which consisted
of the fair value of vested stock options issued to directors and officers of $112,106, patent and licensing legal and filing fees and
costs of $178,012, other consulting and professional fees of $199,884, insurance expense of $107,910, officer salaries and related costs
of $216,880, cash-based director and board committee fees of $42,228, shareholder reporting costs of $3,887, listing fees of $15,500,
filing fees of $4,439, taxes and licenses of $3,946, investor relations of $14,172, rent of $7,323 and other operating costs of $6,914,
offset by a credit to licensing fees of $21,507 relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2022, general and administrative costs were $1,206,113, which consisted of the fair value of vested
stock options issued to directors and officers of $396,883, patent and licensing legal and filing fees and costs of $271,163, other consulting
and professional fees of $108,630, insurance expense of $114,983, officer salaries and related costs of $207,091, cash-based director
and board committee fees of $53,324, licensing fees of $6,301, shareholder reporting costs of $20,487, listing fees of $14,875, filing
fees of $3,048, taxes and licenses of $4,094, investor relations of $2,397, and other operating costs of $2,837.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs decreased by $314,419, or 26.1%, in 2023 as compared to 2022, primarily as a result of a decrease in the fair
value of vested stock options issued to directors and officers of $284,777, a decrease in patent and licensing legal and filing fees
and costs of $93,151, a decrease in licensing fees of $27,808 a decrease in shareholder reporting of $16,600, offset by increases in
investor relations of $11,775 and an increase in consulting and professional fees of $91,254.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the three months ended September 30, 2023, research and development costs were $132,487, which consisted
of clinical and related oversight costs of $8,816, regulatory service costs of $10,919, and pre-clinical research focused on development
of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $124,752, offset by a credit of $12,000
relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2022, research and development costs were $272,388, which consisted of contractor costs incurred
in connection with the synthesis work done to develop a new supply of LB-100 for the Spanish clinical trial of $1,246, clinical and related
oversight costs of $28,902, regulatory service costs of $5,330, and pre-clinical research focused on development of additional novel
anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $236,910.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in pre-clinical research costs for the three months ended September 30, 2023 and 2022 were $51,568 and $46,068, respectively, of costs
paid to the Netherlands Cancer Institute, which employs Dr. Ren&#233; Bernards, a director of the Company since June 15, 2022. On October
8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one of the
world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, as amended
by Amendment No. 1. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provides for additional research activities, extends the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and adds 250,000 Euros (approximately $263,000 at October 3, 2023) to the operating budget being funded by the Company
(see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer Institute&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $139,901, or 51.4%, in 2023 as compared to 2022, primarily as a result of a decrease in
pre-clinical research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of
$112,158 and a credit of $12,000 relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the three months ended September 30, 2023, the Company had interest income of $5,809, as compared to interest income
of $3,911 for the three months ended September 30, 2022, related to the investment of funds generated by the Company&#8217;s financing
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the three months ended September 30, 2023, the Company had interest expense of $279, as compared to interest expense
of $2,119 for the three months ended September 30, 2022, related to the financing of the premium for the Company&#8217;s directors and
officers liability insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Loss</span>. For the three months ended September 30, 2023, the Company had a foreign currency loss of $109, as compared to a foreign
currency loss of $1,300 for the three months ended September 30, 2022, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the three months ended September 30, 2023, the Company incurred a net loss of $1,018,760, as compared to a net loss of
$1,478,009 for the three months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the nine months ended September 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the nine months ended September 30, 2023, general and administrative costs were $3,315,297, which consisted
of the fair value of vested stock options issued to directors and officers of $669,146, patent and licensing legal and filing fees and
costs of $835,362, other consulting and professional fees of $529,830, insurance expense of $316,214, officer salaries and related costs
of $649,483, cash-based director and board committee fees of $127,229, shareholder reporting costs of $64,783, listing fees of $46,500,
filing fees of $14,634, taxes and licenses of $11,483, investor relations of $36,516, rent of $11,436 and other operating costs of $11,790,
offset by a credit to licensing fees of $9,109 relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, general and administrative costs were $3,783,214, which consisted of the fair value of vested
stock options issued to directors and officers of $1,160,649, patent and licensing legal and filing fees and costs of $944,789, other
consulting and professional fees of $344,085, insurance expense of $349,254, officer salaries and related costs of $627,579, cash-based
director and board committee fees of $221,510, licensing fees of $18,699, shareholder reporting costs of $26,811, listing fees of $44,625,
filing fees of $11,460, taxes and licenses of $12,231, investor relations of $7,246, and other operating costs of $14,276.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs decreased by $467,917, or 12.4%, in 2023 as compared to 2022, primarily as a result of a decrease in the fair
value of vested stock options issued to directors and officers of $491,503, a decrease in patent and licensing legal and filing fees
and costs of $109,427, a decrease in licensing fees of $27,808 a decrease in cash-based director and board committee fees of $94,281,
offset by an increase in shareholder reporting of $37,972, an increase in investor relations of $29,270, an increase in rent of $11,436
and an increase in consulting and professional fees of $185,745.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the nine months ended September 30, 2023, research and development costs were $749,029, which consisted
of clinical and related oversight costs of $390,708, regulatory service costs of $18,738, and pre-clinical research focused on development
of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $339,583.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2022, research and development costs were $895,649, which consisted of contractor costs incurred
in connection with the synthesis work done to develop a new supply of LB-100 for the Spanish clinical trial of $352,734, clinical and
related oversight costs of $61,880, regulatory service costs of $5,690, and pre-clinical research focused on development of additional
novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $475,345.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in pre-clinical research costs for the nine months ended September 30, 2023 and 2022 were $156,950 and $149,184, respectively, of costs
paid to the Netherlands Cancer Institute, which employs Dr. Ren&#233; Bernards, a director of the Company since June 15, 2022. On October
8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one of the
world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify
the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well
as to identify the specific molecular mechanisms underlying the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provides for additional research activities, extends the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and adds 250,000 Euros (approximately $263,000 at October 3, 2023) to the operating budget being funded by the Company
(see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer Institute&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $146,620, or 16.4%, in 2023 as compared to 2022, primarily as a result of a decrease in contractor
costs incurred in connection with the synthesis work done to develop a new supply of LB-100 for the Spanish clinical trial of $352,734
and a decrease in pre-clinical research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s
clinical pipeline of $135,762, offset by an increase in clinical and related oversight costs of $328,828.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the nine months ended September 30, 2023, the Company had interest income of $13,538, as compared to interest income
of $4,211 for the nine months ended September 30, 2022, related to the investment of funds generated by the Company&#8217;s financing
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the nine months ended September 30, 2023, the Company had interest expense of $6,088, as compared to interest expense
of $5,240 for the nine months ended September 30, 2022, related to the financing of the premium for the Company&#8217;s directors and
officers liability insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Gain (Loss)</span>. For the nine months ended September 30, 2023, the Company had a foreign currency gain of $2,102, as compared
to a foreign currency loss of $1,339 for the nine months ended September 30, 2022, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the nine months ended September 30, 2023, the Company incurred a net loss of $4,054,774, as compared to a net loss of $4,681,231
for the nine months ended September 30, 2022.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources &#8211; September 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of cash flows as discussed herein are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,391,142</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,403,289</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,143,361</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,141,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(247,781</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,738,095</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company had working capital of $4,922,960, as compared to working capital of $5,165,227 at December 31, 2022,
reflecting a decrease in working capital of $242,267 for the nine months ended September 30, 2023. The decrease in working capital during
the nine months ended September 30, 2023 was primarily the result of the funding of the Company&#8217;s ongoing research and development
activities and other ongoing operating expenses, including maintaining and developing its patent portfolio, offset by proceeds from the
sale of securities on July 20, 2023. At September 30, 2023, the Company had cash of $5,105,611 available to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through at least September 30, 2024. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able
to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating
plans may change as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional
funds may be needed sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company&#8217;s remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements not yet incurred aggregated $6,262,000, which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet
arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Activities</span>. For the nine months ended September 30, 2023, operating activities utilized cash of $3,391,142, as compared to utilizing
cash of $3,403,289 for the nine months ended September 30, 2022, to fund the Company&#8217;s ongoing research and development activities
and to fund its other ongoing operating expenses, including maintaining and developing its patent portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investing
Activities</span>. For the nine months ended September 30, 2023 and 2022, the Company had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Activities</span>. For the nine months ended September 30, 2023, financing activities consisted primarily of the gross proceeds from the
sale of securities in the Company&#8217;s registered direct offering of $3,499,964, reduced by offering costs of $362,925, and $6,281
from the exercise of common stock options. For the nine months September 30, 2022, financing activities consisted of the gross proceeds
from the sale of securities in the Company&#8217;s registered direct offering of $5,800,000, reduced by offering costs of $658,616.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company&#8217;s remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements not yet incurred, as described below, aggregated $6,262,000, which, based on current estimates, are currently scheduled to
be incurred through approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is
subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation
of such funds to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures
will be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration
are not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can
frequently involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified,
suspended or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein
should be considered as estimates only based on current clinical assumptions and conditions, and are typically subject to significant
modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Institution</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
                                            Date</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            End Date</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
                                            Objective</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Update</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NCT
                                            No.</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 10%">Phase 1b</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: left">City of Hope and Sarah Cannon</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: center">March 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: center">March 2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14 to 36</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 9%">Determine RP2D</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 9%">Three patients entered</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 9%">NCT04560972</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LB-100 combined with doxorubicin in sarcoma</td><td>&#160;</td>
    <td style="text-align: left">Phase 1b</td><td>&#160;</td>
    <td style="text-align: left">GEIS</td><td>&#160;</td>
    <td style="text-align: center">June 2023</td><td>&#160;</td>
    <td style="text-align: center">June 2024</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 to 18</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Determine MTD and RP2D</td><td>&#160;</td>
    <td style="text-align: left">One patient entered</td><td>&#160;</td>
    <td style="text-align: center">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Doxorubicin with or without LB-100 in sarcoma</td><td>&#160;</td>
    <td style="text-align: left">Randomized Phase 2</td><td>&#160;</td>
    <td style="text-align: left">GEIS</td><td>&#160;</td>
    <td style="text-align: center">July 2024</td><td>&#160;</td>
    <td style="text-align: center">June 2026</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Determine efficacy: PFS</td><td>&#160;</td>
    <td style="text-align: left">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</td><td>&#160;</td>
    <td style="text-align: center">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LB-100 combined with dostarlimab in ovarian clear cell carcinoma</td><td>&#160;</td>
    <td style="text-align: left">Phase 1b/2</td><td>&#160;</td>
    <td style="text-align: left">MD Anderson</td><td>&#160;</td>
    <td style="text-align: center">March 2024</td><td>&#160;</td>
    <td style="text-align: center">December 2025</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Determine the survival of patients with ovarian clear cell carcinoma</td><td>&#160;</td>
    <td style="text-align: left">No patients entered at September 30, 2023</td><td>&#160;</td>
    <td style="text-align: center">NCT06065462</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a five-year Clinical Trial Research Agreement with the Moffitt Cancer Center
and Research Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;). Pursuant to the Clinical Trial Research Agreement, Moffitt
agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead
anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome
(MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2023, the Phase 1b/2 clinical trial at Moffitt evaluating LB-100 in patients with MDS was closed by the
principal investigator. In this clinical trial, single agent LB-100 was used on a new schedule of days 1, 3, and 5 every 3 weeks. The
Company is not employing this schedule in its other clinical trials. Although the Maximally Tolerated Dose (&#8220;MTD&#8221;) was not
achieved, there was no dose-limiting toxicity on this schedule at doses that were greater than the MTD in the Phase 1 clinical trial
of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred costs of $0 and $9,218, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. During the nine
months ended September 30, 2023 and 2022, the Company incurred costs of $0 and $18,623, respectively, pursuant to this agreement, which
have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30,
2023, total costs of $131,074 have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(&#8220;PFS&#8221;, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative
median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $1,144,000. Although the production of new inventory
has been completed, nominal trailing costs subsequent to September 30, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b section of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the
nine months ended September 30, 2023 and 2022, the Company incurred costs of $268,829 and $0, respectively, pursuant to this agreement.
Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of operations.
Through September 30, 2023, the Company has paid GEIS an aggregate of $684,652 for work done under this agreement through the fourth
milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $3,423,000
as of September 30, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously
untreated ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm
the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free-survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early July 2023, the Company was notified that one of three centers accruing patients to its Phase 1b clinical trial in small cell lung
cancer had a shortage of carboplatin and as a result the clinical trial was placed on a temporary enrollment hold. This matter was resolved
and the temporary enrollment hold was lifted in late July 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the nine months
ended September 30, 2023 and 2022, the Company incurred costs of $69,001 and $0, respectively, pursuant to this agreement, which are
included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30, 2023, total
costs of $447,512 have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $2,433,000
as of September 30, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$800,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theradex.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to conduct a Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin
alone in first line of advanced soft tissue sarcomas. The study is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately
72% to Theradex for services and approximately 28% for payments for pass-through software costs. During the three months and nine months
ended September 30, 2023, the Company incurred costs of $$3,750 and 10,000, respectively, pursuant to this work order. As of September
30, 2023, total costs of $10,000 have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $144,000 as of September 30, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain has not been determined. Many
drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Five patients were entered into this study and analysis of the blood and tissue has been conducted. If there is clinical
evidence in at least two of the patients of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results
of this study are currently being reviewed by the NCI and a report is pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Trial</b>. On September 20, 2023, the Company announced a Phase 1b/2 collaborative clinical trial to assess whether
adding LB-100 to the programmed death receptor-1 (&#8220;PD-1&#8221;)-blocking monoclonal antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab,
may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). The clinical trial
is sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and will be conducted at MD Anderson, and
will also be open at Northwestern University&#8217;s Robert H. Lurie Comprehensive Cancer Center. The Company will provide LB-100 and
GSK will provide dostarlimab and financial support for the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex (&#8220;CRO&#8221;), to monitor the Phase 1b/2
clinical trial being managed and conducted by Moffitt. The clinical trial began in April 2019 and the first patient was entered into
the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the three months ended September 30, 2023 and 2022, the Company incurred costs of $566 and
$11,953, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022, the Company incurred costs
of $20,850 and $19,792, respectively, pursuant to this work order. As of September 30, 2023, total costs of $148,138 have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the three months ended June 30,
2023 (see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to September 30,
2023 are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $335,000. During the three months ended September 30, 2023 and 2022, the Company
incurred costs of $4,500 and $7,731, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022,
the Company incurred costs of $15,740 and $23,466, respectively, pursuant to this work order. As of September 30, 2023, total costs of
$74,181 have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $262,000 as of September 30, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2023, the Company recorded credits to operations of $21,507 and $9,109, respectively,
representing the reversal of obligations previously recorded with respect to the Exclusive License Agreement. During the three months
and nine months ended September 30, 2022, the Company recorded charges to operations of $6,301 and $18,699, respectively, in connection
with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $640,000, payable monthly. These employment agreements were automatically renewable for additional one-year periods unless terminated
by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause.
These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $775,000, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $200,000. In addition,
Mr. Forman is being provided an office allowance of approximately $1,500 per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $150,000. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual may be
increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors. Mr. Van der Baan was appointed as Chairman of the Board
of Directors upon the death of Dr. Kovach on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers increased to $950,000, effective September 26, 2023, which has continued through
September 30, 2023. As a result of Dr. Kovach&#8217;s death on October 5, 2023, aggregate annual compensation of all officers will decrease
to $700,000 from that date forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $4,000. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 and $4,000 for the three months
ended September 30, 2023 and 2022, respectively, and $12,000 and $12,000 for the nine months ended September 30, 2023 and 2022, which
were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation. The Company recorded charges to
operations pursuant to this Collaboration Agreement of $30,000 and $30,000 for the three months ended September 30, 2023 and 2022, respectively,
and $90,000 and $90,000 for the nine months ended September 30, 2023 and 2022, respectively, which were included in research and development
costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht,
a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently modified
by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined with
LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms
underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of 391,000 Euros and provide a sufficient
supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
250,000 Euros (approximately $263,000 at October 3, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $51,568 and $46,068, respectively,
with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements
of operations. During the nine months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $156,949 and $149,184,
respectively, with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated
statements of operations. As of September 30, 2023, total costs of $416,356 have been incurred pursuant to this agreement. The Company&#8217;s
aggregate commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $316,000 as
of September 30, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid
for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $273,980 for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$326,274 for services to be rendered through April 30, 2024. During the three months ended September 30, 2023 and 2022, the Company incurred
costs of $19,845 and $5,549, respectively, pursuant to this contract. During the nine months ended September 30, 2023 and 2022, the Company
incurred costs of $27,028 and $25,902, respectively, pursuant to this work order. As of September 30, 2023, total costs of $241,841 have
been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $84,000 as
of September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends,
Events and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development of new pharmaceutical compounds is, by its nature, unpredictable. Although the Company undertakes research and development
efforts with commercially reasonable diligence, there can be no assurance that the Company&#8217;s cash position will be sufficient to
enable it to develop pharmaceutical compounds to the extent needed to create future revenues sufficient to sustain operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurances that the Company&#8217;s pharmaceutical compounds will obtain the regulatory approvals and market acceptance to
achieve sustainable revenues sufficient to support operations. Even if the Company is able to generate revenues, there can be no assurances
that it will be able to achieve operating profitability or positive operating cash flows. There can be no assurances that the Company
will be able to secure additional financing, to the extent required, on acceptable terms or at all. If cash resources are insufficient
to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to reduce or discontinue its research and development
programs, or attempt to obtain funds, if available (although there can be no assurances), through strategic alliances that may require
the Company to relinquish rights to certain of its pharmaceutical compounds, or to curtail or discontinue its operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, the Company is not currently aware of any trends, events or uncertainties that are likely to have a material
effect on its financial condition in the near term, although it is possible that new trends or events may develop in the future that
could have a material effect on the Company&#8217;s financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), that is designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its
principal executive officer and principal financial officer, or persons performing similar functions, as appropriate, to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed under the supervision and with the participation of
the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design
and operation of the Company&#8217;s disclosure controls and procedures as of September 30, 2023, the end of the most recent fiscal period
covered by this report. Based on that evaluation, the Company&#8217;s management has concluded that the Company&#8217;s disclosure controls
and procedures were effective in providing reasonable assurance that information required to be disclosed in the Company&#8217;s reports
filed or submitted under the Exchange Act was recorded, processed, summarized, and reported within the time periods specified in the
rules and forms of the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Effectiveness of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition,
the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to
apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, has determined that no change in the Company&#8217;s
internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act
of 1934) occurred during the period ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect,
the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not currently subject to any pending or threatened legal actions or claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition, results of operations and cash flows may be impacted by a number of factors, many of which
are beyond the Company&#8217;s control, including those set forth in the Company&#8217;s Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 (the &#8220;2022 Form 10-K&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Risk Factors set forth in the 2022 Form 10-K should be read carefully in connection with evaluating the Company&#8217;s business and
in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the
2022 Form 10-K could materially adversely affect the Company&#8217;s business, financial condition or future results and the actual outcome
of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and
uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect
the Company&#8217;s business, financial condition and/or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, except as disclosed in this document, there have been no material changes to the Risk Factors previously
disclosed in the Company&#8217;s 2022 Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market, the Company held a special
meeting of stockholders on May 26, 2023 to seek approval for an amendment to the Company&#8217;s Certificate of Incorporation to effect
a reverse stock split of its issued and outstanding shares of common stock. As a result of the approval of this amendment, the Company
effected a 1-for-10 reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. Commencing with
the opening of trading on the Nasdaq Capital Market on Monday, June 5, 2023, the Company&#8217;s common stock began trading on a post-split
basis under the same symbol LIXT. The Company subsequently received confirmation from Nasdaq that it had regained compliance with the
minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria
for continued listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum bid price requirement over time,
or that it will be successful in maintaining compliance with any of the other Nasdaq continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising efforts in the future is uncertain and
cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
<span id="xdx_901_eecd--Rule10b51ArrAdoptedFlag_c20230701__20230930_zfnYIItbzspi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_906_eecd--NonRule10b51ArrAdoptedFlag_c20230701__20230930_zmeMoOrXG5Ah" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2023-07-012023-09-30" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2023-07-012023-09-30" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_908_eecd--Rule10b51ArrTrmntdFlag_c20230701__20230930_znNKAG1U6Xp9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrTrmntdFlag_c20230701__20230930_zJN4x364RDp4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2023-07-012023-09-30" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2023-07-012023-09-30" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
6. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Common Stock Purchase Warrant, filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant, filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223016069/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2023, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">Amendment No. 1 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on October 8, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on October 13, 2023, filed as Exhibit 10.2 to the Company Current Report on Form 8-K, as filed with the Securities and Exchange Commission on October 17, 2023 (certain portions of this Exhibit have been omitted)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-5.htm">Termination letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of September 30, 2023</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Bastiaan van der Baan effective as of September 26, 2023, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 27, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BASTIAAN VAN DER BAAN</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    ROBERT N. WEINGARTEN</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 868px; width: 670px">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 6pt; text-align: center"><IMG SRC="ex10-3_002.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex10-3_003.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex10-3_004.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex10-3_005.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>ex10-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.5</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-5_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-5_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bastiaan van der Baan, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BASTIAAN VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert N. Weingarten, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bastiaan van der Baan, the Chief Executive Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2023 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BASTIAAN VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert N. Weingarten, the Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2023 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 9, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-3_001.jpg
<TEXT>
begin 644 ex10-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2Z Z8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY(VB*E20P*N 1@@]11TN!H45S/\ PG_AMEDDBO9[BWB.)+JVLIYK=?7,R(4
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MBHZ;F.6_4DU/Y:>8)-B[P-H;'./3-8OAF?6[NWO+K7-/.GS27!\FT,RR^7$
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M")A]IM1))C>-R@R]/F&,D'Z4HN\H2>_7[FOQ&U:,DMNGSL_PU,[]HLD2^%2
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MQZUQ7Q \0^)_#_Q&\/:1I_B6[CL=7F42(;:V8P@R!2$8Q=,'C=D_6A:M)==
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X;\?=/N;?4_#7B01/)8V4VR<KSL.]6'TS@C/KBO;
M+6YAO;2&ZMY%DAF0.CJ<AE(R#2W-M!>6TEM=01SP2J5DBE4,K ]B#P16':^"
M=!L3BUM[F"#G_18[Z=;?D8(\D/Y>/;;1'2/+YW!ZN_E8Y3XT:5-XF^&EP^E_
MZ2UG<"<K$<[@FY7QZXR?R-;WPOOH-0^&F@R6[AA':)"^#]UD&T@_B*ZN.*.&
M)8HHU2- %5%& H] /2L%O _A\S2R0V<UIYS;IH[*[FMHY2>I=(W56)]P<T+2
MZ[@];>1Y3X+TZ;7?VA/$'B"UW?V=9221M,/NN^T)M![]"?PIW@O_ ).6\4?]
M<9?YQU[19:/I^FZ;_9VGVD=G:8($=L/*QGJ05P0?<<USD'PO\)VNIR:E;V=]
M#?R9WW4>JW:RMGKEQ+DY^M.+Y7'LDU]X/7F\VOP.CNM3AM=1L;%B#/>,X1,\
MA54L6QZ#@?\  A7C&A_\G3:S_P!<&_\ 125ZK9>"]$L-6.JPQ7CW_DM!]HN-
M0N)W"'J 7<XZ#I6='\+_  G%JK:K'9WR:BV=UVNJW0E.1@Y?S<]/>E'22?K^
M(/6+7I^!T=[J<%E>6%JY!GO93'$F>3A2S'Z #]16%K%[-<:[Y$6AWNJVMI$R
MR"U> !97&,-YLB<A#VSP]6;7P3H=IJ\>JI%>RW\4;11SW&HW$[(K#! WR'%3
MZ+X5TKP]-/+IJ7:-.2T@EOIYE9CU8K([#=QUQGWHLGN%WT/(/@_>W'A+X@ZY
MX)OX);2.X8W%I#.REE(Y RI()*$="1\M3_'.-9O&O@>)BP5[@J2CE6P9(^A&
M"#[CFO1;[X9^%=2UG^U[RRNY=1#;EN3J5R'3G(VD2?*!DX P!VI^K?#GPQKM
M_%>ZG:7=U<PX,3OJ-S^[(Q]T"3"] >,<\]::?P-]/T!_:MU_4\S^(BGX;^.M
M UK0GENKJ_)AFM[Z0W3LJE0 CR%I%SN(X;J!]*7X@6<NB?'3PQXENT*:9<M%
M$9C]V-QE2">W# _GZ5ZK9^"/#UGJBZH+%[B_0 )<WMS+=2)C/W6E9BO7MBM;
M4=,L=7LGLM1M(+NV?[T4R!U/X&A.W*^S_#L$O>NNZM_P3G_B3>PV/PW\033.
M%5K*2-<G&68;0/S(KS_X=Z#>:)\!M<DO4>-[ZWN;E(G&"J&+:#CWVY^A%>DI
MX'\/J\9ELYKI(CNBAO+R:XBC(Z%8Y'9%QVP!BK^M:%8>(-/-AJ*3O:M]Z.&Y
MDA#C&,-Y;+N'/0\5+7NR2ZZ%1E9Q;Z.Y\Z^&[+Q3_P *+N+_ ,/:K<B&.ZE^
MV:>J)B2' W%6"^8#ZX;IG&._M'PMU?0-7\#VCZ!:0V448V3VD9R8I>^2>3GK
MD\D5J>'?!.@^% ZZ+:SVL4@.Z$WDTD9SC)V.Y7/ YQFJ5G\,_"FFW%W/I]A<
M6<EV")_LNH7$0<'MA9 ,<G '3M5M[^=OP_0S4=%Y7_']3*\1)/XFM->L_P#A
M'-2O[6ZA-G;7-O);",;>K 22JV?,SVP=BXS6!\ ]>F;1=0\*:AF.^TB=ML;'
MD(2<C\&S^8KTS1_#FFZ!IK:?IRW,5J1@1O>32;!C&$+L2G_ <5CV?PT\*Z?K
M7]LVME=QZENWM<_VE<EW/4[B9/F![@Y![THZ-]FOZ_4J6J\TS+^-O_))]8^L
M/_HU:T_A=_R3'P]_UZ+_ #-:?B+PGHWBNW6WUF">XMU_Y8K=S11MSG+*C ,?
M0D'%2Z!X:TOPQ9FSTF*>&VXVQ274LRIU^Z'8[>O;%*.BEYV_ ):\OE?\3R#6
MO^3I](_ZX+_Z*>CXLZ?-I/Q:\*>*IU(TOS8(99NT;+(2<^G#9_ UZ-/\,?"E
MSJXU>:SO7U('*W1U2Z\U?HWF9'X5TMWIME?Z>UA>VT=U:NH1HK@>8&'ONSGZ
MFB+Y5'O%_FPEJY=FK&5XUOX+#P+K=W*ZB-;&7!SU)4@ ?4D5YA\)]"O-)^#>
MNW=XCQC4(Y9H8V!!V"/ ;'OS^&*]+7P)X= 1)+*:X@C.4MKF\FF@3G(VQ.Y0
M8[87CM6CK.A:?K^FG3]0CF:T/WHX;B2$,,8P?+921['BFM&VNMOSN.^U^FIQ
MGQ1^'2^,M(BO]./D:]8KNMIE.TN!SL)^O(/8_4T?![7-2\0>'=0N]739J$=[
M]GGR,$M'$BDD=CQS[UW>G:?!I=C'9VQG,,?"^=.\S >FYR6/Y\4ZVL;6SEN9
M;>!(GN9/-F*C&]\!=Q]\ ?E0M+KHR=TNZ'W-Q%:6TMQ.X2&)"[L>@ &2:\7^
M)>E:GXB^']R[^%=5COH9SJ!N7DMB@'0C"S%R!'@#Y<_*.*]:USP_IWB.R%GJ
MD<TEN&#;(KF6$$CIG8RY^AI9-#LY=&_LEWO3:XP3]NF\TC.<&7?O/_?73CI4
M--IEIV:.(\+ZK-\1/@K-#'*/[1EL9+&4EO\ EJ%*@GTSP?QK&_9[?[)X<UG1
M;E6AU&TORTT$@PR JH''U4UWOAWP#X;\)W#SZ'8S6;2##JMY,R-]49RI/OCB
MKFI>%-%U6^%_<692^ V_:[:9[>8KZ&2-E8CVSBM'+WFUU,TO=4>QY[J'CSQC
M:?%>V\%))H3+< .MV;&;*J5+<KYW)^7'7\JQOC!')+\5? T2SO#(TB*)H@NY
M#YJ_, P(S]01]:]:L/"6A:;?C4(+!9+\# O+F1[B<#T\R0LWMUK-U7X;>%M;
MU0:GJ5E=7%ZK;DE;4;G,9SGY,280 ] N *F.CCY.[_$IZ\WFCS-KZ?PY\:(+
M?X@2#5()5QI&I7"A5M_FX.U0$!S@,<9! / K<_:(_P"2=VW_ &$(_P#T%Z[W
M6O!7A_Q'I5MINL6+7MM;'=%YUQ*9%.,9,F[>??).:IZA\-_#&JZ?;V&H6M[<
MVEN (H9=3NF1<9QP9.2,D9/...@I-7BH]OZ^\J+M+F_KM]QF>!O#4&EPZ3KL
M4UR8Y]$CCG^T73RJA&QAMWL=H^]P.!CM6-\<+N*_^$)O("3#-/ \9/=2<@_B
M*ZR3X<^&Y=.&G21:F]B$$8MFUB[,04<!=OFXQ[8JSK/@;P_X@L;>QU.TGGL[
M=%CCMQ>SI& O3*JX!(]3D^].I[][=_UN137);^NECF/ASX8AM-/\->(89KD[
M]%\F=9KEY$7=Y; J'8[!PW"X'3BNKU&]AU'3--N[9MT$M] 4;LP\S@CV/4>Q
MJE_PKGPW_9HTWRM3^P!/+%K_ &Q=^5M_N[/-QCVQ5V[\&Z)>V-A92Q7:VU@J
MK;1P7\\03;C:?D<9(QP3DCUJY2YI7\_UN)+2QY28KWP!\=+JUTZ!FL_$T+-"
MBCY5E.3D]/NMDGT5J3XGVT=G\4_AY;1?<B>)%SZ"517L[Z/82WEC=RVXDN;%
M66VFD8LZ!@ W).3D <G-8>J_#GPQK>K+JFHV=U/?(VZ.8ZC< Q'.?D D 09Y
MPN*F+Y7'^Z_PUM^94M>;S7X]?R.#_:/_ .1+TO\ [" _]%O79>%O#EKH,XUM
M+BY\BYTJ%9FNKIY1&4YX+L2!ACQG QVJ[K7P^\-^(XH(M8M;N]C@4+&DVHW)
M48&,X\S!;U8\GN:9<?#GPW=6 L+F/4YK,*%%O)K%VT8 Z#:9<8I+1-+O^E@>
MK7I^MR[?7*7EQX;N8PP2:Z,BAA@X-O*1FO,/B;X1O_">NK\1?"0\N:%M^H6R
MCY74_>? Z@_Q#\:]/U/PAH^KW%I/=I>;[0 6_DZA<0B/ (R C@;L$C=UQWK:
M:-'B,3J'0KM*MSD>ASUHEWCOJ-/H]NIC^#9C<>"M$F(VF2QA?'IE :\KF_Y.
MJA_Z]/\ V@:]HM+.WL;*&SM8Q%;PH(XT4G"J!@ ?A7+'X8>$SJW]K&SO?[2S
MG[7_ &I=>;TQ]_S,]..M4VO:<RVU_&Z)M>#B]W_G<["BD4!5 &< 8Y.:6I&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%AW*1AA@<''&!T)YII=_ZUL'IY?BKGIM%<#_ &OXHT+2=3UG5;G3KG3Q:M/
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M<(B*#NS@ 'C&2:YC5==U:VUR&:VU"6:W_M6*R>"&&,VR1L0IWNRA_-!)^XQ
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M'COV+W,;LS(['&2%)PI. 3C&2,]:ETS1;'2 WV1)2[ *TL\\D\A49PN^1F;
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M/%+&(KNUD\JXB#9"M@$$'N"""#_4&I-3N+BTTJZN+6**6>*)G1)7**Q S@D
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M%00Q^S]?F'3(Z\U+=>)O$5OJ6E6"^']/\_4%DP)=3=!&T?+ X@.1C&#WST%
M?U_D7M$\"^&/#BWBZ5H\%N+T$7 )9]ZGJOS$X7_9''M1HO@7PQX=2]32M'@M
MUO05N.6;>IZK\Q.%]A@>U36VLWEO;:A<:_:6=A#9QB1I;>\:="N"3DM&A!
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M,7EJ+%-,6>SACN0(9+GRU&X*#AW#$^IR3WKZ7HIOK;K?\4E^@)Z)=K?@[_\
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M.PS]6'<UZ313_P"!^O\ F']?E_D>>^'="L[34[CPS/I5H+>VNAJT:_9UV*)
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MP$@/\'F(HS[D=Z]#!! (QCMBEHI+:PWJ[A1110 4444 %%%% !1110 4444
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M5N8E\SS0N0%D 7CL,#VIWAS5;W2;A="UZYEGM+V69-,U"21M[8=AY$CYSY@
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M3C 5-2BN)(IK<=> J_O1G^!B%/>MCQ%HHU_P_<Z8TYB>55*3 9V.I#*V.^&
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ML?L\O!(!(^N#CT-&FB\W^H;W?E^A1\9:M;:_\.O$:^3>6=U81D36TK^7)$X
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MC)Q6YKOARXUO2[5+VUL+S4(5RMRLTEHT#G[S1.@9E'MGG&":J5DW;O\ Y_\
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M#-&TZX33K72HKA+@W$<[R3R+'*65=A0!"2.3O;Z5IZKKNK6VN0S6VH2S6_\
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M4U>TF:YL7C\U'@C:1F7V506)]L9SQBLJ3QUH4-I:73MJ0ANW\N!O[)NB7;L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEI <$F5MQ\P@KQPN,GK1J?A^]O\ Q9I.LQZA;Q0Z>DBBW:U+L_F8#?/Y@ X
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M1WU("\THQ-:WL5OM"M&,*2A8Y!&01GG)QBGI^7ZW_06O]?UM<PM(GN-/\?\
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MUHD-Q:7]C($N;*ZV"6/(RI^5F4J1T()%%MXDC==3EOM/N],MM.)$UQ>-#L.
M&)&R1CC!!Y Z^N16+J.AW%[>7VL:,\<6N6%XWDLQPLZ&-"T,G^RWZ'!K UR]
MF\2> ]3U&WM+J(1:M!->V;(?,5(O*\U".^-IZ=<4EK^'XVU_$/Z_/0[7_A*D
M6!KN;1]5@L @=;N2)-K ]/D#&1?JR*!WP*LZAK\%E>"P@MKF_P!0\OS?LEH%
MWA,XW,SLJ*.N-S#.#C.*MQ:A87FFI>17,,]G.H*2*P99 >@'KGTKE- 5M/\
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M;: H:8-@GC) %.O_ !F=+T6]U2]\.ZQ$ED?W\1-N75-N=XQ-M9>W!)SVJO\
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M<[=R@XSWZU3\2\^$M7)_Y\9NV/X#7'7<KW&A:;9V]W=^?!H:W/D07;VBQG:
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M93)%N9#NC9&5E."K*P#*0>Q --IHE-/8N4444AA1110 4444 %%%% !1110
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M8^2-^UMKL':=63'/!B;.!SSFK6C:YKNK:[JEH8-.@@TV_%O* SNTD1C#@J>
M&RR\$8ZCW*S^ =-D\2OK<-_JUH\SB2YM+6]:.WN7 QF1!UX SR >^:T-&\.1
MZ+J.IWJ:A>W+ZC-YTRS^7M# !1MVHI&% '4_GS4QVU_K;_@E/R,WQ:T^HZKI
M/AV&6.*.]$TTQE1F61(PN$(!&02P)&1D CH:RKF_U2\TM[0Z='+)H>K0I?06
M,9"7$  <-&F2> RMLR3\I SQGL-6T:'5E@9II[:YMG+V]S;D"2)B"#C<"I!!
MP0P(/I4::&(-/>VMM0O+>667S9[I/+,LS<9+%D*\@ < 8 &,8I+3^O-#>O\
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MXW5H61B 06<@@\<8_&M73?&WB/Q'J]_)H.FV,^F:?J8L)X96*SNH^_,'+!0
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M=6(\Q%/[MU8='&!GN"/0@F.V\!VEOHO]G/K.MW4@G2=+V[O/.FC=#E=NX%<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *U];27=L8$N&@#G#
ML@^8KW /8GU__74L$$5K;QV\$:QPQ*$1%& J@8 %244 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-5]&U.\CMM0L;:V-]+IVI"TVM,$(A;8P8D]=B/TZG;ZFBW;^M;?Y#.HHHHI
M%%%% %35+'^T],N+'[5/:B="C2P!-X!ZXWJPY''([TS1M+71='M=-2YGN8[:
M,1))/LWE1P =JJ.!@=.W-7J* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "D90RE3G!&.#@TM% &-8: UB?+;5]1NK,+M2TN/***/]X('
M;_@3'/?-;-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY0(V&<#*(H)SP2<5U=%):#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH4^\[?D![DGC'>N%\917NO'4;:ST74;S[/"$L[JVD@5(KD,'W?O)5)(98QD
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M:.V0\Y'WP1CCGCZ$53_X2;7]=@T6RTR2UM;Z\TJ+4)':Y$!<MU$>Z&8,!W&
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ML2QK;O<VJSLCG"H2N3SZ?TKE]#UO6IO$EE:RZA)<P7^G2W'F26R+ LJ%!F#
M21H_G_CSD8PW6FXM-KM_7Z M5<[ZBO-[+7O$+:!H^J3ZL'GEU=K">);9%BD0
MSO&&Q@L", C#?7/6K5YXGU+0AXC@DN5O#97-JD$]WMB""? ^=D3 5<]=I/KF
ME_7Y?YH+_P!??_DSOJ*\]O[SQIHGA+7;^[O].+P6OVFSD,@N7^7)<';%"N",
M8.TX[YJY<:_J.BZXXN;J2^MI-&EU P^6B^6\13A-H!PVX\,6YZ$4=+_UM?\
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MX."#CW%:NB'4_P"R8!K+6K:@N5F-JY:,D$XP2%.<8SP.<UQ>DVWB&?5/&/\
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M)<*^I2R1YV?:-4N9PI(()"O(0#@GG&16AISWDFEPM>- ;LI\[0H1&3V(4DD
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M]*0>9=L=/M--L(;&R@2WM84V1Q1C 4>U8<7@/0[=YGA?5XFG?S)3'K5XID;
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MX)^T13*\?'7Y@<<5SGA_Q%/JWC;6;2/4;2]TJ*UMY[1K505&\N&RX)W'Y.O
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M;AUP<COFG)I>N'6+"]FU73VBMX6BFB33W4R;B"Q5C,=OW5P,-CGKGA1T^_\
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MZW_X!*OI?^OZU.+TCQAJ$'@ZSU+6+.-[R\E9+:*S:6<RGYFY5(BR@;3]U7P
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M68@N8[EC-:-/N:-@R@8D3 R.>N?:GV]?U_R#OZ?I_F5AJ]W#<WL&E:%937T
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M[:6*-EV211L)#@,K3QQL0#@'"9&1U'-7]5\7W>EG[,^C2/J#EVBAC\Z=#$I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_6HWN.HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4-VMRUI*+.6**X*_NWFB,B*?=0RDC\14U07ERE
MG:2W$BRLD:Y(AB:5S]%4%B?8"D]AHPO!.IZOK7A^+4]6FL6:?/EQVEL\03:S
M*<EI&W9P#VQ[U5O]5\0Q^/K71+:[TM+*YM9+I3)8R/(@1D7:2)@#DMG.!C&,
M'K67X1\1Q:-X,M+2YTK7OML0DS -&NLDEV(&[R]O<<YQ4E]J#1?$W3+N>QU-
MHK?3)H)YH-,N)(EE=HV #*A!& >02.,'FJ^TOZZ?YD]'_77_ "'6'BC7M/\
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M0R64RRAE0!@(RNYN?[H.>V:<K+FM_6Y/;YF;HNJ^+M5\-VVL'4M"0S$A;?\
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MG@$*, \BL26[-[\1="UC2K"%KF^T":55F<1;@6B*AW"L>,XZ'K5V]ZWK^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=S+:P+$&/J0H&::TMY._Z_F#Z^:M^:_4Y/P=<?V?XN\4Z3J4@34;F_-[;[\
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M"6MT)B0C!5>.!CC XQ3[S1M+U&T2TOM-L[JVC(*0SP*Z*1TPI&!2_P"!^O\
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M<ZKX+TF[N9F^TW-C$\DJ@9W,@)8<8SGGI3AX3\-AY7'A_2@\L?E2-]CCRZ8
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M5O;QC"10H$51[ <"H!H^F+J9U,:=:#4"NPW0@7S2OIOQG'XU;=Y\W];W_P"
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MU]:D&D62ZC!>K:VR2V\/DQ,D(#HG]T-UV_[/2A?Y?E8'_7WW+]%%%( HHHH
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M67G=TSZ8.3IGBO5K[2M4O)M&L8I+2>2UAA34'<W$R-@KGR00#V."3Z"C^OT
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MLR<#(W#)Z]Z=A7.CHKDO$_BC6_#UK>7\>A6=QI]O)'&LDNH-%)(6*KD((6&
MS8^]V--U?Q-XCT31-0U&[\/:>191K,1'JCE9$^;=AC #N&!P1CGK26H[=#KZ
M*P;34O$37MK'?:-IL5O,3NDMM3>5T&"<[&@3(S@'GC--_P"$@O-0O;NVT+3H
M;Q;.;R;BXN;DP1;\?,J%4<LR\9X YQG((HL'F=!17*:UXKU'2]%GU"+1$9K>
MZ6VFANKORC\Q4*RE4<,"7'IQ[\5-X@U_6-$M-,ECTFQN);N>.VE1M0=!'(Y
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M8KP&B'60$8(V@]<=:[JBI \DD\-:O9>'XM<BM)Y)D\1-K<FGH/WA@)*[0O\
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M+&I^UL_.6*.1@8X$F" #M'6NM?Q6GEJ(='U2>Z$8EFM$2,2VZ$D!G#.!R5.
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M\-K,(Q&C)^^57B<.ZD,?F7T]2!S6[:6UIX;\.7-QI>B26PV-<G3HV12K[>5
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M>KE2?(SGY .G<GC&"ETO_6J_X(WO_79_\ ZN'Q-9M>:C:W44]C)80BXE-R%
M:$YQ("K'CY6X.",=*R].^(_A_4[JZMK>9I)8('N L$D=P98UQDJ(7<@\CY6
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M0ZA LXU6XMI[MY"5D@B,2M& ,84LQ !)_B/))[US?B"/49?B5H:Z9=6MM/\
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M,US;(99(C,$&=AV*V#R0/IBFEK;^OZU#97_KK_D>D45P=U?ZU%/XKLUUJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\S[EP ,J<9Q\P)I=+^2?WC2N[>=CU:BN"T!=)NKW35LY_%"7>P3.U]-J*Q.
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M<:=<0P$G@?O7C"<GCK5S5/%>DZ-J%M8WK7@N+DX@$5A/,LAP3@,B$$X!.,Y
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M2< #U)/ '>J6G^(M,U*Y^S0R3Q7!!98;NUEMI'48R5655+ 9'(!%)?U^#_1
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MNQG(*.5(/L0014L$<-JNJQ:QX;TZ2VNIY)(]9M(G%W;^5+$XD7Y9$PN#SGH
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M]E1561DV.5$A?Y "067.X<<5NCP/X;'E*VF(\<,XN(89)'>*)^>40DJ@YZ
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MB!@%90V\''&0W3CI6C96-MIUL(+6/8F2QRQ9F)ZEF))8GN2235MIMO\ K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JAK.EC6=,DL6O;VS$A4^?93F*5<$'AATSC!]C5^B@"O8V
M4&G64-I;JPBB7:NYBQ/N2>23U)/)JQ110 4444 %%%% !3/*3SC+@E\;<DDX
M'MZ4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB[QH?)N;<Q/M<,74M*#M.WH0#R..IK<M]3U&ZU"%CX5U&U(5E:XN9K; 7KM
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M[,^=;@2?NA%G_6\#/S<XX]^*7]?E_F_N*CJ]?+\W_P  [;4-:L=,17N'F8,
MV+>WDG(7^\1&K$+_ +1X]ZK2>*]#2XCMUU&*:XEMOM4<-N#+))%V950$G/;
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M/Z_KL=-JNM:;HEO'/J=Y%;1R2"*,N>7<]% ZD^PJ34M3L=&T^6_U&ZBM;2(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV-YY96=L9PK1NP!P#PV"?2JL/C SZGJVGIX>UC[3IL:R2*?(_>AON^7^]YR
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M/TRYNX[:2Y:&,N(8V4,^.P+$#\S7'C5[#4_#EUXIL]1U"S@DMTMH',LC@,2
M2(F?9OW'9N(!R#S46C37-OJ'BK2YI9U@BM8I8+>YOFNI$WI)NR[DD9VCY<D#
ML>:F=TGW28X[KS9V&AZF-:T'3]4$7DB\MTG$9;=MW*#C/&>M7Z\T\.-)#)X
M"W5S'#=:*Z2Q"X<1.5B0K\F=NX9;G&??BHM%U6.\TA-*76;VYG_MJ[M_L\5Z
MS3R1J9"J-,7#Q@*%;=NR0N!G-:324FEW?YV)B_=3?E^5SM?$'B Z#)IBFQEN
M%OKR.T\Q755B+G )SR>_0'ISBI_$>L-X?\/WNK"REO!:QF5H8G525'4Y8@8
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M&(QR5 P6&!@G.,"GMXDTI=.BOEN6EAF)$:P0O+(Y7A@(U!<D8.1C(P<XI?\
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M,*"<@D<Y('39DU;2+G7=)A36"+J:)YK>UAE^6XC*_?90.0 ,@G'-.VW]=_\
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M ?2N"TS1-=;4="O+O3IH)8([B"Z N(EAAWJ,-%&C8V9''&_IN[FO0J*'KO\
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M44)VM_76_P"@/5W_ *Z_YF;8:A>W&I7EI=Z:;9(%C:*<3K(LX8<X P5PP(Y
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M(,XSD#C.:],HIWUOZ_CJ3;2W]=CC].T74-,\4K)IJ7UKI<K/+>6]Q/');LS
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MCF07%K&\:!6PK!L'YAWP1D>E,TS0K72+">SLWF2.:624L6^92Y)PIQP!G ]
M!4=/Z_KS]2^O]?U_P&96BZ_<Z]H=Y)IE_IMUJ4:$*CP20"&4YPLT98NO;OD\
MX KIH]_EKYFWS,#=MZ9[XK%_X1F)CJ,KZC?M>7T/D-=JZ1RQ1\E0A10!@L<$
M@GU)K:C3RXU3<S;0!N8Y)]S3 =1112 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*"Y@ND+V\
M\<R!BI:-PP!'4<=Z?+%'-$\4J+)&ZE61QD,#U!'<5RGP[BCAT*_BB14C35KU
M511@*/.;@"A=?ZZATN=;1110 4444 %4=2UK2M%C235=3L[%)#M1KJ=8@Q]
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METN-Z.P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(&([;@<=L5#K?A#7]:UN/5Q90Z=>!5CF?3?$L\'VA%.0LF+7D<GI@^]=_?\
MVW[&_P#9_P!G^U<;/M&=G49SCGIG\:LT >?RZ#XN?Q);ZU'%:0R6\/V>.W36
M 8A&2I9?FL2W)4$G=GT(K.D\$^*I;&>T:2/9/?+J#G^V$SYP8,"/^)?TW!3C
MV],Y]1HH_K]?S#^OT//&\.^+SJ>J:@!;+-J-NMO*!K"[45<[2O\ H'4;FZY^
M\?;"V?AKQ-96FC0)9V3G2%:."5M;8.T97:4;;9 $8 Y #<#GK7H5%._]??\
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M,]:=XAL]'7XD^'[[4K2S)^R7"I//"I/F*T;( Q'W@-Y'<?,1WKN**5[6\O\
M@_YC[^?_  /\CQ8:MX?3PY9ZO'J6GB[C\3OY=S]H3<D;71+@'/"F,Y('!!R?
M6K-U<:5=^.9K37]6UBTUL7I;3DM;&-Q+#D%/)F\AG52,!AO SNSQFO8**$[-
M?UT7^7XA+6_G_F_\S-U^]M;#P_?7%[<PVT A8&2:0(H)& ,GCDD"O/?!5[X.
MM=!\.3KXF5]2BMX@;(ZS).6D:/9L$#2$ Y;@!1CVKU2BA:?U_7<'JCR+7;7P
MI9ZQJ.KK%ILOA\WD<.MPYCQ]I!)5@,9.TL-R@\Y. <,#MR:EHS_%'3S9ZM!_
MI.B2A!'=!AC=&4*)D@$J&(VCD#/.*]"HI+:W];6_X;RT!ZN_];GF^B1*(-5\
M-W%KI&I(MG(SWE@N1(QQ\MQ'R!*V0>22V">*R;:?P_IVE_#E[:YM+)C<H)(T
MF$*.Q@(D+)D*S;]H+$$AN,Y.*]>HIIZW]/PO_F*WZ_B>*ZK=Z%_8WQ!E_M&U
MFN+2_$MF\MV)7AD\M,&,LQ*G?O QZ$#IBMCQ7J^B-JK2WE[IM]]ITV(V'F7T
M$7V1R7Q.C2.O!R/GCRPVCCI7J5<MK7@\:SK O9UT:[B.T>5JFDK=-&HZK&V]
M=H/)Y#<GVQ2Z6_K:Q5];_P!;W-/0DAT_PQ9F34!<QQVX>2\>Y:57XRS^8[$E
M>IY/ KCKR"7QUHVM:AIOB#1ETJZ4P;Y+1IGA6+.&\P3*%.[+C*\9!YKO=-TZ
MUTFPCLK*"."WCSMCC0(HR23@#@<D\"K5.6K;)CHDCS<>+[#Q-\,8M0.KV<<D
M+VZ:@IF"*6$BAXV)/RJ^" 3P0?3-<_J$VB3^#/%VHV.H06%D+4)9Z?::NNVW
M?'_/."4Q*78# ')YSU(KU37])?6M,-FLT* L&9+BW$\4H'\,B$C<N<' (/'6
MJ?A[PI8Z$YN4L=(AO60QO+ING+:*RDYP5W,3T'5CT[4/5M_UT_KR&M+6Z?U_
M7<Y#Q,FG:=X8TV_C>>+1+R17U:YL8TN,CR=@9T=)%9,@!OEZX/6L^\ETNR\$
MZ?/9:KK-QX3ENW:[N?L,1,<90@8A:#;Y ;J/+QDY%>OT4-WN)*R2/'9YO#-G
MHOAB:SU^ZELI-922!KZ3[(IB_CV1!8U\L$+@[< G@\TW5)_#D6G_ !#MHKC3
M52S(FM(5E0+!-Y0!:-<X5_,XR,'=[U[)12_K\O\ (J.COZ?F_P#,\@\5:OI-
MU>:;)XAU>ZBT*ZL8C97=I:Q7D+W +;P=T,N)/NX*X/7TJ]'_ ,(\GC>SL+_4
M_M5O_8#+)'JUSEG 92#)&V "4!8@J.F2../4:*;_ ,_QO_F3;3[OT_R/';(Z
M)K'A/P/=7XL;^WMM1>VEEF"3+&I24*C$YQD^7@'J=OM7K%IJ%I=SW-O;R;I+
M1UCF785V,5# <CT(Z5:HIM_U]W^0_P"OQ?\ F%%%%2 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOX?\0:KKFL:?=Z=/J=W(CSQVT3@PH%"@;Y(T=P2N2=H&3T[D6O\ 7DO\_P
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M)^O0$U+/%J%[8>*4LM-U1R-:CO1;F*>S:Z@ C#".0A?FRC$;3G('8\TU:_\
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MF"YW^1-'+Y;%'V,&VMZ''0\CBI:X'PQ?6GA[3M7A@M4'F^()K6UMH@$4NQ&
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MN/*OT6\) 3:K;HCY>7.U@<,$[C-.S_KY?YH/Z_/_ "9I_P#"&Z7_ ,_6N?\
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M9;A.B[L2&2)$7/0$.P)[BJDK-KU_7_(F+O%-^7XE_P#X0W2_^?K7/_![>_\
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MH @N[2"_M7MKF/?$_49(((Y!!'((."".014D,9BA2,R/(5 &]\;F]SCO3Z*
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ML79X]66WCY+##*8@ NPC'R^P.2:["BD!R-QX5UNY70VF\1QW$^FW/VJ6:YL
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MI<FR)BFAX^5X_,SGY5.0XY]CBM./PO;#0]3T^20O)J;227,X7:3(XQN [8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH K7VGV6J6C6FH6=O=VSD%H;B)9$.#D94@C
MK4<6D:9 +00Z=:1BS!%L$@4>0#P0F!\N?:KM% %2#2]/M;N6[M[&VAN95"R3
M1PJKN!T!8#) IU_IUCJEJUKJ%G;W=NQ!:*XB61"1TX((JS10!FR^'=$GFM9I
MM&T^26T %N[VJ%H0#D!"1\N#Z4V#PUH-K:W-M;Z)IL-O=?\ 'Q%':1JDW^^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-3_002.jpg
<TEXT>
begin 644 ex10-3_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2Z Z8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXO&=K:Z%?ZBVEQ::\>I-:,ES,L:&7C+RR(&"@GO\W;KFNNM)GGMUDD1%+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGM@'7&5_?IR,@C\Q6'XAM;O0_%GA:[N-7N=<:2]^SQV=ZD2O%O4@SQ^4B<J
M<[@>">E=UJ6BZ5K4:1ZKIEG?)&=R+=0+*%/J P.*BT[PYH6CS-+I>BZ=8RL,
M,]K:I$2/0E0*(Z._G^@WJK>1R4]M<7GCCQG:VC[+F;1+>.)LXPQ\X _G6KX'
MOK.V^'FF>=)';"PM%ANUD(3R'08</Z$$'K6O;^&M!L]1.HVVB:;!?%F8W,5J
MBRDMU.X#.3DYJ2XT+1[O4(]0N=*L9KV/[EQ);HTB_1B,BCI;^M+_ .8/5W_K
M9+]#GOAU97-GX2F>X5T2ZO+FZMXG&#'"\A*#';(Y_&G_  P_Y)SH_P#US?\
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MVMFF;?*88E0R-ZM@<GW-6J;=Q)6"BBBD,**** "BBB@ HHHH **** "BBB@
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M2?XGQ#5K*SM7_L:0(MK=O.&'FIG):-,'\#4NL0QV_P 1/!T,**D4<%XJ*HP
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M_M-4BDM]$N]8O(Y;]>4#F3 CD/6-3_>Z'ID5Z-<3VNCZ/).D2I;6T198X4[
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M]U75(+O2+>VTZSN#>$^>3>LOD@#)9?W9WCMD[>2OKQEV?B3Q+?ZEJMG;Z#I
M.G3"&1Y=7D4-E X(Q;'LPZ]\_6G_ %]P=/ZZFC:>&!:>)[G7!J^H227$:Q/;
M.L'E;%+%5&(PV%+''S9]2:JMX*C6ROK"UUW5K2PN]P^R1&%DA#?>$>^)F4')
MXS@9XQQ4-_XRN]$;3)]9TF*VTZ\;RI;F*Z,IMI,'[R^6/W?'W\]\D"M?4]2U
M*VO].AL;"SN;>[DV/++>-$4^4MD*(V##:I[CG'UI6NK?(+]?F4+;PA-!!:VK
M^)]:FL[?8!;.MJJNJ8PK%80Q' !YYK1T?16TB2]=M4OKXW<WG-]J\OY&QCY=
MB+Q@ 8.>@JCHVOZKJ6O:MIUQI=E!'IS*AECOFD+LRAE^4Q+@8/)SP>QZU!I/
MBRYGM]:N]:LK+3K3297BFEBO6FRRJ&8X,2<8(QW)[47Z_,+6T^1)IO@XZ4FJ
M+;>(-7QJ,C3/O,!$4C'+-&/*P"?0@COC/-:$7A^U/ALZ%?RS:E:&+R7-V$W.
MG0 [%4<#&#C/'KS6?)XCU6*P_M9]!_XE(B\XXN<W83&<^3LV].<"3/MGBHM4
M\5W\-YHJ:/I]AJ%KJ^1;W$M^\/.QI.0(G^7:O7.<GH.M%OL_(+_:^9-J'@V.
M].D>5K6IV:Z4J_9EMQ 0&"%-QWQ,2=K$>GMFK%EX6MK?5(]4O;R\U34(E*0W
M%ZR?NE/78B*J*3W(7)]::FJ>(1!??:-&TU)[>-7B$>I.\<G7<K,804( !^Z<
MY'2LZS\6:U?^%-/U:VT&SEO;_8\%BNHMDQ, =Q<Q<$9Y&,8_BR0*=WO_ %J%
MM+?UH:D_AE)!)'#JNI6MO-(\EQ!%(A64N<L,NK,@Y/W"OY\UJQ6L=O9):6P^
MSQ1QB.,1@?NP!@8SD<>].M6N'M8FNXHXK@J#)'%(9%4^@8JI(]\"N8USQ+K>
MC6-YJ+:/IG]GV[$(T^IR)++@[0 BP-RQX W'.12>F@+5W);'P7'9:5JFG-K.
MI7,&I&1Y?M"6Y*.Y)=E B R<]""/05!:^!&M-)LM+B\4Z[]DLGC:%&-L2 AR
MJD^3E@"!P<]!3=4\5Z]IFEZ+=2>'K-9M1FBMWMY=293!+(?E!(A.0.YXP>QI
M[>(O$3^);K1;?0M*>2"WCN?,DU6104=F4<"W/.5/Z<T]4_ZZ?Y"W7]==#1\2
M>&H_$D5FDFIW]B;2<7$;V31JV\="2R-ZG@8SDYS4L.B31:V-3;6M1EQ$(C;.
ML B8 =3B,-G//WNI].*RM7\3ZUI'APZG)HED\T=P(981J+;,,X561_)^;EAG
M*KCGK5RZU?7DO;*SM-&L;F61-UXW]HLJ6I^ODG<#VX!/ICFDO+^M/\AO;7^M
M?\RY_8%E'JU[JML&M;^\@6":>(+DA<[6P006&>I![9SBLFU\#6]OX=U+0WUC
M4KFTOR[/YZVY:,NQ9RN(@.2QZ@X[8IVH^(=<M_%<>AV6C:=/YML]S%--J3Q9
M52JL&40-@Y?C!/ [=*CU#Q+K^EZ/<:A<>'K646LN)H[74&D+1\?-'F$;V!)&
MP[>1UYHZ>7_!_P QW=_Z[?Y#)/ 8E\/V^BR>)M;>TMWC:,M]F+@1D% 6,/(!
M4'GD]R1Q6I;:!=Q7*S7/B35KS8&V1S+;*JL1C=B.%<D=LY'M3;OQ \OAJ/6M
M!AM=1BD <"6Y,(*GKR$<[@>,$#OZ55D\0ZU#XKT_1)-(L,75NUPTRZBYV*A0
M. OD\D%^.1D#G;TIZMV_K;_(G2VA)IG@ZUL-.U&PN=0O=2M-0=Y)HKP18W.2
M7(,<:$9)_# QBM/1M+DTBQ%K)JE]J 4_))>E&=1C[N55<_5LGWK*.OZPWC"X
MT*/2;$QQVPNEN&OW!9"6504\DX.Y>?F.!SSTJ3PMK^H^(+2\N+O3+6S$%Q);
M((KQIM[QL58G,:X&1QUSZ"DMK_UV&U_7KJ=#17%ZAXNU[3?#.IZU/H6FE=/=
MP\2:HY+*F0Q!, YR!@=\]1CF^?$>H-=6>F1:;9MJ\]L;N2%KUEACBW!<B3RM
MS$YZ;.QR1QD_K]?R!Z'2T55T^[DO(&>6UDM9$D9#'(03P>N02,'J/8CITJU0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <)\2M6TVP'AZ*\U"TMY!K%M,4FF5#Y
M:L=SX)^Z.YZ"K%\WAWQ5KVHZ%+J-I-.]G R)#<*98W5I&#K@Y#+E6SVR/6NS
MHH6UOZZ?Y!UNOZU.'T._U>VNM:M]?M#-<Z=8H//C7Y+Z/,A5E'9B."OK[&LN
MS@LM"\164?@_6',<]PHO?#SOO$$;<M($/S0%<YP< ],=*],HIWUO_7]?TA-:
M6_K^OZ9P?Q&U;3;"\\+I>:A:6SKK$,Q6:94(C"N"_)^Z"1STYJ7XJZE8VWP\
MOEGO;>(W(00!Y57S3O4_+D_-QSQVKMZ*2T7SO^7^0^M_*WY_YG"_$C6-,;X6
M:C.NHVAAN[?;;2"==LQR#A#GYC@'IZ5M:Q&GB3P%?PZ7<0W(O;"2."6)PZ.2
MA P1P>:Z"BAZIKN$7RM/L<<GB?2;[PR=-M[V%]6>S\DZ<&_TA)"FW#1_>7!(
MR2,#KTI=;5='\3>'M8O)!'I]K;7%K<3M]R(N$*LQ_A7Y",G@9%=A13;UO_77
M_,25ER_UT_R,"VU&RUW7;.ZTNZAO+2W@EWW$#AX]S%0%##@GY6S@\8YZU@^)
M=8TNV^*/A2&XU*SBECCN@Z23JK*750@()XW'@>O:N]HI=5Y?\$;V9E:A;^()
M;K=INIZ9;6^T?)<Z=),^>YW+.@Q[8_&IM,AU>)9/[5OK&Z)QY9M;-X-OKG=*
M^?TJ_10!Q<E\WBO7[R+0=:T@IIJ-;3Q3VYNLN^-QPLJ8  VYYR=PXP:SO!/B
M?2K+P[J&@7VN:>USH)DMWD\T(K0J<(XRQX (4\G!&":]%HI6T:[H=];GG@A=
M-)L/&'A1XKZ06B1WUK X9;V)5P0"./-3G'XJ?;I+>^M;+P';7=Y<16T"V$>Z
M2=PBKE !DG@<D"M^BG/WDUW_ .#_ )BCHT^QYUX5@A\3_ ^'2M/O8'FETLVC
M-'(&\J0IC:V.AY&1UYK4T3Q9I6G^'+"QU"X6UU6WM5BDTUSFY+HN"$C^\XRI
MP5!!'(KL:*J3YFWW$E9+R/.-&2S\'>$]#L=?OK.RN;J^>X:"XF50N]F8J,GD
M+O /;)JP-/O_  MKECI=K"]QX<O+Q7MRO)L).6*'_IFW.WT/'0BN_HI7UO\
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MS^?Z6^6X65]?ZU=_P+T?BJTGU>UT^WMKF?[79-?6UQ'Y?E3(NW(!W9!^=>H
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M?::+(R$.8#'EG4>=@R!OEP1D#<#G [UTM_H-OJ$=K#)=7\5O;*5"6U[-"S\
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M;F&. :?]?A_7];']?U_7_!=#XO;4?$>F66GZ?<W.F7]@;M;R-XU&TLH!P7#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<1*58%^,\@@ $GI5S3]<U6;PO-]IOW@NTU-[$32PH;AD#X^5$#(9=O3"[>Y
M&:7_  /T_P QM6?W_K_D=S17FK>)/$4/A^X=;PK/::[%8&2\MHS+)"[1CYA&
M0@;]YU Z#H#TZ;1;Z^'BW6]'NKQ[N&WB@N(7D1%9/,WY3Y% *C8,9R>>2:=O
MZ^2?ZDW_ *^=C5U/6],T983J-Y%;^>XCB#GEV)   ')Y(_,5)J&I6VF0>=<&
M4@]$AA>:1OHB L?P%<_\1/\ D55_Z_[/_P!*(ZZ6XFBMHS/+CY1@$#).>P]2
M3CBETO\ UL5V_KJ5K;6],N]).J0WD1L@"6E)VA<'!# \@@\$'D'BI--U*SUC
M3XK_ $^=9[67)CE4'# $C(S[@U3T+3QI]M=[]BW-U</=SQJ<[&<\#\@!GN03
M6;\.O^1$TW_MI_Z,:CO\B>WS.IK/LM<TS4=0N[&SO(I[FSV_:$C.?+R2 ">F
M?E/'M6A7*:5_R4SQ'_UXV7\YJ:U?WC>QLSZ]IMOJ*V$MP1.6"DB)RB,<;59P
M-JL<C )!.>,U-J.J66E0K+>SK$K':BX+,[8SA5&2QP#P 37!S_:5^&GBXRY_
MM W=YZ$[]_[K'OM\O'X5;%OJ.J^(]<N%U*6QO],AABMCY4;J%:,.Q(93\K-P
M=N#\@Y&*72_];7';6W];V.RDU*T@TT:A<3?9[78'+W"F(J#TR& (/L1FG6-]
M#J-J+BW$PC)('FPO$3@]<. <>AQ@]JX:"\N_%VJ>'!<RS::9-);446)4;$Y*
MKN7>K E0Q(R#]_UZ=+X4U&^U#2YQJ)22XM;N:U,Z+M$P1B ^.Q/<>H-4U9M/
M^M;$W_K\2UJ'B#3=,G%O/+-)<8#&"UMY+B4*>C%(U9@.#R1BJM_XQT+3=+EU
M*YO'-G#)Y<TD-O++Y38R0X124P",YQC-8WP]:1[CQ0;UMVIC691.#]X1@+Y0
M_P!W9C'XUUQM[0"Z)CBQ-S<9QAOE ^;_ (" /I4O:_E<KK8R)?&>B0:!;:Y)
M-=C3KEE6*46$Y+%CA?E";@"<8)&#D8ZBMR&59X(YD#A74, Z%&P?52 0?8C-
M><>'(8M#\2V^E78D_L.9GF\/^=]V-CG=&??!)CS_  D]Z]*Z4W:U_P"O^')Z
MV*<NJ64.JV^F27"K>W$;RQ0G.65<;C^&X5<KR[Q'>Z@6_P"$F@T#4W-A>+=1
M7BR6_E-9H"KC'F^80R-(WW,Y(["NH\1:KJ,&I>&O[-O88[+4+OR9@8=[.IC9
MP58G ^[Z=^O'(E=(;W_KIN=317F]YK>NV>A^*9QK$LDN@77[EV@BS<)Y:2;)
M<)C'SD90*>!S6SK>O7FE:W%->F^M=&,"[;JW@2:%9"3GS_E+H!Q@C"]<GT+;
M?UTN#T.NW*6*Y&X#)&>12UP'VJ[T?6?&NLG4;R[CLH4DCM'$9C/[K<!PFX <
M]#T))R>:=:W7C);&\U*34=)>RELY)K=Q<?:=L@&Y=@6&'*8#<,S'ISP<S?2_
ME_G_ )#MK;^NG^9WM96G^(+/4]8U+2X$N%N-.*"<RQ%%);)&W/)''7&.>":Y
M:QUO66T3PW//J9>;7UMXPWV= +9O*:21AZE@N "" >>1Q56PFN=*\1^-W_M.
M-[F&"S NKQ0/FV-C<(U )Y'"KR<<5;C:33\_O5O\R;Z77E^O^1Z117F\^O\
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M,@5HZEHFHWGB?3=5@U*VAM[))%^SO:,[.7P&.\2#' &/E]>O;!'P_P!0.CF
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M=Q959R8PP+'=ZGUR>E;DOB6:#6K31Y;>R34)+?SY(FO2N[J-L),8\T@CG.W
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MNKP>/M$MX='TI/M-O<7%PJWK*KR8C5V.(?F*@X!/W@3G;5W1M?T^SL]3CM-
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M$^P!-4=$U_3_ !%:-=::]P\"L4WRVLL()'!QYBKG!!!QT(Q6GVKS[0KBYL?
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M (?_ $GCIVU^5_R%T?J=767KGB'3O#EM'<:F]Q'#(X0/%:2S ,2  ?+5L9)
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M[V/G&S9GI_!CV[U0C\5ZU?>'O#L$$MM'J6JK,C7,LPMP6C./D)BD7>W7!0C
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ML;*LMR+HM'/(CK+_ 'U96#(?]TCJ?4U#=>!_#]XLJS6<V)KA;J01W<R;Y5
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M]0M5OW7>EJTRB5E]0F<D?A2&4+3PCH5E>6EY'8^9=6BLEO/<2O,\2GJ%9V)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK7CQH]'OA]KL42-X]*F(GDV,K;6"8<DLG3.>O0$CTRBI:NK>5OPL"=G?SO\
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MGU*R:"XTVZ2U>&V9KCS&<*4V84,V=XXVY!SUK-E^(=U:Z%JFHW/AJ_5K!5?
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MQ@G-0:GXG\1O:Z//8Z19Q17US;A6GOB-ZNF_;\L9V\C!.#QTZ\2W/@B]FAU
M0ZM9V[WVFII\BQZ=B) "^65!)D<.>-W!P<D<5HR^&KJ30=(L?[1B6ZTR6*2.
M<6QV/Y8Q@IOSRIQ][KS[4_\ @?K?] ?^?Y+];D47B6UM]:\0+>:7]C?3+6*:
M>Z!5FG0AR,;>2!M;&<'GH.]>R\<RS2WINM"U&"WM[:2Y2<6MP RKSM;S88\.
M1T"EAP>:F/A&>YUK6KG4+^"YL-5LUM)+9;4HZJH8 ^9O()^=L_*.V,8Y7P[X
M;UW1EECO_%UUJD"ILM(Y;6-#".Q9A\TAQW) ]J/\O\_^ '^?^7_!-70=6;6M
M.2\ LS%(-R26EUY\;#)XW;5.<8SQW[U6U'PMIVHW]]=S6V]KVR-G<+Y\BB9,
MY (!^7&3R.?F-5K/PK-8SZO>6E[;6=]?H%5[2R$<:$$D.T99@[\X+$C( X%=
M* 0H!.3W-)V8*Z*NF67]FZ5:6(E>7[/"L6]R26VC&235NBBFW=W8+0****0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %(S!5+,0% R2>@I:YSQ;<X_L?32#Y6I:@D$N.Z!6D*GV.S:?8FCR O
MVGB/2+_4_P"S;6^CEO!#YYA7.X1Y #'C@'(QZCD9%7GNX(KJ*VDE"S2@F-6X
MWXZX]3[=:XW4$O7^*RKI\MO#<'0FVO<1-(@_?#JH92?S%/N]9FUGX=:GJ3Q)
M!J&G^?\ <)*K/;LWS*>N"4S]#@T=+_UNT-)MV7]:7.UHJ&TG^TV<$^"/-C5\
M$=,C-34VK.Q*=U<****0S.U/7]&T5HUU75K"P,H)C%U<I%OQUQN(SU%58O&?
MA>X$I@\1Z1-Y4;2R"*]C<JBC)8@'H/6M"]@B\BXN-@\WR&3?W"X)Q7,^ H(I
M?AGX>E>,-)%8*48]5)0@_H:3=DWV_P"#_D.VJ\_^ =38WUMJ5C!>V<HFMIT$
MD4BYPRGH1FK%>=^$M8U#3=&\%6LHM7L-1M!"%5&\V-UB+AMV<$$*1MVC'J:O
MZ3XG\1:QJ-G=6VA.VA7+8\YO)4HG.)-XG+-T'R>4I&3SQS<HVE9"V.REEC@A
M>65U2-%+,S' 4#J35+3-:L=7:X2TDD,ENP26.6!XG4GD?*X!P>QQ@]JP?B6;
MU?!%ZUE/!%R@D\V%I-REP,##+@Y(YYXR,<YJ8ZIK4VIOH-K=Z;_:=M:I<W%S
M):/Y3;V8*JQB7(^Z<G><<<'/$K6_]=+@_P"OR-F_UK3=+N;.VO;R*&>]D\JV
MC8_-*WH .>XY[46.M:;J=Y>6EE>17$]DXCN5C.?+8Y^4GIG@\=JXR_UP^(-&
M\-WCPB"=-?CMYXU;<%DC9T;![C(R#Z5+)K*:!K_C74G3S/*^QA$S@,[)M4$]
MADCGM0O\_P#VVWYB?^7YN_Y'>T5RIU?6[+7H=%OI=/>;48)I+&YAMW58W0 E
M)$,A+##9W!ES@C K.7Q/KL5EHMS<S:: ]ZUIJBK9R#RL2%-R$R_*-VQ><_?#
M=.*:5_Z^0_Z_4[*_U"UTRV^T7DOEQ;TCW;2?F9@JC@=R0*LUR.LZ_K6D:0=1
M1;"YB?48X$!1XC'"T@C!^\V]LG.?D&.<=JBO_$FNI?>);>VBTZ$:1!'<1/('
ME\U2K,0P!7:3MQD$X_VNROI?^MD_U';5+^M['9T5RTOB#4+V;38-.^R6C75A
M]O:2\C:12HVYC4*R\_-RV3CC@YK1\+ZQ<Z_X>M-5N;2*U-RGF)'%,91M/0DE
M%Y_#'N:=FK_UY?H2G=)K^NI9TS6M-UH7+:;>1W2VTQ@E:,Y"R  E<]#C(Z5?
MKAM'O)M/_P"$TNK=(6DCU?/[Z0(BCRH<LQ) P!D]1G&*KR^-M8MM \07 BL+
MVYTF2,"812VT<J.H.0C%CD9_O8/J*.WR_&W^8_\ @GH-%<Y:ZUJ,?BFYTJ]2
MWE3["+V V\;*RC<5*-ECO.<$, OTK,L?%.NW,NB'R--E36D:2./,D;V:JH9@
MY^;S",XZ1C(QGFE_7Y_Y,+_U_7J=M17 Q>+M</ANPU%SIQF;6O[.N56W<*Z?
M:##N3]YE#@9Y+59U[Q7J>D:L%467V9;V"V-L8VDFD24JOF[T;$0!8@!UYV]>
M13LWI_73_-!_7Y_Y,[6BN.UWQ1J>G2:U<6T=F+;1HU>6"X5Q)=!EW HX.$';
M.Q\D$<5'J/B?Q&]V;'2-%$][;0Q2W2QF.5 7!(C!DEA8=/O[6[_+Q2Z7#R.U
MJM87]MJ=E'>6<GF029VOM(S@X/!YZBFQ3WDNDI.;18;YH0QMI91M23'W2Z@\
M \9 -<C;>,=8N-$\-7HLK'?JMX;:<&1P(N7QM&/FX0\DCZ<\'6PNE_ZVN=S5
M2_U73M*6-M1O[6S65]D9N)EC#MZ#<1D^U9GAW5[V_O-9L+_[.T^FW0A\VWC*
M+(K1JX.TLQ!&[!Y.<9XZ5F^(+37+#Q(/$.BVT&J@6HMKG3I)1'($W%MT3'@,
M<\@XS@<\4=BK;G7JZNNY&##U!S2UP\'BNT@\-6+>']+G$]]=RV\5B\2(\$WS
MO(&1W1<@AOEWC/8U8MO$>O):VMKJNFQ6&IWMX;6U>;;L<>67,A2.5\8VL-F_
MGCD9X=A'85674+5]2DTY9<W<42S/'M/",2 <XQU4_E7'^(KKQ5%H]HCW%C:7
M7]KV\!G2W9X[B-G7#!/,R@R<%2Q)P>1G-7_^$GO+'7M9L]4BMA::;IJ7PFM]
MQ:0'=NRI^[RAP,MVYI=+^OY7!:NR_K6QU5%<>OB35[.71;J_2PDL=9=(HHX$
M=9+:1T+*&<L1(#C&0JX]#5*U\8ZW)I-CJMS;Z?'$^K'3KBVC#NQS,8@R2$C&
M",X*G(_NT^5WM_6]A75K_P!=SO:B@NK>Z#FWGBE"-L8QN&VMZ''0\BI'19$9
M'4,K#!4C((K@_#Q;2O#'B]]-MT62WU"]:"*-0!N"@@ #WJ6[)OLKE)7:2ZNQ
MV<&I6%U>3V=O>VTUU;X\Z&.56>+/3<H.1^-6JX,JNGZ;X#>TYE>>.)I,?-(C
MP.TF?7) 8^XS71^(]=L]$LXA<ZC9V$ET_E137<RQHIQDMEB <#G'<X%5)6T\
M[$IW2?=7-6*XAG:589HY&B?9($8$HV <''0X(./>I*X/X;7VDRR>(K73=1MK
MH+JDDJ^7<+*S(40;R022"0?F[G-;=]JVH7.O3Z'H\EI!=6]JES++=PM*N'9@
MJA593_"V3GCC@YH[?UT!:W-RYN8;.W:>=]D:XR<$DD\  #DDG@ <DU7TO5K/
M6;0W-E([QJYC821-&Z,.JLC@,I]B!7 ZQKFJ>(-%\/W5G):64O\ ;2VMQ%+
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M.F/>I_ ,VI77@K2[K4[N&YGG@24/'"8SA@#\V6;<V<\C ]A3L_Z^:_072_\
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MWX9@UO1;?2C?7EG!"\;AK;R]S&,@J"71AP0#P!T].*IR^"UEN-7G;7M5WZK
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MP2Y;T[TMF((?A1HNM6K7#%XK>'5[FQ"S3^0NXG*L&5L,P+ J?ES7L5%4W?\
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M;I_I^(+:W]=?\_P/._$HM-*N++5-/&C3V<-L(K?2YU$3$?-@VC <.PR, ?,
M.175>)I+\^$-0ETR.9;W[,6C2/ E!QR%ZC?C..O.*VJ*3U5@6]SQ6VN/"DWA
M;Q-?Z3K^JEA8R+<I- EC''/U7<T<40:7=@=23D@Y!K;TR]T&/QAX62TO+ MJ
M&C2I<!)D8W/^K"!^<OTD SGHP'>O3Z*=]?Z[-?J'3^O+_(\6F3P_I/PY4HUI
MIMS%KBK*(W^SY871&UP,!L19.ULX7!QC!KH;9-%UCXK:U:O=0WBM8VDR1&[+
MA9E=FRHW?*0 AP,<<]^?2**$_P"ODE^EPZ6_K>__  #Q_P ,2Z3?^+8(M3U3
M68_%L$K_ &FS^P1J'4$@YE6#<T!!R TG3'?%:&A>#O#NM^%=<TD:7IT5ZNH7
M0W"U3="XE<Q$\=E(P#_"?0UZA6=K5EJ%_IQ@TS57TNY+J?M*0),0H/S *_'(
MXSVI=+?UN.^O]>?^9S6@0V6M)/X@U/28;66VM3IYS" T83(FVL!G;NRHQV7C
MK74:-]@_L.Q_LO\ Y!_D)]F^]_J]HV_>YZ8Z\U+864>G6,-I&S,L:X+N<LYZ
MEC[DY)]S5FFV2D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8/3O0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,>,#C SGFI/#_A[4M#T?1]-.L1R16 *2^79[/M";2%!R[%2#@Y!YQT%)>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J6I:K:Z5#')<LVZ5Q'%%&A=Y7/\*J.2>I]@"3P*NUQVIVD>H_$%
M+74);B&#^RR;-H;EX6+^9^]PR$$$ 1]#T]J.MAFO=>(DL[*TEN-.O4N[R0Q6
M]A^[,TC $XX?8/E4G)8 #K@\4Z+Q)9-IMQ>3I/;-;2B":VE4&5)3MVIA202=
MRXVD@Y'-<:SSZKX?T*QU*[FCU";4IH].U5<!T$9D\N4]F9T7&.C;NF*5C>'2
M[>._$32Z3KT)U*ZBSY=UP,2GTP70D=%VXZ 525_Z]/\ /7Y">G]>O^1W&EZO
M'J1FB:VN+.[@QYMK<[?,0'[I^1F4@X."">A'4$50U?Q0VDZS::8NAZG>S7:L
M8'MFMPC[1EA\\JD$#U&.>,U#9K)-\2-2N(R3;PZ;!!(0>/,+NV/J%(/_  (>
MM4O%EK->>,_"T,%_<6,A^U$3VZQEQ^['&)%9?TJ>WG_P?\@>E_Z[?YG0Z7JT
MNHRSQ7&DWVG2PA3LNS$=X;."IC=QV/?-+JFM6NEO!"ZRSW=QN$%K NZ27 R<
M9(  [DD 9&3S3-'MGT]KBTN-3DO[EG\XR3!!)M( &X(JJ/ND# &<?6N;NF_L
MWXP07FH2^7:7NE?9;.1SA!,)-SIGH&88(]=I]*>[2_K8-DV='8ZXMU=QV=QI
M][87<D;2B&Y5#\JD G>C,A^\. Q/KBM7M6?J]VUKI]Y+:1+/?PVTDL,/=B <
M#VR0!7'6ES<1+X4U;3=2O+V35I4BO8I;EI(Y%,3,[A"2L94K_  .QI+73^NO
M^0/0ZCPYKS:_;7DKV,ED]K=R6K12NK-E,9)VY'?L3]:V:\SAU*?3=.U(I(T%
MO/XH>"ZN%.##$S#)SVR<+GMNS4VK/J.D?\)/IVG:G?BRMM'%[#</<&>2WFR_
MR!Y-S$,%S@DD<XQD83=HW\OT3_4:5Y6\_P!;'HU%<%L8:/H0?5=5EN-66(O;
M+=,K3;8"6"R;E,0Z.2IR=N,')K.TC6[R71]%TR^U"18[K5;JRN+A;MFD5$,O
MEQB;ALMM #\,<>IJW'5K^M[$IIQ4OZVN=GHOB'^V-5UFP-C+:MIDZPL9'5C)
MN7<&&TG ((/7//(%;=>21ZL-!N_'*Z?>,TD-]9J[R3>9+# 4C1Y"6))V@M\Q
MSR.2>:ZRQ$^F>.(+"QN[N[TN\L9+F5;BY>X\EPRA65W)8!@S?+G'RY '-)*Z
M7]=+C>C?]=O\S1UWQ/\ V'J%C9_V-J-Z]\YC@>U, 4N%9BI\R12#M4G.,>^>
M*73_ !1#>W\^FRZ?>V6IQ0^>+*Z$8>1,XW(RNR,,\?>XR,XK)\<V\MUK'A*&
M&\FLY&U-\3P!"Z?Z/+T#JR_F#6?8Q3Z1\68K:>_DUJ6]TY\W%PJ":R1&!"XC
M"IM<G^Z#D=30E?\ '\ EIKZ?F=9X9UP^(]$343:/:%I98S"[AF4H[(<D<9^7
MMGZFM>O,=/TV>^^&DEQ:SWT=S9WUW<(EG=R0&8+<N6C.QAG<H(YZ9R*T-0UR
M*3PW/XMTJYNU@NV@MTEDN)/+BA,BJ\PC8E%(R><?PY[FBUWIY?BE^K#_ (/X
M-_HCHU\0$^,V\/&QE3%G]K%RSKM<;@N HR>I/7'3O6W7GUF+#3?B[#:QWTC^
M9HK%!<W32LQ,H8A6<DG@$XSP/05V\6I6,S6ZQ7MM(;E"\ 653YJC&2O/S 9'
M(]:.B_KJQ=7_ %T1'JNJVVD6JSW&]C)(L4448R\LC'"JH]3[X ZD@"F:?JPO
MIFMY;&\LKI8Q(\-RBY"DD#YD+(W0_=8X[XS5+Q99:5J6F06.JW$EJ)[A1;7$
M<GEO#, 61E;L>./7IWK$L'UR"^U#PUK5\NI*+%I[?4;;=;SJN<;)-A&UNA#*
M1G!J;V3?]:(JVW]=3N:IQ7DJP74U_;BTCAD8*QE#AXQT?CIGTZUYUI^KM'9?
M#>\N]8G22[3RKAI;U@LQ,#8WJ6VLV_&"03GBFW\<U[X"\10ZCJ-[=&UUHQI-
M)<&-]JRQ@ E-HP 3P !GGKS5RC9V_K=+]2;_ -?)O]#U.BO,/$>HK'X@;0Y/
M%MMH-M;6T<EI)?33DS'+!F\T7$>\@@ J^_H#BO1=-,ATNU,MTMW)Y2[KA4V"
M4X^\%R< ]<9[U.ZN/K8J:9K]IJVHZA8V\=RDM@R++Y\)C!+ D;<\D8'7'>JD
M7B^SFN!LM+PV!N/LHU':GD&;?LV?>W_>XW;=N>]5M!_Y'OQ9];3_ -%&N9LL
MV]Q'KM@_F:)/JS13:/(?FAG,VSS4_P!K=\YC/'.1R.7'6WHOS_KY^0GU]?TO
M_7^9VVH>)+73[F6)K>YFCM@&NYX54I:J1D%\L">.<*&(') '-;"L&4,I!!&0
M1WKAD8:;:^.UNV F>9YUY^9XW@54P/JI4>XKJ/#]M<6?AO2[:Z)-Q#:1)+DY
M^8* >?K0MON_'_(;W^_]#2HHHI %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3ZZ?UU#I;^NQD>(SJ=UI\&GIH]S=0WLGEWC6MQ&GDPY^899U))''R] 3@Y
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M2Q"[2P1R/$\+,H)C<@LA]#@D9'L2*?34=)8UDC971@"K*<@CU!IU#$@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%5-0U*UTNV\^[D94+;55(VD=V_NJB@LQX/
M !/% %NBL3_A+] ^QVUV^IQ117,_V>(2JT;F7."A1@&!'<$#'?%6;37M-O8K
MR2*X*+9,5N1/&T)BP,Y8. 0,<@]".10!I45PT&N/?_%"QAM+^^-C)ID[M:S0
MM"@=70!PK*K-D,<-R#VKH=6OM-AU72;2ZU5[6[EG+6UO')M-R0I!5EQRHSGL
M,@4[;>8=S8HJC!J]E<7LEI$\C21ML+>2XC+#.5#D;6(P<@$XQS3=4US3-%%M
M_:5[%;FYE6&!7/,CDX  ')_I2 T**QV\4Z2MFEV);B2)F9<16DTCKM8J2R*I
M90"",D <=:C?QAH"W!MX]16YG^SBY\FTC>=S$<88+&"3G(/TYZ4 ;E%<;K>J
MFZU'PC?:5JLQL;N_,3QPL!',IC<_-QNR"G3([Y'IMS>)](@U1-.DN76=Y!"&
M\B0Q"0]$,NW8'_V2V>1QS3L#->BLJZ\2:39WZ6<]TRRM((BPA<QHYQA'D V(
MQR,!B"<C'6G7WB'3--N%ANIY$).UI!!(T49XP)) I5,Y'WB,YI :=%<AX]U^
M*Q\,ZM!::A=6VHQ6CRI):PL_E$*64.^UE3=C W$$]N:W+*^6V\,VM]=-,ZI:
M))(RQM*Y^4$G:H+,?H":.C8=C3HK$A\6Z/</I:12W)_M1=UFQLI@L@P3RQ3"
M\ GYL<<]*@U+7]&FBMTN-4NK MJ"6\7R20//,KCY%#+ET)X)&01GFG;6P'14
M5RESXECU2YU_1;4ZC9W-C!Q=+:.H#;2Q*NR%/3&>O)&1S4GA3Q%:7FE:-8SW
M<DFHS:?',3(CXEPHWD.1M<@GD DCO26JO_77_(3=G;^NG^9T]%8GB/Q+;^'%
ML?/@NI3=W*P+Y%M)-MSR20BDYP#@=3^!K%L_$$.CZWXC;5M3NY+2*:!H_-B9
MQ;HZ;CD(OR(">68<=S0M?Z]/\Q_U^?\ D=K16?J&M6.F(KW#S,& ;%O;R3D+
M_>(C5B%_VCQ[U9BNX)[);R"036[Q^8CQ?.'4C(*XZ\>E $]%<'H&N6>O7%WK
M5Q?:M:&QNYH]K)/!;M$&**C(ZA&;N0!O!XXZ5T4>M6.NV5_;Z?>W-O<QQD.&
M@:">'(.&V2ID=#@E2#BD]%?YCMK8VJ*\UT[4=4FT3X>7CZK>%KR98[I"XQ<9
MB=LN<9)RH[X]NE=G?>)](TZ[^SW5TR,&"/((9&BB8@$"20*4C)R,;B,Y%6XV
M=A?U^?\ D:]%8TOBG2HKK4+9GNS-I\:RW"I8SMA#T*D)A\\_=ST/H:DA\1Z9
M<16,T<DYBO86GAD-K*J>6!DLS%<(,$?>QG/%3_7]?<!JT5S6F>)O#MMIEDR:
M_P#:H;Z>5;66XE+O,V\[E7C)53P.P '-:5KX@TN[LKN[CNMD-FS)<^?&T+0D
M#)W*X!'!!Y'(((H TZ*Q[/Q3HM]<?9HKY8[O:7%K<(T$Y4=6$3@.5]\8J_I^
MH6NJZ=;W]E+YMK<()(GVE=RGH<$ C\: +-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %8/BB+4I8;#^S[0W"I=*UQY?EB9$P1NB,A"ALD G.=I
M;'.*WJ* /,YM$UVSTY+2'0[NY">(!?AENXG8PAP^29) 2>WU'88JS?Z)K>JW
MWBV---GM%OOL[VD\\T7ERF'&5.QV8!L8Y7H3GTKT.BA:?UZ?Y(5OZ^__ #9Q
M<5KKVH>.](UR31Q9VD-C-;7"7%RAD1F93E0A8,/DXY'!R<=*M^+;;4;C5O#D
MECI=Q>16E_\ :)WBDB41IY;I_&ZDG+@\ \ ^P/4T4[[>0^_]>1Q]OHM_I_BQ
M)]*COK2QGE>6^BEGC>UDSNYC7)=)"VT\!5Y.<FI?'=GJ-_9Z5%IVFSWK1:E;
MW,OER1+L2-PQSO=<DCIC/X5U=%):6\@[^9YYXOT#49?$T6L6_A+2_$]O/;);
MR6E^\2/;,K,0Z,ZL-IW<@<\"I&:XTGQUIJVVBJ[1Z&Z_8;!HU$?[Y.$WE%('
MX>P[5W]91\.Z<WB%==*W/]H+'Y8?[9-L"?W?+W;,=\8Z\]>:%I;^N_\ F)Z_
MUZ?Y'(2>']7TY?#R0Z;->&+6)M2NS!+$%@63S/E&]U)QY@Z ]#[ OU31]=O;
MN1SI<NZWUF"ZB$%Q%'!+"'7+8#!F<*.?,'4?+G KT&BFG:WE_P #_(;UW_K?
M_,X.VM_%FF:U=Z8=!L=5T>\O&NTOI;P)]F#$,5:,J2Y5L[<8Z#D=J%]X8U"'
MQC>._@G0_$%E?W F74;MHEEM1M *N&1F< CY=OTXKTNBDM+>0/6YY_JFBZZF
MG^+=)MM.^UKK EEMKI9D54+1*GEN&(88*\$ C&,XKL=%AN8-#L8+V*.*YC@1
M)$CDWJ"!CAL#/Y5?HHZ6_K0#A)_#NL1Z9-';PJ9M*O?/T@>8O[Q"V\J>R_*S
M1#/;/K5OQ9IVHMH.E6MAIL^H30W]O<S>2\2<)('<_O'7DX.,=SVKL**:=K?+
M\ >OX_B<C-:ZK:ZEXFGBTF6YCOX(V@,<T0+,(]A3#,,$'!YXQWSQ69I]CK<5
MUX)\W0+U%TVU>&[<S6Y$3%!'VER1\N>,\$=\@>@T4EI_7K_F)J_]>G^1@^*+
M*\NH]+FLK8W+VFH17#Q*ZJQ09!P6(&1NSU[5S.J66O7EKXVB3P[>;]2@6*T(
MN+?$A\ORR>9 0,\\@<=L\5Z)12M_7W?Y%)V:?]:'F.M^']6DU#3]67P7IVOI
M+8Q6LUAJ4D"RVCH6^97(==IW<A2>@KT*PA-EI$,2V4-N8HABUM,!$X^XGW1C
MMG@?2KE%4W<E*UCS:QT/7KKPU=VCZ3/87D.L'5(%NIH3'.//,HC)C=\''!R,
M XQG%;B6FHWFN3>(Y=*N[5X]-:T2Q:6$RS,7W=5<I@8 &6_B.<5UM%)ZJW];
M6_(J^M_ZWO\ F>:6.EZ];Z!X'M'\/7OG:5<A[L">W^15C=,Y\WG)<$8[ ]#@
M'0N-%UB&R\1:$NGO=V^L2SR07WFQA(?-7!$H8AOE/3:&XQTKNZ*;=]_ZO;_(
M+M-/M_P?\SF+G0[VWOM(-D3-&+4Z?>R.X5O*P")/<@J0,?\ /3/:G>&=*O=&
MANX+B+=!:.\.GJA7)@)+J!S@=0F#C[@KI:*&WK_7]=?O)22LOZ_K_(\OLM,\
M0PZ1H5N_AJ_$EIK<M[,//M>(F:1@?]=R?W@X_P!D^V;=U9WR6OCF6_T*_6VO
M'6:V\N2%GFVQH@VA7)W;ER 1R,#KQ7HM5K^PM=3M&M;R(2Q,0<9(((.001R"
M#R".12;[?UM_DBOZ_-_JS@_!NO3ZIXEN[K4-*U^VOYK80PF]TEK.!D0LP4'>
M^7^8Y)('H!S7>:?-=7.G6\U[:?8[IT#2V_F"3RF[KN'!QZBHM.TFUTN,I;M=
M29)^:ZNY;AAGL&D9B!QTSBKU-LE!1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N*\2ZBMMXXT"5K+5)8;-;@SRVVFW$Z+O0
M!?F1""<CH,X[XKM:*.J8=+',77B6*]T_4C#I^K"VBMRNZ32[E7D=\@!$*;F
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M=R,<^F15FBF 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?%
M.KVVD:,6N+ZWLOM,BVZ3SRB-4+=6R>.%W'WQBMJL>33-2D\3PZDVHVYT^*%H
MULS:'>"V,MYF_&>!_#TR.^:6^@;:F#\-]5M9]'OM&L[^VOETBY:WAFAG$BO
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M2=^5VW_6W^=A)>]=_P!:K]+EG3?%DU[>Z-'/IJV\&KVAGMY!<;W#!0Q5EV@
M8/!!.>X%9_Q0TZPO/#MI+>6$%T\>HVBIYD2NP5IT#*,_WAP1WJ>T\(ZK;7'A
MMVUFR=-%A,)4:>P,RE=IY\X[3M ['G)Z' T/%F@W_B&QM[6SU&VLECN([AFF
MM&G+-&ZNH&)$P,KSUR/2K=N;3O\ A?3\!1O;7M^-G^ID:)IWACQ;<P:N^EV9
MN-+_ -&ALY+<*]EM/"NI'## ('0?PYZG5OO$EVMQ?QZ3IB:@NFD"\W7/E,"5
MW[8QM(=@I!P2HY'/7%+4O">JW'B+3]>T[5[&PU"" Q73#3W=;S(Z.!,/E!Y
M))!_BJU)X9O8M3O+S3M4BMAJ*K]OB>T\P.X7;OC^<;&(P.=XX''7,N]M//[_
M /)_>5I?7R^[M\AL7BN>[U'1#9V-O)I&KQ>9%>O=%'4[=VSR_+(R1G'S=FZ8
MYEFUW5XK3S/[(M3)).Z0M]M80"-03OED\K]WG' "L,D<\T:GX/L[SPG;:!:3
M2V,=IY1M9XN7A,9&&!]< C\34NI^'GNYM)>TNHX(M/)'V>>#SHI%( ^[N7#
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M.XVG/1VF=0>>NRNGTG2[31-*MM-L(O+M;= D:YR<>I/<GJ33ON-_YERBBBI
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY^M"V^[\?\AO?[_T-*BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'
M<*6@<*[)QRRC) [X]ZY3P;J$%WJ6L06=[>O:0/&$M-1,OVF)B"68^=\X1N-H
M/]TXQTKH]4_M$:?(=)%J;T8,:W981GD9!*Y(XSS@X/8U2T[3+H:I<:Q?);17
MT]NEOY-NYD1%4LWWRJELEC_",?K0MVP>QLT57L/MOV"#^T?(^V;!YWV?/E[N
M^W=SCZU8H **** "N2^(T;?\(JUQ%=7EM-%<0!7M;N6 X:5%8'8PSP3US76U
MQGQ(N4&@Q:>=1T2R>YF1PVJZA]E!$;JYV_*V[H >F,@^U';Y?FAK^ON96\5V
M<_@W0YO$.C:CJ1^PE9;BTN[V6ZCN(LX9?WK,4."2"I'(&<ULZCXRL]-W.UE>
MSP0Q1S74T*H5MD?[I8,P8]_N!L8YKD]5\0:=XKMET[6?%'A+3]+,B-<Q6>LK
M<R7*J<[-S+&$!(&>&)&>E5_$^H:-KHU:V'BSPI-:3VZK8?:-54"UD4=/+&5.
M2,[\[ATQQ37GW_#03\CL1XGN!XSO-(DTRX2RMK1+AKS?%L ;?\Q&_<%^3 P"
M<YR ,$LT7X@Z!KVM?V597*/.Z&2%EGAD$JC&2!&[,N,]'"GVX-<_<:OX<O-;
MOI[CQ;X:-EJ.EK97(74T#H5+_=&<$$2'DD8QT.>$\+>+7L)?LNO^//!EUI]N
M@2"6VNE6XFQP#)E]J\=E!R>_J*W]?/\ X /:Z_K1?\$[G4]7BTUX85@FN[N?
M<8;6WV^9(%&6(W,J@#(Y) Y [USGB/Q@?^$!UC4]*MKP7=LDD,L>$66SD"]7
M#,!QD'Y2V<@C(JGKGB+P[-K.G:WI7BWPVU]9))"8+G5(TCFBDVY&Y2Q4@JI!
MVGTQZ8^K7VAW'AGQ!;VGBGPJVIZ[)ON/-UE$BA&P( I ); 4=0N<GITI+S_K
M5?I<:T:_KO\ \ [OP[I-A;VDMW;:-)I,UZ ;B NJLQ&1O(C=EW'.=P.X\9/'
M'":;)I<3:W#J%SXMGFMM1FAA:&\U-HU08VJ948H,9ZL>.]==9>//#G]G1_:_
M$GAN.["8:.+5XY(\CIAR%/I_#^=<GH_BL:5'J2-JG@6<7MY+=$-XFP%WX^4C
MR#G&.O&:;^+^NZ_X)*ORKO\ \ V_$EW/;ZOX>\/3:1>ZO93)()PQ@9;K;'C#
M"209P2&.[@\8R15"."PN_%5_X>O_  [='1M,M86@::6(K9\RDRJWFEUR  I7
MYAMQA13-0\46=QXAT'4$\1^#Y5L$D\\OKBQEFD7:P50C<+CC)R>^.M1G6M'N
M_$VO37OB+PF-*U6T6S+1:ZIF15$@#;=@&3OZ;N,=30FUKUU_X'_ 'I\M/^"=
M-HWQ"\/ZUJYTRTNHS*8S)$XN(9%E11DGY'9EP#T<*>O'!JY!XJAN+J.%--U
M+<1-+9RNB!+L*,D)\V5.#QO"9KCM!\2;(9M,\1^//!MUIBP&"*6UNU6YF!&W
M,F7VKQ_=!R>_JOA7Q+_9+IIVJ^//!MSH]I&(K:2*Z474J@87S,OL&!CH#GVH
M?E_6_P".PM34M_%EIJOAK2KWQ!HU_"+N_B2W4*'7S/,_=MNC8A5!P/GQG'0U
MT$7B/S=<U#2CI-_'+9P"<RN80DJDD+L/F9YVMU QCG'%>>7&IV*^$],TB#Q1
MX/EDL;^.<-)K2QAXXY?,'16PS< C&!UR>E;FO:UX:U75-)OK7QMH-JT#-%>
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M,0/F;'WMH]<5TVOZ1?W.IZ9J^E-;->V!D7R;IF2.6.0 ,-R@E3P"#M/3IS6
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MXL-W8ZC<+H6J)+8SBW>V<VXD=SC[O[W;T8'DC.>,U5USXBZ!X>N_LM_.J3(
MUPGVB /;@@$;D:0,W!_Y9AZMR>'KG_A-%U>&[V6$D(^TVO/[R9,B-_3A6.?]
MU?2LV[T3Q;8>)[F\\.ZAI0TW4)%ENX-1BD=H7"A2T6PC.0HX) R*E=/Z_JX=
M_P"OZL=BCK)&KHP9& *D=Q3J100H!;<0.3ZTM !1110 4444 %%%% !1110
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MP@$&/<,CDC!_#->7^,&U]_'WP^TV_P!8D@GGWO<?80GEK,JXWH'0YZD?,#[
M4NCW/B._\6?$+3-/U?R[^S$1M+K[%;"1V )"R$1C>.B\\@=*GS]?PM_F/R]/
MQN>PT5YAX'\6:GXB\-VNK3:I=O+IEK,=4MS%"/.F!.U3B/*\ G"D<;<YZU#\
M/_%7C/Q--IFK2V<L^D7IF%V6-LD5MM)">3M;S6Z8;>#UR.*KEUM_7E]XKZ7.
MX\2>,=#\)112ZY=36L,IPLHM99$SZ%D4@'V)S2Z;XOT/5K_[!;7CI>E/,6VN
MK>2WE9?[RI(JEA[@8K@_VA?^2=0?]A"+_P!!>J?Q55_M_P /GT\'^U_MJ"'9
MG=LPN[IVZ9_&IAKOWM]Z*EHK^3?W'LE,>6.-XT>1%:0[4#'!8X)P/7@$_A7C
M?CSQ]XBT&ZU:XT_5[:1=.O(8Q;6\2O$L;@_).77<),@X\M^G4#BK>N3:A>_'
MGP[8C5KRWM_[.>Y1(A&0C$.& #(1R% )()ZX(HCK;S_RN*6B?E_FE^IZY64W
MB/25NX[3[6#<2W#VL<84Y:5$WLH.,<+WZ=LUYOX=\:>,O$VLS7NFV,T]A;ZL
M;.>VS;)!';C@MN9A*91D'CY<<8S7I8T*R^UQW)1C+%=-=H2>DC(4/X8)II:)
M]_Z_4'H[%FROH;^W\Z$L,,5='7:R,.JL#T-32R+#$\K!BJ*6(12QP/0#))]A
M7/V<DD7Q"U6W4'R);"WN&QT$FZ1,_4JJC_@-='2Z7#9V.8A\?:#<0R30C5I(
MHV9'=-%O"JLIPP)$7!!!SZ5TD4B31)+&<HZAE..H/2O/?"EMXAET[4C8:CI\
M=I_;%WF![)S*1Y[;@)?- !(SCY./>KWB^\U?1;NUU'3]5E.F/&\4UE%%$?)&
MWB=3Y;,53JP)QT_W2=OZZ7_K\1M:M?UN=O17(W&H7%HV@Z(_B"1YM224_P!J
M&*$/(54, @V^6"=W'RGA3U/-5M5U3Q!IR:9H8O;.34[V29%O'F%OE4P4&3%(
MOFE2"1LP<-C'%.PD=O2,RJI9B !U)-<'+?>+K&Z\.66H:C8I)=WTMM<FV3S7
M9/*=T.\J@#87G$8!.#TXK-U^ZU>73M3TF;6;LMI^JV*)>Q)$DDJ2O&=KC9M)
M7=G@ 'Y<@C((E=_UY?YA_7Y_Y'I]%59"]EI;L]T'>&$DW%SM4$@?>?: !ZG
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M^M["3NK_ -;7.^K-U_7+3PWHMQJM\L[6UNNYQ!$9&Q]!V]S@#N:XFT\0Z_\
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MYO+*R2.[N@HGG)+R28  RS$D]/Q//6HKWPOI=_JXU6=;P7HA: 217T\0"-U
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M\QRW)YYJ;1M+@T72+;3K8%8+==D:EV?:N>%RQ)('3GTJ]11<+!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9VO;_\ A'M1\JQ:^<VT@%JK[3-\I^3/;/2M&BDU=6&G9W//-*-Q;^(9
M-2GMM1DMY=$5 PTV2,1E&)*!-IDSSP&W,>U9UK)-!X#\$6\FFZL)[2\@:XB&
MFW!:(1Y#%@$R!R.>_;.#7JE5%U33WU%].2^M6OD3>]L)E,JKZE<Y ]ZJ^O\
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M)G!.>O0$CTZBE;1K^MK#O[R?I^#N>?Z7/=6E_H6H7FGZE+9-I"6BXLI"]M<
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M0X(VR8!/'_ AGTV>X@ME5IYHXE9PBF1@H+$X &>Y/ %/DD2&-I)75$499F.
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M6^IZ=-<30Z/-:WEQ]A>2/YF7RXWE"E3@;AR>.<]>?5*;)(D,;22NJ(HRS,<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^!;W^?X:_P# _$PO$7B)_$7@[Q/87^@7,$<>G33Q336LXB;:/ER9H8\2 X(
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M20,'BKLL=YIVMZEI.G:GJ!L)-):Z\Y[DSR6LH;"[7EW'##/!R/EXQ4RT3?\
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M=4T\72VQOK87#/Y:Q&9=Y;&=N,YSCG'I3[J_L[+;]KNX+?<"1YL@3( R>I[
M$_A2&-T_3+#2;86VFV-M9VX)(BMHEC7)ZG"@"H[G1=*O+B2XNM,LIYY(C \L
ML"LS1GJA)&2OMTI\>JZ=-8QWT5_:O:2$!)UF4QMG@8;.#44^O:/;6)OI]6L(
MK,.8_M$ERBQ[@<%=Q.,YXQZT O(A;PMX>>XFN'T'2VFG0QRR&SC+2*1@JQQD
MC  P?2FCPEX;46P7P]I(%L=T&+*/]T<YRO'R\\\=ZGO-?T;3A;F^U>PMA<_Z
MCS[E$\WI]W)^;J.GK4.HZK92P:A96VO65G?6\6Z5S)&[6N>C.A/ ^N* +7]D
M:9_:?]I_V=:?VAMV?:O(7S=OIOQG'MFJ1\'^&#%+$?#FD&.9Q)(GV&/#L,X8
MC;R1D\^YK0FU&QM)8(+J^MHII\B)))55I<#)V@GG\*CC9SK4X_M*-X_(3%D%
M7=&<G,A.<X((&#Q\OO0 V30='F:!I=*L7:WC,4):W0F)",%5XX&.,#C%,D\.
M:'->QWLNC:<]U$H2.=K5"Z*.P;&0.3Q[U-::OIE_<SVUGJ-I<SVYQ-%#.KM&
M?]H Y'XT?VSI?VF&V_M*S^T3EEAB\]=TA7[P49R<=\=*-P*/_"&^%_LHM?\
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M]K %C,Q,LRKA!C+<G[HR.>G--36-+DN+:W34K-IKF/S8(UG4M*G]Y1G+#W%
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M;*!]Y?:M;I3O_7]=Q?U_7I<X"[@GAE\5:9J6F7=Z=6=I+*6*V:6.13$JK&S
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MGG5E*NBZW;:Q%I&I/I>IS2%;)=.N&?3WZ&79M.S?_$,#KD9^8F:UT^VNM?\
M&5FMEJ-E!>M RSP6$D09U&'=6*;7(8@GKNYZBO0Z*/Z_+_+^K(3_ *_'_/\
MJ[//+D:Y>^#-8AN8IK\Q2Q&WN!8/;SW*(ZEMT)Y+#:>0 &["GZB;-OB)%>RZ
M->O;S:-/#<RC2II%DRR,J.50@G:K?*>1TP"<5Z!11_7X6#^OQ3_0\ETD/:>'
M? < TG5(I;2_+7*#2YP8AY<BDM\G RZC/?Z XH^*/$GAJ#6-6\+ZKJ5G!#<Z
MG'<W#7EM,TB8\L[0HB*.IVX#%A@'H:]HK&AT![>\>2/6=2%K(S.UFS1-&2Q)
M/S%#(.O9^.U.^O\ 7E_D'3^O/_,L7FH6VDZ&UY!;33V\40,4-C TK.,?*$1
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MR=JN &+?,V7(7&1@<GBLVT\#W5O;Z! VN,(]#F+6QAM55GCV% CEBP)VD@L
M,]@#S5*W7^M_^ )[:?U_3*7AZ]LO#C>*FCMU5&UT0P6\*A=\DD<0"@=!ECDG
MZFG:$DX^+&JR7=A:V=U+I$#2K;2^8KGS7 ;<54DX '('3'3%6E\$7<L>K+=Z
MQ$7O+]-1MY+>T,;6\R;=OWI&#C"+Q@=_7B_IWAF\M_%+>(+W5S/<R6:VLL,-
ML(HFVL2&P2S#KT#>O7H$GMZ?I;\_T&^O]=?\A^L^);C3?$%AHUMI3W,][#+)
M#*TZQQEHUR4[G/3G&.>_2LV]\>36UYY$&@W]T(6$=V(+>XD9'P"50I"T;XS@
MY=>AK3U/P_>W_BS2=9CU"WBAT])%%NUJ79_,P&^?S !P!CY>#Z]*H7'@[4X_
M$LVI:/XHNM-LKN42WMBMM'*LK@ $HS9\LD 9P#GVI1Z7\_\ @?@#ZV_KN3ZG
MXNEM(M3N[/3ENK#20WVV5KCRW#*@<K&FTAB 1G<5]LU-'XCO)=?&EIIT'[W3
M?MUO(UT1N.5&QQY?RC+?>!;CMVK \::6="\*^*[N/5((-.OK:622VN(N?/9-
MOR2;AC<0/E(.2>*V+/2_[2GT;Q!I>J0J%L/LSD1B9)8FVGY6# *P*]?F'7BA
M:K^NS_4'I_7FOTN5+?Q>FHVWABYN="!;4[EXTD\U'2UD4/R"0&)(5L$*.,Y(
M[V;?QC-/>:JAT=X;72KHPWDTUR@*((_,\P*,@C[O&<_-[$53@\":A9V>AVMO
MKZ/'I=XUV/M-B'+$AAL&UUVKAVZ[CDCG Q6CI?A6:VNO$#ZA>V]Y;ZS(7DA2
MU,6P;!'MR7;/RCT'/ITH>VGG^G_!'IU_K5_I8CT/QA/K&L"S?0[^WMY8S)#<
MO:W"*, '$GF0HJDYXVLX.#STR_Q)JNLV6O\ A^TTVWM)8;N>19O/N&C)VQLV
M.$;CC/N0!QUIOACPOK&@3F.\\5W>J:=$FRUM9K>-#&.@WR#YI"!ZX'MTQI:Q
MHTNI7NEWD%Y]FFL)VE&8MX=60HPQD8.&X/8CH>E/2Z_KN3K9G):?JA\*Q^([
MBVTN%M/BUK$X201>6KK$"40*0QRV2"5Z]2:V->\:MI5_+9V.DW>I26^TW @M
M[A\9&0JF.%U+XP=K,G4<U3N?!.LW6D:S8/KUC_Q,[Q;II!IK_N\;<J!YW/W$
MY^O7(Q/J'@[5YM:75M)\4S:3<3I&FH)#9I)'<%!C<JR$[&QQGYN .N*2Z?+\
ME^H;7^?Y_P"1TES=W7]CM=V%GYUR8A)';7#F$L<9VL=I*G\.M8%KXNNY[KPZ
MKZ=:):ZQ"7\T7C%H9 A;9M\H9Z8R2O(/' SU4:>7&J;F;: -S')/N:YB7P6D
MFF75FFH2QE[P75M*$&;7$GF;5YY&XO\ @V.U/K_7]>?R'T_K^O\ ARQ+KNJ1
MZ=#.NE6S33R.(R;QA;K&N2'DE\K*9 X&T\D#-9J^,K?4=*\/:@=&^T1:C>B!
M7\V-TMY Q7<&ZMT;:5'(ZXS6OJV@27USI4MM=10QV#']Q-!YT4BD ?=W+AAC
MY6YQD\&L9O!.I)IFG65MKEN%LM1>_#36!<L2[.J_+(N,;R">_' [B\^Z_/\
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M2_/=+%+V&>:Y6.*9&/&"H9AT/5>HZ8YJ-?&]M-8Z!/#'#$VLQ^9$+VX\E5
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MXW#@_6K%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)PGSL7VC@G<3QR<YJMX]U>?1M"@FCNX[*&6ZCAN+R2-G6"-L_,0K*V"=JY#
MC=G/%)Z#6IU-%>=6-VMKX9N4C\9Q:O%+>010OI^Z1D+,,PB1YW;+\_,S@KNS
MP,52C\076AZ7KL5W=W$=K::Q# SM=M=26MLZQESYC L<%CDG.W/!X!IV_K[O
M\PZ7_K^M#O/$>M-H&E?;EL9;M1*D;*CJNP,P7<23T!(Z GGI6M7F^JS:6_@W
M5QI/B0:K9&>VV#[9]J-N3(@*^:S,3D\@,>/I6[I3SVOQ!U;31=7,MJ;&"Z"3
MS-)MD9Y%8KN)V@A1\HP.. *$MU_6UP??^M['5T5QGB3[7+X\\/V":G>P6=[;
MW2S002^6,J@PP(&[=\WKC@8%<Y>ZE/<>([S3Y_&]IHEUITZPVT-X)/-D3:N'
MP)TCFW<_>C8@DCTI+6P/0[W5-9NK>\:QTJPCO[Z.$7$D,EQY.(R2!M;:06)!
MP#@<<D5KH2R*S*5)&2IZCVXKA8-,B_X6MJ=R)+UY8]+@G1/MLP0N7E&-F_;M
MX'RD;1UQG-9'A+5)M<U&SO6\<V:WTP9;K24203AMI!3RWG95*'G<L8SMYXS0
MMOZ\_P#('I_7DG^IZG17E5CJ6IV7PW/B*36+Z2ZBGEMYIIV,L:1?:MIE:,%<
ME5!^Z5X)]!A)+FX@\$>)KO2_'<.I&*T\^+^SV9VMG7)Y>669ANZ;21C'&.:=
MOZ^[_,:6MOZ['JU%<#=7M_H_B,_8YKN[:?09KMH)IFD#S1E I52<)G<00H /
MIFH='UW3KJS;5= \3-J6H/ISRRZ9)=^:TDH4$-Y9/[G!!!"JJG=TZ4GIK_77
M_(4=;>?_  /\ST2JUU/=12VJV]IYZ22[9G\P+Y*;2=^#][D 8'KGM7 ^!]07
M4]6@OH?'-AJ1N("\^FQ+)YA.!\Q1YW\K:>NU5'/TK>\537=MK_A9K>^N(89M
M0,$T"$!)5,3M\W&>"H[XZY!IVLT@3O<ZFCI7EVIW.HQ:1XYNVUC47FTF]\RR
M;SR@CQ%&X4A-H9<L1M8$$=<GFN_UB);SPY>QREPLEJ^XQR,C?=[,I!'X&IEI
M!R_K:XTO>Y?ZWL5[KQ"L&L:-916CS0:GOV7:NH1=J%P,9W$D#TQ[]JVJ\RTF
MSMET[X?6\%S<$2*SN3=/(X)M22 S$E1ST&,9XQ39]>OM)\*WJ'4WAMH-=>P:
M_NS).;>#/!<[U=ADA=VX$ YSQ5R7*VO7\[$1?-KZ?DW^AZ?7-W?BR6V\02:-
M%X<U:[N4A\\-"]L$>/.-P+S*>O&" ?:H? Y'V*[6/Q3::_ )!Y;VS,ZP<<H7
M>65F]?F;(SZ8JEJ5C<7WQ05+?5;S3F71\E[586+#SNA\R-QCZ 5+6J7];#OH
MW_6YU.E:D^I02O+I]W82Q2&-X;K9N!P#G*,RD8(Z&K-P\L=M+)!#YTJH2D6X
M+O;' R>F?6N1US2GE\+FQCUZ]75+68F*>WN&C>:5F+*DBQE VX$97C .1@<U
M2M9)9?!_B.Z74M1M-<1)'NXC=-)]CE52P6-9"RJA'(('(.>.,*3M%OM_7]?\
M$J*NTN_]?U_P#O+=Y)+:)YHO)E9 7CW!MAQR,CKCUI3-&)U@+CS64N%[X! )
M_45Q%U-K/]C>']2ABGU&VAL4EN[>"^:"X9BBD29R!(!\V58@'.>3BF6$6GZC
M\0+?58KJ] GT6&:%FNI$W;G(&8]VT\$<$8SSC-7)6DUYO]?\B(N\4_)?I_F=
MI8SW4\4C7=I]E=9754\P/N0,0KY'3(P<=LXJS7EL-[JW_".6+'7-0:5/$S6<
MDI9-TT7GE &^7T X7 ]L<5JFXU*S;QI8Z?>3DVBQ2VIN9S(T9>/+A6<GT. 3
M@$]A4_U^"_S_ #*>CM_6[7Z'>TC,%4LQ  &23VKD/#L5ZWB.X:UN=:30X8%
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M%CS$5@2F1D9';(J2I:N@/-;33M?CT?P=!)X<O1+IU\9KI1/;'8NUUR#YO/\
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M<07*SW2$J7V89-F[</EXS@^NWOV]%%%Q6"BBBD,**** "BBB@ HHHH ****
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MK=-;2.3",A9"CR!S.&&,$[3%DXZ\UH^/)]0MO"5S+IMU';3;XU+O$9,JSJI
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M,PY)^]SGC$?9\]?OZ%=?+3_@D%CXFOY]2T SQVPLM9M&FCC1&\R!E0/R^[#
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M2%)^48ZX09JM+_UWT^_8G6VO]::_YFAKVLMIC:?:P!#=ZC<BV@,@)1#M9BS
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MXN\@6^51@"=OWLX)&,^AS6%-X%MY](L-.;6]986EREUY\MPDTTTBD%2[2(W
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MF::&]M[.-/(LH[9ED8^7O50V\CJ3GY>2>W2M3PKK\>O6<DBW]I=2QX$J0P/
M\+'/RO&[%E.,=3SSP*LPZ!%!J=W?I>W@ENXT29=ZA2RKM$G"\-C\.G%/L-$B
MLM1N=0>YN+J\N%$;2S[ 5C!)5 $51@%CR03ZDTEM9]@?]?@:=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45U)+%:326
M\)GF1&:.(,%WL!PN3P,GCFI:K:C=FPTVYO%MYK@P1-((8$+/(0,[5 ZD]*3V
M&MSS>XO?B#X=_LO6]7UFSN8[V[AMY]#2S1?)\Q@,1RJ2SLOOQUKU&O'-$\6W
MU]KL&K>)/!WC"6_#[+6"/22+6Q#'&X$L"S8/+D=,@ #K['5]/Z^XGJ%%%%2,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex10-3_003.jpg
<TEXT>
begin 644 ex10-3_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2Z Z8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&VT'DG P,\D_6G:TUQ8^,M,U.:TNKG3$M98?]&@:8P3,RX<HH+8*@C< <=\
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MG[E3R&?GY0?4UYE<VVGZKX.\1W">$/$\%Y+9&V U83W;RR<E!&C/(Q"L<[\
M#KGKC<AGC'C3PW<+INHK!%H\T;R?V9.%C<F,JI.S@_(_!_J,EOZ^3?Z?B']?
MBO\ /\#MVU.P33?[1:^MEL=GF?:3*HBV_P![=G&/?-)'JFGS6D-W%?6SVTQ
MBF692DA/ "MG!S[5Y9%'J'_"':?.NCZY<0V&IW4MU8VZW%G<F-WD*/']QFP&
M'R@]R.HJSJ%EIW_"/:-<VWAC6X/,UF*\:*]MIKRY501YCOS(R9 '!()]*+:_
M=^-O\_P$W9??^%_\OQ.[U'Q;H>G:%=ZP^IVDEG;$H[Q3*P\P<;,@_>SQBM.S
MO;;4+.*[L[B&XMY1N26%PZ,/8C@UYSJD=S?2^/K>UT[4&:Y@B,&ZRE19BB;6
MV,RA6.<#@\]LUW$6MQF^L+,V5^OVR%I$F>V98UVX^5R>48C) (!X/0\4+57_
M *V?^0-ZV_KI_F6;S5]-T^XM[>]U"TMI[EML$<TRHTK<#"@G+'D=/6JZ^)=!
M:"[G76]-,-FP6YD%TFV!B<8<Y^4YXYJ#Q5:S3Z(US:1-+>6,BW=NB#+.R')4
M>[+N7_@59%M9:A%XH+?9IEL]8C6ZN25X@DC(PK=LLGEKCOL:DM?Z_KS_  &_
MZ_K[C;EEN)9M2-GK-LS_ &9&@@,2O]G;#?O&PP+!N."1]W@URUCXCURXTGP-
M>O>0XU641WJ_9QND)C=P5.<*/EZ8SSU]9;)H;#Q[XKN$TV]BAFLX&,L>FS;9
MI$\S?A@F';YEZ9)[9P<8FG//#X:^'T$FFZLLMG=*;E/[-N,PA8G0EODX&YUY
M/7J. :J-M/E_[<-[/Y_DCU&XN8+2%IKF:.&)>KR,%4?B:IOK^C1QW4CZM8+'
M:-LN6:Y0"%O1SGY3]:P/B9;QW7@V:$Z?->SF:,P)#9O<,KA@=P"J2ORAN>.N
M.]4C=0CQ]?7@T[4OLQT5(UD&EW&TL&9MH^3[VUAQUSQUR*B^C_KI?_@!;^OG
M8[.ZU.PL;'[=>7UM;VF ?/FE5(\'I\Q..:CNM9TJRT]+^[U*SM[)\;;B6=4C
M;/3#$X.:\LB34+;PEX3O)]%\0W=I86KVMY9V/VBUNXI#MPZJ&1G48(].<]JZ
M"WMULDT*+3]!U/3;:5;AA-<))=3V[2$$JXW.%+G)W.2HQ@X+<4U:]A'<M?V:
MQQ2-=P!)AF)C(,.,9^4]^.>*+*_L]2M5NK"[@NK=LA98) Z''!P1Q7EUI9&"
MT\ QW6BWYN;"[D6:1M-D<Q)MD7+%4(52Q0]AWZ#-=5X+E=M5\4!K6]@634S-
M$;BTEA5T,:+E2Z@'YE;I]>XIV7]?+_/\!/\ K\?\OQ.OHHHJ1A1110 4444
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MKR*6*;$0N-H&20IXYQP13+;QT?[(ENK[1KZUN5G6WBA^RW!$[,"08]T*R,
M<XCR,'@]VTTVGT!:G845Q+>/;J'PY=ZI<>&[Y)+69(GC*O$C!L8=6F2-BH)
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M()XG#;>7" -\K9!X'8FD](W_ *V3_4;5G;^M['10S17,"3P2I+%(H9)$8,K
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M!!M1!P F8B1@%AR3P3WP19'AD#0X=)_M?43!'$L#L?)W2QC(VM^[P.#C*@'
M'.>:/^!^O_ !;Z_UM_P2I<^*+G3_ !)?6E[#;+IMMI9U 31.SR. <'(P .AP
M!G/'(Z5A:I<:I>>(_ ]Y?-:"&YO7EBAAC8-"#;.=K,6(<\]0%^AZUTB^#[1=
M:_M#[9=F'[%]@^PD1&#R<?=^YOZ\YW?IQ5>/P)8!],,VH:I<)I<WFV227./)
M&,;-R@,RXX^8DD<$D<4XZ-/^NO\ FA:V?]=%^MRG9>*/$>J:G#/I^@O-HLD[
M0F0F%<*'*F4/Y^[MG9Y0/O1I/B3Q'J=AJ=[]BTP?8+FZMWMEE8%VC V8D;
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M)/!/?!%BQT"73KC2A%JNI2PV-NT!262,1S*?N[U51EEP,$ <9ZYI+^OQ_P"
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M#FC->M9;//)$15V9=P3+3QE."/FVN.>G%37'@*&YL];M9==U<Q:Q('N>8,C
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M28E<;TW<9 8;-QP<@ 9[9IK?7NE]X+96\_P1V4>HO'K!TZ[5%>56EMG0G$B
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M=3EFMC")O]$9 @ESM8A\':,<G''X'%6P^(WAW4M>BTBVO(Y)9V*P2)<0NLC
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M1UNYUVP\8Z9<:7>VL&GQND=PMPB E8E<<H^\$Y!QC&."<DBE)V3?;4<5S/\
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M^OQL>D45ST/B^VFNK2W73M0#WMJ;JT)1,3@ $J/G^5AN'WMH]":BE\=:-;Z
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MN!&<YQQUKL**'JK?(:;6J]3BXM$\1)KGA^^:UTOR].L)+691?299GV\K^YY
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M$L6"KE?W/( 0'G'4CMDY\'A+Q7#I?FVT^EV6L6VHW%[:D323P2K,6+1R?(A
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MAE((((!!!!&*S#X.T8WMW>>7>+/=PBWF9=0N%W1CH  ^!C)Z8ZGU-+HTO/\
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M02#@C-5=7^?^0NAQMB-7L;'QO?6VMW$EQ;W<IB6[ACDC3;%&V<*JMG'RCYL
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M[73<5S]",$'W'(J7K_7H-?U^)SRW6K6WCFTT635&GLI=*EE#- BS>8KHN]F
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M70],\.Z9'IND6:6MI']V-,GGN23DD^Y-/^OR_KY@]]#0HHHI %%%% !1110
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ML=Z[+XD7UE8^#+@WEU%;K+-"B&20)N/F*<#WP"?H">U5)6?S_5?YB6K:\O\
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MAD:!=KJ^?)(X^]R^X]=T>3UK2^(%EIES%H<VJVEK-;1:I$)'N8E=$1@P.<C
M!.T?E2?3S'W\CL:*\WU'^QY]:UJS\3I!&Y$;:(9AL(C\L8^SGJ) ^[(7YON]
ML5U_A\:B/!^GC6)&34?L:?:7ZLK[>3]?ZTNE_P"NO^6H=;?UT_S-FBO*5M/-
MT#Q!X9DLM)U1DTZ:1;S3U!WRX! GCYVS$E6!R2<$\58L[[3I_%GA&^T[R[B:
M72)[<W%O$9,N!%M1W4' !W=2-I)Z9I_U^#_RL']?E_F>F2%Q$YC56D .T,<
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M?UO8]3K#UGQ+!HVKZ582PLZWTWE/,& 6#(.PM_O,-HJW8&UTOP_"\M\'MH(
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M1K&9&  &%4850!P!^I)-:E%%-NX!1112 **** "BBB@ HHHH **** "BBB@
MKE-6\&)JVM&^N4T6]B8C*:EI"W,D:@?=CDWKM'4\AN2:ZNB@"M86-MIEC#96
MD216\*[41%"JH]@.!]!Q5FBB@#)\0Z,VN:>MJ);=5#AVBNK47$,N.SH2,C//
M!'(%0>'_  O8Z#NFBL=*@NY$V2/IU@MJC#.?N@L?S8_A6[10M >H4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFWV[3Y;!W$C85P6.2P8^_/%=G_PANE_\_6N?^#V]_P#CU'_"&Z7_ ,_6N?\
M@]O?_CU5S:W\[_BW^I%M+>5OPL;Y 8$$9!X(KS+_ (174[OPUK&D&!HWTAW7
M196& Y#B:,CV&(TS_LL*Z[_A#=+_ .?K7/\ P>WO_P >H_X0W2_^?K7/_![>
M_P#QZI]"KE6V6]?P+?7MUI3S:A?P27$VGEBC,S+@1$]00H5?PKF);>26XO[B
M[T^_O+6[T 0!3I,BJKJQQ&(RI?N,!LGOT&:['_A#=+_Y^M<_\'M[_P#'J/\
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M !1110 4444 %%%% !1110 4444 %%%% %:_U&QTJT:ZU&]M[.V4@&:XE6-
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M<?+SW&>-DZOKA\22:,KZ<K3V'VRVF,#D0X8*5==X\SDC!!3Z4W_7W7_(F_\
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M ^894@M.,@CGU]<5O:;>_P!HV,=R;:>U9BP:&X"AT()!!VDCJ.Q(H7=?UO\
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MRNJIY@?<@8A7R.F1@X[9Q5FD'D<MH'@/3O#FH27%EJ&KO;G(AL)[UGMK?/\
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M48"@< "GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWMU_5/\ S0NEOZV:_5?<<S>ZG?Z%>>,HK&XN94M+&"\A6>1[@Q._F;V4,<X
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M CFO2FTO3WM)K1K"U-M/GSH3"NR3/7<N,'/O2PZ9I]NC)#8VT:-&(BJ1* 4
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M""BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKJ"7;W"6]ZT<D4W[\RA'V,P*D?*<U<\/Z$;K1+^'4? 6F:!]H"QO!83Q^9,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXEFB4NDBRPL Z.C!E89!!P0#@@CU%1:=H46G:E>7ZW=W//=K&)O.==I*# ;
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MUO?Z;_:7_+O]@\K_ &O-\S/Y;<?CFK-) SCA\/H1HZ:8-?UCRDOOMX?%MO\
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MKK6I?:;BU6U9<0;%5<[2!Y6<@LS<DC)Y&,"M=;ZW?49+!9 ;F.)970'E58D
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MLFL>+8+6%XX!J0>']TRQF/RD VMC:1\IX!X&.@Q7=T55_P"ON_R_$5OZ^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1$S%U^;YLORF>J]<>]:'@W4KK6/!VDZC>N'NKFV625E4*"Q] .E"6E_ZZ_Y
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M33SIO]I"_M38;/,^U"9?*V_WM^<8]\US_A+7;O6-:\1137UM>6EK<1+:26R
M(8WC#CD$[OO=<\XX Z46UL'2YU=%4K[6-,TR2&._U&TM))VVPK/.L9D/HH)Y
M/TIKZWI,<UW"^J62RV:>9=(UP@:!<9W.,_*,=SB@"_16%=>,O#]K?:9:/JUE
MOU(%K=OM";77'!!S@Y. /4].E4]!\0.+G4[77-4LA.FJ/:6@(6#S!L1@BJ6)
M8_,>Y/\ *FE<3=CJ:*I7NKZ9ILT,-]J-I:RSMMA2>=4,A]%!/)^E/N]2L+ $
MWE[;6X"%SYTJI\HZGD]!ZTAEJBL*^URRT2'5=4U#6K=K*W1'\D;08!CID'+%
MSTS]!4EOXL\/7/V-4US3#+>*#;QB\C+2Y.,*,_-R"..XH V:*J6NJ:?>W-S;
M6E];3W%JP6>**96:(^C '*G@]:HZ;XJT;5M7U#3+/4+:6ZL6VRQK*I;@#<<=
M< D GIG([4 ;-%4[#5]-U3S?[.U"TO/);9+]GF638WHV"<'V-27U_9Z9:M=7
M]W!:6Z?>EGD$:#ZDG% %BBJW]H67DPR_;+?RIAF)_-7$@QGY3GGCGBLO4O&.
M@:9HL>KRZK9O92RK#%,DZE'<MC 8''')/H 2>E &[16?/KND6MO;7%QJMC#!
M=$"WDDN$59L\C82<-GVJ6XU33[-]ES?VL#8!VRS*IP2 #R>Y('U(H MT52U9
MV3396348].;C%S(JLJ<C/#<<C(_&EN]5T[3T=KV_M;98TWN9IE0*N<9.3P,]
MZ +E%8NH>*]$TS4].T^ZU*UBGO\ )A#S*NY<<$9/.3@#USQTJZVL:8FIKICZ
MC:+?LNY;4SJ)2/4)G./PH NT54U/4K/1]-N-0OYT@M;="\DCG  %<T/%0N]9
MT.[M-5LFT.\MIY)MNUMKHH)S+NP ,X(P,$<GM1_7Y_Y!_7]?>=A169>7L-YI
M$5U8:S;6\,KQM'>*4DC==PRH).#N&5S[\5:?4;&.^6Q>\MUO&7>MN95$A7.,
MA<YQGO0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9++'!$TLLBQQJ,L[G
M]S0!SNK0O'XY\/7S,1!Y5S:_]M'"LOZ1M5'3HXX?BOJ\L6GW,27&GP(]P+&1
M(I959RV9-NUCM*<Y]NV!U5S;6NJ67ER8E@D =61OQ5E8=#T((I[P,]H8//E#
M%-IE! ?Z],9_"FM/Q_$+W_#\#"\.1$ZYXFNUSY$]\JIQP2D**Q'_  ($?\!K
MHZAM;6&SMDM[= D2#  _F3W)ZD]ZFI!OJ%%%% !7$>)KO;X_\,.MGJ,L=HTY
MGEAT^>6-/,CVKEU0KU]^.^*[>BA;I@]FCFO#23VVL>(H)[6XC\S4#/'(T9".
MACC *MT/*MP.F.<<9S[RZC7X@7LLNGZ@\46D>4)ETZ:1"^YF*JP0ACM(X'7.
M.3Q78+<P/</;K-&TZ*&>,,"R@]"1U .*EI-77RM^%@6E_P"NMSRW0%O/[!\-
M6C:9J-K,FERVKW3V$I>)OES%L9=J9V@[W!7Y<#K5FPL+V#P1X;N8YM4TO4].
MLQ"!_9[W"MD*&22%1NP2!R-I&"<XKTFBK<KW_KO_ )@4='>[ET2S>^M4M;MH
M5\V"/[L;8Y ]J\^C>6W\-^%M/NM)U0R6NI W"C3I9%15+@L=JGY?F7!Z'/&<
M''I]%3]J_P#6]PZ6_K:QY?=V^HWZ^-8M/T_4#))?P7,<30S6HNHT6,2+'*0O
M)V, 5.>AZ'-;O@5;*Y>\U*VT#Q!I<TJI%*^MSRO)+MS@*))'.!D\\=>_;LZJ
M6.J:?J?G?8+^UN_)<QR^1,LGEL.JM@\'V--.W]?():ZG+ZQ=^5\2]#D-IJ+P
MPVEQ%)-%8321JTACV NJ%?X3DYP,<XK$U:TU!=%\8:9'I=_-=7.I+=0+%;L5
MEC)BP5?[I/RD$9R.I '->G44E_7WI_H#U_KR:_4X2*^9?'FK7DNG:I%$VC0I
MDV$KC>K2,R!D4JS .O"DY/ SBM/X>AX_ &D03VUS!-!;B*6*XMWB=6'4;6 /
MX]#745'/<0VL#SW$T<,,8W/)(P55'J2>!3OI;^MW_F']?@E^AY[X/T_3T\/^
M(4N]"F2W%_=30P3Z5(I:%^!LC*9.0"-H&?;FLA=:M?"W@+P;J.IB:RFL-T/D
MWUK/$F_RF4AL1LR^S!2.OX>N@@C(Y%9FJ:0VHRPSPZE?6%Q$&59;5D/!QD%9
M%93T'.W/O2U6WE^ ]'OY_B>7Z?>:!=^%89]&4:G)=:]'=7QTW39G$8\W>5<"
M/<553@%@,]AV&U>PW&H3?$&TM=/O]]Y9JMOOLY8TF982AVLRA6.<#@\]LBO0
MK6U^S1X:62>4@!YI<;GQW.T #Z  4Z:Y@M@AGFCB#N$3S'"[F)P ,]23VI^G
M];?Y"3:?-_6[?ZF58ZW&9-+LFL-1C-U;ETEDM61$*@?*Y/*,>2 0.AK%\>PV
MJWOA:\FM%FEAU9 K+$'D"E')"]^P.!UP*ZZ<V\ -U<.D:QJ<O(^%4>O/ ^M8
MVNZ1:ZY>:2SZU<6;V\WVFVCMVA_?.!][YT8L ">G&#]*&[M/S$E9->7Z'+:C
MI6I:A)J^LZ99W L[BYLIOL4D)ADNEA;,IV/@@L,## $[/0BMG3[4:OXPFUFW
MM;B#3IM.^S7*75J\#7$F_(RC@-\J[ADC'S<$UU]%+I;^MK#\_P"NYYY]CUFT
MTRQN8[&YDN?#]U]FACQS=0%MA8>H\LH?]Y3Z4[QC:7NGOHM\VG:OJMA;1RQW
M<.CW$L5PLC[2)0(W4N,A@1G^+->@,RHI9F"J!DDG  IL,T5S D\$J2Q2*&21
M&#*P/0@CJ*-7_7];[^H'F-UIME!/X*DLO#FJVR0ZA)<.D]M+<S01NC[C(XW[
M<N5.TM[]CCO[6^MH=5?1(+&XMU@@66-Q;[(&4G&U&'&1QD=LBM*F")!*9<?.
M1C).>/;TIW_41R_B19W\064<5I<)YEI/$+^&W:8J6*_N\<HF=H.]P1\N.]<G
MH%L+74O K76BW\=Q9Z9);W$S:9*?+.U0@9PA Y#\$C'7C(SZO4:7$,LLD4<L
M;R1XWHK E<],CM0G;^O7_,IO2W]=/\CR_23>QV=E>'3-4:QL]=N[FYMFL)4D
M,<AD,4BQLH9P"P.%!(STR*Z'PA%=)XL\5W$FF75M:7EQ#-;S2QA%D'E*#P?F
MSGDY'UYR*[.BA/\ K[O\A/7^O7_,\[\<6UY?/XBL[73[M)+C20J306K3?:]N
M\B/<043!;IC<V[@\"KJ?:+?Q?%>O87QAO-&2WB*V[-MD5V8J^!B/(88W8';K
MQ7;T4NEOZV:_4=_Z^[_(\U\-0:C9:?X(:[T?4(3:03VTR&'<R,4&TL%)VJ=I
MY;&.^*I:G(UQX=\7"+2=6-Q<ZK') /[*N-\BCR\,OR9(&Q^>W'3(SZO13;UO
M_6Z?Z$M7_KU7ZG!L7BU+Q!'J6F7U[:ZS'&UFZV4D@*>4%\EQC]V0V3\^T?,>
M<YK,T_19;/Q=X6@U.PFNYX-$DM+^[^PO)&S'8%1I=NUNC]3QSG&:]*AN8+E6
M:":.4(Q1C&P;##J#CO4M"=OZ]?\ ,;_K\/\ (\QGT_S)/B'8Z9I%U";RU'D
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MU#8V<]W<.$A@C:21CT50,DU-61K^F:EJD%O#8:C;V:+,LDPFM#.)54@A>'7
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MJYCNU4MU-L"423! WE,]R>379W'@NZN)KE_[6C'F:A%?QNUINE78X;RV??\
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M9KRVUNRCU?R+/5;A;DJML&DBD^7=ABV"IV# V\'N1Q4K9?UU7_!&]]/ZT?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5,1P"!E)Y#(#SSM3'''/%CQ+K]_87=KIFD63W6HW,4DRX2-PB(5!)5Y8MW+
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MRD C//!SV"U<UZ76!XS\/V]C?VT%K*)WDBEMFD+%5'<.O9B!Z'DYZ5*Z>?\
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MN 1YCJ&3]Y\I^3H=W6K%SXIU*U\2VEH_V$VT]_\ 8FMDC=Y8P02LC2JQ1<@
M[&4'!ZTNMOZZ?YBOI?\ KK_D=)8ZUINIWEY:65Y%<3V3B.Y6,Y\MCGY2>F>#
MQVJ_7+:#_P CWXL^MI_Z*-3ZAJ&KVOB5+,7-A%875I*UN\EJ[,DR '#'S &&
M"6P #A3R.M'1?UW_ ,A]7_7;_,Z"21(HVDD=41 69F.  .I-5M,U2RUG3X[_
M $ZX2XM9"=DJ?=;!(./49!YKGO#^M:QJ]E8>=-8QWJSS)J$8M' "H<84&3*G
ME#D[LALXK&\/ZMJ.D:/HS*+5["[U:>SDC*-YN7FEPX;.!@CE=ISZCI32UMZ"
M;M^)Z+17&WOB?5'L=7U?3%LFL-(FEBFMYD8RW'E %RKA@(SG< "K9P.1FGMX
MR0Z_:VCW$%C:W4,<EJ;N!P+LN 0$EW!0PY&P@L3Z"DM?Z^8WH=?17%7WB?Q%
M-JMS'H&A/>VME<&WF)\D"5@%) =IT:/&>\;9_&NU'(!(Q[4=+AUL%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&5#,0K*Y7&,;21C!-7]*_L;4?%GA;5KF.RNY[C13Y5V8UD9YU:/H^#EU^?W
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M]R_ME!53MZ[XE/S$?*!DGG-<WJT&EVGAKQAI9M;=;B#5UNH+1(0716,6V1$
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MEB$&Y-P#'Y6.=IX!QCMWY[4/#'B:]TKQ;:>1I ?6I0T#?;9,(OEK&=W[GKA
M<#/7&>,G5_LG7I/%^GZM);:8EO#ISVDJB[D9@[E6) \H!@"@')&0<\8P3HOZ
M^S_GH$MW_75?\$V])U==7MTN([2YAAD!>)Y=A$B=F&UCC.>AP?4"I-5O'LM.
MDEB :=L1PJ?XI&.%'TR1GVS6'H'AB31==N;JVA@T_3Y(ROV*UN'DBD<D'S-C
M*%B(^887.<Y)J?6=)O=9UNT@O-.TJ\\/1J6FCN9&9VDQ\I\LQE& YX+=3GC
MR-)V$B#P5=WJVVH:-JES)<W^E731-/(<M-$WSQN?JK8^JF@>/=-:R>]6RU+[
M'%>?8YYGM]GDOD*"RL0^,L!PI/J .:IP^%KW0O&D>H>&M*T.STF6V$%Y"CM
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MW#J]RHX$<D6W8W&/F))&.!6;>^#];FTK5=+M9]/2*XU1=0M[B5G9O]:LC*Z
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MP\9[U0\':;J^DV%U;:M#8H7NYKB-K2Y>7/F2,Y!W1IC&['?/M5Z*3MM_P?\
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M<!45,,#&H&0N>">N.V:Z2CHO1 ]V%%%%(04444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLK4?$%GIFKZ9IDZ7!N-1=D@*1$H"JECN;H. >.OM2\@-6BBB@ HHHH ****
M"BBB@ HHH) &3P* "BD!# $$$'D$4$X!/IZ4 +167H.OV?B*QEN[%9UBCG>
MB>(QMN0X;Y3R.?7!K4H ***BNKA+2TFN9%D9(D+L(T+L0!GA0"2?84/0-R6B
MJ&BZO;:]HUKJMF)!;7*;X_,7:V,]QVJ'7/$%GX?BM9+Q+AEN;F.VC\F(N [G
M W'HHR>I-.VM@\S5HHK)LO$-IJ%]JMG!#=^=II59@\)3<2"1LS@MTZ]#D8)I
M :U%06=S]LLH+GR9H/-C5_*G3;(F1G##L1W%3T-6 **** "BD=@B,Y!(49.
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MWBV#;CF!]A5T'HVYL-SBN](R"#T-9T.A:=!=O="&225XS%F:9Y0B$ %4#$A
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M;V_FU">XM;B=OLD,B1A8HP< J54$ACD_,3QCWSLU%;V\5I;16\*!(HD"(HZ
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M,5K>"=3.G>$/#.G76G:I'-)$+9S)92(('4=)-P!4'H#C!-.W]?-K]/Q%TO\
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MX95=58=02#P1Z5YO,9K;PG8:=<Z3JCRPZYYDJ)I\LH\L7+2%OE4Y7:0<]#G
MR00)K^"_U"]\;V^FV5^);A;=X0]O-;I<^6 )$64A0"V-N0<\Y'3-'3^NT?\
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M/O"3IVH6OX@]+G845R5WXTEM1-=II#7&F1WGV 217"B=I]_EX$;A5V[CC<9
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M#ZV_KI_F;T-S!<JS031RA&*,8V#88=0<=ZEKBOAA$D'A_48HX$MT35[Q5A0
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M[MPEHW[YFF 6(XS\_.!V/-8=IXQ_M#2[![6Q5M3O7FBCM'GVHK1$K(3)M)V
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MBANX)6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7M@]JTL4FHR2J0TH =9@^YE.&X8@C X&!7HAA%OH[PV5QM,<3)%-/*TNT@$
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M\GV=N<DO)-*WS9^Z2 -O ZT[7(4T_P 3K-/=W_V;5K62U$2ZA,BK<#!01@,
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M&G4V.-(HUCC14C0!551@*!T %.I#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2&1@P'LJYQ22UU\OU_I#?PW]?R_JYO'QPWVO4;<>&=;;^SF"W3I]F8("-P(
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M>"?"N@:_&)F:%HIXI.HS$YV_51@9]J73;K4M+\1Z7X8U;S;@Q2O+8:@1D7$
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M^X2-5EEV@;V Y; P!DUS/B#Q#?:9XATXP[?[(CN$M=0.T$AY@1&0>P4[,_\
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MI#))Y=]$VQ!U8X;@#UK2@O[.ZL5OK>[@EM&7>L\<@:,KZ[AQCWJIOFYF^O\
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MM@EN9EC4MZ98@9X-9]QXQ\+VCJESXDT>%G19%$E]$I96&0PRW0CD&DM/OO\
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MWUWYQCWS2E[RLPB[.Z,'0$U+3_AU9V=QHMX+^ULTMC:"2 N[!0N5;S-F._+
MX'2LRTLM9A^$ T5]"O!J:Z>;'[/YT&2WE[=X;S-NW)]<^U=E8ZKIVJ6AN]/O
M[6[MAG,UO,LB<=?F!(K/@\9^%KJX2WM_$NCS32':D<=]$S,?0 -DU4VY-WZ_
MU^HHOELUT.9UN#7+S0O#,$'AG46FLKNWN+A//M046+@C)FP2>HP<>I!XK9UN
M"?4K:ZM=4\+_ -L:?,R^3 KP[T^09WAV4##9Y5B?;O745'/<06L?F7$T<2%@
MNZ1@HR3@#)[DD ?6AN][]7^8DK6MT5C+\+:9<Z-X;L]/NYC++"I7)<OM7)*K
MN/+;00N>^*V*JZAJ>GZ3;?:=2OK:R@W!?-N95C7)Z#+$#-.N]0LK"R:]O+NW
MM[10"T\T@1 #T)8G'<4-WU8TK:(L45A_\)IX5W1+_P )+HV91F,?;XOGYQQ\
MW/((JW=Z_HUA?Q6%[J]A;7DV/*MYKE$D?)P,*3DY/'%(#1HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;<!@Y[@C:?2FG:WE_E;\-P?5=[_FB_=:18WEXEW/;HTZ1O#YF,$QN/F4GT.
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MSIQ]W]>:I0^#Y(+#3+-/$NM%-/?=$S_9W=\# #$PG( R/7GDGC!96Y?/^O\
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M 0#[;OQKM],\/G2?#<>BV^K7Y2*,10W+B$RQ(   /W>TX [J??-5;'PB-/\
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M\9ZIJ)T/6M&DM;2-K":.>U-UG?@N?EE3 . O.<[#BEK9?/\ !_TBM+_=^/\
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MCW=B6)]\YIVTO_6U_P!0_K\;%BBO)EM9$\'>.KD:GK/G6%U=):R'5KDM$L:
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MS26@/4BU#2=:N/'=CJL=KIKZ;;VTMJ_F7;B5ED*%FV>41QL(QNYSU%/L=/\
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MK>RE9XQV"&''7DJ20<8SSD:NJ^*M*T6_@L;W[=]HG!,2P:?<3B3 )(!C1@2
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MDW%OITE]:1>5#Y=V_ERCU9C$"G4\!6Z5M:7K%IK$4LEI]H B?RY%N+66!U;
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MMEJ@D^QSB1HB!*A4J\9(R%92 5..<$ ]*%MH-ERBBBD 4444 %%%% !1110
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M/RQLI^?''4<'%=)X8?1XFN;70M(N;"TR)G#Z=)9QAR N$5T7/"Y.!_.JMO\
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M<%6=0'1DC#,,%<@XQ@]:MZ'I<]SXOU/Q1<P26PN+>.SM891A_+0EB[#MN8\
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M'XPUE]6\,X@TO5R&U"W,*#2[@R,D<L;N[+LRHQG&X G'&:%;W?E^?^13W?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2PF696S$N"1E25;/X54K1E8B'O*Z/0:*X7QE<:=XG^$%_JA@@N(9-.:Z@\Q
M_EOL)!&>C#)&>M9>C6=A<>+]&D\)::VEQ6D9;5R+-K-9D9,(IB8*7);)#;<#
M!Y[4^5W:877*I+^MCTZBO--=TC26^*#/)X/AUIIM+\R1([>V)W^;C>WG,H)P
M,9R378>%;*TL]')L]+32TFF>1K-$5!$V=N,*2H/RC."1G-2M5?\ K>PWO8VZ
M*\PU/1](_P"%HZEO\%PZUYFFP2NL=O:G:YDDR[><ZY)P!D9/'-;P\%^'O$/@
MU=.N]$AM+:?=*ENL:J;1VZ[-O"D'K@XSGM1KRW&U9V_K8[&BO+/#>D6&O1Q>
M$-<LM/DC\.OD*D"A;P9(611CA>"' ZN"#QD&QKFF>%K7XAR#4?#4=W'-I:MB
MWTAKD[Q(1DB-&*G  #''3&:'H_42O]QZ717D&I:/Y7@;0Y?$VFFXDBUI!%'=
M0?:KB.U:8[8S@,S';@%1DG@<UT/@^TB?Q=J%_H%HVG^&Q;"W:U,)@5[H.=S"
M$X,>%P#E5)S^--+^ODG^MO43?]?-K]+^AWU%>2V^CZ-;^)_%JCP!#JZ172%&
MBM;0I%F!&*XD=3R23\H/7UKH?$6CW,&AZ*--TA-2TFS):ZT8%0)HV4X"J?E;
M83D(>#]0*71/T*:L['<T5PEI+:^(O"&L1>$+B6RNW41FTN \+6D@ _=;3S$"
M!CY>!DD4WPK?:'-JZZ=_8LOAW6(XW,NF/'LCN 0-SKM^27_>^]U]:=M;?U_7
M];$WTN=[17"> ]"TBPUSQ3-9Z796\L6IM#&\,"HR1^5$=@('"Y.<#C-6/'7@
MZTUB*+6[;2[.XUK3G6>'S8E/VA5Y,39'((SC/0X(I.RLV/>Z1V=%<?I>GZ+X
MUO+/Q;/I4$@2(+8M<0#S!SDL<C/#<+Z8)'WJ/B?8V=[X U-KJU@G,*!XC+&&
MV-D#*YZ'!(R/6FU;3^MP33V.PHKS_P 8>&]*\/>$[W7= L[?1]1T^+[3'+8Q
MB 2;.=D@7 =2,C!SUJO>:?I>J_$7PAJ<^DV?VB[L)[F0O;J6+JL10DD9)7/!
M[=J$KNW];-_H*^E_*_Y?YGHSHLB%&S@]<$C]12JH50J@  8 ':O+FDM=!U2Z
M@\7Z;+!<75Q(+;Q-"N59&?*1O(OS18R%VGY#CWK=G<>(_B)=Z)?+OTK3K".8
MVQ/[NYDE+#+CHRA5("GC))P>,):V_KI?^O\ (;T;_KK8[6BL1?"FCPLZ164"
M6+V[0/8",?9V!(.?+^Z#QS@<]^@K'^%^F6%AX)LYK.QMK>6?>9GBB56DQ(P&
MX@<X' S0NHGT.SHKEO&]_IB:;'I&IZK;:=#J>Z*2:>X6'$8&6P21R<A?7YL]
MJ3P-JL/B;P3 +F2VO6B#V5V4(DCE9#L)[@JPPWN&H6J=N@WI:YU5%>/Z7X1T
M"^\#:_#)H]BI?6IX5D2W1711/M7:P&1@,0,=,UUVA:W>#PR^G7# ZY93_P!F
M-NYWR#[DF/0IB0^V?2C=:>7X_P##@]']_P"!V5%>06>@:6GP:\3&2PMIYEDU
M!FGEA5I'>.24([,1DL.QZBM_P]I&D&\TEH_ ::1,D8F6_-O:J2RJ. T3LW.3
MU XSWIV_3\5<'HOO_!GH%%>>:-X0\-7OB_Q8EUX>TJ94N(-@>SC.W="I;''&
M223COS5WPE/-IWC'Q#X9$\L]A:+#=6IFD,C0B0',>X\X!&1GH#26OW7!Z7.V
MHHKS#Q?XITVS\26^I_V[8Q3:+=I ]BUVJR21R#;,=F<G 9"./^69]:%JTOZ_
MK8.C9Z?17*^-= M=<T^TF1A;ZC'<0_9-0B4>; 2XY5O0]QT(K*EN;/Q-8+I'
MB;3+*36M.O+<3P31*ZLK2J/-CW9^1QGZ<@TTKZ =_17G[^%O#UY\4KQ+K0M,
MG0Z3%*5EM(V!?S7&[D=< #/H!4NF+_PC?Q+'AZP9QI-]IS7:6I<LMK(C!?D!
M^ZA!^Z.,CC%):V\_TO\ Y ]+^7_ _P SNG=8T9W8*JC)8G  H5E=0RL&5AD$
M'((KG]6N1=^*]+T-^8&AEO9E/20(555/MN?=_P !%<=?:-HX^)VLA_!,6LA[
M"WE98K:U.QV>7<Y\UT^9L#D9)QSVH_X/X#_X'XGJ#R1QE0[JI=MJ[CC<?0>]
M((D$IEQ\Y&,DYX]O2N%\ 1Q:GX>U:PNRX1+^51ITY8R:>G!2,D\Y'W@02!D;
M3Q71^%-2DU3P]#-._F3Q/);RO_>:-V0D_7;G\:=OZ]2;FU17DMOH^C6_B?Q:
MH\ 0ZND5TA1HK6T*19@1BN)'4\DD_*#U]:[JZN['PKX-65'M[.WBC5(?-8)%
M&SD!02> H+#Z 4NERFO>L=!17!_#K5+$7.L>'[/5K;4XK.?[1;SPW FW12_,
M<L">0^_\"*/#EO:^-9];U#7K.*\BAU*6SMK2Y4210I%\N0C#&XG)+8SR!VIV
M_*XK_P"7]?([RBN \?\ A[3[?P!KI>W6Z3(N((YP)/(;"K^[+?=X';&,GM65
MXRBMKSP_I5E/X&GL[:&_M(XI+B.S,4*-,@90$E8@,." N#GGBA*[MYI?>'_!
M_ ]4HJM+I]E+IS:?):6[V1C\HV[1@Q[,8V[<8QCM7C^B6%I/X>T-?#.A7-IK
M\=VAEOHM/>WC\H2_O"\VT)*I7C;EL\<<<):RM_6]@>BO_6USVFBN*^(5]I\U
MB-"N]<M-)>ZA>837%RL/*?< )(S\Y4GV4CO5W2M1LO&?P]AO+J"VNHKFU/GQ
M,JR1^8O##!R#A@<?04F_=<NPTM4NYU%%>)^&K+3[S1O"$'AG3&L=?1;>XN[U
M;-K4/ N/-+,0OGJ>!QN&2#QUKK/B?X;T:7P=K^K3:9:3:@8 5N985>1,8 "L
M1E1]/4U<HV=O.WY+]?P$M7;^NIZ!17,?\(!X4GL)K?\ L#3XX+J%4FCBMT16
M(SAL*!AADX8<\US6AZ3;SZ9/\.;_ $RW:.P<--)Y "36Q.8Y!QCS&P5)Z@JS
M9SBE;6W]>8KZ7_K^NAZ915.WTK3K32QIEO8VT=@$,?V98@(]IZC;TP<G/KFO
M-_!L5M9^'=4LH/ T]Y;37]W'+);QV8BF59G"J0\JDA1P 5XQQQ2?7R'T1ZI3
M#$AE60C+*,#)Z?A7CYT32?\ A05O-_8UFTFR.? MX]QD,@4G/3<1\N<].,XK
MK]$T?2!KL+P^!X]"EBA=UF,%JAESA2N87;(PQR&QVIVU:[?Y7$W_ %\[':45
MXF^G>'((_%&G6GA]1K4FIRP:9-;6!B\J0QKL"W 4)'@Y.-P/MS74^/M+#?#F
MP&L6D&IZA:RV:NS1(S.YEC5]I;@;N1R0#GFDM4GZ?C_D/K;U_#_,]#HKBM(T
M+1YM3F2+P6OA]A;,OF"&VC:57RK+F%V&!QUQSBLJ;P;X83XHV-BOAS21:G1Y
M9##]BCV%A*@#$8Y."1GKS3MJE_74.C_KM_F>E45P7V:&Y\=0>$3%MT/3M*%P
M+3^"9F<HJN/XD50?E/!SST%/O8HO"7C7PY;:- EM8:JTUM<6,"A8@57>LBH!
MA2,$$C&0>>@H6MO/_@_Y ^OE_7ZG=4444@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'1M/L]0U72-2L;.=PDLTODD6I+;5\W;(2 <CE=V,\XJFVW?^M?\ ,.G]=_\
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M,DH>C NZ@CIT.>:T()&FMXY'AD@=U#&*0J60^AVDC(]B1[T")**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH KW][!IMA/>7+A(84+L2?T^O:O.-4CUW0I])
M\2ZEIVF6\=E=,;ZXBU!Y':&<A7RIB4 *2A^\<!,<UZ)J&EZ?J]M]FU*QMKVW
MW!O*N85D7(Z'# C-,NM%TJ^T^/3[S3+.XLH\;+::!7C7 P,*1@8[4+1W#R.3
MU65;'XK:-JE[.%TVYTV6TMI6/[M9RZMC/0%E''KMKM6DA,Z1L5,N"RKU('3/
MMZ9J!=)TU=,_LQ=/M!IX79]E$*^5M]-F,8]L5';Z%H]IITNG6VE6,-C*")+:
M.W18W!Z@J!@YHZ6#K<\V\/7NI>'M"M=?GC%_H,3W GB1?WMCB>3,RCHXQ]X?
M> Z=P>_UB6TU'1[.0-%/:7-Q;E2<%9$9UQ]00:?%X5\.P6,]C#H.EQV=P09K
M=+.,1R$="R@8./>H_P#A#?"YMEMCX;T?[.KF01?88MH8@ MC;C. !GVIZ;/R
M%_P3EW6[\)7UGX>E26?1;N]A_LRXY8V["16,#^V 2I]!CL*NZ"K:?\2_%$5\
MP6741;W%FS?\M(D3:RJ>^UNH[;@>]=FT,3HJ/$C(I!52H(!!R"/H0*@O],L-
M5MC;:C8VUY 3DQ7$2R+GZ,"*+_K^G^0['*QQMJ'Q<-]9N&MK'2S;7<B'*F5I
M-RQG_:4 L?3</6L:?2VOG\0^ 0[Q)-*U_"RY&V"0%^#[3@C'I7H]K:6UC;);
M6=O%;P1C"10H$51Z #@4X00BX-P(D\\J$,FT;BH.0,]<9)XI=+?UO?\ ,=W>
M_I_E^1R7@?4YO$EM%JUS&4FMK9;)U8$%9QS/_P"/!1_P$U-X6/\ Q57C'_K_
M (O_ $GCKIX;>"W1DAACC5F9V5% !9CDDX[DDDFL0^!?"+,6;PKH9).23I\7
M/_CM-O6XDK*W]:&+XQD75KGPL+*]FMPVLE%N8 C,"L4H)7>K*>01R#6W;V<N
MF1:A!=:O/J$T\321M<B,2!57!&(T5<9/7'>IKCPEX;NXX([GP]I,T=NGEPK)
M91L(UZ[5!' ]A20^$O#5O;SV\'A[28H+@ 31I91JLH!R P"X.#SS4M7BX^OX
MCOJGV_S,/PSJEAH_PCT>\U*>.&V33(MQ<_>R@^4#N3T '6N/T>UO_"UC\/;[
M7 \6GVPN(I_,'%H\W^I+Y^[@';D],XKTVR\)^&]-N5N;'P_I5K<+]V6"RC1A
M]"!FM9T21"CJ&1A@JPR"*T<KR<N[_P _\R;:<IR/BZ>^75_#:6&MW%I#?7H@
MDCAC@<,NQWW@O&Q!RH&0<8/3/-5%TZZO_B7K_P!FUJ^T[98V>[[*D#;\F7KY
MD;]/;'6NIT_P]HFD3/-INCZ?92O]][:V2-F^I4#-59_!?A6ZN))[CPSHTLTC
M%WDDL(F9F/)))7)-0M/Q_&PWK^!EZIIFEZCIFDZ1>:M)!J5NX2TOX)0DBW")
MS@]"2"<KC!&1BI?"E]K::IJ.AZY-;7UQ8QQ.FHV\?E^<C;L"1>BN-I. <8(-
M;T.CZ9;V L(-.LXK(*RBW2!5C )R1M Q@GK3[#3;'2K46NG65M9VX)(BMXEC
M0$]>% %.^X,S?&?_ ")&O?\ 8/G_ /0#5>W_ .2:Q?\ 8('_ *)K:U#3;#5K
M4VNI65M>6Y(8Q7,2R(2.APP(JO\ \(]H@THZ5_8^G_V:3N^R?9D\G.<YV8QU
MYZ5#5XR7?_@_YE)V:?;_ ('^1YUJ&C7Z_!62Y/B;56B_L4/]E,=KY9'E#Y<B
M'?CM][/O7::W/</HEIIE@D$M]>HJ+%-,8E,8 ,A+ ,0-O&0IY85>;PQX?;3%
MTUM#TPV"OYBVIM(_*#?W@F,9]\40^&/#]O/;3P:%ID4UJ-MO(EI&K0C).$(&
M5Y)/'J:UE*[?F[D15HI=D<QX?FO-$\=WNGZI:V-BFM1_:[:*VNVF4RQA4D +
M(G)78< =B:N>,O\ D8/!O_86/_HB6M^\\/Z+J-]%?7VD6%U=Q8\N>>V1Y$P<
MC#$9&#S3=1\.:'K%PEQJ>C:=>S(NU9+FU21E&<X!8$@5*>WE_P $??S-.N0T
M#_DI'B__ '++_P!%M77@ # & .U9=GX;T+3KYKZQT73K:\;.ZX@M420YZY8#
M/-);W]0>UO0Q-%_Y*AXI_P"O2R_E)747O_'A<_\ 7)OY&J=MX;T*RU%M1M=%
MTZ"^8L6N8K5%D);J2P&>>_K5R]L;34K1[2^M8+JVD^_#/&'1N<\J>#S2DKQY
M?*WY_P"8T[2O_73_ "/+['1K]O@HER/$VJK%_8A?[*([7R\>43LR8=^.WWL^
M]=9>3W#^$]+TRP2"6^O;>-%BFF,2F,*#(2P#$#;QD*>6%:P\,>'UTQM,&AZ8
M+!G\QK46D?E%O[VS&,^^*;;^%?#MI/;SVV@Z7#-;<021V<:M%R3\I RO))X]
M35R=Y-]W_F):)?,YKP_->:)X[O=/U2UL;%-:C^UVT5M=M,IEC"I( 61.2NPX
M [$U#J%C/9SZKXB\(ZW% T<LC:CIEWAK::1,AB><Q.<#D<'C(KL;SP_HNHWT
M5]?:1875W%CRYY[9'D3!R,,1D8/-.NM$TF]N(+B[TNRN)X&+0R2VZ.T9)R2I
M(R#GGBIZ+N&A)I=V;_2;.[,#0&>!)/)88*94':?ITKC)-,O+&)?%&@1>=>Q2
M3)>6:' O81*_'_71>2I^H[UW<L4<\3Q2QK)&ZE71QD,#U!'<55TW2-,T:!H-
M+TZTL87;>T=K L2ENF2% YXIMZMH26B3//=8N!J7A7PWKT D.EV^M_;;D,F"
ML)EDP[*>@4L"?3&>U;OQ)9+_ ,#W.G6KK+>:D8X;)$;YG<LI#+CLH^8GL!FN
MO2&*.,QI&BH22550!DG)X]R35*QT+2-,N)KBPTJQM)YCF66WMTC:0_[1 R>I
MZT:;>=_R_P AK37K_P /_F<Y\1T>/X<W,<C[W5[8,W]XB9,FNS'051U+1=*U
MJ-(]5TRSODC.Y%NH%E"GU 8'%6;:UM[*VCMK6"*"WB4+'%$@54'H . *7?S8
MK;>1PVKQZW)\1[TZ%=64-RNB(<75NT@<^:^ "'7:<]R&^E7?#,6F0>![V+3G
ME,H$[WJW!'G+<-DR"0#@-GTXQC'&*WE\.Z&FJ_VJNC:<NHEBWVL6J";)&"=^
M,YQQUIMUX9T"^N9[B\T/3;B>=0DTLUI&[2*,8#$C)' Z^@I-7@X]U_G_ )EW
M]Y,Y;P9IES:^$O#6I7'B*]>TBM(I&M9U@$2@Q8 !6,.<%AC+'\36G:'_ (NK
MJG_8(MO_ $;+5^#P7X5M;B.XM_#6C0S1,'CDCL(E9&'(((7(-+<>#/"UW<27
M%SX:T>:>5B\DLEC$S.QZDDKDFM)2O+F]?Q(BK1MZ&'\1KN&Y\(74<+!S!?VD
M;D= WGQG'U (_.E\26D][\1/#L5OJ-U8/]BO#YULL3-C,7'[Q'7'X9K=?PAX
M9EM(K23P[I+VT+,T4+6491"W4JNW )P,XIL_@WPM<LC3^&M'E*(L:F2QB;:H
M& HRO  Z"I6G]>5BK_E^MRO);M8^&]8LI]1DOKE8)I7EE""0JRMMW!%51T(X
M Z51MM4L-)^%-A<:C*B0G2HD"-UD8Q@!%'4DDX 'K6W'X6\/1:=+I\>A:8EC
M,P>6V6TC$;L.A*XP3P.3Z4ECX5\.Z7<BYT_0-+M)P,"6WLXXV ^H -2U=-/K
M_P '_,2T:?;_ ('^13\ :=>Z3X"T2QU %;J&U575NJ=PI^@P/PJMX'9;6SUF
MSF=4GM]5NGE0L,JKR%U)]BK YKK*S[[0=&U2YBN=0TFPNYX?]7+<6R2,G?@D
M$C\*MRO)ON)*T>4Y/Q ?,^&'B*:-P$G-Q)%)U!4R':P]0>H]14U_X1U;4U?4
M;_5X;K4+>PG@L%M;4V\<;R)@NV7<EN .H ]*ZG4-'TS5[9+;4M.M+V!&#+%<
MP+(JG&,@," <$U/:VEM8VL=K:6\5O;Q#;'%"@1$'H .!4-)IK^MK%7]Y/^M[
MG->![ZSMOAYIGG21VPL+18;M9"$\AT&'#^A!!ZUB^%].DA\#HM_'BWOM8:>&
M"8?=ADGRJD'U!SC_ &J[6XT+1[O4(]0N=*L9KV/[EQ);HTB_1B,BG:EHFDZT
ML:ZKIEE?+$28Q=6Z2A">I&X'%6W=N3Z_YW)M9)+I_E8XIUN_"5]9^'I4EGT6
M[O8?[,N.6-NPD5C _M@$J?08["N]N[N"PLYKNYD6."%"[NQP  ,FGM#$Z*CQ
M(R*054J" 0<@CZ$"H;_3K'5;1K74;*WO+9B"8;B)9$)'3A@14MNUAK<\YUE-
M?TV.R\47>EZ=$EA>->7$Z7[M,8)/D=2GE!>$*\;S_JQUKL-=M-/UP:9:72Q7
M-E=M(",Y#J8G.0?U!%:,^BZ5<Z8FF3Z99RZ>@4+:R0*T2@= $(P,=N*K#PIX
M<4VI&@:4#:?\>Y%G'^YYW?)Q\O//'?FGIMT%KOU.9TVZU+2_$>E^&-6\VX,4
MKRV&H$9%Q (G&USVD7(!]00?6K'C>TDM=2T;6;"Y-I>R74>FS2*N?,@E."#S
MU4_,I['ZFNR:*-W1W16:,Y0D9*G&,CTX)'XU1U/0-&UIHVU72;"_,0(C-U;)
M+LSUQN!QT%%]K_U_74?>Q=MX(K6WCMX$"11J%51V KBO$<>IR_$?15TFZM;>
MY_LR[(>ZMVF0C?#QA70@YQSD_0UVT44<,211(L<:*%1$& H'0 =A6?-X<T.X
MU1=3FT;3I-05@PNGM4,H(Z'>1G([<T=;_P!=06QB^!HK.&RU!?,<ZS)=-+JJ
M2LOF+.0.PP-F -N.JX/7-8_@G2KK_A#]-OW\17L=I%*TSVDBP" *LK$C<(]^
M.,\OU]J[.\\/:+J-T;J]T?3[FX:,Q&:>V1W*'.5R1G')X]ZIIX'\)1NKIX6T
M174Y5ET^($'U'RT7UOZ?@)KH8]_'JEU\1<Z1J-I:,=(4N;FS:<,#*<8 D0@C
MWS]*H:_X?/A[PKI&GV%UON7UR"9KFYCWAIGE+,S*I7C)Z CCO79CP]HBZK_:
MHT?3QJ.=WVL6R>=G&,[\9Z<=:74] T;6FC;5=)L+\Q B,W5LDNS/7&X''04E
MI;^NMQO6_P#72QS>@0"'QQ?2Z]<QR>(FMQ%;LB>5#):AMV8E))SN/S L2"!V
M(S3T_2;W4O%/C+[+KU_IP^UQ+LMD@96/V>/D^9&S?D179W>BZ5J"6Z7NF6=R
MEL0T"S0*XB(Z%<CY>G:L]_ _A&1V=_"VB,S')8Z?$23Z_=H_RL._Z&=K>G:=
MKDNF6\.L/I^M01R&QO;9QN^7:LBX/#KG&5([=L54@U'5KGPIXJL-:^RRWFGP
MRPM=VBE8[@&+<#M/W6 .",\&NM;1],?3QI[:=9M9"/RQ;&!3&$_N[<8Q[4R3
M0='ETM=+DTFQ?3EQBT:W0Q#'(^3&/TI25TUW"+Y6GVM^!SOAO3+FRT?0M0NO
M$5[/;);1G[/<K J*6CVJ%*1JQ.2  2<Y[FG:QH!UG4+ZXL9UM=9L9(Y;.YQG
M8VP95AW1AP1_45K6O@[PQ974=S:>&](M[B)MT<L5C$CH?4$+D&K=IH6D6%]-
M?6>E6-M>3Y\ZXAMT223)R=S 9.3SS5R=Y7]2(KEC;T,7PAK4FMW&IRW-G)9W
ML#1V]W;O_P LY54YP?XE(((/<$5!X:_Y'_QG_P!=;3_T2*ZY8XUD>144.^-S
M <MCIGUK.LO#FAZ;?/>V.BZ=:W;YW3P6J)(V>3E@,G-3UOY%=+>9E:V]_J>L
M)::;96%]#9(3<QW5XT $CJ0H^6-\D*6)! ^\IJO\/+J6'1Y_#UZ8DO\ 193:
MO''*9,18#1$$@$C80,D#.TUT5GHNE:?=W%W9:99VUS<',\T,"H\ISGYF R>>
M>:9:^']%LM1DU&TTBPM[Z7=YES%;(DCY.3E@,G)ZT+0'J8.B_P#)4/%/_7I9
M?RDIEPK/\6@J-M<Z"X4^A\X5OVWAO0K+46U&UT73H+YBQ:YBM460ENI+ 9Y[
M^M)_PC>A?VI_:G]BZ;_:&[?]K^RIYN[UWXSGWS1V3[6_!_Y@^O\ 7;_(Y_X9
MNECX&@TZZ98KW36EBOD<@%) [$LWL0=P/<'-9WAZW?\ L3Q+J+'&GZCJ[7%H
M&^ZT>Y%WCV8@D>HY[UVM]H6D:G<PW-_I5C=SPG,4L]NDC1G_ &21D=!TI^HZ
M1IFKVRV^IZ=:7L"-N6*Y@615.,9 8$9P33;N[_UT_P @\OZZ_P"9PVJ13^"3
M+911/+X;U*4) $!)L)W883'_ #R8]/[I..AX]&J%;6W2U6U6WB%NBA%B"#8%
M'0 =,"IJ.E@ZW"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XK\0)X8\.
M76JM%YSQ[5BBSCS)&8*JY[ DCFLW48?$FEZ/<:PNLFZO((#-)8-!&ML^T994
MPOF*2 0"7;D\@]*T?%>@)XG\-W6E-+Y+R!7BEQG9(K!E;'<9 XK.OI_$6J:1
M/I']BO:74\!ADOVN(VMEW##,F&\QB,D@%%SCJ.M+6SMOT^[_ #W*5KJ^W7^O
M3\3-O=6O=:U#PK<Z3KU_8V&M1NS10Q6[;0(BX(,D3$'/!YQQT%:/A#6-1O=6
MU[3+NY&H6VFSQQP:AL53+N3<R-MPI93P2H YZ5DZUX8 O/"NDQ>&)=5T72E*
MRF3[.T9!C*+\LC@D@X8_+],GBMK1K;4O#E\-%ATQ[G0R=UI=0R1J;53UCD5F
M!*@_=903@@$<9-Z7=MM?ST_X!GK;7R_7_@7(O&TNJZ>NGZG9:S=65E'=Q17T
M44,+@Q.VTOET8@@E<\XQGC/-5[2_U"T^*,^CWFNW5S9SV7VJTMF@A548,0Z%
MEC#' *D<YQG.>M=/K.F1:SHM[ILX_=74+Q-[9&,UQ-UX9\1W/AO1[[,2>)[:
MY625@XV[63R7&<\X3#8SR5J8_P!?/3\'KZ%/^OEK^*T.H\-+?/;W5W=ZI<WL
M4\[FV6:.)?+B#$#&Q%SG&<G/&/?.=HWB&^N/%]S8WNT6-Y;_ &K2R$ RB-L<
M$]R<HX]F]JO:ZM]IWAZ*PT;2KF]+*MOMMY8HVBBQAFS(R@D+G ]<=.M<]KWA
M672#H^I^&M-U:_O[&Y4K!+JSNBPD;9%Q/*5&5Z;<\@=J:M?RV_X/Y?B'3SW+
MNLG5G\?6.FV_B._LK*ZLI[AHX8K8[&C:-1M+Q,<'>2<D^V*?X4U34]>TC6;>
MXOV)L[R2UMM4MHT!G50/G (9"P.5.!MR.@JAK>D2^(O&FDW&I^#YKK2XK.6&
M4W1M9%CDD,9!VF4GY=K D#/IGK6IISZWH,<ND/HMUJ-E;H19WEO- "T>.(W5
MW0AQTR,@\$D'-)_#;U_,;W^[\CEK?7O$-AX1T'7CK\^HWM_/%$VFW$$ 68,^
MUO+\M$8,!DY)(X.17I6HW@L-/FN=A=D7Y$'5W/"J/J2!^->>>&O"=[H_ARQU
M&Q\/1Z?XDL RS1N8%_M!"<LK/&S<GC:S$$$>A.=Z\;4O$=[I]C?>&]6LM-YF
MGF%]#&R2+]P9AFWXZG*]]O;.*>NG]?UO\Q=;_P!;O_@?(L^$]3U#5-)O;'59
M]NKV%Q):W$L2*O/WDD4$$8*,I&0?QJAH7B#4=/UN70O$%PTZS3R)INI.B)Y^
MWK$X4!1(.2, !A[@U%;:3?\ AKQXTVDZ/J=YI5];*E[<2ZBLQ253\C#SI2Y
M4D$?3&:OPZ6WB71]2T[6M&O-/CDN&EA>66$N"3E70QNVUE(!YQ^-+S\OZ_S7
M]6/+S'V>G:S<17D/_"4:AE;S9YK06V^.-1G"XAVY)(R6!X'&*R?#L?B'4[W6
ME?Q9J+?V;J9MHD>WM=LD:JC$/B$')W$94CM70^%K+5M-T>6'69DNKT3N3-&
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MBC+2Q-D LCJRY# @X'.1C%2VFFWWA35=7GL=-FU.PU.Y^U^5;21++#*5 ?\
MUC(I4X!^]D$GBEM=)O8-1UCQ-=6#RZC=P);P65O(A9(DS@;F*KN)8D\X&  3
MC)E_#\OQM_G^!77Y_A_PQ%X:\07VN:3)I6J2MIWB"*W61Y+<*?,1A\LT6]2I
M!Z$$'!R/2MWPZ+D^'[&2\OIKVXEA61YIE16)8 XPBJ,#/''YU@W7A^\UKPUI
MEQ'#+H_B'3X@+9Y61BC 8*/L9@T;XY&>F#P172Z/!-;:)86]PH6>*WC210<X
M8* 1^=:2M=_UW(6R+M%%%04%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0M3UW2-%$9U75;&P$N?+-U<)%OQUQN(SU%.TW6-+UF)I=+U*SOHT.UGM9UE
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ML9I)M@P&81D;OK@ 9]A4MVC?YEQ5Y<OG8T)/&GA6*.*23Q-HR)*I:-FOX@'
M)!(.[D9!'X4J^,?"[6KW2^)-'-NC!'E%]%L5CD@$[L G!X]C7*^(WNDMOA^U
ME##-<B\CV1S2F)&/V9^K!6(_[Y-:/B:.[?P!XGN]3L[>VOVL)HV%O*9%\L(2
MH#E5+?>)^Z.I%5)<M_*_X6)A[SBN]OQ.IM=5TZ^L!?VE_:W%F<XN(IE>/@X/
MS XX-,T_6=+U:+S=-U*SO(]VS?;3K(-V,XRI/.*XF5VOO%/@O1[M5;33IKWG
MEM]V69%0*".^T,6 ]>>U=S-IMI<7]K?/"OVJVW".4## ,""N?3OCU IM6?W_
M (.Q*=TO1?CJ3RW$$#Q)+-'&TK;(U=@"[8)P/4X!./8U6U+6-,T:!)M4U&TL
M8G;8KW4ZQ*S=< L1SQ7!>/-06YGN9;>+47O=&,<UB;?39YHVG4AW!=$*#*@)
MR1C<V:V/&E_;ZK\)]4U"V;?!<Z<9HSZA@"*E:J_F7UL=38ZA9:G:+=V%Y;W=
MLV=LUO*LB'!P<,#BJ=CXGT#5+O[)I^N:9=W."?)M[N.1\#K\H)/%:$3*EM&6
M(4;5')Q]*YCPL /%?C'C_E_A_P#2>.G;5HE:QOZ&QJ/B30M(N5MM3UK3;*=E
M#+%<W21L0> 0&(..#3[W7]&TRYAMK_5["UGG ,44]RB-)DX&T$Y//'%4_%.A
M)XATDI;R)%J-K()[*YQDPS+R/P/0CN":J>%;N3Q19VOB"_M%@E56BA@)#>4X
M.V1@1W+*0/\ 9 Z9(I+7^N@WI_74W-2U?3='MUGU34+2QA9MBR74RQ*6ZX!8
M@9X-0V?B'1-0M9[JRUC3[FW@!,TL-RCI& ,DL0<#CUK,^()*_#_6RJ[F%JQ"
MYQGVK/M[#5-8\;Z5KLFCRZ1!8VLL4QN)8FEN2X7:N(F8;%()R2#GH*%K_7E<
M&[?UYFY9^+O#6H726MEXBTFYN)#A(H;V-W;Z -DUK2RQP1-+-(L<:C+.YP /
M<FO'5,^L>#;GPU_9KPK?ZQ=10ZI<O'Y$;_:7;*X8OO&"%RJ@GC-==K.^X^(W
MAG1[MC)IZ6D]T$?&V:=-H4L.Y4$L!ZG/:G:]O/\ RO\ \ 'HWY?YV.JTW6-+
MUF%I=+U*SOHT.UGM9UE"GT)4FHK/Q%H>H7[V%EK.GW-Y'G?;PW2/(N#@Y4'(
MP>M<WXW,EAKWA74-/7%_+J:VC[>#+ ZL75O4#:&YZ%:LZ@L>@>.[/50BI;:P
M@L;IP.DRY:%C]077_OFA:_BOF#T_,UYO%/AZVN+BWGU[2XIK89GC>\C5HAD#
M+ G*\D=?457/C?PF(EE/BC11&Q*J_P!OBP2,9 .[MD?F*ETY$GM[[5=BA[PD
MHVW!,2C:G/H0"W_ JX/3/^25^!_^PA9_^C#0E?3T_%A+17]?P5ST;3=<TC60
MYTO5;&^"<,;6X27;]=I.*IW/C'PO97,EM=^)-'@N(FVR12WT2LA]""V0:Y_X
MEPI966F:[9Q*NLVNH6\=M(@^=U=PKQGU4J3Q[4L\VK1?%+4#I5E973'2;?S!
M=7CP!1YLN,%8GS^E):_C^5P_K\;'0R>+?#4-G#>2^(=)2UG+"*9KV,)(5ZA6
MW8..^*L:;K^C:R7&EZO87Q3[XM;E)=OUVDXKE?%23#P98R74"07<NJV4D\:'
M*AS<)G!P,].N!GK1\4X4M?#<>NVL:KK&GW,+64RK\^YI%4ID<D,"01TII?G;
M\O\ ,/Z_/_([2]OK33;1[N^NH+6VC^_-/($1><<L>!S6=:^+?#=[/%!:>(=)
MN)IF*11Q7L;L[>B@'D\CI6E*2;-RPP3&<CTXKSG1-)MM;^#?AZPNPWER&W =
M&VNA\T896'((]:2Z_+\0Z)_UM<[[4M:TK1HXY-5U.SL4D.U&NIUB#'T!8C)J
MZK*Z*Z,&5AD$'((KA8-9NHRGAK7G!U:WN;=X9R,+>PB9 )%_VAT8=CST-=W3
MMI< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M0L(=2LVM;@R"-
MF5CY;E&RK!AAAR.0.E4+;0%BU)+Z[U&]U"6$M]F6Y\O;;[A@[0B+DXXRVXX[
M\FK>J7%];6@;3K..[N6=56.68Q)@GDLX5L #/8^E<Q8^*_$E]>ZI;)X<TXG3
M)UAN-FJNS,2JOE!]G&[ANA(YH6^G]?U<'MJ;-SX;#ZA->V.JZAIDEPP:X2U,
M129@ ,D2(^#@ 97!_(5;?1-/ET>72IX!/9S*RRI,2WF;CEBQ/)))SFLW3->U
M2]\4ZEI$^EV<,-BJ.9TOF=G#Y*?(8@!PIS\W';-5=-\2:]J,^MP#1--CETR4
M0_\ (3<K*^U7Z^1P-K=<'D8QCFET\K7^0^IHZ?X=:PQ$=:U2ZLU 5+6Y>-E4
M#H-X02-_P)SGOFF6OAG[+XHN=>&L:C)+<((I+=Q#Y6Q2Q51B,-A2QP=V?4FL
MG3/'%U?^'])OI-*MHKS6)"EA;"]9E;"EB9)#&-G"GHK=L9KI=/O;NX>6&]L?
MLL\2H6V2^9&^<_<; ) QCE5/M5NZ9/D4=)\-?V3K5_J8UC4+I[XAIH9Q#LR
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M[<CBO4J*E:?UYE=4SB-"O?!\.K6ATKQ*M_>RQF!;;^V7O6.=I)"O(VW&TY(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=&O[2\CGF\3:K>QKG,$\=J$?((Y*0JW'7@CIZ<5L444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-3_004.jpg
<TEXT>
begin 644 ex10-3_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2Z Z8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6+^WLKC[/<ZU:ZA#:+"PE$2-$9&\O&X,=C-MQN]LG%-+O_6J_P _P%_7X/\
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MM1TN/K8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH)P,F
MO+[3Q7I9^(5AJ,&NV%PNKF33Y+2.[5WA"Y,#; <C)#YR.L@%"U=@>BN>H45@
M:AXAN;7Q-;:'!I;2RW-K)/%<23JD1*8!4XW,/O#)V]^,\UG6_C>>73M/U"32
MECMIK[^S[D_:<O%-YAB^0;,.FX=25..<4TK[?UT_,'IO_74["BN/U7QRUEJD
MEK9Z-?:A%;R^5</;VMPY#8!_=[(6C;&><NN,&B]\;7-O'K\D6B.4T0AI_/N5
M0R1[-Y9 H;G;@@'&>Y6DM?Z_KN.VMCKR0JEF( '))[5 ?LFIV++F*YM9E*G!
M#(XZ$<=:P]1UC^TC/I=CIT%^OV59;Q+F78BQ2 X7&UMS$ _*<#'4C-<WX*\0
M2Z5X0\%:9'ILD_\ :,#1K/YJHD;*K-@CEOX?3&/?@NU[K^NO^0NB?];+_,]"
MM8!:VR0"220(,!I6W-CMD]_3)Y]<FF"QB_M WKEGF"[$W'B,=]H[9QR>OX5R
M[>-KN+2KJ^GTB)!I][]DOU6[+;.5&Z([/WGWE."$ZU+KWC5M*OY;.QTF[U*2
MWVFX$%O</C(R%4QPNI?&#M9DZCFEY@NQUE%<I)XOO)-0U.RLM#D,UE:17@-W
M.(5D1]QQP&92-K#!'4<X'-5U\3ZIJ/B/PXNFVEJ=+U+3WO&\^X9) /W>> C#
M(#\#/)/5<<M)_P!?/_)A_7Y?YH[.D=UC0N[!549+$X %+7%2WFI:MJ7BO2]2
ML+"32K> (H,Q<G,989C,>#G//S<8 YZU$G9/T;^X:5W_ %U.RBECGA2:&19(
MG4,CH<A@>A!'44^N)\+:_-9Z?X8TRZLECM[S3%:"X$^6W1QJ6#)MPHP<@AC[
M@5/I7CE]5UBVMX=%O_L%U_J;S[+< *-I(9]T*H%.."KMG(K24;2<5Y_@1&5X
M\QU]%<5\4+/3Y_"L=Q?:?%>?9[VU*AK<3. 9T#!1@DY&1@=>E4M$A6R\57FH
M:!H][8^'HM.;SK463VRSW ;*^5 X4AMN02% )(ZU*_K[KEM;?UUL>A45R,/C
M2<7&J6MSI49NK&S%X(;2\65F0DC:^Y4V/QR#D>YK/U#Q=XAN=!TG4M.T>UAA
MOY;(H\]\1N$K#*?+&2.P)QT;(!/%.Q-]+G=?:(/M/V;SH_/V;_*W#=MSC..N
M,]ZDKF6\0PVWB:ZM;_2UMI;73/M<E]O5@T8/S*I^\5!S]X+TZ<U6TWQQ+>WL
MJ3:%J,-H('GCN/LER.%&=K^9"@#'L%9P<=>F5_7Y_P"0_P"OR_S.OHK'\.ZW
M_;^G)?(+0P2#*/:W7GKC/0G:N&]1C@\9-1W.NW4'BV#0Q8PLEQ92W,,YN"#N
M0J"K+LX'SCD$]^*;33L"UU-RBN,LO'<]S!HI?1'$NIW<]G^[N5:.)XBXY8A6
M(/ED_=_7 -RW\8+_ &=>R7MF(;VTOAI[6T,WF+),VW8$<JN00Z\D#'/I19_U
M\O\ -!_7Y_Y,N:=H]A8:_>W0U&ZNK^XR_E75V9/L\9(RL:?P(2!V].>!6W7F
M]M??V1\1==U35+""TE71899TLW,WFD2. 0=BEF("KRN> .>*V+/QO=3IJ+3>
M'=03[+ UQ&RP31K*J_PEIXH@'[X&1C/)I;+Y?Y_Y#MK_ %Y'845P.H>+O$-S
MH.DZEIVCVL,-_+9%'GOB-PE893Y8R1V!..C9 )XK3UKQ==:'(K7.EPK;))%%
M-))=[&=WVC]PI3$H!;GE3P>*;33L^]B;HN:AHUMJ_B2QO!K5S%<Z6?,%I T)
M4;P02X9"WS#(ZCIQ@\UOUYY;7*:3\1_%8L;6WDOKFWLS#;;O*^T28D)RP4XX
M&2V#TYK:UGQ;<:0(+7^RS<ZJT(FEM[<7$T<8)Q]^*!VY(.,HH.#TI=%_7];#
MZO\ KM_F=315'3=0?4]'@OELY[:2:/>+>[0Q.C?W6!&1S[5RV@>*]4?08)]5
MM+5KZ]OI;6SC@N682,'DR&)0;%4(>1NR!G&3BG;6PKG;T5B:-KTM_J-[I6H6
M:V>IV:I))%'-YL;QOG:Z/M4D?*0<J""/H:@NO$=ZGB.ZT2TTCS)XK/[5'-/<
MK''*-P&/E#,.<C)7J.F.:3T&=%17)V/C1[Q- N3IOE6.LGRHW,^9(Y=K-@H%
MP5^1ANW9Z<5)<^+IK37K.RN-.CBMKNZ-I$\ESMG9QGYQ"5YC.W[P8GVIVUL'
MF='%<P3R2QQ31R/$=LBHX)0^A'8U+7G.@79TKQ'XPM-(LK6:^EU1'BLS+Y"L
M##&7<E4; &[)..2<=36UKGC*;2;D6=OI,]]>11I)<QV\5Q(J;@?E5XX7!;C@
M-LR"#D4NB?<.K1UE%9\FKP0: =8N8YK>!;?[0\<L961!MR5*GD-VQZUA:9XO
MU#5;RXM(O#]S&XA:6VEGBN8(GQC"2/) NQCG^$..#S1UL'2YUM%<UI?B'5-3
MTG3KM-+LXY[B=X[BW:^8_9U4D,<B+YF!&"N ,\9JI9>.FU#6;>WMM%OY=/N'
MV)>):W&!UPS$PB/RSCAA(>HXZX=M;!YG845R-AXLUC6+6ZFTSPVK-;7,UL\=
MU?K&0\>.#M5QR<CC/0=CD3Z=XGO]3L=#GM]-M#+J!8W$1O6_T95^\<^5\Q!^
M4@A?F.,]Z2U_KN#T_KL=/6)8^'TT[Q!J.M'5+V9[U5$L,WE") N=N-J!A@$C
MECUYS3O$7B!-!MH2+>6YNKABD$,44K[B 22PC1V"\<D*<9%<GXC\3:KJ/@8W
M5OH[VDIOH;:>.\:6WR#*@RF^(,Z-G!)5>,\'&*%OIZ??9!Y/^K79V:^(=$;3
M7U)=8T\V$;;7NA<IY2G.,%\X!S[U?BECGB26)UDC<!E=#D,#T(/>N#OY=9A\
M?Z)"FCZ2C7-M//<!+U@)& C4L3Y&6*J<*2.02/E[WCXK33=,&H6FD0KX:MY3
M T\,P1XPK["ZP[,>6".N[..=M-*_]?+\P>AV-%<P/%-]<^(-2TBQT,RR6/D%
MI);I$$B2;OG& W  S@\GGCIEW@C5-7U?0WN]7@M8W-Q,J&"=I,A9&7!!1=N,
M8')R!GCI0E<3=CI:*XY/$^HV6N>)9=4@M4TC3$0J\5PS28*;A\A0 EL_WN.!
MSUK0M_$5W%K=KINKZ;'9F^5VLY8KGS0Y49*/E5VOCG W#@\TEK;^OZV&]/Z_
MKN=#16-XA\01Z#'9[A;B2[G$$;74_DQ D$_,^UL'C &.3@<=13UWQ6^D"""'
M3Y;J_F0RK#&DTB*@8#+-#%(PSGCY<'GD4 =+3)IHK>%IIY$BB099W8*%'N37
M&MXFUN^U;PX++2EM[>^69YX;^22WF4IP1M,9XP=PSC=Q]VLC6KS4];\(^/(-
M8L;!K2S\](-LQE*LD2LORM&!QG=NSG)Z<9H?]?>E^HXZM+O;\?\ ACTM65T5
MT8,K#((.012UQU]XN.CVUG8V>G3W]VMI%+(D<-PZJA! YAADPQVG 8*#ZUTE
MI?2W^C17T-I+#--")%M[L&)D8C.U^"5.>#P:<M+^1,7=+S+,UQ#;A3/-'$'8
M(I=@N6)P ,]R>U25YC+>7^M>#M U;6+"S-X-7MW@:&3S&P9L'&Y5V'^' )X[
MUTW_  F*VJ:NNIV)AN-.FBB,=L[7'G>;CR]N$#$G."H4D=LT=/Z\O\POK;^N
MO^1TTDB0Q/+*ZI&@+,S' 4#J2>U$<B2QK)&ZO&X#*RG(8'H0:X^'QE<7>C:Q
M->>&;W_0H/,:(PR)'<(<Y"M<1Q9( RPV]#QFG_\ "73I<Z7INGZ"SRWNEF]M
MU^T)'%\H7]T#@D8W*,E0.1[X7]?G_D/^OR_S.OJ(W5NMS]G,\0GV&3RBXW;1
MP6QUQR.?>JFJ:M%I&E&^ND8'*(L2D%FD8A50'IDL0*XI)+NW^*%Q>W&CP+>G
M0G=H;297,^)1M^=E3G''/ ]2*/\ @_E<.E_ZW2/08+B&ZMTGMYHYH9!N22-@
MRL/4$<$5)7'6OC"SA\.>'KBVL[2Q35 JV\%Q.((HAC.W<$(W8Z*!R?3K5V[\
M2WT7B&WT2WT;?<W%G)=1RS72I$2A4%25#,/O#G;WXSSAM:V Z2BN0M_&TT]W
MI,!TM8_ME[-I]R&N?GMIHU9B  F'4A>N5ZCBJNJ^+M6/A7Q-<VMA:P7^DSM;
M<W3,A&U6W@^6#G#_ '<=1UHM_7W+]4'K_6_^3.YH)P,GI7(ZIXQN]*\JT.DM
M=:F(EFN(;47,\<:L2!B2.!B6.TX#*H]ZZ&TN(]7T:*>:SEBCNH07MKN+:ZAA
MRCJ>_8BD]FP70LP7$%U$);>:.:,D@/&P89!P1D>A!%25YGX(UN;0/ VC-+IT
M?]DO<O;-<1S8>)GG94_=[<;,D#.[(],5T2^*=2237H;O2;.&YTR-9(8EOF?[
M2K [6_U0V@D%>C'((QT);7;^MO\ ,/Z_%K]#JJ*HR7MS:Z(][<V+-<QPF1[6
MT8S$L!G8APNX]AP*P;3QC/+/K5I/ID3WNF0)<&&QO5F#JV["EF";'&TY![8Y
M-)Z7\@2N=944]S!:Q>;<31PQ[@NZ1@HR3@#)[DD ?6N7LO&-U=MH;'2$2+6K
M;S;9OM6660)O*N-G"X_B!)X^Z*@O/%Z-X?-U?:$+AHM36PN8%E62.&02*H?<
MP!8!BI!"YSV&,T[.]OZWL*Z_KTO^AVE%8&I:_>0W%Y%I6EC438!3=*+C8_(W
M;8U"MO?&#@E1R.?2IXB\83: DERVF*;&!8VFEN;CR&;>?NQ*5(D8=P67J!SF
MDM1O0Z5;F![A[=9HVG10SQA@64'H2.H!Q1)<P0RQ12SQI),2L2,X!<@9( [\
M GCTK@H#=6/Q,\3S:/IEM<3R6%G*\;S>0'.9<DL%;+8 ZCMR13[V^L==UWP'
MKEO;A7N)Y@&D0>8B^1)E"?9AR,XR*:5[>?\ P?\ (3=K_P!=O\SOZ*X^+QTU
MQK4-M:Z+?SV$DWD?:X[6Y.&W%=_^I\LQ\?>$G3M784NEQ];!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9FOV%_J>CS6>G7\5C-,-IGDMS-A3U 4,O)]<U1\2>'
MKO7O"ZZ5#?V]G<AHG%TMH7",A#!D3>-IR!C)..G-=#10!R[>'=;E\0Z7J\^M
M6#R6-M) R+ISKYI?&YL^=\OW5XP>_J,9B^!=870(M,&O6.Z/4_[2\W^S'P6\
MWS=NWS^FXGG/3CKS7=T4[M?UYW_,/Z_"QQ\O@[58_$4FI:5XIN=.M+N02WUE
M':QR+,X !9&?)CR ,XS4=WX,U6ZC\3Q_VU9JFN*$_P"0>Y,*A0G7SOF.P=>.
M>>G%=I12&G9W.6A\+7]M>+>6^L11SS6L=K? 6A*3! 0K("^8V 8C)+#VJA8>
M [_3(?#=O;Z]')!HCLZBXL=S2;E92 5=0HVL<9#'/))Z5W%%.[O?^NO^;)LK
M6_K^M#AKCP/J]QI&M6#:[8C^U+T7;.--?]WTRH'G<_<7GZ]<C$]_X.UB765U
M72_%4VE7,Z1IJ"06:217)08W*LA;RVQQG+< =<5V51S31P('E<(I95!/J2 !
M^)(%):?U\A_U^IS#^%M4_MS5=1BUBU"WUDEFD<MBSM&$W89F$HW'YVSP.W3'
M*:5X0N]-7P^QU:)Y=)M7LV9+3:)HFVXP"YVL-B\Y(// SQUE8&O^*1H%Y8VS
MZ/J-X;Z40PO:F#:9""=AWR*0<*3G&/>FF]OZZ_YL-_Z]/\D7=(CU&(7@U"\%
MT&N7:W;[/Y)2,]$(SSCD;N,_J<^Y\.WIOM9N;+4XH/[3B12DMKYGENJ[-W#K
MD;>W'(SG'%="I)4$@@D=#VI:EJ^C&GU..MO!^J0R^'#)K%E)%H\#0,G]GL#.
MK+L//G':=H'8\Y/0X#O#O@_5/#U^(T\4W<^A19^S:8]O'^Z'93+]YE'8<=AS
M6I?^(EL]1T:VBM)+B#4YFA6Z1U"1D(S<C.3D*<8&..O2MNJN_B]2;)*Q@^*M
M#O\ 7]/AM++4;>R"3QSNTUJT^XQNKJ!B1,<KSUR/2K]_83ZCH5Q827C07$\!
MB:YME*%6(P64$G'/(&3]:OT4NEBKZI]CCAX-OT5FAU6SAE?338,L6G;8L9R&
M">9D<$\;NO?M5A/"5PO@[2]$.IQ_:--:!H;D6Q"L82"NY-YSG&#AA^%=313O
M_7XDV_K\#F;CPO=7GB:;4;K4+::QFL#82VIM"'9#R3YGF8SD_P!SIQ[U#X<\
M*ZWH;/#<^+KS4;"./R[.WFMHU,(Q@%Y!\TA ]<#VZ8ZRF2S1P*K2N%#,$&>Y
M)P!^=):#9B:3X;33M>OM79K4372B-EM+;R%8 Y#2#<V]^V[CCC%/U/0IKO7]
M.UBTO4M[BTCD@=9(?,62)RI8#YAM;*#!Y'7(-;=%'8._F<-;^ M0LI-*^S^(
M$>&PU":_"7%B&),FX%%*NN!\['G<<D=ABIE\$7<L>K+=ZQ$7O+]-1MY+>T,;
M6\R;=OWI&#C"+Q@=_7C876KRYU1H=/TY+FRAN#;74_VD(\3@ DA"N&49 /S
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MH6JG[+XINCH2LSQ:4]M&1&2<[?-^]L!/"C'IFNIL;G[986UULV>=$LFW.<9
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MY.  ,^P J6BETL%CD['P6UI:1:5+J"SZ+!<"YAMC;XE+!_, >3<0RAN<!5/
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M4UO2;>TTR*RD9;N&XD^USM&,1R*^!M1\YVX[8SGGI23^%>?^7_!+W;?K^O\
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MZ,"Z!AQ@G_:_'OO"]HUGH<2OH5CH;N2[6%DRLD9/JRJH+>N!^?6GW#M_7?\
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MF:G=PSQZI;12F")A%*&E"O&92NTD<Y56SZ\5VUW=P6-J]S</LB3&2 2>3@
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M]M<1&XA"1,3&5$4:-L"':0N.>F[&,U32;U\_U_R7WD1V^[\E_P $SX;[5?\
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MF2PF1)H/]8S*X7!D!S\N,XQD]<?-5GP':7^G^$;6RU*PELKF!G#1RO&V06+
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M[74,O7!&13JYSQ)KFHZ5J^A6=G;VKQ:E=-;R2S,VZ,[&8$*!R/E/<?U&9?\
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MBREAZY4@Y[U!<^$[2>^NKF"\O;-+Q=MY;V[J([GY=N6RI*G;QE"IX'/%;]%
M&'+X8@?Q!IVK17UW;_8(&MX;2(1"'8V,@Y0MSM7HPQMXQSFQ%X?L(?$L^OHC
M?;I[=;=SGY=JDG./4\ GT K4JM)]N_M&#ROL_P!AV/YV[=YF_C9M[8^]G/M3
MN']?<<\O@'38O$LFM6]_JUMYTGG3V,%ZR6LTG=GC'4GN,X/I6[JVF6^M:3=:
M;=%Q!<QF-S&V& /<'UK'UOQ-+:Z/;:EI*6UU ]_':2O)(1A6E$3%0 =Q#>I
M[^U=+2MI_7]=@ZW.=_X11O[9CU0:]JOVB.U:U /D%=K<EL&+[VX!O3( QCBL
MV7X:Z;-H-GICZKJZR6,K26E]#.D5S!N^\JLB 8//4'^5=3-?Q)>K8HZ->O"\
MT<3-C*J0,D\X&6 SBJ/A75KK6_#\-]>Q0Q7#22QND))0%)&3@GD_=ZX'T%&_
M]>;_ %N+;^O+_(NZ7IT>E:=%9QS7,XC&#-=3-+*Y]68\DU@7G@#3+VTN;%[S
M44TZXG%S]CCF"QQR[]Y9#MWKEN<;L#.0 >:Z*'[;]LN?/^S_ &7Y?L^S=OZ?
M-OSQUZ8JS1?6X]M#!B\+I#XAN-875=1,D]LMJ82T9147.W!V;\@ECDL22><\
M5B>,M$%KX3\1W*G4-2U+4+-K9"MOYKX^;9&%A0< L>2,^IKJ-=U7^Q=&N;];
M=KF2-?W5NAPTKGA5![9/>IM+U&#5]*M-1M6#07,2RH0<\,,T;_U\QIV=_P"M
M#*T71H'CM]1N+B^NY6MS'"M]&(VMXV W(%V*PZ#)?+<=:KV_@33H(M*B-]J4
MD6E3>;9*;@)Y0P0$R@4LH!(Y))'!)%=113OK<E+2QSMSX+TN\LM4LKF2ZEM=
M0F-PT1EP(9"02T9 !!W*&Y)P>F!Q1I?A"+2M&FT]=;URY>5@3>75\9)U .0%
M8C"CM@"NBHI+0;U(;N![BTDABN9;9W7 FA"ET]QO5ES]0:Y5/A] GA8^'5U_
M6/L)E\S.+?>/FW;<^3TW<],^^.*T-5UR]L/%VA:5';V[6>H^<'E9V\Q2B%L!
M<8QTYR>_'>N@H\_ZT8>7]:D-K ]O:QPRW,MRZ+AII@H=_<[0J_D!7-GP- +;
M3[:'6M6@AL+DW,"(T) .20IW1G*C<P'?GDG QU5%'6X=+','P/83#7([Z]O;
MV#66#W$,QC548 !2A1%8$!5 Y/0'KS5KPUX7A\-6\D2:IJVHLY_UNI79G91_
M=7H%'T'UK=Z57LKVWU&T2ZM9!) Y.QQT;!(R/;BA>0/7<R[OPV;KQ-:ZY_:^
MH126R-&EO&(?*V,5+*<QEOFVKGYL\<8JSJNB1:K/8W!NKFUN+*4RPRP%<\J5
M8$,K @@D=,^A%:=-DW^4_E;?,VG;NZ9[9]J+V7H&YRMQX"LYK*.T35=4AACU
M Z@ CQ-^]W[Q]Z,\!B3ZG/)-;%SH<-SK%KJGVFYBN;>%X,QLH$B,0<,"#W4'
MC'IT.*EAOG@6PM=1D@&I7*'*0$[&95RY7/.T>_J*I^&=6O=7L[Q[^"WAGM[R
M6V*0.77"'&=Q )_(4_+^NP/75_UU,L_#S3I= N-(NM1U*YCENFO$N&DCCF@F
M)+%XVC1<'))Y!ZXZ<5JZ5X<72-)%E#JVK329+&\N[GSYV.".2X(P,\#&/:M%
M?MW]I2;_ +/]@\I?+QN\WS,G=GMMQMQWSFK-(.I0TG28-'M7AA>25Y9&FFFE
MV[I9#U8[0%!..P ]JR1X*LU&Q=0U!85OSJ$40D3$4A8LP!V[B"6;.XDC/!%=
M+5:Z^W>;:_9/L_E^;_I/G;L^7M/W,?Q;MO7C&:.H=+&7I?A>#3+S5K@WUY=_
MVI(9+B.Y\O;G:%XVHIQM ')/Y\U4\-^!K#PO=O+9ZCJ\T&W;!9W5ZTD%L/2-
M.@],G)KJ*KK?6[ZC)8+(#<QQ+*Z \JK$@$_4@_E0O("GJ^APZM-8W!N;BUN;
M*4RP3VY7<,@JP(96!!!(/'TP:Q9_A]8R;S!JVK6QDOQJ#^7,C@R@Y4XD1@ #
MZ 9[YKKJIZGJ$6EV+7,H+'<J)&O61V(55'N20*%IL&_]?UYF'/X(MKJXUB6X
MU;4I!JFSS4S"HC*$%&3$8.5QW)![@U,_@VPN'U%KZYO+T:C:):W2S2*HD5=V
M&PBKAOF/3 Z8 JY>:O)IL%I#/!]IU*Z8K';6O\1').6/"J.K''TR0*CN=9O+
M*SLTN+&#^U;V0Q06L=R6C+ %N9"@( 5<D[3CH >,B\@\Q;'P\EG+Y\FH7MW<
MI&T,$]P8RT"'&50*@7L.6!)P,DUD'X=:;)X<_L:?4M4E5+EKNWNO-2.>WE8D
MED:-% Y9CR#U],"M)->N9+"XN/L:K/82E+^U#EBH"AB8VP-WRD,,@9''!K;A
MFCN((YX7#Q2*'1E.0P(R"*?]?J']?H4=$T>/0]-2S2\OKPKRUQ?7!FED/JS'
M^0P*K'PQ8/=:M)*TTL&JJ!=6KL#$3L"%@,9R5 '7'' !J'Q1KE[H;Z/]EM[>
M6*\U"*TF:5V#('/50!R>O4C'O704M]?E^0;:&+IOAN&PN()IK^^OWME9+7[6
MR-Y"M@$*552> !N;<V,\\FM&]M9+J$I%>W%H^"!+!L)&>^'5E/X@U9HH>H+0
MY+4OAWI&H:?9V\5SJ.GSV;2/#>V%SY,ZF1MTGS 8PQY(QCTQ6D?#%KG2V6[O
MEET[=LE,^]Y0PPPD9@2V>.>#QP16W11<#G+OP=:W.FZQ8+J.H06^JN[S+&T9
MV;\;PFY#@-CODC)QBJNJ?#ZQU7^SY7U;6;:^LHA +ZRNA!-+'_<<HH!'T J[
MI>J:KK%VM[:FR&D"::WDBDC<3@QLR;PX)4@LOW2HX.=W:M=?MW]I2;_L_P!@
M\I?+QN\WS,G=GMMQMQWSFBVW]?UH#!;&%=.^P_O&A\LQ$M(2S C!)8G))]<Y
MK&T_P?:Z?<:9.-0U"9]-A>W@\QT \IMOR$*@R!L7!ZG')-=%13OK</(R]9T*
M#63:RFXN;2[M'+V]U:L!)&2,$?,"I!'!# BL>X^'^G36&LVJ:AJ</]L.'O)$
MF5BQQ@X5E*KD#DA<^_ KK**7]?U]R Q;WPXNI:<EA>:G?2VQ0)<1GRO](4#&
M&PG&>OR;>:YC3--.K^+?%$;2:S8VD\L0P+5X8KJ-8@C+ODCZ9SRA!(Y!Q7H-
M%'6X=+(Q[CPW:2ZE97T$UQ9RVD!M@MN5"O"<?NV!4X&5&"N"/6J-OX'TVSTR
MQL;:ZU",6-U]KAE,^]U<@AA\P("D,PP .I(P>:Z:J]W?6]D(?/D"F:588QW9
MVZ ?J?H#3O\ U_7F']?I^1SDW@#37\2-K4-_J]HTKB2YM+6]:.WN6  S(@Z\
M 9Y /?-;>MZ/!KNF-8W$LT2ETD22%@'1T8,K#((X(!P01ZBJFCZM>WVMZU8W
M<%O$MC+&L)A=F+JR[@6) P>G ''J:VZ71!U9RNI>!+75+;4X9M6U1!J:QK=,
MCQ9?8,=#&0,\9P.W&*N:EX8&J2:3))J^H1OIDHFC,8A_>/@KE\QGL6'RX'/T
MQO5SWB+7;W1]4T&W@M[>2WU&]%K-)(YWIE2PVJ!@\*>2>..#36Z2#HRW=:#'
M>W]O<7-Y=2Q6\GG1VS;/+63.0V=N_(SP-V/:L:3P!#+I=[I[Z_K!BO+P7DK8
MMMWF [N/W. "0IQC^$=LYZ:V^W?:;O[5]G\C>/LWE;MVS:,[\\9W9Z=L59I?
MU_7W!_7]?>SE;_PY-:76I:Y;ZIJUQ?3V(M?*00= #M*XC!W LS=>I/&,"N=\
M":'K=AJQND\0&ZM'.+NWG\+C36<[>&WD*S$<<_,.M>F4=*$[.X/56,S6-$M]
M96W9YI[:YMG\RWNK=@)(F(()&00<@D$$$'TJK-X4L+G1[W3[B6XF>]99+B[9
ME$SR+MVOD *"-JX 4#CI6K97MOJ-HEU:R"2!R=CCHV"1D>W%6* .>'@ZQ?4)
M[^ZN[^ZN;BR^PS-)/M$D?S<E$"KN^8]L#L!S6KI>GC2]-@LEN)[@0H$$DY!<
M@# S@ = .@%7** .>B\'6,,K(MU>'3C-]H&FLR& 2;]^X?+O^]SMW;?:I(O#
M/E>*IM?&L:B998UA>V(A\DQKDJO^KW8!8G.[/J2.*U9KZW@O+:TDD GN2WEI
MW(49)^@_J*2U^W>;=?:_L_E^;_H_D[L^7@??S_%G=TXQBA?U^0,JZQHEOK*V
M[/-/;7-L_F6]U;L!)$Q!!(R"#D$@@@@^E9>H>";34=/^RRZEJ".]U'=W%PGE
M>9<21[=I?,9  VKPH4<?6NGHHV :BE(U5G9R  6;&6]SC _*G444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!RWQ(>VC^'FMO<W)MU6U<QN)S$?,Q\@R",Y;
MQWZ8-<O'?>&K[QM9)=:E87-K-X?/FPS7@>%L%3RA;;]T$GCH,GIFO4:*._\
M71K]0>JM_6Z?Z')?#6_AU#P'IS0W<=SY0>)F20/MVL<*2/1=OX8KF['5=#N/
M$[Z;KT%Y;^+8=1>2WDBMI&DDA\PF,+(%($)3"D$@=<\\UZC13O[UQ6TM_77_
M #/*-1^SW5AK<5[Y2>-X;J9M-)^6Y(W?N?)/4Q[=H('R_>W=Z?>2Z'-XP\5V
MVKWME-C2())H+FZ#QI*/,W$(S$+CY#P!C(/!//JE%+I;^MK?\'U*OK?^M[_\
M#T/'M"U70]6UOPD+_5[6[,_AZ1+N&:]#HSCR^'0MMS_K,Y&3M.>G$":S:O\
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M3_3\0_K\_P#/\#RW^TM$N_">KZEX$^W+;%H3<Q6-HT2HJO\ O#"CIM,A7=G
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M&#R<\5K'P_XBM[GPDTMOI?EZ/;M!<%;V0ELH$R@\D9X /)')QVR4O/\ K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQDJLJJ6 R.0"*Y_Q/YG_  L7P=]H_P"0?NN<9^[]H\OY,^^W?C\:7XAQRO\
M\(Y]B'_$R&LP?9R!R%Y\S_@.S=FA:V\W;]/Z\@?7TO\ G_7J=E)&DL;1R(KH
MX*LK#((/4$54TW1]+T:%X=+TVSL8G;<R6L"Q*Q]2% R:X74->\00:9XOO3JJ
MJ^AWF;=(;9%61!&C['W;B1\^"00>,@CI6Q-J.HZWK&JZ=I>K#3[S34B:.$Q(
MPF+INS)N!/EY(7Y=IX/-"77^MK@^W]=CKZ0G )]/2N3:^U/6]9U33[35&TUM
M-C@93#%'()V="V6WJ<Q]!\NT\'FJ>E>)M0\3IHEHDLFES7NGO>SS0HC-E'5-
ML8D##!)SD@\8]<A6OM_6_P#D'K_6W^9O:5J.D>+['[6EF98K:Z9$%Y;;625#
M@L%894CD<@'K6W7E.BZS>Z3X<EM[.2W^U7_B*\M1<3R^2BG<[9W;' 8E<#*D
M9.*[OPTFOPVDT/B":TEG63,302^8QC(&-Y$<8W9ST0#&*?3^NR_S!Z/[_P V
M;3,%4LQ  &23VK-?7+1/$4.AE+C[7+;M<*WE$1E%(!^<\$\C@9QGG%9?Q#68
M^ M7,%W/:NL!;?#MW$=UY!X/?O[U1O;.Z'C/0+4:G<&;^R[Q3>,D9E^]#R %
M"9_X#CCI0E?^O)L/\OU1VM06]E:6DDTEM:PPO._F3-'&%,C?WF(ZGW->?0^*
M]<O-$T>RAGMQJ5]/=V_VN:5;?<87*C:?*D7S& SC9CAL8J]<W_BS38- @OK[
M3UN;C4_LEP84\XO&5+*2Q5 &PO.$ .<C'2BP?U^?^3.ZJ"[NXK*UFN)!(RQ1
MF1DB0R.0/15R2?8"L/PQ?WLVI:_IUY=O=C3[Q8XII$17*-$CX;8 O!8C( XQ
MGUK.6WNV^)>KN=6O?L\>F0.+7$9B^9I1C[FX#*YX(.>I(P!+V^5_PN4EK_7<
MZC2=3@UG2;34K4.+>ZB66/>,-M(R,CM5RO-O"U]J.FZ;X#C6]:2TU&V^SR6I
MC0(NV%G5U.-V[Y<'+$'/05;TG5O%6NZ@FJ6<^FII:73P3VTEYRB+(5.4^S[E
MEP/^>NWVYK24;2LO/\[$/3^O7_([ZBL?Q->WFGZ(]Q8C$@EC5Y-N[RHRX#OC
MOM4D_AWKD_\ A*]3LM-UN^M]3@U?2K%(TM;TVZDRR.0"S21L$94)Y"H/KD&H
M6O\ 7]=QGHE%<B\^K:?XFM-&EU>YN[?5;>=TN##$)+1T"G*[4"E?FXW*QSC)
M.:KZ)>ZA>J=$N?$-X=9LKU_M<BPP!FA7E>/*V[&5DY !R3SQ0M?Z^_[@?]?U
MYG;45P.DZMXJUW4$U2SGTU-+2Z>">VDN^419"IRGV?<LN!_SUV^W--L]2\37
MMMXEG&M6\<NDWT\4:_808W185901NW9!.<[O7MP$W97\K_U]X[:V^7]?<>@5
M6M+O[7Y_^CW$/E2M%^^3;OQ_$OJI[&N0TG6-7-_X4>YU W$>L6#//"845$=8
MU<,N!NR<D$$D>@%9\OB/Q)#H%S.=1M6N8/$"6#O]CPK0F1$PJ[OE/S9R2Q_I
M?*^;E_K>Q*::NOZT;_0](HKD+?5-7MM8\3:<LS:E)9VD5U:+*J(V]Q)^[^4*
M"N4&,\\\DU5T#6M2O?$%I:6FMQ:G9O;-<7[26R%K:3Y<0@QE/+SN)PX=OE.?
M6DE?^O7_ "_JXWI_7I_F=+JVO6FC7.GP7,=PSW]P+>$Q0EE#'^\W1?Q.3@XS
M6I7+>->OAW_L-6__ +-67JNNZM;:Y#-;:A+-;_VK%9/!##&;9(V(4[W90_F@
MD_<8@<9'6E'73S_R_P Q2=M?+_/_ ".]HK@]2E\00_\ "0:;;:]>'4E\NYTU
MC#;_ '&##R_]5@@,K9)!. OOG>T"]?67CU2#4;B2Q:UB58'2,*9"-Q8X0-NP
M5&,XZ\4+57_K^N@WI_7]>IO5FVNN6EWKM[H\:7 N;.-))#)$50A\XVD_>^Z>
M1QQUK%\2:S?:/K$,MQ]N@T58<M=6D"3(LF2#YZ[2X0#:05QWR:HWPN9O&6O2
MV&HO:.NBVTB3PHCDD/,1C>"N#WX[\$475KO;7\"DKZ>GYG=5EWVOVFGZUINE
M31W!N-09UA98B8P54L=S] < \=?;%<I<>(-6U+P[I=W;7\MM=3Z2+YX+"&-Y
M6D*@C=YJE%BZ]2I)Z'K3[B^EU.Z^'E_.%$US(TS[!@;FM7)Q^=5R^]9][?G_
M )&?,K7\K_E_F=1HVOVFNF^%I'<)]BN3;2B>(QDN%!X!YQAAR0/RI+/Q!9WV
MOZAHL27 NK%(WF,D112'SC:3][H>1Q[UD^#O^0MXM_[#!_\ 1,59@M;N[^)G
MB2.SU*73Y1IMF1-%&CG.Z7J'4C'KQGT(I=O2_P""97?U_4[ZD=@B,QSA1DX!
M)_(=:\Z7Q3K^MV6AV5BUK::A?V;W+R-<" N4<+^ZW0S @]<%<X(P:[;1#J?]
MDP#66M6U!<K,;5RT9()Q@D*<XQG@<YHL%QNCZ]INO132:?.S^1(8IHY(GBDC
M?KAD<!E/U%&FZ[8ZM<W5O:B[\RU;9+YUG-" WH"Z@-V/!/!![URM_I-Y::OJ
M7B;08M^I0W.RZM0<"^A$:?(?]L<E3^'0TT^,(CX=O=:TAX66\U**!'N7,21,
MR1J?,.UMA!R.5.&ZBDM?Z[V_K^M0[ZBN#FA\:V_AW47NM6CCN+8+<6SVDD4\
MTJ $NC[K=$P1]TJ@.>I/>236;V/Q'.%U>ZET[4+$G3P(X0$N  2%/EY.0Z$;
MB1D/D' P[!_7]?F=I<3I;6\D\@D*1J681QL[$#T5023[ $UD:+XLTCQ#:W5S
MIDMS-%:DK*QLIDPPSE0&0%F&.0,D<>M:MI#+!:1137,ES*B@/-(%#.?4A0!^
M0%<7JEG<Z3XX@BTZ58K/Q)N2\7)#1RQIDRI@?>9 5/N%/;E6UL'2YU&BZ]I_
MB"U:YTYKAX5;;NFM98<GV\Q5S^%:5<[KM_)IL^B:-8M]C74)FMEG1%/D*D;-
MA0P*[CM &01UX-<SKGB+Q#HVB^*;6*_66[TB.&>"_FM5)DCD!^5@NU=XP>0,
M8(^6GOM_6W^8?U^?^1V=]X@L]/US3=(F2X-SJ)<0LL1,8VJ6.7Z X'3K[5JU
MYMXMN;K1==\,ZC>33ZB$NKF>.** !T7[,?D 7[W.3GK@]\5VGA]9FTU;F76)
M-46Y_?1RE8PBJ>0J;$7(QW.2?THMI?U%?46QU^TU#7-1TF&.X6XL%C:4RQ%%
M(?=C:3]X?*>1Q[FM2N*6X-IXW\77*S00M%I=JXDN#B-"/.(+'^[ZU#I5[K=]
MJU_I/]K7ZK+IR75O=SVL*/'(6(.Q=@^3@<2)N]Z71>G^?^0^K]?\O\SNZ*\^
MMM=U*-O#=_<ZQ<FU/^BZK$R0!!/ED#$B,$?O%*\$#ITYSV.C)<KIR/=7<]S)
M*3*#,J*R*W(3Y%4<# Y&?>G;^OZ^\1H45P=QKNJQ^(K)X=0DN+6;5#8RQ10I
M]E1,-CYRH<R# !VLR@@C Q52YU[Q!#HVO:C)JJ^9I6K>2D45LBQRQYC&Q]VY
ML8<\@@Y[XXI+7^O3_-#>G]>O^3.\U348-(TRYU"Y$I@MT,CB*-I&P.N%49-.
MTZ^BU33+6_@#B&YA69 XPP5@",^_-<=KFH7>L6?BN..^DLK;287A:)8T(G)@
MWDN6!(7#@#:5/!Y/2M[PDI;P/HJARA.GP@,N,C]V.1GBA;-^GXW_ ,@>Z7K^
MG^99U77;/1S9BX6=_M=REK&88BZJ[' W,.%&?4_3)K3KRNSM[M/ ^G/-JEU=
MR2:_'M:Z5#L(NV&?E52<]3DGVP.*U;SQ/J>A#Q'#+=+>&RN;5+>>[VQ",3X!
MWLB8"J2?FVDXZYI_U^$?\Q7U_KN_\COZ*YSPRGB6&6X77;FSG@=5>V:.X$LO
M?=DK#$NWE<87/7)-9_C+5=2M&NUTW49HI+6Q-TL%G#')(S#=_K?,4JL9QQAE
M8X;'2D]"DKZ([.D+*" 2 3T&>M<<NLWNN:HND6^J'3+M=,AO@T4<;-,S[@1A
MPWR#:,X&?FZCO#<P:G/X\\."?6)H9/[.G>>&T$9@>1&B#8#H3@DD=<@ 8(YS
M7*[V_KK_ )"3NKKM_E_F=?:7?VOS_P#1[B'RI6B_?)MWX_B7U4]C5FN!@\4:
MO:Z%?27MQ#/=KK@TQ)U@V1Q(SH@;;D],GJ3R1SBDUC5]?\/RZMIT>IF]>/29
M-1MKNZMD+1LC89'$812"#P< CG.:B^E_ZVO^0TKNW];V_,[^BN.T_5-4C\3:
M';7-^US!J>F23R1M$BK'(GE\I@ \[SD$GMC%:'BN^U*PBLY;."_>T$N;M]/C
M22=%'(PC@[EZYV@MZ535M_ZUL2G=7^9?GUNUM]>M-&=+C[3=1O+&PB/EX7KE
M^F?89/(JVUE:/>I>M:PF[1#&LYC&]5/)4-U ]JY&ZNEUC7O"MS8WY*3P716Y
M6(!ONKDA6&%8>A!P1R*KV.NZI=Z!!%-JACN?[3N;%YXH5:YF2-G ,:;"F_Y5
M+$KM W'BDK_/_@V'Y]/^!_P#J=<UZT\/VL-Q>)<,DTZ0+Y,)?#.<#<1PHR1R
M2*+;7K2[\07FBQI<"ZM(DED,D)5"K$@;2?O=#R...M<-?:G?:K\,DFU%F:YB
MUB*W9G55<B.\5 6"?+NP!G;QGI716G_)5=4_[!%M_P"C9:I+]?R3_4;5E_7>
MQK3^(+.W\1VFA.MQ]LNH7FC/E'R]J]?G/!/3@9/(SUK5KB?$<,L_Q)\-10W,
MEL[65Z!-&JED_P!7R-P(S]01[52E\4ZU:V#::TT,E]_:S:9'J%PPMU<>7O#D
MB-U#_P /W"I8=!TJ5JO/_@V!Z/[ORN>AT5B>&DU^&TFA\036DLZR9B:"7S&,
M9 QO(CC&[.>B 8Q6W38@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UC1
MK+7M/:QU!)GMG(++%<20DX]2C X]LXJ+5O#NFZYHO]CZC'//8D*&C^TRJ7 Z
M;G#!F_$G/>L[Q]J>HZ-X/O-1TNXB@N("AW21>9E2P! &0 >>IS]*V;35=/O?
M/6VO[6=[<[9Q%,K&(XZ-@_*?K1NF&S1)964.GV,5G!YGDQ+M3S96E;'NSDL?
MQ-1Z9I5CHUB++3K=;>V#.XC0G +,68\^Y-$>K:;-YGE:A:2>5&))-LRG8ASA
MCSP#@\^U0#Q)H1TLZF-:TXZ>&V&[^U)Y0;.,;\XSGWHW"W0S8_ FAPSSS1-J
M\<MP^^9H]:O%,C8QEL2\G  ^@K<T_3[;2["*RLT9((@0H9V<\G))9B23DGDG
M--35-/EU Z?'?6KWJQB4VRS*9 AZ-MSG'(YH@U33[N\N+*VO[6:[M\>=!',K
M/%GIN4'(_&@-]2G'X7T>+4&O8[5ED:3S3&)G\DR9SO\ *W;-^>=VW/O3],\/
M:;H]Y>7=E'.L]Z_F7#274LH=N!G#L0. !QT QTK+\-Z^SQSVVMZI9F^.HSVL
M PL/FA#P$0L2>/<FM"R\4:/J&OWNBVU_;27UH!YD(E7?GN O4XXR>Q.*%TM_
M6P/K<OWUA::E;&VO;>.>$D-M<9P0<@CT(/((Y%5-.\.Z;IEQ]H@CGDN,%1/=
M7,MS(JG&55Y68J.!P#BI[EV&J62C48X%._=:LJEKCCC!/(VX)XH;6-+2XBMV
MU*S6::0QQ1F=0SN.2H&<DCT%"!F3+X%T":#4H9(;QH]2<27:G4;C$K>_[SCC
M P,#  Z 4W5/A_X6UN6REU32([R6S0)#)/([OM'0.Q;+C_>S6MK.L6.@:1<Z
MIJ,Z0VMNA9W8X^@'J2> /6N>_P"$J63Q+ILT>KV#>'[G3I[AG4J51XV0%C+N
MQCYR,<8(.<]A>7]:#L_Z^1MWWAO2M0NHKJ:W=)XT$8DMYY(2R#^!MC#<O^RV
M1[4M[X=TK4$M%FM=IL^+9X)&A>(<#"LA! P ",X..:M-J=@FF_VBU];+8[/,
M^TF51%M_O;LXQ[YJ2TN[:_M8[JSN(KBWD&4EA<.C#U!'!H$8S^"?#4FDWNEO
MHUL;.]D,MQ'@_O')SNW9R#Z$'CMBHHO ^A66BVVDZ=IZ6MI!<K<H(Y75ED7H
M^X'+'_>./7/2MK^T[#[;)9?;K;[5&H=X/-7>JGH2N<@<&LW1_%VA:[:WES8Z
MI:20VDC+,PG7Y "1N;GA3@X)ZCFA?U\@:_KU-2^L;;4[">QO(5FMIT,<D;=&
M4]1Q68?"6D'4K;4-EX+JVA,$3B_G&$/4$;\$G@DG)) ).0*2_P#&&@V&@-K9
MU6REL-VQ)HIU9'?. H8'&<_ESZ5;EU_1H+6UN9M6L([>[(%O*]R@68GH$).&
M_"@#*D^'_AB;0GT2XTYKC3WE,_E7%S+*5<]65F8LI.2>".I]34@\#>'DL=.L
MH;*6WMM.?S+6.VNYH0C_ -X['&YNO+9/)]371 Y&1TJE;:OIEY>SV5KJ-I/=
MP?ZZ"*=6>/\ WE!R/QI_U]P?U]Y!IOA[3M)O[V^LTN%N+U]]PTEW+*';UVNQ
M XP. . !T%%[X>TS4+R2\GAD%Q)!]G>2*XDB)CSG'R,.02<'J,G!&35E-4T^
M6Z%M'?6SW!+ 1+,I<E<;N,YXR,^F16#XL\5V&BW>G:9/K%KITU_(5>=YXU>W
MCV,?, ?(Y90H)!&3WI;V0^Y/#X'T&!-,2*&\5=+.;-?[1N,1?^1.1C(P<\''
M3BE7P+X87Q-_PD:Z/ -6SG[0"WWO[VW.W=_M8S[U:L=0M]/%II>IZ]:76IR@
MF/>T<4LZY."(P>3C&2HP>N!TJCXW\0#0_#E\]IJ=E:ZJMM)/;17!#-)L&XA4
MW G@=><=<'I0W;7^O,(KF]TF\8Z=<ZKX?>SMH[M]\B,YLKH07"!3N!C9L+NR
M!@,0*RO"?A2:RAN3?W_B*[M;J(Q2V/B"[BNCUZC9N &,\;CG/(XK=AURRM-(
MTV?5=1M;:2ZBC"M<2K'YCE0<+DC)]A5RZU33[(XN[ZV@.S?B695^7(&>3TR0
M,^XIVLVB4^9)_,KZ9X?TW1V+V<4N[;M5IKB28HO'RJ78[5X'RC XZ58BTNR@
MU2XU..W1;VXC2.68=65<[1^&33?[8TO^TQIG]I6?]H%=XM?/7S=OKLSG'OBL
MCPUJ6I7>M>([34+B*9;*]6.#RX?+"HT:N >22?FQG/..W2C5CMH/'@7PPOB;
M_A(UT> :MG/V@%OO?WMN=N[_ &L9]ZDM_"&C6MKJ-M#'>+'J+%[K-_.6D8]3
MN+Y4D #@CCCI6C?:KIVE^5_:%_:VGG/LB^T3+'O;T7)&3["B_P!7TW2DC?4=
M0M+-96V1M<3+&';T&XC)I=+?(.MS,A\%Z);RZ;)''>AM,79:9U&X(C7TP7P1
MVYSP .@ J!O 'AY[:6W:&_,4MR+IU_M2ZYE!R'SYF<YP?J >PK;?5-/COH;%
M[^U6\F0R16[3*))%'5E7.2/<4RWUO2KNS^V6VIV4UKO\OSH[A63?TV[@<9]J
M=^O];_Y_B']?U\OP,J^\*V<?]J7]A#<R:E>VQMY#)J$X5UQ@#!8J",G! &,G
MD9-8/A'PE?Z=J45Z^J^,HUBRKVNLZE!<12*1V6,MC!QSD'BNBE\:>'8]:L]*
M_MBQ:ZN@VQ1<)U5MNWK]XMP!U.#Z&M:WU&QNKB:WM[VWFF@;9+''*K-&W7#
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M[:6/+IF.0C>O(X. 1D?B/K2!&/KW@_P_XFT^&PU?2X;BV@QY* E#'[*5(('
MX!K4L;"UTRQAL;&!+>UA4)'%&,!1Z"N;\.^*+NXU>ZT'74@AU.)W-M-"A2&\
MC4\L@9F(9>C*2?7H:TM%N-5(U!]8O-/DC@F*(UO;- % &26+2/GJ/3&/R/UU
M#_ABQI>A6.CS7,MH;O?<MOE\^\FG!;U D9@#VXQT'H*6;0=*N+&]LIK"![6]
M<R7,++E9&.,DCUX'3OSUJ,^)M &FC4CKFFBP+^6+K[7'Y6[^[OSC/MFI4U[1
MY+V6R35K%KN*/S9(!<(71, [BN<@8(.?<4/S#S*WA[PIH?A6P>RT33X[2"1M
MSJ&9RY]V8DG\34L/AS2+>UTZVBL8TATZ3S+1 3^Z;!&1SSPQZYJS'=IJ6F?:
M=*O+6594)@N%_?1$]C\K#<,^A'UKE]!\0ZRTNOV7B*YTV"_T[#1K;6L@4Q,,
MI+\TA+@GC:,$%2,G(IW=P6QV=8VI^%]+U?4[;4;P7AN;;_4M%?SQ!#W(5'"Y
M(."<<C@T:-/J\&D-=^)KG3HY,;S]GB:%(5]&+R-D^IR /?K5R#6=+N=-.HP:
ME9RV(!)N8YU:(8Z_,#C]:.H;BZGI5EK%I]EOX!+%N#+ABK(PZ,K*058=B""*
MH77A+1KW1Y=*N+>=[29@TP^US!YB !\\@;>_  ^8GH/2LW5M?N4\7^';33M1
MM9+"ZN)H+N*-5=MZ1,X!?/R]N,9]^U=%8ZIIVJ"4Z??VMV(7,<IMYEDV,.JM
M@G!]C26U_P"M OJ4+KPKI5[=Z==3I=M-IW_'JPOIQL[9.'^8D<$MG(X/%3Z-
MH&G:!%-%IL4L44TAE:-[B210Q))*AV(7)).!BEUY]3AT>XFTF:TCNHE,@^UP
MM(C  G&%92,^N3CT-9.E>)9_$'AJYGLUBT_6;9=MS:W<9E%O(!D@JK*64CD$
M'D$'VHO9-]@M>R+K^$]&EU#4+V6WFEFU"'R+H2W4KQR)_=\LL5 &3C &,G'4
MU-9>&]+L+N&[@@E-S##Y"2RW$DK;,YP2['/L3DBFV^JKI_A^WOO$&I:? SHK
M23G_ $>$%N@&]VQU ^]S^E6'UO28KNWM)-4LDN;E=\$+7"!Y5]5&<L..HIM6
M=NW]?YBW5_Z_K8BD\.Z1+:7EJ]C&T%[-]HN$R</)D'=UXY4'BM3I65%XFT":
MR:]BUS39+191"TZW<902'HI;.-QR..M+K_\ ;8TJ1_#[V(OT!94O8F=)./N_
M*RE23CGGZ4GHOZ_K8K=V*Y\(:&68_8VPUS]K"?:)-BRYSN5=V%R220  <G.:
MKOX#\/R6=Y:/#?&"\F$]PAU*Y^=QW_UGTZ>@]!BA9>(M7U;P9I]WI]QIYUNZ
MD\MHY;1Q&C@GS$9!+N4I@Y.X].G(%=#+J=OHVG0RZ]JFGV\APKSNPMXF?_9#
ML<?3)IM6T_KI_P #\!;_ ->O_!_$K7'A'1;J<S36LC2-!]GD;[3*#-'C $F&
M_>8'0ODCJ#FM+3].L])L(K'3[:*VM81B.*)<*H^E$^HV5LD;W%Y;Q+("4,DJ
MJ& &3C)YX!/T%<U9>(YAXUUB"[U*S.BP:=!>P2 *B1JY8$M(20P^7.>!@].]
M'D'2_P#78NW'@C0+F)8FMKA(UN3=*L-[/$%E)W;AM<8Y)('0$D@9)J9?".BB
MYU&=[:69M239=I<74LL<J^A1V*C'08 P.!6K:7EKJ%K'=65S#<VT@RDT+AT8
M>H(X--O;ZTTZU>ZOKJ"UMT^]+/($1?J3P*3TW#<S/#GA'0?"5O+!H6G1V:3-
MNDPS.S'MEF)/X9J:]\.:5J%\][<VS-/) ;>0K,Z++'S\KJI ;&3C(.,G&*MQ
MZG82VT%S'>VSV\^/)E652LF>FTYP?PHM-2L+^T:ZL[VVN+920TT,JN@(Z@D'
M''>A^8+R,75/ 'A;6K.QM=2T>*XBL0%M][ON0#L6!RP]B2#6E)H&ER2V$IM%
M1K!2EMY;,@12 "N%(!7@<'(X![5A:/XDFU7Q[?65MJ=G>Z0NGQW%N;4*P#%V
M1@7!.XY4],=<8XS70WKLM_IZKJ4=L#(VZ!E4FY&P_*,G(Q][CTIZ_?\ \$+6
MT[%*T\(Z+9V=]9I;2RV]\YDN8[FYEG#L>K?O&;!]QCH/04'PEH[:9<Z>\5R\
M%R@CF9[V9I70$D(92^_;R?EW8Y([U>;6-+2XBMVU*S6::0QQ1F=0SN.2H&<D
MCT%.U/4K/1]-N-0OYT@M;="\DCG  %2VDM=AJ]]-S.A\(Z/!?6%ZB7GVBPB\
MFV9M0N&"(>H(+X;/&<@YP/05I7VGV^H1>7.9U&"NZ"X>%P#C.&0@CH.]<R/%
M0N]9T.[M-5LFT.\MIY)MNUMKHH)S+NP ,X(P,$<GM73+J=@^G?VBE];-8E/,
M^TB53%M_O;LXQ[YJGYDKR,YO">C-?V5ZL$\<UBACM_)NYHT13U^16"G/<D'/
M&<XJ"V\#Z#:1)'#;W2^7<&Z1S?W#.LASN8.7W#=DY&<-GD&MNSOK34;5+JQN
MH+JW?[DL$@=&^A'!J*XU;3K2]@LKG4+6&[N/]3!),JO+_NJ3D_A0/<R[CP5H
M%SI[V+VDR6SW)NF2&[FBS+NW9RK@XW'('0'D#-6K?PWIMKK;ZS$MU]NDB$+R
M/>3.I0=!L9RO')Z=23U)JS-K&F6^HPZ=/J-G%?3#,5L\ZK))_NJ3D_A4AU&Q
M%^; WMO]L"AS;^:OF;2< [<YQGO27D#\R#5-$L-8$1O(G,D6?*FAF>&6/.,[
M9$(89P,X/-0WOAG1=1T-]%N].AETY_O0L#R<YW9Z[L\[LYSSFK7]K::-3_LP
MZA:?VAMW_9?.7S=OKLSG'OBK,LL<,32RNL<:#+.YP /4FCH/6YGZ%X>TGPSI
MJZ=HUE':6JL6V(2<D]R222?<FM.LZ/7M'FTJ35(=5L9=/C!+W27"&)<=<N#@
M?G6'X/UA_$T4>M6VOQ7%M+&?/TZ,1.+9SRH#+AE..H8G.>-M/5L6B1UM%%%(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .<\>:;=ZOX)U.QL83-<R(NR,$ MA@
M2.?8&L>\@AUC4SJZZ;=KIT&E3VMS'/I\BO<%BNU!$5WN%VG^$CYN,\UW=%*V
MC7?_ "L.^J?];W_0\QTK2;M?AOX9DATJ876GO;&^M7M3'-+'&22F& )P3N Z
M$CBI]9TJ\U^/Q3J&E6ES';W^C?9DAGMVMWN+@%^=C@," 0N2!G/<"O1Z*IN[
M;_KI_D*.EOZZW.&MI;F[\;:'J$.E:E]C.DS6\DTEN8?)<LA^97VL/N$< GIV
MYKB])\2^$M3UG0-"O-2L"-*NG,"7-K*9YI3N4*X>((C D'(<Y8#&*]KEC$L3
MQL6 =2I*L5//H1R*RM/T)['Y)-7O[RV7 CMK@0[(P#Q@K&K'''WF/2A/WK_U
MNW^HK>[;^MK'GMY,TWA75#%I&KBXE\0)<(O]DW D:,3JX?&S.-JL<_AU.*[/
M1C+'XPUUGM;I8KL6\T,K0LJ,HCVGYB,!@1@KUYZ8KH8[F":66**:-Y(6"RJK
M E"0" P['!!Y]:EI+1?UV2_0;U_KSN<9KZ0Q_$7PW=C3KF21(YXYKJ&PDD"J
MRX16D52 -V>">,Y.,UR0C6W\%:C;VFB:G"[>(%GBACTBX5O*%PL@8*(\X"*3
M[=.I KV"BB.G]>:?Z#_K\&OU,/Q9;S:EX(UBWLXGEFN+&58H]I#,2AP,'D'V
M-<^;Y)_&GAZX;3-4$,.F3AI'TV;;&S>65!.SY6PC<'!'3N,]Y133M_7DU^H7
MTM_73_(\AABU >#-.G71M;G@L-3NI+FQMUN+.Y,;O(4>/[C-@,/E!P<D=1QW
MG@RWM(M%:>STG5-,CNI6F:'5)7>=F( +-N=R,XZ$_@*Z*BB_]?=_D3;^OO\
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M5VDQ%Y2&!] O'MBO3$N(999(HY8WDCQO16!*YZ9':I*7]?G_ )LE+2W]=/\
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MWDMKJ-O;I;6W]G2F62Y0MF7RMNY#@J-Q Z?3/K#NL:%W8*JC)8G  IL,T5S
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M-6-7T*;4M7TV_BO$C%GO#030>:C[L?,HW#:XQ@-S@,PQS0]E_7?_ ( +K?\
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M_P"[BDOZ^[]'^ W_ %]_ZHSM2\87FF06\#Z.9=6DA$\EK;_:)XXE)P,O% [
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M=]HLL$;Q6MU/#MW.AE6-B.> 5W8Y[BN<L/!E[9P:)%)J\$_]F6IM"&LCM9>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNN);:K<0SPZ);-]J$432.RO,<D%=G..0%'7C%/1)M^?Y7&E?^O.QWM%>=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M')] /<GB@"W16?IEUJ=PUPFI:;':&-AY3Q7/G)*I[YVJ01W!'T)K0H ****
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MJZ58K(TWVAG%N@)EQC>3C[W)YZU;E>5_4??^NYP5W_R*WQ-_Z^+C_P!)HZ]
ML%+Z+:HKLA:W0!UQE?E'(SD54'A3PX(KF(:!I0CNB&N$^QQXF(.07&/F(//-
M7X+&SMK%;&"U@BM%38L$<86,+Z!1QCVJ/LV]/P5A]?O_ !L>;6%[JTFA>&'?
M6]09Y==GM)W+KNG022XW';VV#@8'MTP:O/=V_A[QO;Q:AJ"KI=W&]I)]ME\R
M(&.-R-^[<RY9CAB1SZ 5VR^#?"R)&B^&M'"QN9$46,6%8XRP^7@\#GV%6K?P
M_HMI+=2VVD6$,EV"+AXK9%,P/)WD#YLY/6G?^O\ P'_)_>+^OS_S_ X[6K\V
M_C+4;6#6KBVDN-"::*-;K=B53G='&Y*AMHYPO3GWK.FU*\TWP+X>U.;7+BW3
M58K:*^O+QY)8H 8F.["NC(68J"P8=CZUZ#_PCVB&T^R?V/I_V;R_*\G[,FS9
MG.W;C&,\XZ5+'H^F1:8=,CTZT2P*E3:K HB(/4;,8Q^%+I;^MW_G^ +^ON2_
M0QO!)/\ 9<X7Q-:Z_")OW<UL698A@?)O:61F.>?F8GGTQ6"Z'2-;\<ZII_VB
M;4H8D>"![N5D=S!N_P!66VGD<<< 8&*[VSL;33K5+6QM8+6W3[D4$81%^@'
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M>#BO.O#"3V/@OP;?:?>71O998K9[7[0QBEB+'S 8B=H*KEMP ;CKVKU8 *
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M>GR9WVJ6Z")L]<H!@_E4L&EZ?;%S!8VL1>,1/Y<*KN0<!3@<@9X%/K?^N@'
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MBRM([&SCMH6F:-!P9YWF<]^7<EC^)JQ4-K:6UC:QVMI;Q6]O$-L<4*!$0>@
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MT_ (:VOIM_P?N.@_M?3]/T>TG,]U<PO"K1,D$D\TJX'S%$4L>H)..,\XI_\
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M@G:$3)S@MGCIFE->Z[=O\_U'#XE\OT_X)OZ%K]C>166GFZ=[\V:3$21N/-7
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MLLC;$<P2>4SYQL$NW9NR#\N[/M69H^CZG8>)=01S'_8>\W5FHQN663_6+CL
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MOX9IXWM)-V[F-<ETD+;3P%7DYR:%L@>[.BL]9L;\.8)7V)D[Y(7C5@,9968
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M1%49P!@9))_,]:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,K2O#NG:-=WEU9)<K->OYEP9;N64.W3.'8@'&!QC@ =
M*U:** "BBB@ HHHH **** "BBB@ HHHH ;)&DT3Q2('C<%65AD$'J#6;I_A[
M3],E:2V%W@](Y;V:6-/3:CN57'^R!BM2B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@*%S@<D<#-=+;6T-G;I;VZ;(D&$0$X4>@]!Z#M2+:P)=270C'GR*%9R<G Z
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M@MM2GUC3/LUH\MEME6>6W>-)XR=NWYF(*QG!W;/FR%[9KHJ*'K_7K_F"TO\
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M0PPZI%!?W\*ZA(TI\J4*8';&XQD#()(SSG'.,5L@84#)..YI=%\@ZL6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*A>",8-2[VT_K;_,TBKR2]/Q.VTS6?[2N)HO[.O[5457CEN(U"3(W1E96/\
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M1>%M)BU*\U 17#W%Y#Y%QYMW-(DB8P%*,Q7C)QQQD^IK-?Q)Y7BR)I-7L?\
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MGX;MKG1X+RTN[>X%EHYDBLV6)G,T38==J@$L57"< DD$5U]%+I;^OZW^\?\
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MSJ>OL>A!KTUF5%+,P50,DDX %-AFBN8$G@E26*10R2(P96!Z$$=13>O]>O\
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MN;:2%E=4 (PZ@D>XX]ZZ.BA.RM_77_,'KK_73_(****0!1110 4444 %%%%
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M93!,T@8;CU!5=N.F.> .:9?^*+J)M0ETW2UOK33'*7K_ &CRY,A0S")=I#D
MC.67GCFK_AW1Y="TE-/>\%S'$S"(^5L*H6) /)R><9XSCH*SY_"MRM]J3Z=J
M:6MGJI+7L#VWF-O*!"\3;AL) &<AAQTH?E_3T_X(*W7O^&O_  #)U#6=1O\
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M/&31E\ W_P#8>B0V?B-K'6='A-O!J-O: J\1 !5XG9@V0J]^HS[4:6^[]?\
M@#ZZ?UM_P36G\1Z@FEV]PFBF*YD$AE2^G,$,&PX.Z4(V,]5.WYAZ5@ZC?VGB
M&3P%KT=JB23ZA\C-M9T4PRY4,.Q*CIUP*VY/#%_+<:3<SZV;N>R#B9KNU5EF
M+8^=44JJ.,8!P< G@Y)JBO@K48;30;:#6[?9I%TUR#+8EC)D, O$BXPKMSSD
MX/'2A?%\PZ?)_D4M,DN-$OO',^BZ3;W4L5^DOV02^0'S C-@A6^8G)Z<D]:Z
M*RU^[U";1Q;6=G+!>VOVJ>5+MCY*\8VCR_GR6[[>AXJE#;GP?-XA\0ZUJT#V
M%W*MQ((K%U:'"J@Y#N6X Z*.<GIP)O!FF06EI=WUNLZ07T[26\<ZE6BAR2JA
M2 5&6=@#R ^.V*%MZ)?\-^OR"6^G?_+^OF:&JZR]G>VVFV5O'<ZE=(\D44LI
MB0(F-S,P5B!EE'"GD_6L*;Q\;>UC\S1YOMBZG'IEU LZ;;>1RN&W'!92&!!
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M4'R]VT]0=I!&><9J/Z_/_(K^OR_S.OL9KJXMO,N[3[++O<>5Y@D^4,0K9'J
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MYSPK<[&52  '* @  <GC!Q0EI_7>P?U^%SO+V6X@L9Y;6V^TW"1LT<&\)YC
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M7SL']?A<]4HJ"&XMG<V\-Q'))&BLR"3<P4_=)YSS@\GK@U/2 **** "BBB@
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MV96MD(@QTV#'R_A39_#>A7-Y->3Z+ITMU.ACEGDM49Y%(P59B,D8XP>U:E%
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M.!))DHO=L=: )**R?#^M-KEI<S/926;P7,ENT4KJS H<$DJ2/R)K6H ****
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M0 /7/IAK3[P>OW&C1112 **** (+W_CPN?\ KDW\C7,^ "!\+=$).!_9Z_\
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M+:7 (#8VXS@GGWJY-H>D7$R33Z792RQQ&%'>W1BL9&"@)'"XXQTI=+?ULO\
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MBGC#HWU!X-9.M>';:]T6^LK.QT]&O%5)UDBVK,@P-K%>1\HP#SM[#BE>R?\
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M6H)8=[V=MYC-&Q(^<^9/*R=QM&T>W%=5;^']%M+\W]MI%A#>%-AN([9%DVX
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ML9\E_+D9<[D63;L9A@Y4$G@\<5Q7@[PSJ&DZG#97_@C0HOL8*IX@A:(2S #
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MU,DBW4$D!"#JX\Q5W)_M#(]ZY6XTF;6M4\>:= ZQRW,5M'&TBY3=Y1P&'<=
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MXS@<8/6IWU[6M-UF72+Y=/N[F:REN[&6%7@1C&0&CD!+D?>!W \\\#O/2_\
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M(Q]'\/QZ)X?MM'M;^\,-JH2*5S'YBJ!@#A I_$56/@^R-F(OM=Y]I^V+?->
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M*)98YQ%L5@ HV[44\* .2>GKS6S10M/Z_KL@>O\ 7]=PHHHH **** "BBB@
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M' )SF98-S0D'(#2=,=\5Z)#H=RVO+J6HZ@EV+=I39(+<1M"LF 0S!B'P!@'
MZG.:VZJ^M_7\7<5M+>AY?HFJZ#=^(XK#5X+NV\9V]W(Q9+:0R2Q[VV_O0I'D
M%2."P''K6YX$LM)L;OQ!%9V5I;WJZE,)1%"J.$R"@8@=,'(S[XKM**2T^[_+
M_(;U_KU_S/,M0D\.3?$#Q/:ZC>V<T)TB)YH+JZ#HCJS[OD9B%P AP ,9![YK
M-T76-(C3X<Z@VI60U"ZC,%U<-<+YLJ^2PV.Q.2!)M&#T; ZUZ_13B[6_KO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:G-/#8:C9W4MNVV9()UD,9]& /!^M0R:K:WT5_:Z5JMBVH6R$,JLLQ@;'&]
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M12>: 50H,##$$;. >*T[ZVU32_$$<^FSW5U)=RPB[LI[)G@DVA%:5)@,1$*
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MQO91V''3!S2:'X,U'0=2VVWBB[;059GBTIK>,["23M\TC?L!/"C'IFNPHIW
MY*'P4T=G_8[:@DGA\3"=+-K;]XI$GF!/,W8V;NVS..-U)J7@J6^7Q#;QZJ(+
M+6P&E3[/NDCDV*A*MNQM(4<%<Y[]JZZBE_7Y?Y(/Z_K[SE(_"^L0Z[-J2:Y;
M2E]/6Q43V!+_ "Y(=BLB@G<22 JC'''6H])\&WFF67A^$ZO$\NCJ\0D2TVB6
M)EQC:7.&& =V2/\ 9KKZ*=_Z^_\ S8>7]=OT./\ ^$*NA,7&KH2NI_V@DC6F
M93R?D=]WS  [5.!@ #!Q5:?P/J]QH^M6#:[8C^U+T7;2#37_ '?3*X\[G[B\
M_7KD8[FBE_7Y?Y('KO\ UO\ YLP[?0KR#7+G5/[23?=6L4,R);X'F)NPZDL<
M#YS\IST'/7-'_A%[BSN=7U.SO;:RU"\A\I);/3\*I!R'="Q\UQTR<<<8KJJ*
M ((%G:QC2Y<"X,8$C(,?-CDCKCFN5T_P7>Z>=,=-8@:;3_."R?8N9Q(,;I/G
MRSY );(W<\#.:[&BA[W_ *_K4.ECA8? ^L0Z+I>G+KUB387YOA(=-?YSN+!<
M>?QRS<YZ8Z8R9;_P'/=Z7J>CPZT8-)OIC<>4+8-+#(T@=MK[L;2<G!4D$]<<
M5VM%']?E_D@_K\_\V5)+>Y_LIK:*Z!N?)V+<3Q;@6QC<RJ5SZX!'X5QW_"OM
M1BT#1[:S\2-9:OI*-#;ZC;V8PT38RCQ,[!LX!Z]0#BN\HH!:*QY[XU74=-\-
M:=9MKE@]]YWF2W^L[K:%L C/F0[?);+#;M()QWY-,T#1-;U7PRMI=7&A0K%<
MQW<%SIIEN[:[')(E$C!I.Q+;SDXYXQ7HM%-=0['%W_@B^N=)UBP@UJ")=2NU
MN27L=PC " J )%[QC!SP"1@]:[&$2K!&L[H\H4!V1"JL>Y ).![9/UI]%+^O
MT%8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^*M:_L#0V
MO=Z1YFAA\V096+S)%3>>1P-V?PK)U74-7\+Z5=W$VI+J,4DD"6DT\:"2(R.$
M9G$:JI1=RD8&>Q/>NIO;*VU&RFL[R".>VF4I)%(N593V(K&TCP/X9T'2[K3=
M.T>WBM+L8N(VS)YH]&+$DCD\9XH7]?U^H=C,GNM7TWQ ^B2:O=745[I\UU!=
MM#")K5XRH(X0(5.\8RI((Y)SQ1TW7=9N;7P%=/J3EM5B*WD9ACV2MY#/NX4$
M'<!]T@>U=?IN@Z?I(;[+%*2R["]Q<23L%_NAI&8A?]D''M5%?!/AU8K:(Z<'
MCM93-;++*[B!O]C<QV =@, =@*::_KY_YK[@?]?@<O:>(=?_ +"L-6N=3624
M:V=/FACMT2*6,W!BR0<L"!R,,/?-;4NNW=CXMDMM5:^M+2:5(K&00(]I+G'#
M.%W)(3D?,0#Q@$]; \ ^'AIRV AOOLRW/VH)_:=SD2YSOSYF<Y^;KUYZ\UJR
MZ'837<5S+'+(T3;T1KB0Q[L@ABF[:6! ()&1VIW6G]=%^M_O!]?ZZLY+2=6\
M5:[J":I9SZ:FEI=/!/;27G*(LA4Y3[/N67 _YZ[?;FM+P@ VJ^+@1D'5R"/^
MV$56QX%\,+XF_P"$C71X!JV<_: 6^]_>VYV[O]K&?>I(-!@T,7TVBP3&[OY-
M\K7%Y+*F_&-Y#L<8&/NC)P!T'$K16\O\O\OQ!ZOY_P"?^9%X'EDD\+Q1R @6
M\\]O'G^Y'*Z+_P".J!^%=%659^'[&TM=-B*-*^GDM#*S$'>P(9CC@D[FSGUK
M5IL2_K\0HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;N=[:UDFB
MMI;IT&1#"5#O[#>RK^9%34A^Z?I2>P'&1_$>T.A1ZY-H>L6^DM)Y;W<@@*Q#
M=L+,JRE@H;(R >E=!JVM?V9IT5[!876I1R,J@6;19PW"M\[J""2!P3U]*Y#P
MD$;X6:<L@4HUZ 0W0@WG2FW<=QX+N(='\N27P]?7<(L9!EC92F53Y+?],SSM
M/;IZ5=M;?UT_ST#S]?P;_P M3N[F\EM]-:[6PN9Y%0/]EB*>:3_=&6"Y'^]C
MC@FN7?XB6Z>'+'71X?UEK.\E$*8%ON1BP5=X,OR@L<>V.<<5V5>93Z6U\_B'
MP"'>))I6OX67(VP2 OP?:<$8]*F^O]?/\!I?U^7XG;WNN26>H:?9C2+^=[P$
MAXC#MBP,G?F0'C/4 BLFT\<&]>^BB\-:UYUE.MM)$3;9,I .T8FQPK!B20,
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M\_U0K_E^AT:G*@^HI:X2\O7T/Q)JR/JMU#9G1#>223.TXAD5BOF(A.!Q_"N
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MGE^-_P#(+-+7S_ ]/HKS.?7+[1= \01IJ$L=O8ZTEJ+NZ,ER;:!EC+%B7#L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ./\4?VE_:]GY7F?9_.B^S[]
MNSS\2?=V_-TZ[_EZ8[UT^GF<Z;;&Z$HN/*7S!+LW[L<YV?+G/]WCTJS10MK
M][G"Z>=7'B^3S%N#-Y</VC)CW^1YDVS=_P L\?>SL^;&WOFNLUC[9_9DG]G^
M;]JRNSRO+S]X9^_\N,9SWQG'.*O44=+!UN<IX+-YY$P</]BW2>41C9O\Z3?]
M[]YG/K\N,8YS75T44Q!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M")N1TP05!]66K]QHWB"X2P9M<L3-!<&XE9M.<JYP0JHHF&P $]2Q)YSVI?\
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MFRU0882E01QP0"0/8XJ_XP\-Z5X>\)WNNZ!9V^CZCI\7VF.6QC$ DV<[) N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !116=KVG3ZOH-]IUK?/8SW,+1)<HNYHB1C
M(&1_,4GMH-;ZG&2^--2OOB/H=AII1?#\\ES \^ 3=2QQDMM..$4X&0>2#V%>
MB5XW)X&\8Z7XL\'PKXIDO+2T:58Y8M%CCCLT"#*MM)'SCY03TZCFO9*K3E7S
M$]_N_4****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10-3_005.jpg
<TEXT>
begin 644 ex10-3_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2Z Z8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1)V@76[*RO-'1-1A@GNDC:XF#95 "02-BN,>KKZ4Y>[9/^O^&!>]JOZ_I_\
M!/2Z*Y'Q/;:5XM\ 27KPQ3QR6OVFUFP"\+%<AT;^%AZBL'4[PR>&]9\)^*XX
M;K4+:RDFLYYHP5O(U4[9%SP)%_BQR#R.#19\SCU_K\OZZB4D[-;,],HKRSQG
MI^A:'XN\.7J^'+6X2WL[I_(M[-"3Y:ILX Z+DD8!QS@5U/AW0?#M[*_BBW@T
M^]O-17<UY%$N"I&"J^G'!SR><^@2=]O/_@?>-NS2]#JJ*\<TO2=%MH?$@_X5
M_;:@D&I7"QW7V2T,42C&!AG$@5>N%7Z5L>,=%\/6&O\ A#[=I$5Y!'YEN^;
MW4DD:0G:"JHS, >>F!UH3ND^]OQ5P;W\K_G8]+HKAOAY:NLVL7]C&UMX=NY4
M;3+1N-@"X=@F?W8+?P\8QT%=S3Z($[A1110,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW>(+B7[/M9E#'!"RDKG:0,@#/>F6?CL7PN!!X:UHRP71LS%FVW-*!EE'[['
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M%I:+;S"9Q/9M,7(Z $2)@<GU[=*6'Q%:7WAI-=TN.74;9XO-1+8H'8=Q\[*
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MEW+>%M3UFUO[+4'BO+][NUGM;*6X5U<+E6\M6V$,"/FP,8.:W="MYA:W<]S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>)T=0RLI!!&013JANX7N;66&.YEMG=2!-$%+I[C<"N?J#4R5XM#1YOX:N9O
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M8!YS^7%='12M_7W?Y+[B_P"OS_S9S=UX/74M,DL=3UO5;Y'EAE#RF%60QN'
M 2-5P2.<@D^M7)/#=G+?:O=M+/YFJ6R6TX##"JH8 KQP?G/7/:MBBAI-6?\
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MXTQ?">NF]MX%N)8@UH2(V) .?/P>0>!S6]::A/>3P-'9,MC-:K.MPTB@AC_
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M&IZ-AP"5/8C@]J/,+]#:HK&LO%6CZA#=R0W$J_9(_.G2>VEAD1,$AMCJ&*D
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M@)C0QH?+'RH1@J/08[5(\,4K*TD2.R_=+*"1R#_, _@*?10 R.&.% D4:(H
M4!5   Z"GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]"1QUYP-.BA:*Q76XBDE06&"1R,]*6BB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_A._!_\ T->A_P#@QA_^*KH** .?_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\
MT->A_P#@QA_^*KH** .?_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*KH** *&F:YI&M"0Z5JMC?B+ D-K<)+LSTSM)Q5^BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(%<)G:K;23D 'FH33V_KXO\ Y%E-VW_K;_,]-HKR'2]6O+G1/#B6WB&\9O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 1B>(W!MQ*AF50YCW#<%)(!QU
MQD'GV-25RYN!%\4#"_ GTA A_O,LKDC\ ?UKJ* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKBKGQCK>C:R-/U;PQ-/'*2;:Z
MTR59!,!DXV/M(< 9*@DG!(! . #M:*Y^U\<>&KHE#K%M:SC[UM>M]GF4^A23
M##\JM-XH\/HP5M<TW<WW5^U(2?H,\T :U%><?$+Q[)IU@MAH=Q]GO9UWO>3P
MN%@BS@% 5_>.Q^50H/<]JZ3P2^L/X=@;5XYXVV@1B[;=<L.[RXX4D\A1]T8!
M)/0 B\5I%8ZCHOB QEGL9WBE(.,02(?,)_W=JM_P$CO745FZW&LEC&&4,/M4
M ((R"#*H(_(FH]&:2S7^Q[ERTMLO[B0_\MH1PK>[#(5O?!X#"@#6HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J]\;H:?<FR"&[\IO)#_=WX^7/MG%6*K:C#<7.F74%
MK-Y-Q)"R12YQL8@@'\#4R5TT-;G!>$M7M+ZZMK&75M4LO$D)5M0T_49V)GP,
M-L5LJ%SR#%@<<\4>+M%-A=:(Z:MK7F7^LI%<%-5N8U,;[R45%D"J!P!@ \5M
M7^@:KK>HZ8=2ATM(].N4N$OH'<SR%?X0A7$8/?YVX_1?&.D:WJ]SHS:7!I[Q
MV%ZEXYNKMXBQ4$; %B?KGKG\*K=I^?X?IZ$).S7E^-G_ %?_ ",3QSHS:)X0
MGFM-7UI6%] 8F_M2XW1J[QHR;O,RP/)&[.-QQBKT,[ZUXPO?#,5W>V^F:/:Q
M><8[EQ-<22 D RY\S 4=0<DGKQ5[QSH^L^(/#\>G:;#8;WEBEE:YNG0(4=7P
MNV-MV<$9.,=>>E,GT+6;?7?^$CTL6*7]S;I#?V,TS^3+M/RLLH3<&&2,E#D=
MA27GM?\ 16^5[_F.6NW;]=?P+5QH$EO;WB#4]1;3VM"%B:\E\R)U.=RR@^8<
M]\L>GH37!6OB"U/P=.^X\4-J3:>;@W?E:B3YX3(83XP%R/[VS\*](F77)]*N
M"T%@+R2/8EL+E_*!/!)E\O<?;Y!_48%OX>\00_"P^&3!IAOQ9FQ#B\D\HJ4V
M[\^5D'G[N/\ @53)/EDO3\W_ ,#^D5"W-%O:_P#E_P '^F-;P^DGA"._?5-9
MW1Z7YD875;E3YA4N79A)ECDC .0 .*3PAX?2]\*Z1J4VJ:T\MUIZFY#ZK<L)
M"Z@[AF3Y&!'!7'4UL?8=;_X0?^S?LNG_ -I?9OLVS[8_DXV[=V_RL].<;?;/
M>CPY8:SHW@NTTV:VL'U"SMU@C5+M_*DV@ $N8\KGTVG'O5U-YV^7_DW^:_I&
M4$^6"?S^Y?JG_3/*M'A\2:QX<6[T_P 07UG/:742"XGO+FX:=WGV %6EV!%&
MW@JV?:M2^?Q)XG\+75EJFI6T>K:?>0K)!&LMI+!*9%".'20AU.<JVS\,BKV@
M:!XHTJQNO#ZVND274,EK>ES?2B,H9Y'Z^3G.8]N,>^>U=/XJ\+Q:G+8:W]IB
MTZ_LWB:XE\S$<D(=6>-R0,C(R"0,$#IDT]VK[:?DM?SO_5]-M5OK^;T_*W]6
MY:P\2:QXEUF;P_<Z5J:0Z1"L5_'IUT@::;)7/FR2*XCPN00=QSR?6WHGB:PL
M_$=SI&EQ:Q)?1HT)T>[#R-&X9?WIG^9=G/)9VQ_",G!HZL;_ $SQ5K_B30)/
M*D\F'SK>>-A]K1QMB$0VDB0R)( Q!!W#@BK?AWPOJOA73[[7]5FM(]2DL9$<
MQN9&EGDD+AW<A>=Q5< $  <\4ET^=_Q_KR):W^5OP_X)5D$\NOZ)=W$D3:WX
MAN'1+Q$RMI9Q!B! &!P6!SN//SGITK?\3M)X&M+76K&]OY;;[7%#>VUW=R7
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M4E#W!;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0W=W;6%K)=7EQ%;V\
M8W22S.$1!ZDG@4 345BVOC#PS?W*6UGXCTBXG<X2*&]C=F/L V36U0 4444
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M%-?*F;Z[E6."( [4FD&26W9 9D[#J*W+D6=N%CG\RXD?E82S2%\=]O3'3G
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MMJ\<TKFU^SPM'^YW$(S9=LDC!R,#FMBLF]UBPT(0VCV^H%1& @M--N+A54<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#G'7K23]U/O_ ,#_ #L.^K7;_@_Y7)]+U^TU?4M6L+>.99=,G6"8R* K,5#
MK@G(P>^*U:\1\Q+KQ!J&J7)W^$;[7@;J?K!-&MOM5F/0Q;^"?N\<U)<VUI>W
M\\&F*O\ PBTFN:>MH+=BL+/AO-\HJ<!?N_=XSFB+;2[NWZ;_ 'Z$N5KOM?\
M7_+4]JJCK&JP:)I<VH7*2/#%MW+& 6.6 XR1ZUYKXHTZVT'7IK31[3[#ID]K
M;2ZA!8IL4QBX"N^U/]@D,1SMS6?K*>&YO^$EB\,FU6Q;3+56:P8"$,;AL[-O
MR@^N._O23OM_6J_I#D[7\CVBBO*_&6D'P[J-HOA*S6SU"[TZ^5OLJ;7G=45E
M+8^^X.2"<G)IG@^"U'BG2FTO4]-E=8)#>QZ5IC1?P@8NG,[?O-W3<I;(/09J
MHOF?]>?X: W;^O0]7HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'(/0@BJNEZ(FFW,]W+>W5_>SJJ/<W6S=L7)50$55 !8G@=^:U**-@>H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >?Z;K.ER?&C5X(]2LWF;38(5C6=2QD5Y"R 9^\!R1U%-
MNFTF;XK7]A)<03RW6BE);26?S-S;ONB-B0,J 2 !D<UZ%14.-XI=DU]]_P#/
M\ ZM^:?W6_R/&;&[T#2_ ?@E(Y=/LI/[3MVN1\D1,B@B0MTRP. Q/(XS3]<F
MTB?QS>67B75=8L=1:Y#:5]ELHY0\>U=ODR>0[H<@[L,!G/J:]CHK2]Y\S[M_
ME_D3RZ6_K=_Y_@9%C_9'_"1:A]GS_:WDP_;,[L[,-L_V?[WW?QK7HHI#2L%<
MEXCN[O1O%V@:B+F7^S;IVTZZA+GRU9^8I,= =PVY_P!JNMK(\3Z#'XE\/W6E
MO,;=I0&BG5=QBD4AE<#(S@@'K2=U9KI_3_ =KIK^OZN<SIVM:A-JOB/7H8[W
M4+6.ZCTRPL87;860A7DQR%&]CEL<!*K^(/%M]<^&_$5H8TL=2T](',MA>F9,
M.^!M?:C _*P(('XUKR^!83X(M/#D=VO^CNDKRS0>8EPX;<WFQ[AN5F))7/?K
M5&3X>7$R:JCZK:1KJ5M##(EOIWEI&T;[E**).!@D$')[Y[46MIVM^FOW\WX$
MN[5UU_X/Z6^9:N_&UU%!JM[9:0MUI>D.T=W.UUY<C,@!?RTV$-M]V7.#C--C
M\:3:I-K:6NE*^FZ?;K(]V;TQM*KP^8H0*N0>0,Y&.H.>*6Z\#73Q:M86>LK;
M:1JTC2W=L;7?(I<8D\N3> H;W5NIQ5VS\'Q6,6O0P76V'5(TC1/+_P!0JPB(
M=_FX&>U2[\C[V_&W^>Q4=&O7\+_Y;F=?^+=5TOP]IVHVFC6=S;W4,(MH)=4D
M^TRR.H(C \EMQ_VBW0$G'-7-7\4ZMIB32#0HO*M;=9KF2XO?)4L028X3Y9$C
M  ]=HZ<^E.+P7K5IJ=C>6VO6#K8V:6EK%=Z8\@APH#.NV=?F;'7L,#ZKJ/@*
M?4=3O[U]1LO,U"W6&>233A)+%A-I\AV?]VIZ[2&Y[U52^O+Y_P# _KT1,$[+
MF\OTN9=WXQU5M=ULO KZ)#H":@D"71BE^8,<AE3<K'&.&^7 ())Q6Q'XQO+E
M;A-&T9;R/3H(WO&GO3&RLR!]B91O,8*1DL5'(YZX@?X?W,D<ZMK$.ZYT4:3.
MPLSR%W;)%'F?+C=R#G..HJ8>";ZS:\71];2SBU"&..\62S\TEE0)YD9WKL8J
M.X8=.*)7LU'SM^-K^6P1OIS>5_NC>WXC--\=7WB&YG3P_HL-U#';07(FNK[R
M PD4MMP(W(88QZ>XK?TS6%UOPO'JL,<D'G0,VQC\R,,@C(]"#S5/PWX1MO#%
MS=&SF)MI8+>".)EYC$2E<EL_,3G/05=T71/[(\.QZ3]H\W8KKYNS;G<Q/3)]
M?6E45XR4>VGKK^EAP;NG+O\ Y?K<X7P]I5Q=_"VSUZ+6=936?L1N1/)J<\J,
MZ@G#1NY0@XP1C\JL?\+#-O:7&IC299[D:=I]PT8O6".9W*[50@JA![CEN >E
M7[#P3KEKX7@\,R>([7^RHXO(=K?36CN'C[C>9F4$YQG9],5-J?P_BO[B]>"^
M%M%<0V4*1"#=Y2V\A<<[AG.<>WO6C:<V^G_#$V:BN_\ PY'JOQ &DZ@FEW<>
MCVNI"$7$Z7NKB")4)(4*[1Y=SCH% '][IDLOB"=>-K%X<TQ;VYDM#=S)/=")
M(4#%,;U5]S%E8# QQG(K5U#PY>-KLNLZ/J<=C>7%NMO<>=;>>CHI)4@!UPPW
M'G)'M5$>"[RRO8=0TK7I(]0^QBSN;B^A^TF=02P8_,N'!)P<D8XQ6:O;7^M[
M?+;^KE.]]/ZV_'<R5\<ZI'XJ::^M&L=#CT0W\]M<96>(AB"2OEYW9&W;NP1\
MV>U;$'C*\BNM+35]'2R@U;(LY([OS6W;2X65=B["5'\)89XS4,OP_2>>/S]5
MGNH7TM],O/M:F26=&);>)-PVMD]PPQQQ4UOX.O9;S3)=8UE+Z'2E;[''':>2
M=Q78'E.]M[!3V"CDG%#O;3^OB_\ M;>0M?Z^7_!N7O"'B"]\3Z)#JUQID=A;
MW"!H5%SYKMR021M  XXY)/<"N@K*\-:+_P ([X<L=(^T?:/LL?E^;LV;N>N,
MG'YUJUI*U]!KS"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(P4J@0 8N1V _&NPHH_RM_7W(/\ ARI86]W;:>L5W>"ZN^2\_E;%+$D\)DX
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M /A,M+_Y]=<_\$5[_P#&:/\ A,M+_P"?77/_  17O_QFN@HH Y__ (3+2_\
MGUUS_P $5[_\9H_X3+2_^?77/_!%>_\ QFN@HH H:9K%MJPD-M%?)Y>,_:K&
M:VSGT\U%S^&:OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'U&\:_D\J![8P[2^"VT[Y%(.%)SC'OFGKXC+^)7T6/1M2D,:J\MXHB,$889
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %5=1-Z-/F_LX1&\*XA\X$H&/=@""0.IP<U:HH X2
M+5/&4WBV^T%-2T+=:V<=T)CI<V'+LPVX^T<8V]>>O2NA%^UK.+G5-6M;98[
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MR6 QS6QX BNK/X?Z-;WUE<6EQ;6JQR0S*-X*C&<*3UQP.OM7,^$M$TC6-?\
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-5_001.jpg
<TEXT>
begin 644 ex10-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -C IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MKX8_:-_;?3]GWQSXL\$Z9^S/^T1\>F^''P0LOVAOB=J_P33X(WJ>"_AI>Z_X
MVT)+F'PQ\1OC3\.?'GCSQ&J_#KQ?JL?A/X9>$_&>O:A:Z;;:=I-GJ'B76=$T
M+4.AD_X*"?L812>-8I?VBOAQ$W@'1;'7M=:34[E(KZSU#6/ _AJ&R\%S-9"'
MXD^)+?Q?\4?A7X$U7P?\.9/%7BW0_B'\5OA7\/=;T33_ !M\2O!&@:Z ?8U%
M?-/@K]L3]F?XBVN@W?@KXP>%/$$/B76?!_AK25M)-1CN&\4>.YO%]IX;\*:A
M97.GP7NB^*Y=2\ >.-#UCPQK-O8:]X5\2>$?$?ACQ9I^B>(=(O=,B^5_V?/^
M"K/P)^/GPUT3XS3>"?'_ ,&?A%XFNM ?0/B?\8?%?[/.G^ [K0=:\!_%+XDZ
MIJFK^*? OQS\>Z-X*\0?#?PE\)?$&J_&7X5^/;SPM\8/A%::CHE[X[\!:-I]
MQ?7FG 'Z?45\$S_\%/\ ]@ZRTE=;U/\ :,\)Z)IRZ]XL\-Z@_B#1O&WAZZ\.
MZG\/]!^%_BWX@2>,--UOPM8:GX*T7P!X-^,_PQ\;^.?$WBZST3PWX/\  WBR
MU\:>(]6TSPM8ZMJVGVOVMOV\O!7[)/CKX3_#?7?ASXK^('BSXO\ @OXL>//#
M\&B?$G]F;X6Z38:)\'M<^$/AWQ'#J/B+]I?X\_ S0KS5]0U7XU>$H]#TCPY?
MZ]?3V]OK5YJ$6FVUG;R7@!]V45\F6'[='[)VI?$/Q#\*+3XV>%&^(7A;Q3#X
M'UKPW/'K5I+#XR?XH>"O@M<^%[/4[K28=$U?6]&^*OQ,^%_@;Q-8Z-J>H2^%
M=<^*GPLB\2#2H/B7X&GU_E?B/_P40_90^'/A+Q5XH;XF6/C*Y\.?!OQY\;M,
M\-^#(GOM3\=>&? ?P\\=_%8Z'X(UK5SHG@;4_&_C7X=?#+Q[X\^&GA/4/%VE
M:IX_^'WA#Q3\2_#4=_\ #?POXC\6Z4 ?;M%?'.O_ /!0']CCPE?^.]*\6_'_
M , ^&-3^&EUH6G^-;/6KZZM1I6IZYX[\ ?"Z32[*^%G)IGB>_P#"GQ+^*_PO
M^'WQ)@\(WNO_ /"K/&?Q%\#>'/B.WA?4_%OA^WU'<\._MN_LJ>*]2^'6D:!\
M:_"6HZE\4Q#'X6LHQJ\-Q8ZE=^+O$_PZT_PWX_CNM+@/PE\::M\3_ WC[X3:
M)X&^*W_"%^,=<^+GP\^(?PIT?0[[XA^ O%WAK1@#ZJHKX.^.'[>GACX._&;1
M/V?=$^"7QH^,WQ;\4>+/ACX.\,^&/AS-\'=)@UO4_B?\)/VKOC993PZ]\6/B
MY\--"L;'PYX$_8[^*=SXBDU6_L;AM2U#P?IWA^VUZ34]3?1?:?@;^TGX3^/G
M@J3Q1X8\)_$'PYK^GOX]TOQ/\-?&VAZ=IGB[P?XS^&'Q(\;?"#Q[X UK7='U
MK7_A5?\ B7P_\2?AYXJ\._:_"/Q)\4>$M;L;73/&GAKQ/K?@#Q'X<\5:L ?1
M%%?G&/\ @H_X5\._#']IOXH_&#]GKX^?!K3OV7;K0?#GB+PUK-S\!OB5XR^(
MWQ-\0>%(?&-I\&_A-HOP&^.'Q7C\2?$^+2-:\""?2-8O/#FC+<?$7PXBZ^T>
MD^/9?!F=\./^"IG[/?Q*_:'^*O[/6G6TN@:A\$O!$'Q!^)_C'Q5\7?V7M+M/
M"OA4?!;X8_&_5_$-W\+X?CW>_M#2^$O"^B_%?P[X2\4>/H/@V_@'1?'NG^(]
M N?$XBTAM0G /TMHK\NHO^"J?PWO?A/\./B1IG[.W[3MUXH\;>#_ -I#XD>+
M/@9JFA?!WP5\8O@C\-_V1O%OA7P5^T%XQ^+^G?$+XT^$O!>E1^#-;^('PV72
MO"OA/QOXQ\?>-M-^(OA;Q)X/\)ZQX2C\3>(?#G06O_!3WX/WMQXTO[/X3_M
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M&#0?@1\"?"VDZ+X%^-'B?6/@QX@_:#^)/B_P5!\$8_VM[#]G+2/'G@WQ1/\
M$FTUFV\"?#GXV:]\+N=^,/\ P5"\+? ;PUX4U+XL_LR_'[X=^+?$7B7XF^'K
M_P !?$KQG^R!\)/[!M_A9X+\+?$'5O%$/Q>^+O[4W@/]G#QQX4U_PIXT\/7G
MAO5_AK\:/&2PZG_PE'A7QG#X-\7_  V^*&@>"P#]0:*_,SP)_P %4?@3X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ7LDVH2KUJ.(PM%U)1Y935*A&E&3<:?-%*3_ +BO^'U'[ __ $=7X(_\,_\
MM$?_ #LZ/^'U'[ __1U?@C_PS_[1'_SLZ_AU\F/^Z/R7_"CR8_[H_)?\*[?^
M)3^!?^B@XK_\&Y/_ /.TX_\ B:KC?_HG^%?_  7F_P#\\#^XK_A]1^P/_P!'
M5^"/_#/_ +1'_P [.C_A]1^P/_T=7X(_\,_^T1_\[.OX=?)C_NC\E_PH\F/^
MZ/R7_"C_ (E/X%_Z*#BO_P &Y/\ _.T/^)JN-_\ HG^%?_!>;_\ SP/[BO\
MA]1^P/\ ]'5^"/\ PS_[1'_SLZ/^'U'[ _\ T=7X(_\ #/\ [1'_ ,[.OX=?
M)C_NC\E_PH\F/^Z/R7_"C_B4_@7_ **#BO\ \&Y/_P#.T/\ B:KC?_HG^%?_
M  7F_P#\\#^XK_A]1^P/_P!'5^"/_#/_ +1'_P [.C_A]1^P/_T=7X(_\,_^
MT1_\[.OX=?)C_NC\E_PH\F/^Z/R7_"C_ (E/X%_Z*#BO_P &Y/\ _.T/^)JN
M-_\ HG^%?_!>;_\ SP/[BO\ A]1^P/\ ]'5^"/\ PS_[1'_SLZ/^'U'[ _\
MT=7X(_\ #/\ [1'_ ,[.OX=?)C_NC\E_PH\F/^Z/R7_"C_B4_@7_ **#BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^6/\
MX. B9/A;\#V;!(_::^(PR!C_ )I-X>^N01D'.3C S7]3E?RQ?\%__P#DE?P0
M_P"SF_B-_P"JE\/5^L^!?_)VN"?^QGB'_P"8K-C\K\;O^34\:_\ 8KI?^K/*
MC^9-LE2!U(('U/&?P[U^\7['W_!$"+]J_P#9E^%?[1Q_:GE^'T/Q*T+5-:E\
M)-\$HO$O]A?V9XCUO0)(#KS_ !8T,ZB'.CM<B;^R+''G>6(3LWO^#U?WA_\
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M2.:::-&_HV^$W_! 7S_@9X9^)O[3/[0VL?!3QOJNCMXA\4^ =#\'>'O$=EX
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M&&4X>IA<7!5JM:OAY0A.5/$3E5KTTN9+V<OQG_X<6_LM_P#1_FH_^$7X$_\
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MJKB/_P!7>9G^HO!?_)'<)?\ 9,</_P#JFRX****^7/I@HHHH **** "BBB@
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M71\3*_7JOR%_X(\_\F7_ +*G_9&?$'_JZ/B97Z]5_E%QQ_R6O&'_ &57$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFV,D$R7-S$T3A?1* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M41%4(B*JJ H $@15&!D#). S=^N.>/PQ0!_/_P"+/@S\9)/VBM"^!O@+Q%X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRSU;P_<7%W8:UYWPG\8/VE/V0_%'PC\3?!OQ'\:?V)O'OAGQU_P4E_X**?&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (E\'ZMXA^/-.^.?[??Q9^+?_!1KX;_ OQ9^R?8:G^R!\5?AOX!^#?AKXF_
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M"OI?P]3X'^$?BEX[^(>M?%[6_@YK/PD\&^ ?A/J$7Q CM9M<;Q-H0!O^-/\
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M ()]_&7Q9\-]&7XC>.?"/PZM?#O[.W[>?[*W@+3;7]GQ/!GC3Q+\,_VXM7^
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MB7XH> ?B'\6?%OB#POX'^ 7CRQ^/'@7X:_\ "P]>^%6DZQX#\6Z#!\2+SQ@
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M\X_8,UGXXZS\.OBI_P +?^+US^T)X2TGX_?$#0_V;OCWK_A'P+X(\?\ Q<^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\>6?@@^(_A)XFT&R/[1?[2MUK7P[N/@)XE/B_P""F@_!OQE>?%ZX\:? _P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>_: TWXD_$VU_9!_X*CZ;\1/A%\1/$/P@^$.F?!3PMX:^'VD_M%Z'_P4[F^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -V+S\HY 4\#E1G"_P"Z,GY>G)XY-.Z=***  @'&>QR/8]./P)'T
M)'0T@      Z < >P'8>U+10 4444 (54D$@9!R#W!P1D'J#@D9ZX)'0G(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:O/IMAI\&H7FN>)QH>@7C>'M&U/5?%_AWYXU_P#X)R_\)5KWQHTKQ!\9C=_
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M?%"^"_&;ZSK0\*:]\']5^-7C'Q#\,/%L>C:E>PZEIG@E]9L+Y]"U:7Q+Y/X
M_P"".^K^ - -MI/[2F@:3X@L_B?^PU\9O#\?@S]FOPGX)^&NA_$']C;3],\,
MZE)#\-]+\>SS/X8^+7A321<7&B6WC"PU3PC\0_$/B_QG-XD\8:/J'A_P1X5
M/UG^,WQC\&? GP'/X_\ '$VH-8/XB\$>"-!TC1+,:AX@\8?$'XG>-- ^&_PT
M\!^&K*6>TM9O$/COX@>*O#GA31I=5U#2= L+S5X]3\3:YH/ARRU76K#XD^*?
M_!5S]E[X%^$[#Q#\;;?XD_"#75L/C1XF\6_#7XF>&M$\#_$+P/\ #K]G;Q38
M^#_C-\3Y]/\ $GBS3] ^)?@[PYJFJ:;=>#8O@#XD^,/BWX]Z-<W>K_LW^%?C
M#9>'?%DF@?2O[6_[-=M^U3\$[WX6)\0_$_PF\7:5XR^&/Q6^%WQ>\(Z7X7US
MQ+\,_C#\%/B%X:^*OPN\;VWAWQAH^M>$/$^GZ9XU\(Z0OBGPCKVDR:3XO\)W
M6O>%YY=-35QJ-G\L:_\ L!?&Z^^(?PJ_:#\,_MS?$+PA^U!H/AGQE\-/C5\2
MX/A/\/O$/P\^+_P@\?7_ (2UF\\"^'/@AXFN-3\-_"2\^%OB#P5I6O\ [/OB
M;3=:\53^#-5UGQ_<_%?3?CL_Q(\:'5P#/^+?_!6#X2>"/#'QA\3?#;X1?'+X
MX:5\%_BU\.O@=XH\5^$?"VD:%\.9/B3\5/$W[+FB^!M)TKQCXN\0Z-)X@T[Q
M5H/[6OPX\?\ A+Q'X9T/6_#?B_P5IOB+6?#^L7EHWAZ?7?3_ !U^WW\*=(^)
M7B3]G_6=.^./PK\<ZAX/^,1\%>/K_P"$%SKVCZYXO^#WP;\'?&3XCZ1\-]$L
MI/$6O_$+7_ASX(^(6@:TM_;>"K_X6>,O%&E^(/AKX3\:>*_'>A:QX3AX3QE_
MP3;3Q-\(?VOOAE8_&[5=+U7]J+]IWX.?M6Z3XQU+P8/$\_P]^(7P$L/V7-/^
M'>FZUI^J>+UO/B5X>N8OV1_AI/X[-[K_ (8\0^*[S6_'MU9Z_P"'9-:T7_A&
MO.+G_@E3KT_[1NL_M$R?M/7NI:]J?Q1^+GQ(C?Q%\&?#.L^,KC3_ (R?LUS?
M G5/AMXC^(J^*;#5M<^'7PWUL1^(_@=X>M-.T*#X<> =?\>_#&?_ (2;5]<\
M)_$WX?@'1#_@JS^SK\+_ (0?#+Q'XRU+X^?%.%OV*?@?^VGX_P#BAHGP#U2"
MVTW]G'XBG3M$O_V@OB!;Z%#IW@[P^=)D&I^._B'\-? $WB#Q?X:\.66NW/A7
MP7K=EHSVT7U=^WM\6_&_[/O[$7[7/[0?PVO;"S\?_ #]FGXY?'+PA'J^FP:Q
MX?U3Q'\)/ACXH\?Z/H?B;393#<WGAG6M1\/V^FZ]#I6H:+K;Z7<7(TC7-(OS
M#?0_$VM?\$BM'UCX*ZS\$#\>]:AT#6_^"77@;_@EM=:LWP]TR75U^''@PW]@
M?BE'M\3P6:^/-5\.ZSJ]B^GFW/ANSUB33]9CL)K.RN-"U']!?VH?@1=_M-_L
MP_&_]FO5/&$'A2U^/OP=\??!3QGXNL/#<FJ7&G>&?BCX.U3P-XTU'PQHMQXA
MM(['75T76]3F\+3ZKJ>MV&BZH;&YU;3O$UI;7%A? 'QUX&_;&N/#5A\4/B5X
MM^->J_''P#\#?V;/#'QK^,WP_P# _P"RUXP\/_$?0+3XA:SKO_"'^-/!$_\
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M\+VOAJZN;KQMXB_;"\5^)_ GP T7P+>B:/2-4NO%GC3P5XMT+6;C5M2T+3/
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MZV^&=CH,C^#/ WV'\"OC7\4!^TO\9?V1_C3KG@CQSXV^&OP'_9V_:-TCXD^
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M7_#.[L=2>W\9-\6-6\>^#3^S+H'B&V\ :S\5AXBM5\50?"Q=,\3R^'Z>K?\
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M  9\-] _9"^/OBWXN>/_ (E_'7X2^$-$T;5/A;H/PX\4^)O@K\$= ^.L&O\
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MO\5--^,GQZ\!?%WQ5^TMX)_:S\,_%/P1JGPCA\4?"KXP^$/V;]'_ &1=0O/
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MZ;XX\#-/X\MFUVQU;X>7W@Z-8-:BT:]LO[.^(VGSZ5)K^G^!M/\ &^Q\6_\
M@FS\*_C/K_Q0\2>)_BQ\==.OOBW\!/V9_@IXH3PWK'PNTN"'Q'^Q]\8?%GQV
M_9U_:"T43?"2]N=,^,OP\^(WC77M533?M-Q\!_$UM-:V'C#X(:_;V5L(X=-_
MX)P>#--\267CL?M"?M)WOQ'@_; \)?MM7WQ U/5_@GJ'B#5?C!H?[(EG^Q!X
MKTZ[LI_@2?"=GX"^*/P"CU#1?%7AC0?#.B3>$]7UJYU3X)ZM\)8M*\+67AX
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MS]HO_@I8GQ3U?XL_'WX:?!+]M3]@7]F#X&_"_P *Z%^S]H.H>!C^V?\ #/\
M97L],=-:NM-^$>H>(;%?C5^T7%93WWC/QWXDO]/\.RZ8C1K%IVJZ^/H'PK_P
M4=MO'^G2>$_ G[/?Q%\0_M)VGBW]JKPOJ7[.S>*?A[I^I6,'['.O^$- ^+?B
M(?$B77Y? 6H:1J6H_%#X+^'? $&E:A>ZSK?C/XS^"=*\2Z7X,\,Z)\5O&GPU
MZ;Q!_P $Y?A?XB\7?M!^,KGXL_'"SU7]I+]H7]EC]ISQ[;V-]\)5L=.^)_['
M6L_"#6O@I-X6CO/A!>75AH-A+\!OA9:>(-(U6[UM=?L_#,GVBXBO-;\0W>J\
M[K?_  3!^%,_B6+XB^"OC1^T5\)OC'IG[0?QX_:$\+_&3X=^)?AA;>-?"E[^
MTQ9^'K'XV_"FTTGQ9\(O%_PV\3?!KQPGA'PC?7/A;XB^ /&NMZ7X@\(^$_%>
MA^*=,\5>&M$UJQ /T#\$^)+CQCX.\*>+;SPOXE\#W?B?PWH/B&Z\%^-(-*M?
M&7A"YUK2K34Y_"_BVUT+5]?T2U\3^'Y;I](U^VT?7M;TJ#5;.[BT_5]2M%AO
M)OE;]L_XU>-_AG:_LW_"[X93W&B_$+]K3]IWP5^SEH'CFWMO#U])\-M /@7X
MF_'3XN>.['3_ !1!?Z%>>*-+^"'P.^)6G?#E=8T3Q1H=K\4=9\#ZAXD\(>+_
M  S9:UX;U/Z)^''PW@^&6G+X>T?Q5XOU?PAINB^$?#O@_P +>*+[2=:@\#Z)
MX0\,:9X9@L=)\2-H=OX]\33:X=-.O^(M;^)GB_QYXCOO$%[?7%MJ]CI\T>F0
M^0?M4_L^W_QQTOX->)_">L1:)\5OV:OCQX,_:-^$5QJ%YJ-EX>U?Q-X9T+QA
MX!\8> O%-SIBSW6G^'_BS\&?B5\4OA1=>)4TOQ(? =WXUL/B+'X,\<W'@^#P
M=K@!YOHOA?\ ;AC\8C3?%>N_"S2?A*OB#]JO2KSQ=X)^)VLZI\6--^'VM3^#
M=1_9"\=:!X8\??LTZWX/O?B-X$T6W\<?#[XH_#[Q?XL\0>#K_4;C1?C6_CGX
MD:M>W/PM\/\ YB_LW_\ !1#]I?6?^"?/QE^'WQ5\;>'_ !#_ ,%)O@ZH\ VW
MCJ7PKX(\-:3XXT#XQ_"/6_VF_P!G[]L.Q^&FA!O!">'M(_95A\4_$[Q)\-;J
MX\-:?XT^*G[.7Q?^"FB76EZY>Z0K?T&:E97GB#PY=V,=_K/A*^U?2Y(!J%C'
MX>N==T">[MRIE@BU2Q\4>%Y]1L&<C;=V&NZ-)/&3Y5]:E3)\26__  3B_9YM
M=2'BZ";QY'\5?^&,++]@AOB\-<T;_A,I/V=M.U>ZUNRT:713X;_X5A+XGMKR
M^O4@\6R?#QM5AM+V[M(7CAN9U< ^5_V<_P#@HSXPM?V(/V=_B#XN\#_%7]J?
MXVZ3_P $SOV:/V__ -JF]\&67PK\*Z]:>#/C-\/=8UB*7PCH$2?#;P?XK^)G
MC[Q+\//C-<?#OX9>&-+\->'WT#X6^*(O$WC+PEK]_P##C0_B/\9_M._MV_'S
MXB:%^W=^T'^SUXR^,WAKP9^R2G[,6H_LQ>+OA?K7P)7X6_$CP%^TA\#?AEXK
MU/7_ (G_  _^*%[XD_X3J7QA:_'O2/B?X"U+7O"UI?>"8?A5\-K'1QX.N]<^
M-O@[XK?IUI7_  2W^$'A7PK\+/"?@#XR?M'_  ZMOAS^R'X>_82US5?!GC/P
M#IFO?%[]E_P1!-:_#KP%\2-2N_A;J1L=<^&EKJOB^'P%\4OA3#\,/BUX=;Q]
MXVNK?QR]]K2W5I-XE_X)<? K7O!G[4?PXTSQ_P#&/P-X"_:L@^!]GXL\'^"+
MWX5:9HOP[TW]G_P=X#^'OP[TKX2QZA\)=7NO#NDP>#/AIX/\/W]AX@NO%EO-
M;:7)/9+I]_=WEW, ?(GBC]J_Q3^Q%IW[?%MX=M?VO?C]\0/@WH_[&/C[0/AW
M^U'\4O@;XD\%_#7P_P#MF?$?XA>"?"'A#X:^,/"6L1>.?$7A_P"%/B?3/%6E
M^.9_C!XP\2_$?QG=>&_"OAO2?B-J/@^"P^)\WK?Q@_;G^--A\-?^"F'Q3TKX
M5ZO\/(_^"8/BVV\61V6M:_X(U6P^.O@3P+^R-\#?VMOBU\+O%MKH'BCQ'/X;
M\3>*/ GQ6U[0_ _BG1[.?2/!^L)X \7S:EXEN[#QU\,IOH_XN?\ !/#X6?&F
MZ_::U/Q;\1_C%'K?[4_PY_9T^'/C36M(U+X;6-WX3C_9:\3>*/'/PE\7> ;:
M;X77NCVOBNQ\=>,=?\6:VGC#2O&GA'7+V[32+OPF/"UK:Z!#P'QJ_8$U'Q=X
M-_; \ ^$OBA\1M6T?_@H>?!_A']I>#QCJWPZM/#_ (0\)2_!+X<_LR_&OXD_
M#.'PS\)=.\5O\8/BA^SS\+?#'@W3M+U_7M9^&'AWQS;VOCC0O"_@VPE\6Z-X
MO /TE\/Z[I7BC0=$\3:%=K?Z)XBTG3M=T:^2.:%;W2=7LX=0TZ[6&YBAN(A<
MV=Q#,(IX8IHP^R6-'#*/SF\:_P#!3;X>_#_]I/QC^S7X@^%/Q G\5>'O!OQL
M\7>'X-'\1?"N7Q7XQMO@7\*O"'Q;U6]@\!ZYX\\/ZIX4\'?$[2?$VN^%?@?X
M^\;7WA_P[XW\;_"OXI6>OR>"/"^F>#O%WCG])=/L+'2K"RTO3+.UT[3=-M+>
MPT[3[&WBM+*PL;.%+>TLK.U@2."VM;6WCC@M[>%$BAAC2.-550!^9FH?\$JO
M@]=?%WQ-\7-/^,W[16@S>)/B/^T/\4O^$(T[Q!\)KWP9I'B?]J?X66WPN^-(
ML9/$GP9U[QSJ6G:^FFZ!XNT*W\5^./$D_@36/#FE^$/ MUX=^#<^L_"W50#F
M/ W_  5E\$>+O!FM^)]6_9Z^-/@K6+WX9_L#?%'X->!]=UCX/7GB3XX:1_P4
M?\7>+/A?^SII'AMM"^)6J:3X6\0/\5?A]XXT3QW9>-]0T*W\%^"=)M?B3J]Y
M'H\FNV'AOT?_ ()T?%?XQ?%5OVY#\:=4\17.N?#S]OOXQ?#3PQX?\0ZEX+UA
M? ?@;0OAU\&=5T'P9X9U;P'H^A:/J?@:QGU[4M4\$ZCJNEV?CS4/#.L:;>_$
M^VL_B1<>*[*VQ-0_X)4? >_\(CPE_P +%^.%K_9?P&_8J^!7@;Q'::U\,H_%
M/PT;_@GQ\0/%?Q4_97^+O@C4Y?A1/!:_%OP%\0?&_BCQ#J5_KMCX@\">,8]6
MN/#GBWP!K'A(C0!]._LR?LP>'?V8--^*]MI'Q%^)WQ/UOXU_%_6?CC\0?%OQ
M6O? UUKVI_$'Q+X6\&>$-:O+*W^'O@'X<^&-&TO4+/P-H]U%H>E^'+33-.OI
M+V/1[?3]+>UTRS /G?\ ; ^*7Q?\$?MC_P#!+_X=> ?BIXB\%> /V@?CQ\=?
M WQC\(Z7X<^&&KV'C?PU\/?V0OCO\<?#]G/JOC+X?^*/%?AZ=?&GPX\/0W=Y
MX.\0^'+BXT.35+!G6YNH+^T]8^.?Q<L/ O[4W['OP_;_ (75=:]\6-/_ &EK
M;PWH?@K6_A[IGP<U^^\!_#32?&5SI_QALO$=TGC74/$'V:R;_A4UQX2MH?#N
ME:A)XMN?'6MZ>LGAS3]:V_VA?V2]!_:#^(G[/_Q4O/BQ\6OA?XV_9G\5^,?&
MWPJU/X9CX4RPV'B?QY\-O%_PB\2:GJ^G?$[X4_$RPUG[7\/?'?BKP_#8W5N-
M.M3J:ZM;VB:W8Z=J5IREC^P[X6C^(_PK^+VN_&WX]^,OBA\)_&'QF\=Z;XQ\
M4:O\+YKC7_$/QI^&>D?"#4)-<\/Z3\*-'\'Z9I?@KP)X=T+3/ N@^!/#?@S0
MX;W36UOQ9I_B[6M5UZ_U8 ^4OB?_ ,%7WA_8Q_;*_:>^#'[-_P 4-1\0?LA?
M"#XHZWX]\(_%>\^''A!/A_\ M!?#*ZU^U\4_L\_$_3=-^)&HZ_%XP\ :+INB
M?%/Q?=>#X];\$^*?A5XQ\$ZU\)/B%XXN?&>B"O>-:_X**^"M)^/&G? NW^#W
MQEUW4M/^+GPI^ /Q4U3PYX<@\2W'P>^+GQE^%_@[XN>&M.\5:-X8N=<75? ?
MA#PG\2/AA'\7OBGX6U76/!_P_P!1^*7@VZ@NO$GA/1OBYXK^%6+XI_X)9_ +
MQ5X3_:&\&3^-?C'I.C_M6_LJK^RY^T-_8&M?#[2;SXLW,&C>)-$M?VE_&=Y%
M\,Y)-:_:O^S>+O$#:S\6KX3VGC5+G3-,\?\ A3Q9H/A7PAI&@=YH7[!OAWPY
M\>-1^/.E_M"?M.VNH>/#\(-<^/WPYM/'?@K2_A9^TA\4_@;X6T;PCX#^-OQ(
M\.:-\,].U?P3\19-'\)^ ;#QW9_LZ>)/@5\-/BQH7P[\%>"/BG\//&/P[TN?
MP?? 'W<IW*K#HP!_,9I:0   #H  /H.*6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "JE_9PZC975A<27<4%[!+:S26-_>Z7>K'.AC<VFI:;<
M6FHV%P%8^5=V-U;7=N^V6WGBE57%NLW6-,MM:TK4=(O);^"TU2RNK"YGTK5M
M4T'4XH+N%X)I-.US0[W3=:T>]2-V:UU32-0L=3L)@EU8WEM<Q13( ?R5_P#!
M._\ :)^,'A/X2?\ !"CXS_%/QO\ M5>'])_:>U+5_@W\=?CU^T#^U;XW^._P
MN_:.\=_$KX1_%BX^"_P=TGX)ZW\8/B]K'AWXB_$;XGZ'H?CWPO\ &V[\%_".
MW^'VF?"?7OAQKVN7EE\4=/\ ".K?IM^R-^V-XM\9?"G]ESX&_L]?!CX<_#WX
ME_$OX+?MB?&JQ\)_$7XP_%3XB?#KP'X9_9C_ &D?#'P5'@X?$K6/"G_"S/']
M]\4O'7Q.T2T3QQ<Z':?\*U\/P^(/&6J>!M:DM/!7PK\7_9WP;_X)Y?L9_!P?
M!_4OA?\ "YVTKX(:=??\,_Z?XD^*'Q8^*W@SX-V_B&PDL[W6/@MX5^)7C_QI
MX.^&^K:EHUY=:6GBCP)H^BZU_86IZCI5MJ:Z5JE];7.O%^P%^RI8^%/A#X1T
M;P!XA\+6GP&UCXC:Q\(_$G@SXP_&[P3\2_!+_%^ZU/4?BGHVF?%[PE\2-$^*
MUQX0^(>KZDFN>,O NI^,[_P5XAU[0_!VO:GX?N-9\">"K_P^ ?F%\+_^"NGQ
M;\;7GQ6^,MU\(]&3X0W_ .RW_P $I?%OP=^#C^(Y['Q]X8_:"_X*!?M-_'#]
MEB\\-_$+Q3>>$+.QOO"^C_%WP]HVE^)?%>C_ &RUTSX<^ =/\:>!_"GB36O'
M^JZ)I?TWHO[;G[7/B?QE;?L\6'[-/@[PA^TQ-X._:P^*OAFW^)WB^?P]\/?B
MS\*OV;=5^ .A>!->T2P\.W?B[Q3\+=5_:%\1_M'^"?#-YH_C:ZUV_P#@!/X8
M^(OB+4K/XP^'K7X:3_%;Z0\4_P#!/K]B'QEI?CFT\2? _P &7G@?QO\ LT>"
MOV0/&_@.VUKQ-I'P<O/V?/@OK'BG5/AKX)?X3Z1XDL?A7HVI_!W5/$_BN/X=
M_$+3/"FG_$SX:6VH7ND>%?&.AZ="EE#D:I_P32_8O\2>%_AIH.K?#3Q'K%S\
M*_%7B7QQX)^)UQ\<OC_<?'IM8\=^&[+P;XW3Q1^TO_PM0_M!?$?PQX\\":3X
M8\ ^-?!GQ#^)WBOP5XP^'G@CX<^!/$.@:EX0^'/@71O#X!^<_A7]KKXO_!G]
ML+]K#Q38^'O"/Q$^#7Q'_;N_X)N?!'Q0NI_'#QGXBU3P+!^UG^S'^SQX)T:X
M^ UF?".L^#=1\(^&_B?\0O#WCO5E&N>#]!\6^&M4\:7VA:+I'B5K.?Q#WUK_
M ,%<_B#X*TSQ'\1/CG\!?!6C_"_1?A+_ ,%;/B$MK\)/B;KWCWQS_:?_  2:
M^/VK?"KQY8D>,OA]\,-!N=*^+'AW3KJ_\(7'FV5]I&MZ99MK-J+#Q1<6W@K]
M$]2_8?\ V4]0\0:UJ4_PV@M-5\6?%+X(?'?4M-TSQS\0]#TJ[^(_[+FG^%]"
M^"7BG3_">C>,=.T#3+/X8V/AWP39:?H6C:19>%)G\/>$7US1M0N=%T.2U-$_
M82_93T&\\+7<'PKBU/\ X1 ?M)1Z/8>*O&GQ%\:Z+=6_[7_B-_%_[3%AXE\/
M^,O&&O:%XVTSXR>*9)/$7C#2O&6G:]IMQK4L^IV=K9W<TLK 'YL?MB?M0_&7
M_A*? O[-7Q?\(:-X*\93_&[_ ())?M+?#+XC? OXC>-M2\#>(/"'B[_@J]^R
MQ\$_C=\%?%\UWI/A*[U>Z^'B^-/#>DVOB+48#X3^/WA+QX?&*?#/X6ZOX3O/
M"EG]%3_\%#/'MOK'PV^(,'P:T?5_V<_B)^W3\7O^"?DC:-XJNI?C7X0^(/PM
M^)OQ?^ ^C_%[5M"NM,MO!M]X+^(W[07PEO/AO;^ !KNE:MX$\!^(_!GQOUWQ
M]JRZWXJ^%?PY]ZT#_@G3^R'X<\(VG@G3?ASXDGT73I?@2=,O=;^-/QW\3^+]
M+TW]F+QJGQ)_9Z\+:3\0O$OQ.U?Q]I?@+X-_$)6\<?#WX=Z?XFMO GAOQ9-<
M>(;'PZFJW,]U):\2?L+_  8@USXF?%#X3:#IGPY^._C'5_'OQ.\(>,M8D\;_
M !!^%/@#]I+QG\+=4^%2_M&6?[,^H_$+1/@S<?$I] U.ZL_&/B3P_HG@SQI\
M0=)U?QCI>N^-H;CQUXHU:_ /S[TG_@K)\>/$GP2\<?&CP'^RSX,^)UA\/OV$
M/A+^W/\ $'1/#/Q7\7:=J_PRU#QQK_BM?BA^R+JD3?"37;+Q3^T!\"_ ?P]\
M<^*+ZUNM2^'7BSQOXLTRR^'&J?!OX62:A:>++G]3/@W\58?VC=%^*VKZ6-"O
M?@S_ ,)K>>"OA!\3OAU\0-4N3\7/!^G^$?#47C'QSI6L>'HM%N_"0T7XK7GQ
M#^&.CW/AOQ%JYU2/X=CQUHWB&&R\2Z=9Z?\ GA^R[^P#\9/V8II_%OPB?X%?
M#?QWX=\(:!\(+;P!H/QI_;3^)_P'\0^'I?%'PON]<\:>)? ?Q7^+6N67@S5/
M"'P[T3Q+_P *8^%GAW0K_4O"-]KUIHDWQ\D\&^(/$L5_^E'P/_9^\"? 3]G?
MX7_LT^!X+G3/ /PL^&'ACX6Z,^AROX.U.72O#FA6VBOJL5WX.DT2;1-;U>2&
M?5[Z_P##\VFW$>K7MS>6DT,K!P ?S'^"?CM^T'XB_P""5O\ P1,UW6KW]LG1
M?$WQ2_:X_P""8VE_$W]HO4?VJ=9:\^+^B_&OXS^%_#_Q1T?Q?XC\-?M(ZE\:
M?%GAKXDZ)K=[8-X2\9^''T+2H;R-!HOAO^Q[-[3]7-9_;[\8>._#OPZ\1)\/
M=*B_9O\ VH/VD/VJ_P!A?PSXF\(^/O'NA?''X?\ C7X.3?M(>"/#/Q@U"7P_
MHVG26'AKXH>+?V=_&6C#3=#U_P %?$'X#MJOP_\ %FH>)/$6J:IXPT3X4?78
M_P""?O[*"_!CX-?L]1_#G6H?@Y^SWXO\&>//@MX+M_BS\9[>'X=^+/AQJ]OK
MWP[U;0-9@^(D?B-#X UBSLK_ ,#V5WJ]UIOA&>TMCX>L].6&,+MV/[$'[,FD
M^,O%GCW3/AY>:7KGC#QAX\^)%_9V'Q!^)UEX,T'XH_%'P;JG@#XD_%KX=_#B
MW\:1?#OX3_%WQ]X4\1>,;'QA\6/A=X6\'_$7Q#>_$/XGZ]J?B:X\0?$_X@:I
MXD /P'\;_M(?&KQ?_P $,=2^$7P[E@/BOX4_\&[_ .S?^UI\9/B]XM^*/Q+\
M)>/K^X^,_P"SG\1]#\!V_P .->\ P7.OWOC.UN_V;_C3\1_'/B'QAK]MH^MZ
MEI'PY^%.I>'_ !%X<^-7C_XA_!G]&O%O[7WB7X"Z]^UIJ'PU_9^\%ZQXQG_X
M*W?LF?LE>,(_$GQ^^(=EI'B^X_:4_9]_8,TK1/C1;W%]\./'$/@_4M \*?&'
MX>^%M4^$WA'P]H_@ZV7P=KWC>VUOQ%XMU+5(/&GT1XR_X)@_L+?$?PIX)\ :
MY\(KS_A%OA;^SYJ/[(.EZ'X3^,GQQ\#)>_LVZIX>M-+A^ _Q+E\!?$_PY??%
M;X>Z#I$MOJ/@;PO\6[CQG:_#[5+^;Q5X#C\.Z]JESJ]SZ[JO[%7[.&N7WB74
M=7\$ZUJ%WXP^//PI_:=\3/<?$_XM-'K'QV^"&C>"O#_PL^(=W;_\)W]G_M#P
MCH_PV^'EA:Z9%%%X?OX? G@XZSI&I2^&=&DL@#X A_X*C?$/3_AIX&U7QM\-
M_A3X#\:W6L?\%,O"/C?Q;XD\<>,K3X!3_$C_ ()K_%OQ/\+;GX9>$O&H\%R:
MS8>*?VE[+PEXI^)O@&T\1Z8^L>"/AK\.?C!KD'AOXKZC\/4T7Q%Z5X$_X*&_
M$O5?V@OV8?@W\9_@2O[,4G[0OPJ^&7CFST[XL_\ "QTAUOQ7\0_A;\6?'GB3
MX2_#3XN?\*]T;X<:I^T#\%/$W@3P9X-\>?LT_$.T^'/Q8\0^'/'7B?XL^$X7
M\,_#&'2OB'SO[1/_  3'LO%OBKP!=?!_PM\*;_X;Z)K/QZ\4Z_X!^(GQ0_:Q
M^'OC33OB9^TQ\3/#WQ5^,'Q3\+?'+X3?%JY\3W6A>+/%GAV#Q#XI_9\U#PSI
M?@?Q;XXG@\?#QEX:US2;>.Z^C?AG_P $]O@KX&T;P%=>(KGQ_P#$?XB>!K#1
M9[3Q5XO^,?[0&L^'AXQ\/>&]<\(^&/&=GX#\4?&;Q98S>)/ 'A7Q!/X/^'7Q
M \8:SXW^.^A>%-$\(C7/C7XK\<>&[7QY( >)?\%P?$WB_P %_P#!+O\ :D\;
M_#[Q[\1_AGXV\):3\/-6\-^-?A1\2/'?PJ\::+?/\7/ 6E7)L/%_PX\1>%_$
MUO;W6FZE?Z?J%A'JJV.H6EU-;7UM<1$*.<^(O_!0WXP?##]H+Q_\*]/^"'PY
MU'X-_!']L3]A?]D?Q7XOU/XT>-=0^*?B>P_;;TKX::#X3\;:!X<NOA;)HMKJ
MGP[\<?%WP9/XHTGQ)X]U8^*/!NB^*;^T\26_BB\T^QK[0UG]C;X3?$3]ES1_
MV2_CJWC#XV_#"WT71M'\1Q>-/B-\4)M<\7PZ%J<.LZ5;^(O&A\=W/Q+\1Z=I
M-_;6"Z</&_C[QCXBN[;2-'N/&'BCQCXCM+CQ)?5O$/[$O[+NKZMX@\1>)O!V
MJWFK>-OBK^S]\7/$>I:M\6?BVT_B+XM?LV1>']/^ ?BN]EN/B /M6O>"YO#/
MABXLHE/D^)->T'0-;\3VFOZ]I.FW]N <)^R5^U;\1OVGH?!_Q=M?"7POTS]F
M+XRZ9\6)/A1K]IX]U$?%?2?$7PT^)=WX.\->%_%WA+4=#@TOQ'K'Q2\$Z)XV
M^)&N6'AR^TB]^ VI> M6^&^OV_Q)DOU\<Z54_:3\?^*M;_;*_8<_96TV^N-+
M^'GQ1\/?M._M%?%V73M7U'2KSQMX7_9>L?@SX7\+_"6ZFTH0WK>%?$_Q._:2
M\#^/?&=E'JEAI_BW0?A3/\-?%UMXD^'GCWQIX2U[T/PK^PA^S%X%\3_%WQCX
M'\$>)/!>O_&V+QK'XTG\)?%[XU>&K#1Y_B;J>GZ]\4-4^$6AZ+\1K+0OV?/$
M'Q3\3:/HOB[XH^)/@%IOPTU_XD>,M$T7Q?XVU+7?$FD:=JEMVOQB_9^TKXD_
M$'X#?&G2KN#1OB]^SAXH\4ZSX#UNYMEFTW7?"7Q(\,7'@SXL?"SQ48%75(O"
M?CO1'TC7+6\T>ZAG\-?%#P#\+/'=]IOC'0_!^K?#[Q> ?FO^U_\ "7]JS]G_
M /X)]?MP_$;Q-^V!J'C75OAC_P $O_VD-/T'7_ G@WXB?!/XD:;\<_A;H'QP
M^)O@?]HOPQ\0]!_:$\2W?A7QAK7AS5_"VA?%S1K/2+NT\;^.OA]X;\>>$-3^
M%WA+[1\(:^AOVQ_&>B?"+_@E7\<O&6N>%G^,.E>!/V,O&GCG6? /CKXW?$WP
M?K_Q+T3P/\);KQMXMT:X^,VE3>*/BTOB2_\ #ND:S>1:[;ZC/XAU#48X8K_Q
M+H5O=W?B73/N3XO_  C\ _'GX9^./@Y\5-&N/$OPU^)7AC6O!?CSPM#KOB+P
M[!XH\)>)-/N-(\0^'-3U'PMJ^AZR^C:YI-W=Z7K&GPZC%;:GIMW=6%]'/:7$
ML+?.FI_\$]_V6-?\.>*O"?BKPI\1?&WA_P 9?![Q?^S]K=C\0/VBOVD?B \7
MP6^(-SX4NO'_ ,-O#M]XT^+FO:AX-\+^/&\"^#+;QO8^#KK03XNTSPQHNC^(
M9-1TFP@LD . \;_MB_%3P5^VMX:_8\U#X7_"BS/Q9M_!_B_X"_$?5?CC!8+X
M]^'ND:?XUU#]H_3M>\#3>$(O$/AOXU?"JT\+66L?##X8:+-XRL?V@/!]_P"(
MO&VA^,/"'A[X/?M%7/P3^.?A]_P4<_:OU33I/A]'\'? ?Q*_: \>_&[_ (*I
MP_"K2O#FL:PG@VW^%7_!/+]K)_V=+?P?XA_XDVA:^/%OC#Q%XR^$WA&Q\5V%
MKK=CI?A:\\>_''7]+N+_ ,*Z;\#/%/ZA>.OV0?@#\2T0>.O!^K^(YX/B_P##
M7X]V&I7OQ%^*":WHWQ<^$/AK0?"'P\\9^'=?M/&EMK?AJ[T#0/#EA;R:=H&H
M:=HFMW]WXAUWQ%IFK:[XL\4ZCK'CGB[_ ()M_L6>,)/[-UOP'XHL==G^-GQ.
M_:?\+ZSX7_:"_:$\ _$/P%\6?BC<7Y^,_C#X+>-O WQ:\-^//@MH7Q&U/QMJ
M]_\ $_P5\&]<\$?#CQ?K_C+5=8\6>%M1UGQ'>7EX 5O"O[,L7QAU#PI^T?XH
MU+XR?"OQ/\3?&'P#_:/\2_!.X^,_Q$U?1_AYXG\+_ NZ\":Y\.+G2O#GQ?U[
MX.ZI/XDL?$USX"^,UIH.A:Q\"_'_ (.\/:?<:)\-K;XLQV_[04_RYXC_ &T/
MB%^RW^RC_P %?=9OE;XA>)/^"9_BCXIVGP:U'Q/-JVNR>+/"^O\ [*OPA_:T
M^"'AKX@ZD^H:=K&MP_#R]^.UC\']=UIM0?Q1K/P^\ Z1XC\1:_XF\<:IKGB#
M5/V!\-Z'X>\*^#]!\-?#_1/#FB>%/#GAK2]#\$^&_#EK9:!X1TCP]I&EP6'A
MO0]!LM%LWT[1?#FGZ;;V5AI=KI.GO9:;ID,$5A9M!#%"?F?P-^QW\/;'X)_M
M _"'XK0V'Q0/[7FN_%[Q-^U-JBV6I^%[#XI:A\:?#D7P^\2:/;:=::]J&J>'
M?"WA[X/Z7X0^"_@JUM_$-WKVF_#[P)X7_M7Q#K/BJ/5/$FI 'Y;?MF^._P!H
M#X':9\5_V0] \:/JOPPTC_@B]^W3\>/&_P 6KOQUXTTS]H?Q3\=/ 5MX$\.V
MWQ7'C'1["WU'3=7AUWQ)=WFF:3X;\7>%;2UC\6Z[=0S6-CX+\">%HN@\&_\
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MT_P;X1_8X\7?'/5OA+\4;?6/!5[I'[4UWJTWC?Q!\'OBCXPL?A]I#^$OV?\
MP-I-S\1K+6?B1X9\-77QQFTSQ;\+O[+^"WC;PI-/J?GO@G]I7XA_M._MQ_\
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M/A3K'Q!U#X3^ Y/BSJLDGB7X@6W@WP1H=CXI\9S7/C?5[6Z\77,VM, ?F?\
M W]IKXR_ ;]H3]JNSOO"=K\1?@%\2/\ @L-J7[-VI^*M:^+'CWQ/\5_A;XK^
M-/[.?[+\WPSU/PSX(\2Z%J.BW/P;\._$6_\ ^$<U[P9I?Q$TH>&O#WCR/Q#X
M.L/#OA[X<3^#O$MKXI?\%7?C%J'[#>B_M _#/X1^"O!?CSXN_P#!'S]L[_@H
M[X';7/'6J>*]+^&GC7]EK3OV>I)?!&I60\!:.OC_ $F_MOVB].U[2M3D'A/[
M=J/@2;PYJVD6>G>*SKOA[]4-(_8\_9VT'XSZ[\?]+^'S0?$OQ%XU?XG7\\WB
M_P >WW@BW^*TOP[@^$5S\7M$^$E_XINOA'X:^,%_\+8&^'NK?%CPYX&TGXB:
MQX/O=6\/ZGXEN],UK6+:^\;T3_@E[^P[X?TS7M#TSX,7G]@>(?A+\?/@#<^'
M=0^*_P ;-:\.:5\!OVF[CPK=?&3X)>$?#^M?$C4=%\"?"/7;GP7X>N/#/PW\
M$6'A[P;\+Y[>^F^%>B^"I=;UQ]2 -+]I+]I3XR?L^>$_V4+33OAK\-?'7Q'_
M &B/VAOA]^SQKT6I?%'Q-X8\'>#M0\9>#?'OBJX\8:5JMK\)];UCQ?;6;^!F
MM%T2Z\/^"GFBU1KR.]B>PCTJ^^6/@9_P4=^-O[1S>"OA3\.?A3\&=._:8@^%
M7[6?Q!^)F@>*/B3XN@^%EUX@_9+_ &NO$7[&,?A/X>Z_%X(M_&DGA7X[_%#P
M)XXUBT^)M]X1UF]_9]\(V_A>X\:?#+XCZYXMT71;O]%-6_9C^#OB#PW\$?"O
MB31?$_B;3OV=O&_A;XD_"B^\3_%#XJ^)/%&D^/O!FFZMI.A>+O$WC;7?&VH>
M,_B5KHL->UN+6;[XG:_XQE\42:MJ5UXH.L7=Y/,_F,/[ /[+=EHO@[0M&\%^
M,/#,/@/6OC1KOAG6/"'QP^/?@[QE;S?M&>,)/B)\=](U3X@>%?BAHWCKQ+X-
M^+7Q#-G\0/'?@#Q-XCUCP-K_ ([T3PSXRO/#K^)?"WAW5-+ /FK_ ()]_MR_
M$_\ ;8^+_P 8/%3>'?#WA;]G.Y_9M_86^,_P6\.3W-VOQ*T)?VG?A%JGQAOT
M\>QC1&TO4];NK;5XM&U";1_%$GA[1[3P?X<7P[IFI2Z_XB\27OPWXS_X*$^(
M[KXN_LY_\%!-<T>8?LPV'_!/?_@K5^TSX"^&?@'QMXMOO$GC;X7_ +/>L_LT
M:KX1U?Q_X<UV'0O $/Q1\7^"[>?Q%I,::;:W?PIO_B!XA^%>IZ[XKLO#MWX\
MUW]QOAW^RW\!?A'\0]8^)WPN^'EA\//$>N_#;X;_  CU#2_!FK>(_#GPZ'@'
MX/V=]I?PPTC3OA!I6LVWPFT:]\#Z%J-SX6\.^(]&\%6'BBP\'+:>#4UH^%M/
MT_2+;QKP_P#\$W?V,?#?C2Z\<6/P9BOKVY'[0$$7A7Q/X]^*?C3X3:1I7[5=
MW::C^TAX9\,_ [QCXZU[X+^$_!?QLU:QAUSXB^"/"_@'1_"/B/Q"]WXBO-%;
M7+^^U"X /SN_:?\ VD_VUO&-K\*/@YXT_9^\-?#;1O&'[=/[*_PQUK6=9\>W
M&D?#S]H_X/\ Q'\+^.?''B?X7W&C:?I?B[XCZ+X?T3X@_#JZ^&GQ4E\0Z%:^
M"/CA\,UTN\M;+4_#/Q0^*7P3^'MOX*_M%S?LJ>'[_P#9[_9T_9WT*#3S_P %
M7O$G[!6BK\4?VM_CU\4IHK*Y_9PL/C?I'QBU;Q]\5?!WQ+^(.I7<VA:39^')
M/A(FI6OA_P %6\%MHGAOQIKMGI::IJ_WIX*_X)E?L8?#[PC\/_ _A?X8^*;;
M0/A3X\^'WQ%^&S:I\=OVA?$OB#P5K?PDTS5=&^%.B^'_ !CXG^*^L^,-/^&W
MPPTSQ!XELOAS\'HM='PD\#0>*O%J^%_!&E-XK\1MJGIW_#%7[-IUT>)CX!OO
M[<7]I@_MAB_'Q ^)H?\ X:-/A$^ 3\13!_PFGV4_\42?^$5'A P'P&-!)TS_
M (1?[*?+ !^9OA#_ (*P?'OXH^%O"/A+X1_LLZ-\0_VH]-^#G[0OQ6^(_P *
MM \;7[>"_%>L_LX_M3^.OV19_A]\*_&^LZ3X?U+1=/\ C/\ $+X5_$+6_#?Q
M3\>>&FTOX2:;_P *XT?X@>#=9_X3[4_$?@;:\8?M*>/OVAOVG?\ @GYXU\*V
MFG^$/@5HG_!43]J']F1+&V\=>*&\?^+_ !-\ _V'?^"@/A+XCS?$?PCHXC^&
M\GAQOC=\,?%MAX2T%]0\676BZ;\+/ _Q5T?Q=JJ_&>_\'_"K[-UC_@F9^Q7K
MNB?#GP_>_"/4H;+X5>(OBOXC\&WND_%OXW:!XFC;X\^*M4\;_''PMXF\9Z!\
M2=,\7^/_ (8_&7Q7K&H:W\5/@_X_USQ/\*?B!>3*?%7@S58X+=(NLA_8#_93
MM?C$?CM9?#G5]+^(/_"Y=)_:'2/1?BG\8=$^'MO\=-(^%OB'X*CXLV7P9TCX
M@67P;L/'NM_"WQ5K?@WQGXDL_ 4&H^/M-N+:7QQ-XAO],TJ\L@#['Z]**0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$$GAWP7HWB+Q3J5GHNCVEWJFH)HVB:C<V^GVEU>/ +>WFD3TQ'61%=<X958
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MW7AW4;J\\#Z3XPO?&^DZ')I'B75_#UCX=\0Z!JFI '<T4W>F =ZX/ .X8)]
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M$@#)( ]2<"@$$9!!!Z$'(/XB@!:*3<N<;AG.,9&<XSC'7..?IS0&4Y 8$CJ
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M\/\ 2M;\(-XH7QE:)XJTO4V\/G2))+^/U?<N<;ESQQD9YZ<9SSV]: '4444
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MXM"\,1VOB6X\;?VSX=T;1-#\2:Y=:YX-T7PS<Z/X]\)CPSXB\0ZI%XKTWPR
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ME_J)_P $U$^(^F? #Q]X-^)MS\9+V_\ AU^UY^VYX#\"7WQXU'XI>)/B'??
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MO"/QQ@^-VE>./#.NQ>+-9THZ>?!O[0#1>-O VDRZ5IVEZGIWA^STG0_#%_\
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M$_X?ZS:>)_AYXD\)^*K*X\->/?!_AOQ):I9ZU!;W-WI-O#J$%U9M-;2>O*"
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M_&FY_:C\-_M6Z]\6=.\0^/?@%\%=1\%_$JW3P=I=E\%/$E]E_LMVW[17AO\
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M GQ[\.$\:?$34? /A;PAXMN/&_BS2M1\&?".74;>ROO"OB'6_!GBKPW^M]%
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MAO\ 9'^&'P3^*'[.WQT^-'C;0M/_ &M/'<][XCT[XQ6^O_!S1= M?@7^T_\
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M:B@!^,_[0'_!/WX[^.=#^(OC#1OV3=7\0?%S0O\ @G7_ ,$H/!WP"UJV\6?
MS3?%?@G]K/\ 99^/GQZ\7_%"?PCK6I?%W1],\(_%3X8>"OB3X%;0?B]!JUCI
M\VCV'BOPO\.OB+J4<]]HNO=AIGAJ^C_;)TOXP>)?@U\:/'GP.T;_ (*E>._%
M^D_M5VFE_LD_$K1M>\3>,/"G_#"/A7]GWQ9XET[]L&7]H6V^$?P0_:LNO[5T
M_3XOV5+BZ^&>N?"/X/V6L:#HD7P0UOXWZY^UGP__ &P_V6?BGXK\9>!_A_\
MM _"+Q3XM\!?$R\^#?B30=)^('ABYU&'XGZ9I&D:QJW@O3;=-2WZ[K6C)K,6
MDZS;:(-0.E>*--\1>$K\V_B3PQX@TO3:OP__ &<?V-6^)>K_ +3WPL^!/[,S
M?&+Q1JWB--?_ &AOA_\ ##X5'XF>(]<@GU+PGXM36?BUX<T+_A*M7U6*YM]7
M\->)%O?$%Q>)/!J6C:IB2.ZM@ ?328V+C@;1@ D@# QR>3]3R:=110 4444
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M?PDNKSPKH_PW\5_$J^O_ (/M\.?B?\1/A/X3_P"$7\<S?$BWG\/?H/+_ ,%
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MU8_\))]N>)/VVOV5?";VIUCXU^$FL+GPQ\)O&C>(-%_M7Q1X2T_PK\?-9O\
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M\5+F"\\06>O>&? GB$_ C4'TGX[V7@?XJ^(])TOX6_$+6/@7JUOJ&E?&O0_
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MO[-NG_!3X-ZC^UCHOPM^"_QI\+V4GQ>U[2_@#I7@#XU>(?BQX8U2Y\<>-)?
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MM2>(OC;^T3;^#O@W\,/B)X1^-?[;7_!,;]LGP-\</$?Q.T[PUK?PZ\,_L?\
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M(?\ A&/B#?ZWXJ\-^*=9\#_#+PYK7BJUU.ZM+NV\5WVL^3I7A^V\C0M.YO\
M9^_;1U']HKX^_M3_  I\&?#_ $J#P7\%/AA^SY\0_@_X_P!2\6W,-M\<]/\
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M _LV_P#!0;X7_$+]GS]C#QI\:_%'A[P7\8OVF_V=/V4/BQXK\-^%_#OC?4?
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M5- _X)CZEX>\.^ O"/Q.T;X6ZE\2/^";?[8/Q=_:FMIO$&M^(/$'B/Q1X?\
M!GQP/Q,U#0+FUT?P]KVL?"^75+-H9OB(O@>XO/B;)X6_X)V?M=?"CXC6_P"T
M7\+OVA?@-/\ '^']H3]LGQA=Z-XI^#7C>V^"7B#X _ML:_\  'Q#XZ\!:W86
M?Q1U?X@V_P 2? /B[]G/X=?$+P?XS\/>)M&T364T_5/AGKF@6MCK\_C[3_IO
MXG?\%2?V2?A'X(MO'GC'Q5JUIIXE_:DN-;T;['I-CXF\-^&OV)/BY<_ _P#:
MP\876E:]KFC1^)M,^#?Q&MUT63P]\.KSQM\1?B<+FVG^"/@?XG*[B+Z'\?\
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MG^SY%\1KGX9:QX8^/'AC6])_:'^'G[,GBC5/$_P4\::/X8\%_$;XUZ!H6O\
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MJ_PFU7QY\7JT7[*/[6/B']E^?]E[XE>./V)]<\!^*O /Q-^#_BWPMX<_9?\
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M7^3\2?\ !4G]B_P?\8O$7P=\4_%73]!N?"T_Q>T;6_B#J,FG+\-M.\:?L_\
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M_$&K>+O1OVL/V,_B%\>?VBO@I\:? /B'P=\+=>^%<GPYM])^.GA;7/B#X/\
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MZ[K7Q3^&?B[6_B9XVU#Q+\$KG0$\#^$O _T5\4OV%=-O/AG^QMX2_9N\>P?
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M6_82T/X@KXL\1RZ=KFE:?\/M9T#XI_$_X3_$/X1^#/#FB>/[CQ?X=G_X5/\
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M90Q6]Y?6>H6?YZ?LU_M#1?M.?'K]GO\ 9ELM ^-/PP^&OPL_X)]:S^T;\5?
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M34O#.EZ?X,T.TUGQSK6BZ9?@'Z]4F1ZCKCJ.OI]?;K7X/_'C]I#XQ?'KXS?
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M>\?:#X:\8>!K77Y_#7B>RN)]$.NZJ ?2>1G&>>N.^/6BOPJ_89_;(^(/B/\
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MK_X-A/V\KWQ)X$^''PZT;PM\,M*\,ZG)_P $Z-<TSX7>%_"+IJ$6G_"GP?\
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M/#_Q L_$&JIX3^&WBR]^%_[0/BSQKI?A;6OA3^T?9Z1XATW0F\+?$[1/@SX
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M^.OA1\13^U[\$?@9\1?AN/!W@_XI^%/$OC[3?A5X"^,B^!OC)K?BZY^'^O\
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M$-M87VE_#CX>>)?#'@FWCTG0]/\ [";3="T>SL>Z\>?L1?LM^,_^&CM:\?\
MA7Q/J$'[4'P8T#X'_M%W6J?&[XW6&G>.O@UX*TGQ#INE>%M5BB^)-GI_AW3[
M'1O%7C&VU36?#D6@ZQJMGXM\8C7M6OT\3^(#J'UEJ6FZ?K.GWFDZM866JZ7J
M-O+8ZCINI6D%]87]E<*8KFTO;*ZCEMKJVN(6>.:">)XI8V*LC*V#^%W_  2B
MU/P9\.?^"#_[&&GV-M\+M UGX@?LBRV/A3PWXL\)66N>%?B'\2M8^''C3QAJ
M-EKOP\TO5?"M[\31JFG:#XD\8?$;0[+6]+U36?!>B>-->UOQ!HVEZ=K7B/30
M#]$_''[#?[)_QPF^(/B_Q/X6\1^)3\=OAY\'_"'C?7?#OQU^-^@VGC/P[\%_
M%5I\1_@GXPL[GP5\3='LK/XC^!/$T-EK_@WXY^&SI_Q;M$2WAMO'KZ9LMJZW
MXX_L:_LZ_M'67@&Q^,7@K6_$Y^&>B>,/"WA/4].^)OQ6\%^(T\(?$3PQ;>#O
MB)X*\1>*O OC?PUXE\;^!OB#X?L=,M?'G@KQOJWB+PKXSNM&T'5_$ND:IK&A
M:/?V7Y5:)^W3^T'\/O@?_P $WO%%E+^S)\.O@S^U3^RA^R';^(-=LO@7\1IO
M!?[''QB^+R_!^T\&:Q\0=+\&?%31?#&C_LR?&&VUWQ;\!/@7H#O\.]2\%?'>
M+X<:??\ B_QA\,-1^(>M_!^UXT_;1_:/^!WQ?_:G\(ZSXW\*>+M'^(/_  5N
M^"?[%WPGU35-'M?"5O\  #P=\1_^"<7[-_[1H&G:GXP\=WO@O4=3\8>)M2_X
M5'\-['Q+%H^A-^TI\9++Q_JMKXTTGQ!IOP%N0#J_'7_!*?Q%K'Q.URT\&Z[_
M ,(=\+9/#/PO\&_";XK>"?VMOV[OA9\>/@)X.^%?P[\(^!]!T6_\#^!OBX/
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ME??D_P##+_@HY^V=XE^''Q-.JW/PHT[QQX,_:)_X)(>!]'U_QC\&-1LHM>\
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MIVO^(KSQ/XFG\5ZKKLGB'66O?*/V ?B/\:O'WQ(_X*(V7Q>^*.@_$+2_A_\
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M\%_#+QM_P4_\9^ OVPM&UCPQX;\#Z-I'PT^'7@KX;?$SQ7=?$!_B!;77Q'^
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MG:O8S67B*RTB[NTU+3H;S2KWYP_;R^)'CKX7>+/V _"6D?M1>)OV>/"/QO\
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M;XN>'/L/@#2=4U;X:>-]#;X1^*_@AK/@[Q7!\-M6\$>.]52?P=;^*M+FGTT
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M^(/!R:5%X1URV\>ZMX9N_%4&L>%8]"T2/PYJ<6JK>Z&FCZ4FF3VJZ?:"'O\
M4?@S\']7USQIXGU;X4_#;5/$OQ(\)/X!^(GB'4? OA>]USQ[X%DM38R>"O&F
MK7.ERW_BGPE)8DV;^'-<N+[1WM2;=K,PDI7X[?\ !;7]L_XI_LG_  YL(?@I
M^T':?!#XI:G^S%^W-\;_  -I>I0?!72-/\>^(OV8_A?X&\8Z9"WC'XU>'_B+
M!KE]X>NO%4<NE?L[_#;X4:W\1OCS?ZQ%=R_$GX.?#3X8?$?Q+?>$>*?V^_C,
M?V@_BAXF\(?MF^'-7^%O@W_@H9_P2L^ W@SX1Z/8?LX:Q\/?$_PI_;F^'7P
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M\:(?%ESKU[\9O@=X:^%FIZSXFZ;P-^VD?B-^VAXT\$:_^V?X?^$M]X(_:/\
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MI;CXT1:;JOAN[LHOBQ.M]>K-\1HX%\8RB\N@^LL+B7?Z#H_PG^%OAWX;Z?\
M!O0/AKX T3X1:3X=A\'Z7\+-(\&^'-,^'&F^$[: 6MOX7L/ ]CIL'ABS\.P6
MRBWAT2VTN+3(H (8[58P%K^8C4?^"B7[5,O@/X%Z1J'[?'[,/PTL/C/\&/VH
M/'_@#]KSQU\<?V4Y?A+KOQB\)_M V'A'X0? ?5_%?PF^ OQJ^ ?Q%^)/PO\
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M^%/PRLP#^@+Q+^RI^R]XRNYK[Q=^SA\!/%%_<?$WPU\:Y[WQ'\'OAWKEY/\
M&7P9H]QX>\'?%J:XU7PY=RR_$WPIH%S=:'X:\>NS>*M"T>>?3-+U:ULI9(&N
M>!/V8_V;_A;XB\,^+OAG\ /@E\._%7@OX:1?!CP=XD\"_"CP#X1U_P )?!V#
M7;CQ3;_"?PSK7A_P]IVIZ#\-(/$UW=^(X? FE75IX6CUZZN=872AJ,\MR_\
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M(!(Z8)'/&3_,_4TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@;6AX)CB\8^'O%>D?ECX*^-?[3/P]_9&_83\ _%GPO\ M5ZMXL_8Z_:U\?\
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MKQ/KE]J/B'Q3XEU75O$?B'4]3US5-0O[GJ\#C@<# XZ#T'MP./:EHH 3:O/
MYY/ Y/J?R'Y48&<X&?7'/K_/FEHH 3 ]!Z=.WI2X&,8&/3M^5%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU[XCTZ'7K +HOC7Q-;:QI\M8?[:O_!0;X.?LC?LQZA^T+I_B_P"#7Q%U76?
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M@M=)N_$>N?$?P3I.GV7C#X)'3].MS<_%+1/AA<>(;KP'X.U-_'NA_JC^P_\
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MX>\,>)=+TK4]2\/Z_JZV>DZQ8:=?7>GWEQ!:7$D?Y?\ Q:_9$_:S\4?\%!O
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MUJGB;PY%H'BSX:_M;?M3^ ;5]2M]#^'NNR 'Z,Q?MM_!#PYJ'P:\)?%7XI_
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M>?%#5?@AXO\ $/P-TKR?!FKZW'^TTFE^%=)^*'@/6_"GQ6\1? .P^(?A/6/
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MXGU3Q$NH/?>%;/PMXK_,K7/^"1OQYU']G3PI\#+3XK_":&\\,?\ !)KX6_\
M!-E/$5U9^,Y;>Y\0_#?QKX3OG^+']GPV,4L6AZWX4\*QNW@];K[?9:Y>#3CX
MBO-.LUU2Y /V9MOVB/@Y<?%RY^!D'C%KGXFV.HG0K[2(="\4W.C67BH>!K/X
MGOX&OO&]OHK^ ;3XBQ?#'4]'^)%Q\.IO$D?C>W\ ZWH/C2;P_'X;US2-3O?
M-*_:^ET3]J?]LWX2_%B;P-X.^$?[-OPG_9!^(OA7QE"^N-XEUF]_:0U;X\>&
M=0\/Z_;227%MJFM3^+/A1H>@_#OPWX0TFXUWQ'J?B6ST2TCUSQ!J^FZ5;^=:
M=^QM\4K;_@H-J?[76B:]X-^%'AC6]1M9/B79?#;QC\3+AOVF? UC^SK9_"[P
MS\/_ (__  1U^T7X07'Q2^&'Q:(^(GP]_;'\&:II/Q17X->%/#'[+^M?#^X\
M*7NI^,;3SO\ :B_X)T?$/]H3QK^VOXJL/'?PST./]H'PI_P3VE^$]CXN\(:K
M\0- TCXA_P#!/_X\>,_VC?#L7QE\%3W.B:;XU^&'Q.\9^)=,\(>+_"NEZO:W
MUOX*TG5;F"]O-5U^UMO#X!]"M_P4D_95N/&_PZ\!:'XE\<^)==^(WAO]H/Q-
M;0:!\'OBWJ-[X3C_ &7M1\(Z-\:/#'C_ ,-0^"6\:>"_B+X0UKQUX6TR^^&N
MO^&;+QM;7&KZ<+[1;(ZSX=76IO!G_!2#]D[Q5\$O@+\>M6\<ZO\ #SP7^T+\
M,?A[\7_"MOX_\%^+-)U;P?X ^)BZ%!X:\6_%MM.TC5]#^%G@B;6?$6F>'/\
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MZ!J&I_L\^+=#N/BC\(='US5/B[\5=#ONUA_X)T_%+4/$EK<>)_B#X0DT*?\
MX*'?M+?MCZS>^$[SQ-X<\31^"/C]^QE\:OV0H?"'AN2\TC7K?1_&?AZ/XX:M
M\1X-:FO+W2X+KPII?A>&*X_MNX\3Z, =[X2_X*6_"_QI^UAXL^'.A>-OA]-^
MS-X0_8W/[3=]\:=0LO&>@)JTLWQ@?P!I?B;P=XF\1V>C>"OB#\"O$^@QRWO@
M#XG_  Y7QCX2^(NLVNIIX0\9:C!ILEG/[?>_\%$OV.-/M?#IN_C''#K_ (J\
M3?$3P7H_PX_X0/XG2?&@^,/A)I_A_6_B=X7U3X%Q>"W^,GA_Q!X#\,>+?"WC
M?Q1H^O\ @73+_2/A[XDT+XAWEO'X(U:PU^?\NI_^"1?[37Q+^'F@?#KXR_'+
MX!V ^$_[%7P9_9+^&'B?P;\*M>\86GC3Q=^RS^T[\+_VAO@;\:_BK\-/'5]8
M^![3PAXN'P<\&Z!\;/V;[ >+]'U:&\\5Z=H'Q870=7LK#2/JCX%_L'_%SP7\
M7_V8/C3XD\._L;?""Z^&/B/]HCQ9\4_A;^R?\,]9^'7@+5-9^,OP>^%'PETS
M4-%OY-)TJ]\>>)+7_A55OKFN>,O&^AZ%JW_"/:IX=^&UC:S:?\.-/\3>)@#K
M_P!C?_@I7\*?C9\*;C5/CWX^^%?PI^,G@_2OVF_&WQ#T5)_$7A7X<:3\+_V<
M/CY\2OA'XT\<^'?'OCT0^&O$ND?#[1_!_A_5/C/-HWBG5+CX7WGB;1+KQ]IO
M@NS\4>&+6Z^BXOVZ_P!EZ?P-+X^@\?ZY-I\/Q"7X4'PG%\*?C#)\8)?B2_PX
M_P"%SQ>"K7X#)X!/QNO?$$WP4S\;K>PM/A]/)<?!-)/C!#YGPWCD\3K\!>%?
M^"9WQXTKP'I'@9OB_P##3PCKG[/6B_\ !1&3]E7XM>'_  M?^-M:O/B;^W1K
M7Q!O_!_Q'^*GPT\<:7'X.T;0?@!HGQ&U[0-8^$T6L?%S0?CGK1T/QM?^(?AG
MIWAJ3X<^(N4\(?\ !-W]K3PW>>(8X/'OP0TKP)\2?VL_A%^T;\5/AF?'G[2/
MC:?Q9H.G_L%?#[]DGX@^!/&?QJ\37]M\9?BO9^&?B1\.O#_QIOIO$NOZ#JG[
M9.F1^)_AC\?O$'@#PI\2/%UM* ?HIXB_X*&_L4^%]0\.:=J7[17P_N7\5>'O
M@!XRT>_\/3ZIXNT ^!/VIO$NH>#/V?\ XBZKXF\*:9K7ASP]\-/B=XLL(?#F
MA?$CQ!JFE^!H-9\0>"M/U;Q!IUSX_P#!$?B#D_B'^TWXYU'Q/J.D?#;7OAG\
M+O!5A\63\!_#'Q&^)/P_^(_QS\2_'7XW:5I>J:GXX^'?P.^ WPJ\4?#OQ#XD
MT#X<V>E>*9O'OQ/B^(6IWGA&_P#@U\>(?$/PJTOX?_#77/BY9_GQX6_X)2_M
M%:?^RQ=_ G6OB/\ !8>*KS_@GS_P3%_8L_M_2_\ A.Y/#]OJW_!//XL_%KX@
M7?BXV=WH5KJ5YI?Q*T'XO77A^*W\RSN=&U3PE#K4MM=6?BN70O"FC\</@?JW
M@KXEZU<:W^U3X._8WUCP]\*_^"FW@/X5?&+XG^!)(_!6D^)/^"B_QC\/_';P
M1\<O@I\6M2\6>"?ASI_QE^$?BG0[WP-XF^%WBSQ#+\3M9T3PKXD\4>'?#_A7
MP'XVL_&7BL ]QOO^"COBNY^%'P-\:>"K3X6^-;KXD?M.?L0?#U/%]E9?$71/
M"'Q4_9=_;&^*=G\,O"/[2OPT\(^([?2_%G@BY\7:E8^.(_"?@GQCK7BJQTF3
MP9J.LVWBKXE>"-6\%^+/&'U=\+_VNOAO?/%H_C_XU?"?Q+X@\9_M0_';]G?X
M87/PPT'QO;>&]1\6_#+7?&&IV7P8U/5-5G\1V&H?'3PA\/O#&H_\+#BL-6TW
M1_$/B/P=X^U#P7H-EI/AS5]/TCX1\#?L7>.?B7\(/A5H_@Q/"/@[PS\+/CQ_
MP3Y\4^"K_P 2^"?'W@""/X+_ +!WBW2?$.G_  6^&7A+Q/!)\08OA=I*Z ^A
M?#WQU\2]-\)ZUXV^(OC?XU_&32_ NF_"#7?A)I/B#O/$7_!,_6OBG\!?C_\
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M!G _#)_,T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(\<+K7A;Q-JGA[4?"%UXY^)L7@?XF?"+5?AC\8/!]M\4?'":#\0K*2]TN;2
M#\Q_$/[4WQ2\27WQ.\6_#3]H3QMK7P\U#_@MQ_P3I^'WPZU:P;P]'INL_LO_
M +0G[)O_  3N^)VJ_"RS2?PK;W5C\-O$6H?&[Q5XEBBTZ/1?%MY/J@;Q!XAU
M,:EXFM]>^V[[_@I#X<M]8\ 7VF?![QGX@^$GQ?\ VC/C1^QW\*/BSIWB7P5%
M8^(_VF?@EJ/Q>\-ZCX7U_P /W^K6MUX1^&_Q$^(?P1\=_"/X3_%.ZU&_C\1?
M$JPL(?$_A3P1X#\4^!O'WBOL;O\ X)U?!6:37TL?%'Q)T'2M?_:Q^ O[8@\.
M^'IOAUI7A_0OB1^S;\/_ (3_  N^%GACPYI\/PX/]E?#32O _P "_A-H=WX:
M66;4;N+P;;S)K]O<ZSXFEUO9\&?L"_"+P3\0HO%UCXL^*>J^!=(_: \>?M4^
M!_V?M?\ $'A_4_@G\-_VA/B?9^+1X]^(_@VQ/A.+XCE-<\2_$?XH_$>T^'_B
MGXE>)_A1X6^*/Q$UGX@^#? 7A[Q+H'P_OO!H!X7X'_X*Q?![X@1>$(M#\!>+
MX?$'Q)_8K\(?MH_#7P;J>L^$+;Q=XNL?%GQ.T7X)R_L^-HT6LW,N@?M#^%_C
M+XG\)?"?Q)X6UI[;PDGQ$\9^&?"VB^-M:OHO&?\ PAFA=_ME:#^TOI/[9_PH
M\ +XD\$>(/V;-(^,NG>)_$/A3XH:-HOQ7^&WCSX0^)-;\.>'(/B3\/;*:S\=
M?#?3?C)?>$]7^*'P"U>ZM/$G@CXW_ "VM?%TFK:7>ZKK'@/1_6O#?_!.3]EK
MPGK/@'7]$\):O!J7P\_:S^-O[:&D277B"]U.&\^,?Q^N/B!J?CJUO[;4A=PV
M_P /8/$WCRV\;^&O .@KHN@Z)X[^'GPT\8+!<Z]X9FO=3XSQU^P[9Z!X@^-7
MQ_\ "&I^._CU^T9XV^$/QY^!OPYF^,'C#P'H=O\ #CX6?M&_$ZR^*OC#X7:+
MXZ\-?"_3/&6L?"_PKXUTW0M1^'F@?%75?BM>_"WPSX?D\'?"JY\+:5XC\46?
MB  ]Z_8;\<^+/B?^Q1^Q]\2_'VMW/B7QU\0_V6_V?O'/C3Q'>16=O=^(/%GB
MWX3>$M?\1ZW=0:=;66GPW.JZQJ%Y?SQ6-G:6<<L[);6T$*I$GU)7SQ^R)\*_
M$OP+_9/_ &8/@EXTFTBY\8_!W]GCX*_"OQ9<>'[NYO\ 09_$OP]^&WAKPEKL
MVB7U[8Z9>7ND2ZII%T^FW=WINGW-Q9M#-/8VDKO!']#T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-5_002.jpg
<TEXT>
begin 644 ex10-5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -C IX# 2(  A$! Q$!_\0
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MO"OA/QOXQ\?>-M-^(OA;Q)X/\)ZQX2C\3>(?#G06O_!3WX/WMQXTO[/X3_M
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M&#0?@1\"?"VDZ+X%^-'B?6/@QX@_:#^)/B_P5!\$8_VM[#]G+2/'G@WQ1/\
M$FTUFV\"?#GXV:]\+N=^,/\ P5"\+? ;PUX4U+XL_LR_'[X=^+?$7B7XF^'K
M_P !?$KQG^R!\)/[!M_A9X+\+?$'5O%$/Q>^+O[4W@/]G#QQX4U_PIXT\/7G
MAO5_AK\:/&2PZG_PE'A7QG#X-\7_  V^*&@>"P#]0:*_,SP)_P %4?@3X_\
MVA(OV=-,^'7QYT[Q;-\,]#^*J-J_@C05\5P>%M>^ OAO]H>VU/4OV>-,\8:G
M^UQI'AJ#PKXGLOA[<?$C5/V?+7X5+^T9:7O[,J>.7^.UQH/@/7.8\7_\%:_A
M%X9\&_LQ^+;/X-?&"^G_ &I_AE\;/BOX.\+>+O%O[,'P+UWP=X<^ WC'X3^!
MO&>E?$6]_:)_:)^$WA/1_&DNO?&3PK%IW@W1/$WB+74@LO$TNKVNE-H-TC '
MZM45#;RO-!#-);RVLDL2/):SF%IK=V4,\$K6\L]NTD3$QNT$\T#,I:&:6(I(
MTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'PO\ M%?L1R_'WQ]XL\<:3^TM\>O@0GQ(^!5M^SM\3=(^#<'P
M9@F\7?#JTUSQUK< L/%7Q#^$GQ!\8> _$J'XC>*K"+Q/X!USP]JMG;WEK?:;
M-8Z_I6E:S9^*Z]_P2<^$.IZA?'0?C%\<_ ?A;0_$/BWQS\"? /@^?X.V?A+]
MFKXC>._VJ_@[^VQXN\;_  PM]1^#FJ:IXEEU3]I/X'>#O'EGX3^-6K?%;P/X
M?TO4O&7PZT#PYI_PTU[3_"/A_P#5*B@#\VK?_@F[H<GQ'\%_$WQ%^T[^TUXO
MUG0M4^'WBWQW8Z]J_P (?L?QC^(WPWO/C!<:#X\\7:OI7P<TWQIX+NDM?C7X
MBTFS\*_!7Q5\,/ GA;1O"WPYTGP-X8\+:;X7O;37O"?'W_!'CP=XP^'OQ:T_
MQ5\=_C+\>OB-XZ^#;?":V\2?&K4?A7X5N?&FB:%\"OVBO@MX3T3XV^./@5\$
M?A]XW^(]S>V/[1_C"?Q'\5_$TOB/XKZ.D:S^ -9\,W.O?$*/Q]^S=% 'XD?"
M/_@E=X\\<^$_VK]:_;0^,'B75_BS^U[X(_:O^$7C1_AYXZ\">.$\+_#']JO]
MG']AO]F_Q+<Q?$"Q_91_9C\.>*OB#X>T?]AKPGXH\&:MI?[.'PS\+:"OCG5_
M#'B?PG\2=1T2+Q_K?W-^TM^QS!^T1\2/A9\5].^,?C7X0>,_A5X!^+?PWTRY
M\+^!O@1\0]+UKPW\8_$7P:\5>(DU;1/CM\)?BGIEO?Z;K'P.\(RZ+J6A6^CW
M207.L6]^U['<6@L_M&B@#\ZO$G_!-[X9^)K#5H;KXF_%NQUJ\TG]K1-&\6:7
MJ'@JS\0>#/&_[67QY^#W[2]W\5O"$H\#R66D?$+X&?&?X'>!/&GP+U$VESIG
MA_4[-[CQ-I7BNXCLY[7Q[QU_P1=_9(\5^+-8\1Z!;WGP^L-;^ ;?L_R^'M#^
M&W[-_BR\T#0+#]F[Q#^REX4\0?#_ .*_Q6^!?Q"^/?PPU?PG\(-9T:QM-(^&
MWQ7\)>#]3UGP#X5U#4_#DMKXA^,>F_%C]=J* /QX^.?_  2ID\4I/K'P>^/?
MQ-\-:Y'\>/!OQ1\#>&O$E_\ #0>!_@C;_$#_ (*2?LN?\% _VPO&/PUF7X'>
M)O$GBGXD>/\ QS^S_?\ CKX;:3\<+OXI> ?#?CW6YO ]I8>%?A#K4FC>'-?P
MY_P1W^ 6B_&GX4_'_5_'GC3Q_P#$_P"'NJ67B+Q/XE^)GPQ_9,^(6I_$WQ;I
MO[2GQI_:UL/%TVJ^+/V;-4UCX+>(+;XW?'WXAZ]'??LRZE\%)TTD>#=%MY;=
MO 'A+4M,_7"B@#X(^.'[!>A?%[XTZ)^T)X=^-WQ:^#OQ9\+>*OA?XO\ "_B+
MP/8_"C7K+1M3^%_PB_:R^"-I OA_XE_#7QSI&H67B3P-^V-\3HM>348+F>/5
M-*\(7^ASZ.;#4XM7]S^ '[/ME^SUX6B\':%\0O'GC?2I[WQUXK\17WQ!'@JZ
M\0>+_BG\4_BAXU^+WQ/^*NOZEX1\%^#K2WU_QOXQ\=ZM)/X8\+Z5X9^&7A32
M;72= ^'_ ($\):%IMIIL7T)10!\#>,?^"<G[/GQ$^!A^!OCF;XC:[96_Q%_:
M:^+FB>.]/^(_BKP+\0?#?Q'_ &L_$?QJ\1?%KQ)H^N?#?4/!]L([V/X__$GP
MS8^';_3;WPI_PAFLR^%-1T*_T6:[M+GRWQS_ ,$J_AW\2?#7A3X8^.?V@/VD
M/%OP$\!Z5I.C^"_@-XH\2_#_ ,0^$?#]E)\"+K]EWXAV@\<:O\-;SXWZYI7Q
M6_9Y\3_%SX<>*-#\4?%37=)TN;X[?$SQKX6MM&\9:=\*=7^&7ZET4 ?D/\:/
M^",/[+GQ?\.>,/ $6K>*? _PJ\>_$75?BKXG^%]CX-^ 'Q+\*GQUXE^$?A7X
M)>*O%/A63]H'X*?&+7/AWXQU3P-X(\.KH_Q!\ :OX<\?>#M;E\6:KX7\2:>O
MCGQ/:7_J'@C_ ()>? ;P5^T7\3OVFHM5U?5/'_Q!\!?$?X;Z27\ ?L^^&[OP
M-X4^)MGX-TO5=-MO'W@/X*^$?BY\1XO"^@>!/#WA+X:?\+M^(7Q./P[\$Q7'
MA'0"ND2016OZ444 ?)OPN_8X^%?PN\8>#?&MK)J?BW6/ G[./P-_9J\,R>,[
M+PIJITGPU\ ]3\;:KX6\7:?/!X:LKW3O&^MW/CB\/B>_TZ[L]'N?[&T!],T3
M2Y;.62X\W\1_\$^/AS=W?@O1_ 7Q+^+?PB^#?ASQ5\+?&GB7]GOP1J/@?4OA
M7\0?$OP=^,MM\=_!FN:JWQ"\!^.?'?A'6Y?'MCI\?BS6_AEXT\$ZKXO\+:9H
MOA[5KL_\(WX5U#0OOJB@#\I'_P""4WA/6/AOKWPF\=?M/?M$_$#X?CX)_'[X
M&_"[PIKNG?L]Z?HOP8T?]HG3G\/^+?&_A>#PS\"M#O/%GQ)T'PC<ZOX)\(>(
MOBA?>-]/T_PGXH\9:9J&AZI-XLUN]NM_QA_P32B\>>&)M)\1?M4?&NW\4S^%
M_C7\+Y_B)X3^&W[(GA'Q!<? O]H[2?AO8?&SX-3^']-_9JD^'3:-XTU7X1?#
MCQ='XW'@H?%'1O$?A'2K:S\9OX/N-=\):W^GE% 'YS_'3_@E9^QK\>O!'C;P
MCKG@?QAX+U+QMX/^,O@^[\=?#+XM_%7P/XRL[3X\Z3X/TSXD7,E[I'C&/3?%
M$6NS?#OP!JUYX?\ '>E>*_!]_JG@_1Y]4\.7\8O8+O@/&'_!(']F+Q3X0^)>
MAV6L?$KPEXQ^-7A/]LKP#\9?BWH?B#2[WXA_$SP-^W+HOCB#XR^$O$=SXGT'
MQ!H']BV/B_Q'X&^('@E+/0H-3T;6O@;\(M'U+5=;\*:1XBT3Q+^J]% 'QM^T
MM^QOHO[17@*Y^&.F?%GXG? 3P%XB\%?%/X:?$GP?\&+/X41>$_BA\//C1IVE
M:3X_\.^,/"7Q)^%_Q%\+OJEQ8:68?#GCK1M&T?QMX575_$UOIFM'3/%7B'3=
M1\+_ &@?^"2?[)G[0MKX<T#Q!X>&A^ [+Q#X\\0^-? D?@CX+?$.R^(5U\33
MX(A\<W*^,/CE\*?BQ\3_ (0^(O$>C> ].\+:AX[_ &>/'7P@\='P]JNIW%MX
MBMO&VB?#3QK\._T]HH ^)?&/[#_@_P 4O\1-=TOXD_$CP1\2O''[3^@_M=:9
M\3O#\?P[U?6?!'Q<\,?!'P3^SEHJ:+X3\<> /%GPSUOPI;_!7P-I_@:32O&7
M@CQ'J4)O[OQSHFM:'\5M.\+_ ! \/>3^$/\ @FCX;^&7C[P-X]^%W[0/Q9\(
MW/A3X=_"+X>>(-.O_ ?[,?C./X@Q_"?XE_&/XKMXHU2_\6? /4]0\!^(/''B
MSX[_ !$F\0V'P7F^&?@KPW97^F:7\+?"/P]T?0=%TRP_3*B@#\_Y_P#@G_X6
MT;XH?!GQS\*/B[\1O@]X%^"-Y/K?A?X!^&]#^$WBSX33>,-?UJ_N/B#X_G7X
MG?#GQOXWLOB#X\\&WTWPJE\:Z1XOT_Q#X!^'5]XMT3X2WWP_E^)OQ4N_&_5:
M#^P!^SAI?P5^'/P1U3PYK>M:-\,?$6C^-/#WB_3/%6O?##XEOXW\/R>*VT3Q
M?>?$#X+7OPV\2MKNF0^-O$]I;W-M>VT;0:Q>M/!-/<33/]K44 ?FM\(?^"9_
M@;X.Z'^RS\/]*^/O[17BCX+?LFZ3\(V\"?!?QWXA^'7B[PMJOCWX)_#2?X8>
M"?B1>^+M6^&,OQ@\)7KZ7):Z[K7P^^%_Q+\"?"&Y\0Z39Q:9X T?PKKWQ)\+
M?$+8\:_\$\- \6?LP_#;]E#3/VA_C_X)^&WA'X#^*OV<?B.WAVX^$.JWO[17
MPZ^(7A;P_P"%OB7J'QHTWQY\(_&?A34OB/XZ_L74/$%_\3/"WAOPOXMTOQ%X
MU^(%UI-]!9>,M;L+K]$:* /S<\5?\$U_!WQ"\3:QXL^)/[0O[1_CK6-)TS7M
M+^ %_K6M_"O^U?V7TU?]H?X+?M4Z7>_#76K?X21ZC\0K[P3\:_V</@%K?@R+
M]I.7XYZ):^&?A+X=\$>)-$\4^'_$7Q.A^(%'Q?\ \$Y=3\;KX8UWQ)^V1^TA
MXC^*/ASQE\2?%_\ PL[QKX<_9C^(+20?$SP)X'^'>H^#/#_PL\;?L]ZW\$OA
MYX&\/Z#\._#=SH&C?#WX<^&[N[\2W'B[QCXPU3Q9XN^('CO7/$?Z8T4 ?F;\
M!O\ @E[\*?V>_&7P<USPA\6?C7J_@?X$:CX%\7_#[X2^*+WX87WAE/BI\/OV
M*M*_X)^:)\5/$GB[3/A9HWQ8\4^(I?V9]*/AJ\T/6/B!<>"#XBU2_P#$UKX7
MM7L/">G^&'^)O^":/A._M?V?CX+^.GQ2^'NM?L\?#W]H7X8^'-=B\&_L]?$=
MO$?A7]I+XD?"3XI>-8/$N@_&#X+^/_"POM)\3?!?P>GAG4] T31+VTTM]6LK
M^74?MQEC_2^B@#/TFTN[#2].LK_4KG6;VSLK6VN]8O(K*WO-6N8(4BGU.[M]
M-M+'3;>YOY5:[N+?3[*SL()IGBL[6"V2*)-"BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#G0_%O]&1 /7^9[<C]:7&?_ -9'\J /Y1+[]L']K;PIX9^%ND?M=?'CXX_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB^.&K^"-,BM]/T+Q%\4_%&F>*UUO5-)M[?1)6\.VGAS2;.RL?#UM /H"BB@
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M^-O!/CG1?#_B?P_K,6B^(?#WB+3GN],&F>)?"7B/PUXS\*ZCKGA#Q)H&NZD
M>V4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ5X0VOAM_P $]/BG\%_B#X3^,?PZ_: \#7'Q.\,^/_\ @H3=W(\5_!7Q1=>
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M)S:[::7IFG?-_P ?OV0?C%\#=0^&7@W4?B5XBO7\1_$;_@I-\3;S]H;X3?\
M!/?]M/XU^';8?\%!_C;I?Q$\8_L]:IX7_85_;-\/_M,^ 8[-?$_C#5(/B#XR
M\5Z?\!KFV\-?#3Q7)9VW[0OPF^&OQ \*?TN44 ?AY\&?^"9OQ'TKXJ>"/VBE
M?]E+X3ZIXM\'_ +0OC%\*+W]C?P]XWU3P(W[-5E=>!OAIK/[)7BC5/C/KVG_
M +*>H>*_@SI/P[\,^,_AAJDG[4_@GX6:UX:6#X=>,_%&I:??>/O%GI7[.?\
MP3;^,/P(^,'[-WB*_P#VE_ GC;X*_LDW'[8/AWX,_#^7X!>(-'^*$WPF_:CU
MOPYXG\.^#_'?Q>'Q[U'PYKOB;X,WOA^P\,:;XVT_X/:2/''@O3(1XA\/VOC'
M5+SQ9;?KS10!^2WQJ_X)S_%GXL_MG>#/VJT_:%^'1T[X8?M _!_XV?"SPK\0
M?@1XP^('B_X<>&/!_P "O'/P1^*'P.\"^-;3]H;P;X9\'> /B;?>-+SXS7&K
M>'OAI9>+K_XH2Q0_$K5OB7X(\)?#KPQX0\4O/^"-'B;6_@G\,?@YK_[5&FJ?
MA?\ L7?M1?LKZ1XQ\+? B^T+6/\ A,OC_P#M"? []HCP=\9K:RUGXX^+-.@L
M_A+XG_9X^'5E)\,=1CUJS^($$GBG^TO%V@V&M6.D:+^ZE% 'PS^RK^S)\9_@
M]\6_VG/C=\;?C'\,?BEXS_:9E^!FIZKIGPL^"GBKX.>&?"&M?"/X80_#G53I
MT?BWXZ?&_5-8TCQ*MK9:GIUI=7EA?>'Y(KZ.ZU+Q FH6J:/\\?'O_@E=H'[0
M7P2^->D^)?%OPET#]L7XG_&BW^.G@S]N/PQ^SK#9?$[X/^// /C_ ,*>)?V=
MM?\ "EE<_%:[\4_VU\"O!'PX^&'PSL9]-^*/AW1/&NC>#);OQ)X=\GQ7XJTC
M5?UMHH _G'^+7PO_ &@=7_;3^*FIZ'X8LKSX@WGQ/_9N^).G?#CQK_P3^_;(
MU/\ 9\_:2^(G[.GPM\"#P+\<7_:<^#G[8>A?L:_"JQT?QI<ZZ?"LO[2_AWXO
M?M%?#;4/A7\/=;U;P_\ &&;X,_LL^"?#/V%\1?\ @F+XI\9_L\>%/A=:_&OX
M;W/Q)^%/[>/[0_[=_P +/$_C[]F[3/B+\%M0US]HWXM_M,>.?&OP;^-?P&\3
M_$F^G^(O@.;P%^UG\6_AK#XA\+?$WX:>,-+U-?!7Q+\/7>C:]X5?2]8_7:B@
M#\73_P $H/$FE_&7P9\:_#7Q2_9I3Q%K7PJ\(?"/X^Z9XG_82^'GB/PQ;:=X
M'^)?Q:^)OA3QK^Q;X:?XBV>E_LI^-?"K?&WQ[X(T"/QY'^T[X6UC0;/X=>*/
MBYH/Q<\?^#_%7B'XG=C\#?\ @G!\7/@[\9?V=_$MS^TAX"\4?!+]E?Q]^V-K
MOPD^'LOP%\3V?Q0N? 7[6-]JFOV?@GQQ\7I_V@M2T'7-6^$^M:S)I.C^,K/X
M2:=-XM\&:186?B'15\6W]_XR7]<:* .>\(V_BNT\*>&+3QYJWA[7_'%KX>T6
MW\9Z[X1\.ZEX0\*:UXKATVVC\1:MX8\)ZSXH\;ZOX7\/:EJZWEYHOAW5?&GB
M_4M$TV:VTV^\4:_=6TNK7?0T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !116=J^EVNN:5J.CWLFH0VFJ6-UI]S-I.KZMH&JQ07D#V\LN
MFZ[H-[INMZ-?I'(S6FJ:1J%CJ=A.$N;&[M[F..5 #0R/4?F*6OY,/@G^U)^T
MKX]_X)3?\$J/&WBJT_;"L_&WQI_:J_X)_>&OBG^U#>?'GPI9Z3\3/#OQ\_:P
M\!_#;XK:1=S^%/VE+GXQQZ%XX\%>)-9\-:+I3_#/2T\&W%Y;ZKH&F>"+_3[?
M6M*_J_U#3K?4-,N]*N)+Z.UO;233YI;'5-3TO4D@N(S;R26FLZ9=VFL6%ZL;
MEH-2L+ZVU&VG"W-M=17")*H!H45^1_\ P2 ^-VOZ_P#\$B/V7OVDOC]\1O&'
MC;Q+K?P*U?XN?%OXC^.=?\1>,_$&HS6-UXBU3Q%K,TVH7&IWD-M;:9I1:ST+
M1(+;3+..%;31]*@\Q8'\Y\.?\%BM4U3P;X<\7Z_^QS\:_"MG\:/^&>Q^R_?7
MGA;X[W'A_P"*FI?M V7C'Q#%X$\4WS?LUV?B/1_B9\*O ?@?6/B+\3M(^!O@
M_P#:9\"/X0N-,N?AI\2OB1J$]YIU@ ?MM17YO_$7XW>-OC3_ ,$U_P!H[XMZ
MQX+^,/[+OQ)T;X)_M*R'2[>\\??#[Q_X+\9_!^Q\>V6B?$#X;^(/%W@OX9^-
M[[P;XCU+P?IGQ$^%?B#QC\-_!M_XM\!:WH!^(/PS\/W6H^)? 5E^87Q9_;:_
M:FT/_@E5^UY\%3X^U?P[_P %%/V-/AE^V+\+OC9\6[>"RTKQ!!H7[(?P(_X7
M+HW[7OA[3=0M9UOH/VD_A1XO_9FU#2+S2_[)O_!GC_\ :@&LZ/ P^&&JP0@'
M]+M%?DQ\0O\ @H7)\ _!/QO\2:#\'-:^)OP/_85'P;T/]K[XBZI\5]=G^*7A
M&U\=_#3X9_&7QIXL^'W@/5O"7CG7/C-I?P>^"GQ<\%?%OXBZGXK^(OP_O=2T
M)_$^A^ W\;^,?"MUX>N/SR\;?$W]LKQ7X9^./[0\/B.]\.>-/"/_  5I^$7[
M$>E^&?!_[9?QP\-_"S6O@3\3?VTOV;?V;O&'@/4OAE#\#KOPEX8UE?#]UH.C
M:)\9_ MAHOQ;T&?XH?%WXI>'_$6C:[HMKX!^)@!_3I17\_O@O]HCXI_LK^%?
M&_P5^!_@_P 6>//$>@?\%??AM^Q[XL\0_M@?MQ?'K]HO5_["^-OPF^ 7[0RW
M7@#Q_P#$+X>?$'QCI'@W1O OQ2TKX+^#/ M_Y"^%+71;GXN^)-6\??$K7O%\
M'B?[J_9?_:Y^+_Q0_9__ &I_CA\5/AGX-LY?@=\>/VTOAMX2\)?"WQEXB\5:
MAXJT?]D[XO?%3X4'3[E=<^'OA673]>U^[^&#-8W=F_B&/7)]9&J#3_"XDB\)
M:< ?HQD>HHK\>_V&/AA\1_VF_P!CS]CO]L+QO^U%\<8OV@?CQX6_9U_:M^)&
ML>$?B-XTM?@]=:/XPNO!OQ7\0?LWZ)^SH?%EY\$?"_PULO 4[? >35=$\'6G
MQ*N+?3I/B#XM\8>)/B+JGC+5O$_GWCO_ (+(ZM\.XOVR?[=_9?M[V[_9:^!_
MQZ^/.@V7AGX\Z1XFM/'OAO\ 9S_:&UWX%?$'PEXG\:Z-\.+KX7^"_B7%:6_A
MGQ9+X+^'WCWXZ7?@/6]5\2?"7XVW/PG^)G@RXT+5@#]Q:*_+C3?^"A_C2X^(
M?B[]G[5/@3X/TO\ :0L_VUY?V.?A_P"%H_C?K=_\(O%<P_8NT?\ X* )\0O%
M'Q63X&V_BWP5%!^SK=:KINI^%]*^#7CLVOQLM=%\"6/B/5? NM7OQ;T#B]4_
MX*>_$_1_''A/X57/[#?Q@U+XN^&/"?[,WB+]K#X8>"+WQ9\6=<^ ^I?M(>*-
M?\-MX>\$>+?@]\(_B#\(?BM+\*=+\,:E\4/'>J^./B9\ =,U+X47FC:EX"E\
M7_$5O$GPO\+@'Z]TF1ZC\Q7QY^Q]^T=\3/VG?#7C7QYXG^$?@KX8^"-!^*'Q
MU^#_ (;GT3XQZK\2?%>M^,/V=?VF/CK^S?\ $.;7=!F^$'@/0?#GAV[O?A!I
M/BOP?JFD^,O&5WK5MXNO])U32?#[>%[?4_$_YT?\$^;;XD_\%(?V,!^VKXS_
M &@?VD/A%\;OC]\4?CGJWPYM/!?Q8\5:5X!_9Q\$_"O]H[XD?#3X8_!JW^!6
M@W7A;X1>/-/TSPSX!BT_XQ:Y\2/!>M?%WQIKOBKQO&GQ*\*OHOPOD^&H!^[=
M%?BO\3/^"O6L^"M-_:%\?>%?V/\ XL?$/X)? SPG^WI=M\4]/@^)^A:*OCO]
M@ ?%"P\?:%\2/$FJ? EO@OX*\#_$[Q7\$/BAX0^%/CGP%\:_C/XAN-;'P]T[
MQS\-?!&K^,-<TGP-D_%C_@IS^T;HEEXI\(^%?V;/A?X2^,7A']JK_@FK\.)M
M)\:_'K6?$'@[5O@1^W]\6_"W@OPWK\VO^$_@M<76B_%^TN5\5^ _&O@JUTOQ
M%X(^':SVWQ1\)?%'XUQZ5:_#GQ* ?M]17XN?$G_@KKKO@NT_: \;>&?V//BS
M\0?@O\#_  U^W@9OBEIMO\3M%T:'X@?L!P_%&R^(&B?$?Q)J_P "4^"_@KP'
M\2?&'P.^*?@?X7>._!'QL^+_ (DG\1CX<Z?XV^&/@S4/&FN6'@7[@U/]H;XN
M^"_V2_B9^TE\2O@U\-M!\3>#? OBWXF>'/AWHG[27A^/P??^"=,\/CQ'X<U3
MXE?'7XP> O@CX&^$8333+?\ Q2O[ZS\3^$_AOI6G:MJ6C>*_B-':VD6H 'V'
M1D>M?C=X'_X*E?$?XHW7P@\$_#_]EK1+CXM_%;]HS]KW]F-]'\<?&OQE\./A
MUX8\<_LO_#CQ#\5=%\07_B;Q)^S<OQ<E\$?$WPKH]E:S7=W^S]I/BSP7XAU0
MP1>#?&'ABVM_%NH_,'[9W_!1WQW^T+_P3Y^(OC+]F7P7X@\ ZC)^PE^R#^V9
M\0_B!!^T!XE^$/Q%^!VF?M=7TWBSX5>&/AA??#CPEJFI_$CQGX7TCX?>+M2^
M+&GZOXL^#?AN;PSJ'@S1]#U+XB)XY\7Z!X+ /Z,,@=2!17Y(?\%=_&OC;P%X
M$_8QN_ OBWXJ>%I?'G_!1C]D;X,^-[3X2>/?%/@/Q)XT^%OQ4\:W.@>/O PO
M_#/B;PM,3XBTF)+6TU!-5T[5]#GS?^'M9T;42;L_.W[(/[?GQ ^'O[$:_'3X
MHW7C'XTV_P >?V[/B-\#_P!B3X8^($\9>(_VAO!'PTOO$>K:5X/^#'[6MQX'
M^'GQ#\?V/QH^#"?#GXR:A\3K>T\*?&'XEZ%X4\-Z#X9\3:E\0OBA:ZW>7X!^
M_%%?DE<_\%/?$.C:O^Q_X6\>_LX7GP6\4_M1?$SQ!\*)T_: \9^._@?X4L_&
M7A;XZZ!\([GP_P#"3Q3\1/@+HK?$?Q;\0/!EYX@^//P ^'_Q6T;]F[Q[\=?A
MSINA:%X0\-I\4M7\1> ?!'.>$_\ @K)J_C[PGX_^*/@W]EGQC<_!.R^$OQ7^
M*OPL^-'C;Q)XI^"WPIU;3_A5\0=%\%RS?'/XO_''X0?#?X$_!7PKXR\.:[)\
M8/"/BSP;\7/CS(_PO\#_ !-?Q#H'A_XAZ#X2^'GCX _9"BOQJ\"_\%1_BQ\7
M7^!/@_X5_LH>&KGXO?&7XN?MO?!O4/#OQ0^/'C7X3^ O!?B+]B?Q>V@:[JES
MXDU/]F+6_BO=Z)\0])0ZEH-OK?P#\(^+- UB6WT+Q'X6M;%KGQ):^1?MH_MH
M?&SXR_\ !.3]K;XX_"CX<:_\-/@1J'[-/QS^)'[//[5'PN_:,U3PS\8$\3?"
M'XBZ%X=\%KKOP^TO0OACXN^&E]\6;.#7/B#\/V\-?$CQ[IC^"O"NM>%/CQ'\
M,];\06G@C6@#]\J,CU]OQ]*^4_V:OVA/%/QM\2_M1> /'OPXT'X<>-?V8/C_
M  _!#7K7PG\0]0^)?ACQ/I_B'X%_!3]H7P7XLTOQ!JOP\^%^J6%]J'@'XZ>&
M=/\ %7ABX\,36_ACQAI6O:5H_BCQCHD.F^)M2_)7]D+]K[X\>!(/&_@JP\.Z
MU^TKXT^,O_!8#_@I!^QE\*+OXT?M&>,_#NB_#/P_^SQX0_:-^+OP;\.:AKVK
M>"OC+K47@>#PI\!-3\%Z[K>C>'M2\56%O>P>*KO3/B+K]M#H>J ']"U%?C;\
M,?\ @KC8?$V\_8;L3\$K+X;S_MJ?!KX+_%+P[/\ %OXK7'@KP_?^)?B1XNU'
MPG\0O@M\#_'Y^%^I_#'XV?&'X&6NEGQ[XI^'&O>./@WX^\=_#CQ!X2U[X2>$
MO'.L7GB?PWX/XO\ 9J_;=^-'QT\5_LHZQ\4/@_X9TWXP_%KQ'_P5:\+?#/3_
M (=?M4_&'2O@;IVD_LO?&FS^'V@:+\5O!R_"OP_I'Q$UK5'\.6/A/1OB3XC^
M&_B74_ FF:-X@^*'@[PQX?U?XJ:[\*M# /W&HK\(_@Y_P5R^)]]^R%XP^./Q
M<^ /@RY\??"[_@DC^S]_P52U^P\"?%O6(O"WCSPA\8/#/QI\1:GX&TW^V?A/
M'J?P_P#%5A8? WQ#?6&E3)\0-%@N]?T7PY<^-;^"QO\ QA<^L>(O^"C_ ,4?
MA9\1OVIO"GQ(^#_A37X?"/[>7P__ &*/V8=%^&WB/XK^+O$_CO7O&'[&7P=_
M:^N;SXB:#X-^ 7C/Q3I-GI'PT\5>.?'6M:UX$\.>/[^QN-+E^'&G^"]7@\-P
M?%#QL ?L)1D=,\^E>#?LS_&+Q)\>?@QX7^)?C'X2^-?@?XLU.^\7:'XC^&WC
MO2?%.D:II&K^"O&?B#P5>:OHB^-O"'P]\7ZM\/O&3^'QXU^%WB7Q1\/_  #X
ME\3_  X\0^%M>\2> O ^OZAJ7A+1OS _:'_:I\4_LE?M6?\ !0CXJ_V?\1/B
M_P"#?@/^Q)^P=\7_  W\"F^,?B;0?#%QXU^-O[0W[8'PJ^(VJ^'++Q)J.M>!
M_#VI:SX7^&'PV,%G+H5MH,-[X1,NGGPWJ'BSQ=X@U( _;BBOR]L?^"@_CJ[\
M<ZW^SY-\"_ MM^U5;?M;^*_V6?#O@3_A>VOR?!G6H/"G[)?P^_;<O?BCJ'QG
M/P$B\8:/HJ? WXG>#]$N_#5G\"M?\00?&C5HO!]FFI_#JTUCXQ:5^@'PF\4>
M,_&WPP^'WB[XC_#B\^#WQ"\1^#O#VL>._A/?^*O#/CF[^&WC&^TNVG\3>!IO
M&G@V[O?"OBUO"VM/>Z*/$>@7!TS6DLUU"VAM5N/LL(!Z%1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC37-91<INRBG-VN^I:4X4]^2"@ZDDG5JM;U*LUR*526[E&%)7V@DDE]K> ?
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M10!\S?\ "J/VA?\ HZW5?_#,_#'_ .1*/^%4?M"_]'6ZK_X9GX8__(E?3-%
M'S-_PJC]H7_HZW5?_#,_#'_Y$H_X51^T+_T=;JO_ (9GX8__ ")7TS10!\S?
M\*H_:%_Z.MU7_P ,S\,?_D2C_A5'[0O_ $=;JO\ X9GX8_\ R)7TS10!\S?\
M*H_:%_Z.MU7_ ,,S\,?_ )$KLO G@3XM>'M>&H^,_CK??$+1?L-U;GP[<?#K
MP5X8C-Y*\#6^H?VIH,$=_NM$CF06V[R)OM!:4$Q1U[/10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ-KTND_#?5/"&F7.K?$BY^(OBOX:^&V^&'B[P%K?B?\ $GX(_P#!.+X@P_\
M!&?PE\0O'&E_M6-^V]^SA_P36_:^^ G[+_P&GT)? 6M_L^?'+XW>!=7T;4[[
MX36GPZ^&_@CXPZ[XT^(VJ:%\.= N?$OC;XD?$;P=H^@G5HM!/AO2-3\:W5X
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M6^+UE#\1/VCO'_P<_9O_ &I/@7\3_AMX,\4:5XQ\0?LL:G-\// 6O?"?PO\
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M7AN/XR:3\-[O1/"7Q6AU#XB:#\51%^\U !1110 4444 %%%% !1110 4444
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M-XR;P;'\*;J[M(?"'_"PD\=ZGH_A?4?D2[_8M_:3\$:3^S]XW_9\TO\ 9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4G@#P;=>;XP\.Z_=:/>^'=-OM!GTN\@\\@'\ZNA?\%"?VJ?#FE_L^?MV>*O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK.U?5])\/Z7J.N:]J>GZ+H
MFD65SJ6K:QJUY;Z=I>E:;90O<WNH:EJ%Y)#:6-C9V\<EQ=7=U-%;V\$;RS2(
MBE@ :-%>,S?M&_L]V_AC2_&UQ\=O@W!X,US5;W0M%\7S?$_P1%X7U?7--65]
M1T;2_$#ZXND:AJVGI!.]]IMG>37EHD,C7$,81B/5[[5=,TO3+O6M3U&PT[1[
M"RFU*_U:_O+>TTVRTZVA:YN+^[O[B2.UMK*WMT>>>ZFE2"*%6E>18U+  OT5
MR7@KQ]X%^).AIXG^'7C3PEX^\-2W=W81^(?!7B/1_%6AR7UA*8+ZS35M"O;^
MP>ZLY@8KNW6X,UM+^[F1'^6NMH **Y_Q3XL\+>!M U'Q5XU\2Z!X/\+Z/'%-
MJ_B3Q3K.G>'] TJ&>XBM(9=2UC5KFTTZQBFNKB"UBDN;B)9+B>&%"9)45G7/
MBKPQ9>&+CQM>>(M"M/!EIH4OBBZ\6W.K6$'AFV\,P6#:K/XCN->EN$TJ'08=
M*1M3EUB2Z73H].5KYKD6H,M &]167HFN:+XETFPU[PYJ^EZ_H>JVT=YI>M:+
M?VNJ:3J5G*,Q7>GZC8RSV=Y;2#F.>VFDB<<JYKS'6/VB/V?_  ]XUU?X;>(/
MCE\']!^(WA_PUJGC37O &M?$OP7I7C?1/!VB0Z!<ZSXMUCPI?ZU;Z]IGAG2;
M;Q7X7N=2UZ]L(-+L;?Q+X?GNKJ*/6=.:Y /8J*\B^"_[0/P%_:0\+W_CC]G?
MXW?"+X]>"M*UV?PMJ?B_X+_$GP;\4O"^G>)K72M(URY\.7_B#P/K6NZ39Z[;
MZ)X@T'6)](N+N/4(M*UO2-0DMUM-2LIIO72< D]AG\J "BO()/V@_@)%\1;[
MX02_&[X11_%O3)M+MM2^%LGQ)\&I\1]/N=<M]+N]$MK[P.VM#Q/:7&L6NMZ+
M<Z7#<:7')J$&L:7+:+-'J%HTOK] !1110 445X_XB_:$^ ?A#QY!\+/%GQO^
M$'A?XGW5C8ZI:_#CQ%\2_!>B^/+G3-4_M'^S-2M_"&I:W;>()K#43I&K"PNX
M].:WNSIFH>1))]BN?* /8**** "BBB@ HHKC?'WQ%^'_ ,*?"FJ>//BCXY\(
M?#?P-H8LSKGC3Q[XET;P?X2T4:CJ%II&GG5_$GB&]T[1M-%_JVH6&EV1O;V#
M[7J-]:6-OYES<PQ. =E17G_C_P"+/PL^%%E9ZE\4OB5X!^&NG:A+/!I^H>/_
M !CX=\&6-]-:PBYNH;.[\2:CIMO=2VUN1/<Q022/!"PEE5$(:NF\.>)/#OC#
M0M*\4>$M>T;Q1X9UVR@U/0_$7AW5+'6]"UK3;J,2VNHZ1J^FSW.GZE87,3+)
M;WEE<3V\R'='(PH VJ*** "BBN-^('Q%^'_PG\(ZS\0/BEXY\'_#7P%X=BMY
M_$/C?Q]XET;P=X/T""[O;73;2?6_$WB*]T[1=)ANM2O;+3K:6_O;=+B^O+6T
MB9[BXBC< [*BFE@JEV.%"EB2", #))'7@=1C-</X(^*'PT^)L&HW7PW^(?@?
MX@VNCW@T_5[GP1XLT'Q9;Z5?LC2+9:E/H&H:A%87;QH[K;7;PSLB,RQD*2 #
MNJ**Y'5/B!X#T/QCX2^'>M>-O".D?$#Q]IOBG6? O@75/$FC6'C'QII'@8:&
M?&VJ^$_#%U>Q:WXCTWP</$_AL^*K[1[&\M?#P\0Z&=7ELQJU@;@ ZZBBB@ H
MHKAM/^)_PUU;QEJOPZTOXA^!M2^(.AQ^=K?@6P\6Z!>>,='A\BVN?-U3PQ;:
MA)K>GQ_9KRTN-]W8PIY%U;RY\N>)G .YHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "FNZ1(TDCK&B#<[N0JJHZLS' 5
M1W)( ')(%.JO=VEK?VMQ8WUM;WME=PRVUW:7<,=S:W5O,ACFM[BWF5XIH98V
M9)8I$:.1&*NI4D4 ?QN?LX7'Q.MO^")__!$_7=:^+WP/N_@Z_P"V;_P2JM--
M\*:?\*O$6D>.K.ZT?]NWX;"]LKSXK77[0NL^%;W4?#MUI>J2^)?)^$EDYATW
M5+:73M FAFN[#^Q+3?$&@ZY;WUUHFMZ1J]MI6JZEH>J7&EZG97\&G:SHEZ]A
MK>CW\UI/+'9ZII%[#-9:II]PT=W8744MM=PQ3(R#B(-1^$&I^-]?^$\/_""7
MGCWPSX5\.?$+Q#X%%KHTNNZ3X/\ B1J7B[PKX;\6W^CF S0Z1XOU7X:>,]!L
M]2>+RM2N/!^J63NWV#8.YBT?04L;_3(=)TE--U.:^EU33X["S6QU"XU=VFU*
M34+581;W4VJ27+S7KW,<DE\UPTDYE,K,P!^!_P#P1:_:<^$W@#_@C9^P/X<T
M3QMX#\:?&+4/@/J7A_X=?!/0/&FA7?Q ^(?Q(T&R^)/B]/A]HOA[2IM4UF+5
MSIO@_P 0ZAKUQ+I36WA+0-"\2>)O$;6&C>'=7NK7Y+\+_P#!5']JFV_9V\%?
M'C6/VK?V0?&W@/XW_P##&$'Q.\8^&/B?H=XW_!/[7_C9XFUWP[\5M7^,VNZ3
M^R4OA;]F#X7ZUXPE\%_!'X9^%/VI/#/QY^)'PF^*A^(NK_$OQ]\3/"7P^\;+
MX'_JAL_#?AW3KQ]1T_0-%L-0D1HWO[/2K&UO'C?;OC>Z@@2=D?8FY"Y5MBY!
MVC&?%X(\$VNG^*M*@\'^%H-+\<WNJZCXUTV+0-(AT_QCJ6OV4&E:W?>*;-+1
M;;Q!?:WIUO;:;JMUJ\=W/J5E!!9W<DT$4<:@'Y;ZM\1_%/Q"_P""1_[6?B3X
MU_$_X)?'*ZTS]GW]M?PWJOQ6^'&OV'C7X2_$'P)X9T+XKZ1X9O==\7?\*U^$
MGP^\8^)K/P1;:1X7^-^N> ? 'A?X4:E\5-&\?Q^$_#7A'1$_X0KPY^1G[1FE
M>./ O_!.7_@I]_P2N\77/B"#X=_L$_LR?M/_ !3\!_$34[?5&T[XB?L->(/@
M-X\\=?\ !.[X<)XSUFVL$NO$GA;XMVWB#X*R7_A2]O!J^F_L">)_#_B&T^Q_
M%.!;K^I#X8^*/AA\5OAMHFK_  _T^VO?ALTE]H&@Z;J'@G5_"-C:K\/_ !'?
M^%)+"W\'>+-!T'4=+LM!U[PO<6NC"71+2RDM]/L=5T)KC29],OI_09-#T673
M[729='TN32K$6@L=,DT^T?3[,6&S["+6R:$VUN++RT^R"&-/LVQ/)V;1@ _!
MSXY?MF_M$>'-/_;!USX5?$VR\+>,OV+[;]C34/@#^S+<^%_!FH:!^V[X(^.7
M@?X5ZUIC7OB?7O".N_$/4;[]HKXL>)/BE^R'\!]6^"_B/PEHWA+XT?"ZVU;Q
M%/\ $ S^(?!5M\9^(/"VE^)/V?\ ]HSQCK?[3WBG5_%'@C_@XI_9[\":)XLU
M1/V7M8\0_#G6M/\ ^"D/[+WA3Q)9:+KNH?!*\U3P[KL7@K5-#\1:WX<GN_L]
MEI'PJ\%Z5<:+;_"C_A8'@SQO_4O+X#\"R:OX8\13>#/"<FO>!X-8MO!FNR>'
M='?5_"%MXAMX[77X/#&IM9F]\/P:W:Q16VL1:5/:1ZE;Q1PWJS1(JCYJNOVG
MOV,(/'3_  PNO'OPP36IOB39?!B>^ET4_P#"N?\ A>MU))I.G_ .Z^*S:(?A
M1'^T'<?VQ):67P(N/&2?%Z>WU=1;>#'M]5C-P ?C;\6_C)\1/"Q^+/@>T_:4
MN?@C\//AG_P7P^ /P0O/%GPW\/?L[?"ZVOOAS\4_@'^S!^TMX[T[XB:G=?"Z
M_P##FIZ[K?[0OQ6\<>-/''B:XM=,U_QYXKU74M&\;7.K>&]0U#PA-]K_ /!/
M_P ??%SQY^S[^W&-)^/NK_&?X_>$_P!L/_@HE\._!NF_$/5?AC?7'PYOOAG^
MTI\>/AI\"='U73_"/@_PO=:'HNH^'_!GA&YAT[Q@M[8+IEDP\*6^C^$X[71[
M;Z[^+?[3G[''PF\66_PT^,'B_P !>%]0UO4[S4;Z?Q+X1U%_A[IOB[X?>#]4
M_:'BTSQO\1_^$;N?AAX.^).D> _">L_&WPOX1\;>*M$\?:CX:\.WWQ \)Z-?
MV.G2:I%M_LY_M/\ [-G[0VO?&?1?@)JUS?\ B?X7^.(-$^.VE7_PG^(_PKUW
MPU\2;VRGTV/2O&MA\1? O@G4KCQHVA>%;*:XM;B&[UJV\(-X*UF\2#PSXG\%
M7NK@'YT_\$NT_92\<?\ !,']ACPAX\L-(U7QUX+\1_"*T^*O@[XA6WB#_A<G
MAK_@II\._&5MXZ^.4WC[PYK*M\3=*_:!T/\ :8T7XA?$+X@3>)+.#7$T5/$_
MBSQ:4^'%QKEZWYQ>/?\ @K/^T)I?A3]N#Q5\.OVO/ WB?1K#]B[]KS]I#]G/
M5O%/@SX#Z'XC\)>-/V?/VMO$_P /O"^D:+\&=(35=?\ "_A/4?A[<-X.N_#?
MQ\^(?Q/^,/BJ/P!9_$'Q1X/_ &;_ !G+XU^%#?U66O@'P)8^,=3^(EEX*\)6
M?Q UK2H="UGQS:^'-'M_&.K:);M:-;Z/J?B:*S36K_2H&L+!H=/NKV6TB:RM
M"D*FVA*1P_#KX?6UW<7]OX%\'6]]=W.NWEW>0^&-$BN[J[\4:IHVM^)KJXN$
ML5FFN?$6M>'/#VKZ[/([2ZOJF@Z-?Z@UQ=Z78RP 'X9>*OVUOB_\)/BY\8?@
M5\5_VH9?#'PK\._\%1/!G[-OBC]K#Q=I7[/WA+Q;\ ?@O\3_ /@F?X1_;.\!
MZ/=7E[\-+;X)Z18>*_VH-6TS]G'P5XT^*'PQ\37EQX!\8+X,U'Q+J_QIOO"W
MQ,M/+;O]O']J.7XN_#_X-^&OVV?V5]1?X=_![]D7QYX1^*7Q)CTKX*6'_!2F
MT\;_ !A^)OP[^./C7X5? S3?@U\<_&GQ:T_QOIG@#2/!?P.T3]D?XH?#\I\7
M_%WA'XDZ--\7_A!\;?@]\/A^V7[1/Q>_9@_9^\":_J/Q]D\+Z1X)U;PWK6N>
M,-*?X>:S\0$E^'7@^ZTI?&GCSQIX0\&>%/%FJ6OPA^&\OBS1+SXE_$OQ)HL'
MPV^&%EXCT[5O'GB/PY8:K;W4_5?&'XG? ;X7+\/?'/Q:U'PM;ZW=^(;CP_\
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MBU[X7^%-)_5OXS?%SQ5^S+_P3B^*OQZ\<?M6>+-5\2S?#FV\;:'\>/$OPO\
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MC]H.;Q?=_!W5[SXR?##]L2>U_8A\*_$;XT>"M/\ !$/PM\&>*/V<+7XM^*O
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M&S3I]5\8ZIX@D47OB&_Q_+SINEO'_P $$]2_X)>ZGX,\0-_P48?0O$_[.O\
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MBY7PSI>JZ./$.EZGXA:"\<:+I^I: 1KNGWNI&UMKS1O^)I;2R6(,] 'YE?\
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M_!CQGK7B6]\'_"KX=_$K4)O#'C;XDZ'=^!?BZ?AQ8;]N1]4LO&NE?#[]E/\
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M7A>Q\4_05%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMX;_ &3F\1_L:6'QE^''@;X@?\%>/!WC3]FN#Q9^SJD7PST?]O7]K/5OBM\
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M7T4 ?F'X7UO]K;QI^VM8>)_B/^Q3KFA?"_P9J7Q"^''PO^+^O?M!?!.[\*>
M?A;?:?\ VEKGQ5MOAAX0U#Q-\0_$_P 6_C;X@\'>$/"UI9:N--L_AO\ #J_B
MT[3;WPY>7OQ;7XGY/PP\*_M2?L^V?_!4+XD^#_V<]1^(GC_XS_MBGXS_ +.?
MP]NOB+\*?#UM\2/#5[^S#^RK\!K?5-;\0W7CE].\&Z9I?BSX0^,/$NM6&O7&
MG>)+CP7#IAT;3+KQ-JAT*P_5*B@#\H/A%\$_VO/B5\'M2T:?Q3\:/^";WCNU
M^+?B;QCXF\8>'M6_8W_:0^*_[1VJ>,-'M=6\3>.OB&OB?X.?&#X8^"M*B\1:
MBGAKP-X=\*WJ:SX>\+>!M%\)6R:%\/\ 1?"6AG!U+_@G5JWB7XL6\/@#Q3\1
M_P!FSX"?#+XK_M#?M)_#32[/QAX4\=>(]*_;&_:!\ ?&WX>^(/C#\'_"GB+1
M?'WAKP%\'](G_:*^)GQPT_P3XZUKQ#_;?[05YHL^A?"/X)_#KPIXMT3X_P#Z
M^T4 ?AAX,_X)I>/- ^+O[7T/QD\4_$SXY?L]^./V;_V"_A]\%]-\#7OPH^$'
MQ/L_'G[)_P 3OC/\1O!NM^"?$/@J;X6ZIX$\7?L]^)-1^'7BKX9>+=3\::.F
MKZKJ]_/K5UXDNO#&FQ0?0OA+]F/]I;X7? ']M#QAX=\56NM?MR?MAZG_ &I#
MXPA\06>H>&?A)XDMOA)X#_9O^$6KVFJ7OAWX>:3X@TKX/^%/"5A\:_B+)H'@
M7P+#XZ^(5[\2K?X=>!?#.C:SX)\$Z/\ J510!Q/PT^'G@_X1?#CP!\)_A[HT
M'AWP#\,/!/A3X>>!_#]L7-MH7A#P5H5AX:\-:-;F0LYATO1=,LK&(NS.8X%W
M,3DUVU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4451U
M/4]/T73K_5]6O+?3M+TNRNM1U+4+R5(+2PL+&"2ZO+V[GD*QP6UK;12SSS2,
MJ1Q1N[$ 4 7J*_/FQ_X*B_L97_@^W\;KXZ^(5OI-YX]_9_\ AQ9Z?<?L]?M"
MKXLN?$7[5>@:7XG_ &<)4\$0_"Z;Q?'H7QAT?6])B\*>(+C18=)C\6WO_"L=
M=NM&^*MI?^"+3/\ '/\ P4<^!MS^SQ-\4_A)X@\8:GXT\9^!_P!J*_\ A?X.
MU+]F[]H'Q7XZT?Q5^REJ&M>!_C9=_%+X :+X;\+_ !?\/^&?@A\5[#3_  +\
M3K;7O^$#:]\6:SX5^'GAKQ*?&?Q(^'EMKX!^BU%?/'[(?Q.\4?&W]D[]F#XS
M^.%TI?&GQ<_9W^"OQ.\7KH-L]GH:^*/'WPV\->*O$"Z-:27=^]KI0U;5KL:=
M;/?7KP68AB:[N2IF?Z'H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#X@^&]6\9
M> _&OA'0?%^L_#[7?%'A+Q)X>T3Q]X<@TZY\1>!]7UO1KW3-,\8:!;ZQ:WVD
M3ZWX9O;J#6]*AU6QO=.DO[&!+VTN+9I(FZ^B@#\*/AC_ ,$>/B%X#O6O+[]I
M?X47;:K\;_V!?CUXRD\+?LN>,_#NH^,/&_[$_B6?Q%X@US7-?\1_M8^/O$7B
M'QI^T+=1V.K>/_B3X[U;QMXVD\:7?BKQCXCU3QU=>(+:PT3U*T_X)C_%7POJ
M$/BSP!^TW\/]%\?W-W_P4E\->(-7\3?LY>*O%7A75O@W_P %'?VHX_VMO$GA
M6T\(6'[37A2?2OB1\(?B1:6FE>#?B?\ \)+?:%KO@^YUO3/$OPMN-1O=)UC0
M/V%HH \,_9A^#U]^SS^S?\ _@%J/BJU\<7?P1^#7PS^$3^,;+P[+X1M?$\?P
MV\&:+X-@UZ+PQ/XA\63:"=6@T6.^ETN3Q-KIM)YY8DU*XC5"/<Z** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBL[5]+M];TK4='O)=1@M-5L;K3[J;2-6U70-
M5CM[R![>9]-UW0KW3=;T:^6.1FM=4TC4+'4["<)=6-W;W,44R &C17\X'["/
M[7?[2MM^R-XL_9&^*?Q*\6^+_P!M#2?#OP=UWX$_'OQ\)-0\2_$G]F;]LOX=
M>+?CK\-/VC;W5=6\))X2\7^.OV8O!'@W]I7P-XIT&ZLH]&^(?CS]DFQT"^UB
MSU?XN:'YOK_[)_[='QCT#]A7]G(^#OA5XC_:H^,7P^_X)1_L@?M[_M+ZW\2?
MCIK^@>,/&MO\?/AWXTU&VTSX8:CJO@WXMZG\1OC!X\\0_ KXYZA:>$/$4_PM
M^'>B7\/@301XXT72_%LL_A$ _=XLJYW,HQC.2!C.<9R>,X.,]<'%+N7.,C/)
MQD9P,9..O&Y<_P"\/45_*S^T=^U7^T7\9_A1_P %5?VP?@_XWU'PWX>_9)^$
MO@CXA?L<^+?!G[2OQC^'5I:^ ?BQ^PM\/?C#HMYX^^ \/P<D^'7Q O=:T;X^
M:]\7Y(_B%!JNO:-\4/#7PS\ Q:G9Z/X \/?$;2/J+XK_ !E^)'[ WAC_ (*?
MZE\+?!WB7Q#\9?AM^S)^RS^UG9P_'3]O#]I?]I#X/>%[S]H#QC^U!\+KSP;\
M+]!^+'@35K[P!X:^&?C/X$^.?B8-%T#3-/\ ^%T7?C[2O"&MZS\+O!?@WP+H
MW@4 _H%HKX%_9A_:*^/7Q;_:9_;-^$?Q/\!?"KP?X2_9MU_X*>"]%N? WQ(\
M5^-M:N_$_C[X$^ /C+KZWH\0?"?P';ZCI*R?$.73-/UZ.\TRX2W\.V$,G@Z&
M?4+[4Q\>_LI^&/B'_P %#O@=^TS\=?'O[0_Q^^$GQ7\5_M"_MA_ /X,0?"/X
ML_$GX::7^R9X*^!7QD^('P*^%VE7OP9\->-]-^&7Q$^*&FW/@Z3XN^.O$OQG
M\'^)?$_B[7?&S^%KB?3OACH7@#PEX9 /V\HK\D_'G_!3OQ!X$_:?^)7[.]U^
MS]H]_9>%_!G[2>L^"_&&G_&V+6;[6?%G[._P6^%?QI'A?XH:5X3^&'BCP+\&
M&^(.A?$&^NM&\.:A\6/%OQ\\-^#(_AQ\2_%W[/\ I7@_XM:'=Z5RW@O_ (*N
M^)=7\+V]WXY_9U\.^"?'7Q#^&/\ P39^(W[/_@S3OCK>^+-,\:S_ /!3GQQ\
M3/A=\(_"?Q4\8O\ !?PW;_";5OAMXZ^$?C:]^+%YX4T7XU:8GP\LK'7_ (>7
M'CWQOJEI\,G /V5HK\A_C'_P4G^.'P:/A;X8ZO\ L2Z]XD_:S\0>"_VG?BR/
M@)X ^(OC7XJ>'M3^$7[._P 4_#'PW\,>)/!WQ/\ @Y^SW\2M7N/$O[1%G\1/
MAYXI^%?AWXG_  K^$'ASPS!J7B30OC=X^^%.N:/X=MO&GTI^S7^U-\6/VB/B
ME\<_#<GP%\/_  U^&WP+^(FE?#/Q!KOBWXL>(?\ A<TGB/Q=^S%^RU^U#X,M
MM0^"T?P6M_#F@W">&_VDKCPA\0K"Y^--U=^"O%_@-X-'3QQIWB)K[P\ ?<E%
M?A[^RB/%7_!1/Q1_P4@\<?%3XX_M#_#FZ^$'[;G[1/[#?P.\)? ?X]>-O@]I
MGP%\#? /1_!OABQ\?V_AGP)?:+X=\??%[XB>*]1U#XX'7/V@?#GQ7TO3]$\1
M>#/!^@^'H_AM'J&E^+/9]&_X*#^-U_:&_P"&9O!'[/?Q+^/ND_"3XR^!OV5/
MC]\>?#F@?$G2E\-?%G6/@1X#^+>H?$V71;'X2^*?@]:_!?2'^)OP\T3Q[J.O
M?M(:!\6/"^J:OXLU31/@YXR\&^&_#GBCQZ ?JW17\\OBO_@LE\>=:_9"^*7Q
MG\)?LP?#SX;^/M8_X)@?'W_@H;^SPWB7X]:G\0_#[Z7^S]J?A?PQ\2M'^*>F
M:+\%_#,^EZEH]UX_\)^,?A3HOA[4_$%I\8=,BO\ PSX_\0?LZZF9;ZR^Q]/_
M ."C7C[6/VC9_@%X5_9/\;>/[+X>_'#P5^S5^T)X^^'EY\5_%.A_"GXJ>+O@
MEX&^,UYXHTK79?V>]+^%WB?X$>"8OBO\-?"_C3QIXQ^+7PK^,5C<WOB_Q)IG
M[/>L^%?#_AO5?'@!^J=%?$/[!7[3WQ;_ &P_@7X4_:%\=?!;X?\ P8\#?$WP
MUX>\4_"[2_#'QOU[XO\ B[4=/OO[6MO$*>/=/U#X'?"71/!=QIFH6%FOA^/P
M]XB^(@\1:9?2WNK-X/OK'^Q[K[>H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *IZA91ZC8W=A+-=V\5[;S6LDUA>7.G7T4<\
M;1N]I?V4L%Y97*JQ,-U:S0W%O(%EAE21587** /DWPY^Q!^S-X2O/ ^K^'OA
MY-I_BCX;_LX7O[(O@OQZ?&GQ N_B7H_[.5]JGAG6Y/A>WQ*OO%=SX[U73[;4
M_"&@WNF:]K7B#4?&.D3P7\VF>([2;7=>EU/SIO\ @FI^R7;^#_!W@+P]X4\:
M^#_"O@W]G:W_ &08K+PM\7OBII^H>*?V5;&WDMM'^ 7CWQ++XPN_%7C+P1X7
M6>\'@74]8UN;Q[\.H=<\8V/@#QGX9TWXA_$*S\5?G=IG[1?Q+\"?\%*O@G^U
M%XOT[XI:#^R?^WE=>,?V$]'O_%T_P[T[X4:!K_PXUO7O&7[ 7Q&\(SZ1XBU3
MQ?XCL/VE;[3OVIM2\.^(-6T#PS)>?\-._!+P5?B^_L'P_<W<OPW_ &BOVZ/%
M?Q4^!-G??'SX51^'?&O_  69_;._96U[18_V?=?A2^^#GP'_ &:/VS_%?A?P
MF+L?'EA'I:W?[/NC:K'/IMMINL_\)X^D>)-:U?7M&TGQ3X,\? 'Z8^*?^"?/
M[*GC+0OVF_"VN>!/$_\ PB_[8FF^$M&_:'\,Z-\8OC7X6\/>--'\#>"M!^&_
MAG2]"T7PM\1-&TWX6V-I\/\ POX?\%ZE!\)+;P*OB;PUI-II7BG^VK=&#Z_Q
M/_8<_9W^,-C\<K/Q]X?\7:S/^T=\#O G[.GQ:U9_BC\38]5U_P"%?POO?'NK
M_#K2]/G7Q:;?PYKOA+Q#\4/B!XDL?&'A^UT[Q5J&N^*]5OM>U;5W>%8?R#L?
M^"K_ .VGXN_9/UW]L;P9\&_@CI7PO\=_!0_%'X)6GQ!FT!-3\/\ C+3/VE_A
M;\*=5^$_BRR^&O[4OQ%\>_$Z:V\&_$?7-$^)/C)_A9^SM=_L^?%SX:2:3XJ^
M'WCF?X@VO@SP1[U?_M/_ +9^M_M'?!SX'W7Q+^".AW/@?_@J[XM_9$^*>N>%
MO@9XUT_0/C'\++K_ ()(^)_^"A'@MD\+:W^T#XBUKP'J/A^XU^R\&:U)9>.O
M$">*/&'A/PE\2;9O#WA*/Q1\&/%H!^F?PQ_9=^$WPC^*WQ(^,W@?_A/8?&OQ
M;\/_  ]\/_$-]=^+/Q/\8Z!XEN?A?X5TOP#X;\7:AX8\6>+M:T"7XB2>#?#G
MAGPSXA\?R:>_BS7['PW9/J>J2W]]XAN]:X>S_88^ &B^/_BWX[\*:9XP\$6O
M[0/B=?''Q]^&O@WQ]XL\/_![XR>.3I-AH=_XV\9?#.RU1?#-MXJ\5:7I6DV'
MQ-UGPC:^%[GXT6&EV.F?&?\ X6#I4)L7_._]D7]J'XH^(_!G[,?[-GP7\%?L
MG?LW^-?BU<?\%5/%XU70/@EXGMO@5X>L/V*/VW[/X"S:5X)_9V\+?%SX?:G=
M^-?C%KGQCTKXQ^.=3'QIM8[&_P##WQ)OI=(U*Y\;V&H^%?%]-_X*Q?M@>*_A
MWJGQET;P)\ ?"GACX=_!3_@F_P#&CX@_#GQ)X.^(/B7Q%XG?]IS]L7]J#]D;
MX\>#_AQ\4/#_ ,8=-\-KX7OKC]GZW^*/[.?QMN? /B33Y?!NN:8WB7X:>-H/
M$]OJWAL _2^^_P""7O[)&H^/M9^(MQH_Q<@U;6_&WQZ\?S:'I/[1GQ]T#P/I
MVO?M1>&SH/[04?ASP5H/Q'TWP_X8TWXJ:A)<>-_$=EX?L].V?$"_U/Q5I4NG
M7NK:FMWTVH?\$XOV1]1\(ZEX)F\ ^*HM%U+X)_LZ?L^QS6_QD^-,6O:)\-_V
M1?$VN>-OV8SX5\4?\+";Q'X6\?\ P3\;>)=>\9^"OB]H.J6'Q9B\6ZG/XAU7
MQKJFJ)!<P_7^B6?BV"_\6R>)M=\.ZOI-[XC@N/ MEHGA74O#U_X=\)+X;\-V
ML^B>+M2O_%_B>W\:^(YO&-KXNUQ/%&CZ5X!TJ'PSKGASPF_@V?5/"NJ>-/&7
M\UWP#O3^PU\8?!>I_M(_#WX0^-=%\>Z1^U1\:_V/?^"M7A#QROA7P3^TAH?B
M#X1?%C]IW7OAO_P4-O8?#>N:[X2\9Z-\&/!7BGXG:3\<+>S\?> ]2\$>"95^
M'%MX<N])\7>#?% !^P7B#_@F[^S3XDT'X9Z;>W/Q\L?%/PJU7Q;JV@_&KP[^
MU1^TEX8_:0UMOB*/"]O\2],\=?M':!\4].^-/CG0?'^E>!O OA_6="\2>-K_
M $S2/#WP_P#AKHO@NV\*V'PP^','A7Z,^$7[/7PC^!%]\2+[X3^%/^$.'Q9\
M5>'_ !IXWTRQUKQ#=^'[KQ!X4^&'@+X+^&I= \-ZIJU]H'@C3-#^%7PM^'7@
M;3?#W@C3?#WAZWT3P?HRC2S=Q3W4_P"+O@[_ (*8?MC:9X%^)GQ"^,?A3X,:
M)X+_ &9/VF/V.]$_:3\43_!'XP_"[4;?]D;]IGX2?"C6_&/Q?\/_  V\4?&W
MQIXN^%UW\&?&/Q)3XI>,=:^.4_AO7O"/[-VE^*[OXJ_ GX:_$KX?:KH'B#HO
MVM_^"DO[4OP$^#GA_P"+'@*P_9_\9W\_P._:1_:^U+X:3?#CXFWWCNX_9G\$
M_%OX=#X!ZIKXF^,7@_PC\(+3Q3\$/%=[8?$WX@^)/%WC'QX?C/J&EV_P2_93
M^*^B>"_BKHGA4 _4+5?V//A!>?%/QS\7="N/B+\/?$WQ9M-.MOC/IWPS^)OC
M7P)X3^,%SHNDVF@:'XC\<^&- UBUTM?'VF>']/TWPTWQ.\)Q>%OB5K7A/1_#
M_@[Q-XMUSPGX7\,:)H_/O^P9^S6OQU;]H33/#/BSPWXPND\%7&O^$?"/Q1^)
MGA/X(>,_$WPPT71/#7PI\>>/_P!G_P .^+--^#'COQ]\*?#WAOP[I'PZ\4^*
M_!&K:CX6B\+>!+ZP9=8^&GPVU+PC\.:O^V_^UQI7[6%U\,$E_9WNOA!8_P#!
M3J?]@26P;X4?$R'XF3>&/'/_  38\'_ML?#OXD+XQ'QVF\+1ZWX"\<>(+CPG
MXVT5OAX=-^*/A"6*70+[X1ZQIQOM8^*E_P""G_[:_P (_P!A#X1_'*?Q/\ ?
MCG\6+[]GK]JW]KSXJ>$'^#?Q"L?%4_P[^$GQC\%:;I5I':V_QWT'P)\)_AI)
MINM?$+PFOQ/USQSXP\<VU^WPSTCX._LN_'E?!'Q:FL0#]@+;_@F#^Q=9?#NV
M^%5K\-/$X\#6/[)_Q<_8@T[1K_XT_'+Q +#]F3XYZII^M?$[X>0W/B7XD:U<
MS7WB#4M&T*:#Q[>RW?Q%T.UT'1='T+Q7INAZ=;::G3:;_P $^_V;]*^,=C\=
MK:S^*LGCQ;7P-)XJ@O/CW\;;WP-\5_%_PNTK2-"^&7Q4^-_PTN/'S_#[XT?%
MWX=Z5H.B6W@[XC_$OPWXE\2Z+<>'?!>JPWC:Q\./AOJ'A'XU\6?MV_M3^$_V
MI/B7X-?3O@)JGP(^&/\ P4D_9J_8>GTA/ WQ&LOBUXE\+?M-_LM? 'XOV/C"
M/QU_PM.\\&>'?$'PM\<_&N-KY6^&_B+3?B9X4L?^$=BT[X6:M;IXQU7S;_@I
M;\/]'\=_\%(_^"=/AFY^ _A?]H0^+?V5_P#@IW'>_"OQ'JVA^%-/\<:KX=LO
MV0$\#-JGB[6+*\3P\_A/5?%6LW>C>+K:&Z\1> 8==\1:_P"";6[\0S)I.K@'
M['_ ?X%_#/\ 9H^$?@?X%?!O1=2\-_"_X;Z2^A>"] U?Q=XR\>7^CZ2]]=ZC
M]AE\6_$+Q#XJ\9:Q'%=7UR+5]<\0:E-9VA@T^UDAL+2UMH?7<CUK^>+PW^T1
M^V[_ ,$]/V2/CQ\%OC;\3/AA^TE\<OV"_P#@G)^P]\=)_BKXIT?QWJTOQ(^)
M/QD^+7[7OPZ^(?@[QCXGNO&/AC7OB#HFC:+^SGX7\._#SXCW6B>"O'VO7VH7
MGC7XD:3XHUW4KG1:K_M@_'?XZ_$3PA^U3J?Q TSX:^-/AG^Q'_P5Z_X)K_"S
MX9_#?X8_!3Q(WQ\\9:JO[5'_  2?^/WA+7](\=>+/CQJ'@V3Q@_AKX]_$?X2
M77A_3_AYX8C\;WNI>'-8M/%W@/2%\1>&?$0!_1+17X$_M)_\%.?V@? 7[&/A
MO]I_X#>*/V7?BQKGCGX#?MA_M9^%_"&F_"GXU^(M1MOA)^SEX1L/%(\!^(-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]>(S/%%:VB,EG96=O!Z?10 4444 %%%% !1110 4444 %%%% !1110 4444
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M&O[-OQ+_ &4/C9\!?$/Q6_:+\>R:#;75KX4^#7A*/X,^,OB=X!^.DFI)\/\
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MK:VL[>*U@B2")$7\4OB[\6_C+\+C^U4U[KG[1OB;]E[P?_P4V^!_AWXM^*O
MNL?%7QA\6/AK_P $_M3_ ."=/[.$GB;QI\'/$WA34;CXJ_\ "M= _;(T_4=-
M^-7COX77.M^-/#GAF/\ :9\2KJEKX^T'Q5XIT?YU^-GC[X[VWB7X<?#OX?\
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M)-X%\!^&/&.NZ/K !_1!)\(/A#+\/K7X32_"[X;R_"JP@TRSL?AG)X)\,/\
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M?"GP@UG2++XC^+_"WC+]C+2_V]OV9?VA?AWJWA?XD>(?!VA6'C72OV4O@_\
M\)5\#OC3JFG7&HR?#(?L[ZCK?Q,O-%;5;6YO0#]^/"O[4WP2\;ZI<Z-X2\2:
M_P"(-0L?V@?&7[+FIQZ;\./B9/!HWQM^'_@W7O'_ (N\,Z]??\(>MCH.A:5X
M7\-ZG=+\1]9N;'X8ZEJ,FD>'=)\97_B/Q#X?TG4_H/<O/S#@@'D<$] ?<]O6
MOYX?AUK?Q:\%_&;18_"D_P 4?"OA_P ;_P#!?_X^VWQ0L=*T3Q7I&D>+_@7K
MO[&WQ3@T?7/%2?V3%_:OPDOOC7I?PLTW2_%S2GP+?>.W\-:4FK76JSV-J?@[
MQ7^U!^U?JWA3]N'5/A;\1?VZ_#5U\0_V/OVA/&_PX\*>)='^-_C#XU?#_P#:
M'^%7[;GB/P[I.AVYOOA9I_PY^%WQ0TWP7XQT_P %:E\#?V>? VD^"/#OA+4/
MAMX3U/Q7\?-5/@#XL:R ?V';EY^9>.#R.#TP>>.>.:7<N<;AG@XR,X/0_CV]
M:_GA\>?%'Q_\&O'/Q@\+>-?'W[35S^Q)X=_X*@:3IGQ3\=Z-XL_:6\?_ !&\
M,?LQ_$;_ ()I?#_XC>$]2\+?%_P%=Z]\=M$^ 3?\%)[[6M%\2^(_AGXRT[P[
M\-]4LM2^"M[/X<^ &G>._ VE><:GXZ_:5M?VCOA-\')OVDOVV/AKX>\/_"O]
MD[6_V(=?^+?[+7QY^(_Q/_:RM?"OQ#\<V/[0EI\<I/AGXQ^!'P.M_C+\4O!F
MD>$_#OQ9\+_MJ?#C2-8^!/P5\8^!OVA9-"^!'Q1T?XV^-?#8!_3*&4D@,"0,
MD @D#U(ZXI:_&O\ 8&^)OQ8UC]L+]K#P+XRUOQW\7/!,]UX]\<>#/C!!\1/B
MA<>#?!U@WQY\:V&C?L_?%W]G3XK:=8K^SM\=O F@ZI;Z5X%UWX/7>H_"+]IC
MX"^%_#OQITK2O"Z7NCW7B_\ 92@ HHHH **** "BBB@ HHHH **** "BBB@
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M#GB+XQ:GX,\3?#Z/0!^S]!X@TOXQZ)X<\">(@#^E7]H[X\>"_P!EWX"_%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>lixt-20230930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSPObP9z5Z8SekhvWB6bcla7yYsU6fBiyMl8ctWwaAC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:LIXT="http://lixte.com/20230930" elementFormDefault="qualified" targetNamespace="http://lixte.com/20230930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
          <link:definition>995513 - Disclosure - Organization and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Business" id="Business">
          <link:definition>995514 - Disclosure - Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>995515 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" id="ResearchAndDevelopmentCosts">
          <link:definition>995516 - Disclosure - Research and Development Costs</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>995517 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>995518 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>995519 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>995520 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995521 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>995522 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>995523 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>995524 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" id="ResearchAndDevelopmentCostsTables">
          <link:definition>995525 - Disclosure - Research and Development Costs (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>995526 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>995527 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>995528 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>995529 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
          <link:definition>995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BusinessDetailsNarrative" id="BusinessDetailsNarrative">
          <link:definition>995531 - Disclosure - Business (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" id="ScheduleOfResearchAndDevelopmentCostsDetails">
          <link:definition>995534 - Disclosure - Schedule of Research and Development Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>995535 - Disclosure - Schedule of Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>995537 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" id="SummaryOfRelatedPartyCostsDetails">
          <link:definition>995538 - Disclosure - Summary of Related Party Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>995539 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" id="ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails">
          <link:definition>995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" id="SummmaryOfStock-basedCompensationCostsDetails">
          <link:definition>995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" id="SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails">
          <link:definition>995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails">
          <link:definition>995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>995544 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" id="ScheduleOfContractualClinicalTrialsDetails">
          <link:definition>995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995546 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" name="StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorOneMember" name="VendorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorTwoMember" name="VendorTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantOneMember" name="VendorAndConsultantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantTwoMember" name="VendorAndConsultantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantThreeMember" name="VendorAndConsultantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantFourMember" name="VendorAndConsultantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantMember" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrKovachMember" name="DrKovachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesSMiserMDMember" name="DrJamesSMiserMDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EricJFormanMember" name="EricJFormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FormanMember" name="FormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RobertNWeingartenMember" name="RobertNWeingartenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrVanderBaanMember" name="MrVanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfAuditCommitteeMember" name="ChairmanOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfOtherCommitteesMember" name="ChairmanOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfAuditCommitteeMember" name="MemberOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfOtherCommitteesMember" name="MemberOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NewIndependentDirectorMember" name="NewIndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualGrantOfOptionsMember" name="AnnualGrantOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IndependentDirectorMember" name="IndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockBasedMember" name="StockBasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesMiserMember" name="DrJamesMiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrSchwartbergMember" name="MrSchwartbergMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MsReginaBrownMember" name="MsReginaBrownMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsMember" name="FiveNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonOfficerDirectorsMember" name="NonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BasvanderBaanMember" name="BasvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourOfficersMember" name="FourOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficersMember" name="FourNonOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RelatedPartiesMember" name="RelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonRelatedPartiesMember" name="NonRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFifteenMember" name="ExercisePriceFifteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchAgreementMember" name="ClinicalTrialResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OtherClinicalAgreementsMember" name="OtherClinicalAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" name="GrupoEspanolDeInvestigacionEnSarcomasMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CityOfHopeNationalMedicalCenterMember" name="CityOfHopeNationalMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalResearchSupportAgreementMember" name="ClinicalResearchSupportAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementMember" name="WorkOrderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TheradexSystemsIncMember" name="TheradexSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" name="MoffittCancerCenterandResearchInstituteHospitalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_Dr.JamesMember" name="Dr.JamesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BastiaanVanDerBaanMember" name="BastiaanVanDerBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NDAConsultingCorpMember" name="NDAConsultingCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BioPharmaWorksLLCMember" name="BioPharmaWorksLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DevelopmentCollaborationAgreementMember" name="DevelopmentCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NetherlandsCancerInstituteMember" name="NetherlandsCancerInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MRIGlobalMember" name="MRIGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bMember" name="ClinicalTrialPhase1bMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bTwoMember" name="ClinicalTrialPhase1bTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialRandomizedPhaseTwoMember" name="ClinicalTrialRandomizedPhaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1b2Member" name="ClinicalTrialPhase1b2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvancesOnResearchAndDevelopmentContractServices" name="AdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" name="ResearchAndDevelopmentContractLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" name="ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" name="ShareBasedCompensationIncludedInResearchAndDevelopmentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PrepaidInsurancePolicyTextBlock" name="PrepaidInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchDevelopmentTableTextBlock" name="ResearchDevelopmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" name="NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" name="AnnualNetRevenueDividedByConvertedOrRedeemedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" name="ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ManagementFeePayableQuarterly" name="ManagementFeePayableQuarterly" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FairValueOfStockOptions" name="FairValueOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" name="SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialDescription" name="ClinicalTrialDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodStartDate" name="ContractualClinicalTrialPeriodStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodEndDate" name="ContractualClinicalTrialPeriodEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfPatientInTrial" name="NumberOfPatientInTrial" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AmountRelatedToMilestonePayment" name="AmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EstimatedWorkCost" name="EstimatedWorkCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentinServices" name="ExpectedPaymentinServices" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentThroughSoftware" name="ExpectedPaymentThroughSoftware" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvanceAmountRelatedToMilestonePayment" name="AdvanceAmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonRefundableLicenseIssueFee" name="NonRefundableLicenseIssueFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PaymentsOnNonrefundableMilestone" name="PaymentsOnNonrefundableMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultingAndAdvisoryCashFee" name="ConsultingAndAdvisoryCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ReimbursementExpense" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractPrice" name="ContractPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase2Member" name="ClinicalTrialPhase2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>lixt-20230930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230930.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230930.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230930.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20230930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230930.xsd#SummmaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="995514 - Disclosure - Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995515 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995516 - Disclosure - Research and Development Costs" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995517 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995519 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995520 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995521 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995522 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995524 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995525 - Disclosure - Research and Development Costs (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995527 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995528 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="995531 - Disclosure - Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995534 - Disclosure - Schedule of Research and Development Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995537 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995538 - Disclosure - Summary of Related Party Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995539 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:title="995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995544 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995546 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>lixt-20230930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230930.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230930.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230930.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20230930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230930.xsd#SummmaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="995514 - Disclosure - Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995515 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995516 - Disclosure - Research and Development Costs" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995517 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995519 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995520 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995521 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995522 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995524 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995525 - Disclosure - Research and Development Costs (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995527 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995528 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="995531 - Disclosure - Business (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember_110" xlink:type="arc" order="114" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorOneMember" xlink:label="loc_LIXTVendorOneMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorOneMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorTwoMember" xlink:label="loc_LIXTVendorTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorTwoMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_340" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995534 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995537 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantMember" xlink:label="loc_LIXTCommonStockWarrantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_340" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_340" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_340" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_340" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_340" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_340" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:label="loc_LIXTClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_340" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_340" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_340" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_340" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_340" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_340" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995538 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockBasedMember" xlink:label="loc_LIXTStockBasedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTStockBasedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995539 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="loc_LIXTDrJamesSMiserMDMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMDMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrVanderBaanMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_450" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:title="995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RelatedPartiesMember" xlink:label="loc_LIXTRelatedPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRelatedPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRelatedPartiesMember" xlink:label="loc_LIXTNonRelatedPartiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonRelatedPartiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_320" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995544 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesMiserMember" xlink:label="loc_LIXTDrJamesMiserMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesMiserMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrSchwartbergMember" xlink:label="loc_LIXTMrSchwartbergMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrSchwartbergMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember_760" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrVanderBaanMember_760" xlink:type="arc" order="761" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourNonOfficersMember" xlink:label="loc_LIXTFourNonOfficersMember_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficersMember_720" xlink:type="arc" order="721" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_620" xlink:type="arc" order="622" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_840" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_840" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_840" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_840" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_840" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_840" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_840" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions_840" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_840" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_840" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_840" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_840" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_840" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_840" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_840" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_840" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_840" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_840" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_840" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_840" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_840" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1b2Member" xlink:label="loc_LIXTClinicalTrialPhase1b2Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1b2Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995546 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="loc_LIXTOtherClinicalAgreementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTOtherClinicalAgreementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember_590" xlink:type="arc" order="591" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_470" xlink:type="arc" order="472" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_520" xlink:type="arc" order="522" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_Dr.JamesMember" xlink:label="loc_LIXTDr.JamesMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDr.JamesMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="loc_LIXTBastiaanVanDerBaanMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBastiaanVanDerBaanMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_410" xlink:type="arc" order="412" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_410" xlink:type="arc" order="413" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation_660" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_660" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_660" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment_660" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment_660" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts_660" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost_660" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices_660" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware_660" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment_660" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee_660" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee_660" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone_660" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses_660" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_660" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_660" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOfficersCompensation_660" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent_660" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalariesAndWages_660" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee_660" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense_660" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTContractPrice_660" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>lixt-20230930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:to="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_lbl" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorOneMember" xlink:label="LIXT_VendorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorOneMember" xlink:to="LIXT_VendorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorOneMember_lbl" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorTwoMember" xlink:label="LIXT_VendorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorTwoMember" xlink:to="LIXT_VendorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="LIXT_VendorAndConsultantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantOneMember_lbl" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="LIXT_VendorAndConsultantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantTwoMember_lbl" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="LIXT_VendorAndConsultantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantThreeMember_lbl" xml:lang="en-US">Vendor And Consultant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="LIXT_VendorAndConsultantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantFourMember_lbl" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="LIXT_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockOptionsMember" xlink:label="LIXT_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="country_ES" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US">SPAIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="LIXT_UndesignatedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_UndesignatedPreferredStockMember_lbl" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PlacementAgentsMember" xlink:label="LIXT_PlacementAgentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantMember" xlink:label="LIXT_CommonStockWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantMember" xlink:to="LIXT_CommonStockWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantMember_lbl" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceOneMember" xlink:label="LIXT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="LIXT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="LIXT_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourMember" xlink:label="LIXT_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="LIXT_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="LIXT_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrKovachMember" xlink:label="LIXT_DrKovachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrKovachMember_lbl" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="LIXT_DrJamesSMiserMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMDMember" xlink:to="LIXT_DrJamesSMiserMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesSMiserMDMember_lbl" xml:lang="en-US">Dr. James S. Miser, M.D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EricJFormanMember" xlink:label="LIXT_EricJFormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EricJFormanMember_lbl" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FormanMember" xlink:label="LIXT_FormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FormanMember" xlink:to="LIXT_FormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FormanMember_lbl" xml:lang="en-US">Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RobertNWeingartenMember" xlink:label="LIXT_RobertNWeingartenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RobertNWeingartenMember_lbl" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrVanderBaanMember" xlink:label="LIXT_MrVanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrVanderBaanMember" xlink:to="LIXT_MrVanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrVanderBaanMember_lbl" xml:lang="en-US">Mr Vander Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="LIXT_ChairmanOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_lbl" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="LIXT_ChairmanOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_lbl" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="LIXT_MemberOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfAuditCommitteeMember_lbl" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="LIXT_MemberOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfOtherCommitteesMember_lbl" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="LIXT_NewIndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NewIndependentDirectorMember_lbl" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="LIXT_AnnualGrantOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualGrantOfOptionsMember_lbl" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IndependentDirectorMember" xlink:label="LIXT_IndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IndependentDirectorMember_lbl" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockBasedMember" xlink:label="LIXT_StockBasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedMember" xlink:to="LIXT_StockBasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockBasedMember_lbl" xml:lang="en-US">Stock Based [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesMiserMember" xlink:label="LIXT_DrJamesMiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesMiserMember" xlink:to="LIXT_DrJamesMiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesMiserMember_lbl" xml:lang="en-US">Dr. James Miser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrSchwartbergMember" xlink:label="LIXT_MrSchwartbergMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrSchwartbergMember" xlink:to="LIXT_MrSchwartbergMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrSchwartbergMember_lbl" xml:lang="en-US">Mr Schwartberg [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MsReginaBrownMember" xlink:label="LIXT_MsReginaBrownMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MsReginaBrownMember_lbl" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="LIXT_FiveNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsMember_lbl" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="LIXT_NonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonOfficerDirectorsMember_lbl" xml:lang="en-US">Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BasvanderBaanMember" xlink:label="LIXT_BasvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BasvanderBaanMember_lbl" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourOfficersMember" xlink:label="LIXT_FourOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourOfficersMember_lbl" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourNonOfficersMember" xlink:label="LIXT_FourNonOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficersMember" xlink:to="LIXT_FourNonOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficersMember_lbl" xml:lang="en-US">Four Non Officers[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RelatedPartiesMember" xlink:label="LIXT_RelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RelatedPartiesMember" xlink:to="LIXT_RelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RelatedPartiesMember_lbl" xml:lang="en-US">Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRelatedPartiesMember" xlink:label="LIXT_NonRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRelatedPartiesMember" xlink:to="LIXT_NonRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonRelatedPartiesMember_lbl" xml:lang="en-US">Non Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSixMember" xlink:label="LIXT_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="LIXT_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceEightMember" xlink:label="LIXT_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceNineMember" xlink:label="LIXT_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTenMember" xlink:label="LIXT_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="LIXT_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="LIXT_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="LIXT_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThirteenMember_lbl" xml:lang="en-US">ExercisePriceThirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="LIXT_ExercisePriceFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="LIXT_ExercisePriceFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="LIXT_ClinicalTrialResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_lbl" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="LIXT_OtherClinicalAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherClinicalAgreementsMember" xlink:to="LIXT_OtherClinicalAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OtherClinicalAgreementsMember_lbl" xml:lang="en-US">Other Clinical Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xml:lang="en-US">GEIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CollaborationAgreementMember" xlink:label="LIXT_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="LIXT_ClinicalResearchSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_lbl" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="LIXT_WorkOrderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementMember_lbl" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="LIXT_TheradexSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TheradexSystemsIncMember_lbl" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="LIXT_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExecutiveOfficersMember" xlink:label="LIXT_ExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExecutiveOfficersMember_lbl" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_Dr.JamesMember" xlink:label="LIXT_Dr.JamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_Dr.JamesMember" xlink:to="LIXT_Dr.JamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_Dr.JamesMember_lbl" xml:lang="en-US">Dr.James [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="LIXT_BastiaanVanDerBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BastiaanVanDerBaanMember" xlink:to="LIXT_BastiaanVanDerBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BastiaanVanDerBaanMember_lbl" xml:lang="en-US">Bastiaan van der Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="LIXT_NDAConsultingCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NDAConsultingCorpMember_lbl" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="LIXT_BioPharmaWorksLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BioPharmaWorksLLCMember_lbl" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="LIXT_DevelopmentCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_lbl" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="LIXT_NetherlandsCancerInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NetherlandsCancerInstituteMember_lbl" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MRIGlobalMember" xlink:label="LIXT_MRIGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MRIGlobalMember_lbl" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="LIXT_ClinicalTrialPhase1bMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bMember_lbl" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xml:lang="en-US">Phase 1b Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1b2Member" xlink:label="LIXT_ClinicalTrialPhase1b2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1b2Member" xlink:to="LIXT_ClinicalTrialPhase1b2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1b2Member_lbl" xml:lang="en-US">Clinical Trial Phase 1b 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, including $43,895 and $46,982 to related parties at September 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares and 1,664,706 shares at September 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Related parties accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, issuable upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Compensation to related parties, including stock-based compensation expense of $112,106 and $396,883 for the three months ended September 30, 2023 and 2022, respectively, and $669,146 and $1,160,649 for the nine months ended September 30, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated share based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation expense included in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Award Underlying Securities Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Award Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Award Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="LIXT_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ResearchDevelopmentTableTextBlock" xlink:label="LIXT_ResearchDevelopmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchDevelopmentTableTextBlock" xlink:to="LIXT_ResearchDevelopmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchDevelopmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Summary of Related Party Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Each Option Award Estimated Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Summmary of Stock-based Compensation Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="LIXT_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash SIPC insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Legal Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration of risk, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants exercisable, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants exercisable, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xml:lang="en-US">Principal cash obligations and commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xml:lang="en-US">Annual net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock, conversion description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds from sale of transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock shares issued during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:label="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:to="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Related party costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Increase in annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Paid office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Cash board fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="LIXT_ManagementFeePayableQuarterly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ManagementFeePayableQuarterly_lbl" xml:lang="en-US">Cash board fee payable quarterly</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based payment award, award vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Annual cash fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, stock options exercisable, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares avaliable for issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares were available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Stock option vested exercisable term</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FairValueOfStockOptions" xlink:label="LIXT_FairValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FairValueOfStockOptions_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock options fully vested amount, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options are exercisable price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xml:lang="en-US">Share based compensation vesting rights, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_lbl" xml:lang="en-US">Share based compensation issuance, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Total deferred compensation expense for outstanding value of unvested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair market value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Outstanding stock options to acquire shares of common stock not vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialDescription" xlink:label="LIXT_ClinicalTrialDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialDescription_lbl" xml:lang="en-US">Description of Clinical Trial</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xml:lang="en-US">Estimated Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xml:lang="en-US">Estimated End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="LIXT_NumberOfPatientInTrial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfPatientInTrial_lbl" xml:lang="en-US">Number of Patients in Trial</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_2_lbl" xml:lang="en-US">Contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development process costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="LIXT_AmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Aggregate commitments expected</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Total costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EstimatedWorkCost" xlink:label="LIXT_EstimatedWorkCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EstimatedWorkCost_lbl" xml:lang="en-US">Work cost</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="LIXT_ExpectedPaymentinServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentinServices_lbl" xml:lang="en-US">Percentage of payment through services</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="LIXT_ExpectedPaymentThroughSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentThroughSoftware_lbl" xml:lang="en-US">Percentage of payment through software</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Advance amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="LIXT_NonRefundableLicenseIssueFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonRefundableLicenseIssueFee_lbl" xml:lang="en-US">Non refundable license issue fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="LIXT_AnnualLicenseMaintenanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="LIXT_PaymentsOnNonrefundableMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_lbl" xml:lang="en-US">Payment on non refundable milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Operating costs and expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xml:lang="en-US">Salary and compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Annual compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="LIXT_ConsultingAndAdvisoryCashFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_lbl" xml:lang="en-US">Consulting and advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ReimbursementExpense" xlink:label="LIXT_ReimbursementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ReimbursementExpense_lbl" xml:lang="en-US">Reimbursed expense</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractPrice" xlink:label="LIXT_ContractPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractPrice_lbl" xml:lang="en-US">Contract price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash SIPC insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_doc" xml:lang="en-US">Prepaid Insurance [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:to="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_doc" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorOneMember" xlink:to="LIXT_VendorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorOneMember_doc" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorTwoMember" xlink:to="LIXT_VendorTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorTwoMember_doc" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xml:lang="en-US">Research and development contract liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchDevelopmentTableTextBlock" xlink:to="LIXT_ResearchDevelopmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchDevelopmentTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of research and developement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xml:lang="en-US">Number of share tranche of the series a convertible preferred stock receive a per share dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_UndesignatedPreferredStockMember_doc" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xml:lang="en-US">Annual net revenue divided by converted or redeemed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsMember_doc" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Increase decrease in advances on research and development contract services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Increase decrease in research and development contract liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of warrants outstanding and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantMember" xlink:to="LIXT_CommonStockWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantMember_doc" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrKovachMember_doc" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMDMember" xlink:to="LIXT_DrJamesSMiserMDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesSMiserMDMember_doc" xml:lang="en-US">Dr. James S. Miser, M.D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EricJFormanMember_doc" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FormanMember" xlink:to="LIXT_FormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FormanMember_doc" xml:lang="en-US">Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RobertNWeingartenMember_doc" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ManagementFeePayableQuarterly_doc" xml:lang="en-US">Management fee payable quarterly.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_doc" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_doc" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfAuditCommitteeMember_doc" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfOtherCommitteesMember_doc" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NewIndependentDirectorMember_doc" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualGrantOfOptionsMember_doc" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IndependentDirectorMember_doc" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FairValueOfStockOptions_doc" xml:lang="en-US">Fair value of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesMiserMember" xlink:to="LIXT_DrJamesMiserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesMiserMember_doc" xml:lang="en-US">Dr. James Miser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrSchwartbergMember" xlink:to="LIXT_MrSchwartbergMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrSchwartbergMember_doc" xml:lang="en-US">Mr Schwartberg [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MsReginaBrownMember_doc" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsMember_doc" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonOfficerDirectorsMember_doc" xml:lang="en-US">Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BasvanderBaanMember_doc" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourOfficersMember_doc" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award issuance percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficersMember" xlink:to="LIXT_FourNonOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficersMember_doc" xml:lang="en-US">Four Non Officers[Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourteenMember_doc" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFifteenMember_doc" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xml:lang="en-US">Advance amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_doc" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xml:lang="en-US">GEIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_doc" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentinServices_doc" xml:lang="en-US">Expected payment in services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementMember_doc" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TheradexSystemsIncMember_doc" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EstimatedWorkCost_doc" xml:lang="en-US">Estimated work cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentThroughSoftware_doc" xml:lang="en-US">Percentage of expected paymen through software.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonRefundableLicenseIssueFee_doc" xml:lang="en-US">Company is obligated to pay non refundable license issue fee..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualLicenseMaintenanceFee_doc" xml:lang="en-US">Company is obligated to pay annual license maintenance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_doc" xml:lang="en-US">Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExecutiveOfficersMember_doc" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_Dr.JamesMember" xlink:to="LIXT_Dr.JamesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_Dr.JamesMember_doc" xml:lang="en-US">Dr.James [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BastiaanVanDerBaanMember" xlink:to="LIXT_BastiaanVanDerBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BastiaanVanDerBaanMember_doc" xml:lang="en-US">Bastiaan van der Baan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_doc" xml:lang="en-US">Consulting and advisory quarterly cash fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NDAConsultingCorpMember_doc" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BioPharmaWorksLLCMember_doc" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ReimbursementExpense_doc" xml:lang="en-US">Reimbursement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_doc" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NetherlandsCancerInstituteMember_doc" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractPrice_doc" xml:lang="en-US">Contract price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MRIGlobalMember_doc" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfPatientInTrial_doc" xml:lang="en-US">Number of patient in trial.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bMember_doc" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_doc" xml:lang="en-US">Phase 1b&#9;Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase2Member" xlink:label="LIXT_ClinicalTrialPhase2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase2Member" xlink:to="LIXT_ClinicalTrialPhase2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase2Member_doc" xml:lang="en-US">Phase 2 Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xml:lang="en-US">Contractual clinical trial period start date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantOneMember_doc" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantTwoMember_doc" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantThreeMember_doc" xml:lang="en-US">Vendor And Consultant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xml:lang="en-US">Stock based compensation expense included in research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xml:lang="en-US">Stock based compensation expense included in general and administrative costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xml:lang="en-US">Contractual clinical trial period end date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherClinicalAgreementsMember" xlink:to="LIXT_OtherClinicalAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OtherClinicalAgreementsMember_doc" xml:lang="en-US">Other Clinical Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AmountRelatedToMilestonePayment_doc" xml:lang="en-US">Amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialDescription_doc" xml:lang="en-US">Clinical trial description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantFourMember_doc" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:to="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_doc" xml:lang="en-US">Class of warrant or righst term from which warrants or rights exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xml:lang="en-US">ShareBasedCompensationIncludedInResearchAndDevelopmentCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xml:lang="en-US">IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_4_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average number of share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>lixt-20230930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230930.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230930.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230930.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230930.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230930.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20230930.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230930.xsd#SummmaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20230930.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaapShareBasedCompensationAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="995514 - Disclosure - Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995515 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995516 - Disclosure - Research and Development Costs">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995517 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995519 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995520 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995521 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995522 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="loc_LIXTPrepaidInsurancePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTPrepaidInsurancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="loc_LIXTWarrantsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995524 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995525 - Disclosure - Research and Development Costs (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ResearchDevelopmentTableTextBlock" xlink:label="loc_LIXTResearchDevelopmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_LIXTResearchDevelopmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995527 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995528 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="995531 - Disclosure - Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorOneMember" xlink:label="loc_LIXTVendorOneMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorTwoMember" xlink:label="loc_LIXTVendorTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995534 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995537 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CommonStockWarrantMember" xlink:label="loc_LIXTCommonStockWarrantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:label="loc_LIXTClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995538 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_StockBasedMember" xlink:label="loc_LIXTStockBasedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTStockBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995539 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="loc_LIXTDrJamesSMiserMDMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMrVanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails" xlink:title="995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RelatedPartiesMember" xlink:label="loc_LIXTRelatedPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRelatedPartiesMember" xlink:label="loc_LIXTNonRelatedPartiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995544 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DrJamesMiserMember" xlink:label="loc_LIXTDrJamesMiserMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrSchwartbergMember" xlink:label="loc_LIXTMrSchwartbergMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrSchwartbergMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrVanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FourNonOfficersMember" xlink:label="loc_LIXTFourNonOfficersMember" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialPhase1b2Member" xlink:label="loc_LIXTClinicalTrialPhase1b2Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1b2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995546 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="loc_LIXTOtherClinicalAgreementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTOtherClinicalAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_Dr.JamesMember" xlink:label="loc_LIXTDr.JamesMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDr.JamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="loc_LIXTBastiaanVanDerBaanMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBastiaanVanDerBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230930.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTContractPrice" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091342688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
East Colorado Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090405728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 5,105,611<span></span>
</td>
<td class="nump">$ 5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">78,015<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">23,230<span></span>
</td>
<td class="nump">49,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">27,840<span></span>
</td>
<td class="nump">10,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,234,696<span></span>
</td>
<td class="nump">5,560,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,234,696<span></span>
</td>
<td class="nump">5,560,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, including $43,895 and $46,982 to related parties at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">221,171<span></span>
</td>
<td class="nump">229,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent', window );">Research and development contract liabilities</a></td>
<td class="nump">90,565<span></span>
</td>
<td class="nump">165,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">311,736<span></span>
</td>
<td class="nump">394,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares and 1,664,706 shares at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">48,872,208<span></span>
</td>
<td class="nump">45,059,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(47,449,473)<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,922,960<span></span>
</td>
<td class="nump">5,165,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 5,234,696<span></span>
</td>
<td class="nump">$ 5,560,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091168096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 43,895<span></span>
</td>
<td class="nump">$ 46,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734089923440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Compensation to related parties, including stock-based compensation expense of $112,106 and $396,883 for the three months ended September 30, 2023 and 2022, respectively, and $669,146 and $1,160,649 for the nine months ended September 30, 2023 and 2022, respectively</a></td>
<td class="nump">356,001<span></span>
</td>
<td class="nump">643,957<span></span>
</td>
<td class="nump">1,398,042<span></span>
</td>
<td class="nump">1,963,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">178,012<span></span>
</td>
<td class="nump">271,163<span></span>
</td>
<td class="nump">835,362<span></span>
</td>
<td class="nump">944,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses</a></td>
<td class="nump">357,681<span></span>
</td>
<td class="nump">290,993<span></span>
</td>
<td class="nump">1,081,893<span></span>
</td>
<td class="nump">875,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">132,487<span></span>
</td>
<td class="nump">272,388<span></span>
</td>
<td class="nump">749,029<span></span>
</td>
<td class="nump">895,649<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">1,024,181<span></span>
</td>
<td class="nump">1,478,501<span></span>
</td>
<td class="nump">4,064,326<span></span>
</td>
<td class="nump">4,678,863<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,024,181)<span></span>
</td>
<td class="num">(1,478,501)<span></span>
</td>
<td class="num">(4,064,326)<span></span>
</td>
<td class="num">(4,678,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">5,809<span></span>
</td>
<td class="nump">3,911<span></span>
</td>
<td class="nump">13,538<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(6,088)<span></span>
</td>
<td class="num">(5,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
<td class="num">(1,339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,018,760)<span></span>
</td>
<td class="num">$ (1,478,009)<span></span>
</td>
<td class="num">$ (4,054,774)<span></span>
</td>
<td class="num">$ (4,681,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share basic</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share diluted</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">2,074,938<span></span>
</td>
<td class="nump">1,664,659<span></span>
</td>
<td class="nump">1,803,466<span></span>
</td>
<td class="nump">1,554,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">2,074,938<span></span>
</td>
<td class="nump">1,664,659<span></span>
</td>
<td class="nump">1,803,466<span></span>
</td>
<td class="nump">1,554,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734095699616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 112,106<span></span>
</td>
<td class="nump">$ 396,883<span></span>
</td>
<td class="nump">$ 669,146<span></span>
</td>
<td class="nump">$ 1,160,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090100224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 38,372,365<span></span>
</td>
<td class="num">$ (37,082,164)<span></span>
</td>
<td class="nump">$ 4,790,338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,374,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">5,141,355<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,160,649<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,160,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,681,231)<span></span>
</td>
<td class="num">(4,681,231)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">44,674,369<span></span>
</td>
<td class="num">(41,763,395)<span></span>
</td>
<td class="nump">6,411,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">44,277,486<span></span>
</td>
<td class="num">(40,285,386)<span></span>
</td>
<td class="nump">7,492,266<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">396,883<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">396,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,478,009)<span></span>
</td>
<td class="num">(1,478,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">44,674,369<span></span>
</td>
<td class="num">(41,763,395)<span></span>
</td>
<td class="nump">6,411,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">45,059,760<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
<td class="nump">5,165,227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,137,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">669,146<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">669,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,054,774)<span></span>
</td>
<td class="num">(4,054,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">48,872,208<span></span>
</td>
<td class="num">(47,449,473)<span></span>
</td>
<td class="nump">$ 4,922,960<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">45,623,081<span></span>
</td>
<td class="num">(46,430,713)<span></span>
</td>
<td class="nump">2,692,534<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,665,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,137,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">112,106<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">112,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,018,760)<span></span>
</td>
<td class="num">(1,018,760)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 48,872,208<span></span>
</td>
<td class="num">$ (47,449,473)<span></span>
</td>
<td class="nump">$ 4,922,960<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090088576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,054,774)<span></span>
</td>
<td class="num">$ (4,681,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense included in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost', window );">General and administrative costs</a></td>
<td class="nump">669,146<span></span>
</td>
<td class="nump">1,160,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost', window );">Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">69,002<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">25,994<span></span>
</td>
<td class="nump">22,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other prepaid expenses and current assets</a></td>
<td class="num">(17,460)<span></span>
</td>
<td class="num">(13,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(8,593)<span></span>
</td>
<td class="nump">81,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
<td class="num">(74,457)<span></span>
</td>
<td class="nump">23,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,391,142)<span></span>
</td>
<td class="num">(3,403,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="nump">3,137,039<span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="nump">41<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,143,361<span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease)</a></td>
<td class="num">(247,781)<span></span>
</td>
<td class="nump">1,738,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of period</a></td>
<td class="nump">5,353,392<span></span>
</td>
<td class="nump">4,823,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of period</a></td>
<td class="nump">5,105,611<span></span>
</td>
<td class="nump">6,561,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in advances on research and development contract services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734092572976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (1,018,760)<span></span>
</td>
<td class="num">$ (1,478,009)<span></span>
</td>
<td class="num">$ (4,054,774)<span></span>
</td>
<td class="num">$ (4,681,231)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734092781312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734092048576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zoUNYkcAGija" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_827_zYhBMmcl4Du5">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at September 30, 2023, and for the three months
and nine months ended September 30, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2023, and the results of its operations for the three months and nine months ended September 30, 2023 and 2022, and its cash flows
for the nine months ended September 30, 2023 and 2022. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#8217;s
audited consolidated financial statements at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>President
and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan was appointed as the Company&#8217;s President and Chief Executive Officer, at which time he replaced
Dr. John S. Kovach as the Company&#8217;s President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE1TzfK1NL9i" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market, the Company held a special
meeting of stockholders on May 26, 2023 to seek approval for an amendment to the Company&#8217;s Certificate of Incorporation to effect
a reverse stock split of its issued and outstanding shares of common stock. As a result of the approval of this amendment, the Company
effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z02S4g9t2jY3" title="Reverse stock split">1-for-10</span> reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. Commencing with
the opening of trading on the Nasdaq Capital Market on Monday, June 5, 2023, the Company&#8217;s common stock began trading on a post-split
basis under the same symbol LIXT. The Company subsequently received confirmation from Nasdaq that it had regained compliance with the
minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria
for continued listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum bid price requirement over time,
or that it will be successful in maintaining compliance with any of the other Nasdaq continued listing requirements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734181535552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--NatureOfOperations_z9OGZ05Ow1c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82E_zyfvEivLRqCd">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug research company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
reflected in the accompanying financial statements, for the nine months ended September 30, 2023, the Company recorded a net loss of
$<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930_zp7FFVQsogdk">4,054,774</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
used cash in operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230930_zbOVMBwcis9">3,391,142</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
At September 30, 2023, the Company had cash of $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230930_zcCr2UZflSJk">5,105,611
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available to fund its operations. Because the
Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time and
resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2023, the Company&#8217;s
remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated
approximately $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pp0p0_c20230930_zsauRVl4oQ5g">6,262,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see
Note 9), which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through at least September 30, 2024. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able
to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating
plans may change as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional
funds may be needed sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091293936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zhCCLzEw3wsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_ztDvgeDNAQcd">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_z2eti3b7lHA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z1cYKXmAmo18">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zsUiVAlVqDP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zgeelSlJlfZc">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense denominated in a foreign currency. Such cost or expense is converted into United States
dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company
purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase
of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations. As of September 30,
2023 and December 31, 2022, the Company did not hold any currencies other than the United States dollar in its bank account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWzwfpwvFc43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zGhku7413rFf">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--UseOfEstimates_zYGhTCfb0Tx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zL3s4xHNvmGj">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSoAG8Iwlnka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmYUevFxr3g8">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230930_zzVrO5ZoyS68" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_905_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230930_zs0T6H0X5Owg" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2WDGaqCYUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zqpONPVFXKPi">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--PrepaidInsurancePolicyTextBlock_zI8WxieDP9T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_znLMoh1EJMVc">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zajv7XUxgz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwxMXWdWwNmf">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230701__20230930_zLzVVea1Id54">178,012</span> and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220701__20220930_zzVJ8sD3ciy8">271,163</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20230101__20230930_zwRoGlqq5qKg">835,362 </span>and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20220101__20220930_zGZuG1zKNcy8">944,789</span>
for the nine months ended September 30, 2023 and 2022, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6qs5gImq235" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zwN75KICZ743">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zSIu73Xo3yge" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgxsksCwncR2" title="Concentration of risk, percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE1JebAMNyQ7" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztsybRVNETe3" title="Concentration of risk, percentage">10</span></span></span></span>% or more of general and administrative costs or research and development costs for the three months and nine months
ended September 30, 2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2023 and 2022 included charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWabCorlhdT6" title="Concentration risk percentage">20.0</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEz1rVlkt6z1" title="Concentration of risk, percentage">22.5</span>% of
total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2023
and 2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z5BMLGPUFem" title="Concentration of risk, percentage">12.6</span>% and
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zpVWgiFEylqb" title="Concentration of risk, percentage">32.9</span>%, respectively, of total general and administrative costs. General and administrative costs for the three months ended September
30, 2023 also included charges from two vendors representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zVWHsjU8QUo8" title="Concentration of risk, percentage">11.9</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zWLC2BdhvGA2" title="Concentration of risk, percentage">10.6</span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2023 included charges from four vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLh24gMc58ta" title="Concentration of risk, percentage">38.9</span>%,
<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgPU1rru6XKc" title="Concentration of risk, percentage">24.9</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zovs1r0vOTTh" title="Concentration of risk, percentage">15.9</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zbeSvniRKGf2" title="Concentration of risk, percentage">14.9</span>%, respectively, of total research and development costs. Research and development costs for the three months ended
September 30, 2022 include charges from four vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4FV76f6LBx3" title="Concentration of risk, percentage">32.0</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5NlA7ZRYwlb" title="Concentration of risk, percentage">23.2</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze6F9qyZMwA6" title="Concentration of risk, percentage">16.9</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7foDi94gOH2" title="Concentration of risk, percentage">11.0</span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2023 and 2022 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsFHITlsxmP7" title="Concentration risk percentage">25.2</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJhUDYmnON21" title="Concentration of risk, percentage">25.0</span>% of
total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2023 and
2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zxaPfYTaCZ2g" title="Concentration of risk, percentage">20.2</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zh85uOaSUJHc" title="Concentration of risk, percentage">30.7</span>%,
respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zANX9VkcZwbc" title="Concentration of risk, percentage">35.9</span>%,
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1oh68qZT2Pj" title="Concentration of risk, percentage">21.0</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z90sPG8XIzll" title="Concentration of risk, percentage">12.4</span>%, respectively, of total research and development costs. Research and development costs for the nine months ended September
30, 2022 include charges from three vendors and consultants representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz5Uc8IabDkj" title="Concentration of risk, percentage">31.0</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zidbKL6e9gZh" title="Concentration of risk, percentage">16.7</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zMKkchs4NhHf" title="Concentration of risk, percentage">10.0</span>%, respectively, of total research and
development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zziQ71bS1YUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaEsmGGKefQ1">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of September 30, 2023 or
December 31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2023 or December
31, 2022. Subsequent to September 30, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7FnXFc6LX6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_znKG4J2eNzWl">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash
for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_841_ecustom--WarrantsPolicyTextBlock_zkM34u8aIrf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5AI7k5nQ0qb">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480,
Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 5)
meet the requirements for equity classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zK6hNr4oWbFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_ztxdQ1PgXS5g">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2XT2q3Vedm7" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,556,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">745,448</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z2KMGOqhgLY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zUuzLaadsK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z9fPxBAs9CCa">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zruReJoFaQ4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zOp60YNQ3pK">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting
Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212;
Stock Compensation (Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB
Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC
Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280
&#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new
guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03
immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial
statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

<p id="xdx_85E_zAgxAESh4uPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091293936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zav7OskLkOUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_823_zuqL31HSGgy8">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_ecustom--ResearchDevelopmentTableTextBlock_zrcsjMtV2fXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated
with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical
regions where such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zqLHcZFdzSM1" style="display: none">Schedule
of Research and Development Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20230930_zDf90xcyndd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220701__20220930_zyM03hvMlOoh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zgJohYyjc56h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220930_zZzDEHQsVGT9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_z4XvV3CYrPli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">161,744</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">291,846</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">316,565</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_z26fC9u1fpM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,850</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zCxObD6nrZf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,050</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zsPXl1vtkSM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Netherlands</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">156,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">149,184</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zglxOoL5IBL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">749,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">895,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_z3zd7m1rEQN8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expense</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">749,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">895,649</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AC_zXuSXx688aw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091815888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFi765UO65il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_823_zfu8SkSLRn2a">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930_zVOvVYqk9H17" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zdgCSf0uwmi8" title="Preferred stock, par value">0.0001</span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLf9Y3SMfuIa" title="Preferred stock, shares authorized">350,000</span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_90F_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpVwzFi0nyj5" title="Principal cash obligations and commitments">175,000</span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20230317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNljoFshXUYb" title="Preferred stock dividend, percentage">1</span>% of the annual net revenue of the Company divided by <span id="xdx_908_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpUeHq1XHSdb" title="Annual net revenue">175,000</span>, until converted or redeemed. As of September 30, 2023 and December
31, 2022, the Company had <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zlNIZJ2fGsNl" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_z86k5TX1qdDj" title="Preferred stock, shares authorized">9,650,000</span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board
of Directors may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PreferredStockConversionBasis_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPuSIA5glSH8" title="Preferred stock, conversion description">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY3kHZF7Q5ah" title="Preferred stock convertible into common stock">0.20833</span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOilYgJeMsxh" title="Gross proceeds from sale of transaction">21,875,000</span>.</span> The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znbcJ1IsMZx9" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAgGmKMPaGpa" title="Preferred stock, shares outstanding">350,000</span></span> outstanding shares
of Series A Convertible Preferred Stock would convert into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zZx7AkhOApz7" title="Preferred stock convertible into common stock"><span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zx8mj8rfHaZh" title="Preferred stock convertible into common stock">72,917</span></span> shares of common stock at September 30, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zDMiMyDvqmck" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zmTuNU4F7F2k" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zje6so0n6zP4" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zXAmlxuUq3ta" title="Common Stock, Par or Stated Value Per Share">0.0001</span></span> per share. As of September 30, 2023 and
December 31, 2022, the Company had <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_zNQcDkJi7dWe" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_z1HVGKzPq8T" title="Common stock, shares outstanding">2,249,290</span></span> shares and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zhRNheIEPIl7" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zSc4285ahqmd" title="Common stock, shares outstanding">1,664,706</span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBCKEusXGYIk" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share. All share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock
split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOCcJDLGXmI6" title="Stock issued new issue shares">1,250</span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwUEtA7CkeOi" title="Stock issued new issue shares">1,250</span> shares exercisable at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxIBCYzLaWv9" title="Warrant exercise price">5.025</span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT0IowCaph3f" title="Proceeds from warrant exercises">6,281</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">April
12, 2022 Sale of Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDeecwPVTVb" title="Number of common stock shares issued during period">290,000</span> shares of common stock at a price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztBLVJqBgMdk" title="Sale of stock price per share">20.00</span> per share in a registered direct
offering, generating gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjHFMs0JNXX8" title="Proceeds from issuance initial public offering">5,800,000</span>. The total cash costs of this offering were $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaZIGzFEQDS8" title="Costs of public offering">658,616</span>, resulting in net proceeds of
$<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9XzJ6DEShb" title="Net proceeds from issuance of stock">5,141,384</span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zsT3UBdm5KOb" title="Warrants to purchase shares">29,000</span>
shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zpmApYfQ69k9" title="Warrant exercise price">20.00</span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July
20, 2023 Sale of Common Stock and Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM5B4ifsL0x4" title="Number of common stock shares issued during period">180,000</span> shares of common stock at a price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znlNev8VOTVh" title="Sale of stock price per share">6.00</span> per share and pre-funded warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zohoH8AhPbh7" title="Warrants to purchase shares">403,334</span>
shares of common stock at a price of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeNMvMvR4K81" title="Common Stock, Par or Stated Value Per Share">5.9999</span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ2sH5F1OJLd" title="Warrant exercise price">0.0001</span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full. As of August 7, 2023, all pre-funded warrants had been exercised in full. The pre-funded
warrants were determined to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLRTMyMZnBp6" title="Warrants to purchase shares">583,334</span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYY2Ha97JPo4" title="Warrant exercise price">6.00</span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_dc_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zompdFE1Cmci" title="Warrant expires term">five years</span>
thereafter on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zl3jqtrpUpC8" title="Warrant expires date">July 20, 2028</span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zW72K4rRfD7e" title="Proceeds from issuance initial public offering">3,499,964</span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCUYrMqlYixg" title="Costs of public offering">362,925</span>, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIO5Kc5WkjRf" title="Net proceeds from issuance of stock">3,137,039</span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zTP1n2U2wBcg" title="Warrants to purchase shares"> 35,000</span> shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zLZ2nMjb2Yvj" title="Warrant exercise price">6.60</span> per share and
expiring on <span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zRn4KhYvCkd3" title="Warrant expires date">July 20, 2028</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8C2hmOT7cYb" title="Warrants to purchase shares">403,334</span> pre-funded warrants, exercisable at $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGvERjmtHQ8" title="Common Stock, Par or Stated Value Per Share">0.0001</span> per common share, were
exercised for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5YPkzyOgLjb" title="Exercise of common stock options">41</span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfmliIOR7mej" title="Issuance of common stock">403,334</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_znoHxzeoS0f" title="Common Stock, Par or Stated Value Per Share">6.00</span>
per share) and to the placement agent (exercisable at $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3qc6XEbZfh8" title="Common Stock, Par or Stated Value Per Share">6.60</span>
per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications,
reorganizations or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional
investor contain a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction (a sale or
transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control, the holder
of the unexercised common stock warrants will be entitled to receive cash consideration equal to a Black-Scholes valuation, as
defined in the warrant agreement. If such fundamental transaction is not within the Company&#8217;s control, the warrant holder
would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#8217;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash
payment for a warrant redemption as a distribution from stockholders&#8217; equity, as and when such cash payment is
made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhHFKCNEJo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the nine months ended September 30, 2023, excluding the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6kO1BxglUn3" title="Warrants to purchase shares">403,334</span> pre-funded warrants,
exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePO4syuM9ra" title="Common stock, par or stated value per share">0.0001</span> per common share, to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTPSlCjBRr9" title="Warrants to purchase shares">403,334</span> shares of common stock described above, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zC8PkhwyBa0i" style="display: none">Schedule of Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTWGXOVzX9ja" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb805odK5IS2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0ZP2vMYjG3j" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKfJ7FaYHen8" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLlRcrdfaY9h" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztbqlLNImt76" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5mOK4pPyyS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0kqxgwjAGn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0829">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwpfFTAA1YE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK3fWOMCO5ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN2ejtbtuaL8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">4.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7uclRtbEc5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance">190,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBrpG9xzXPT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">50.161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhcNZbWrYLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcHvkMxTNhee" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgTYyU7QM2G9" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">4.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z1K878rCBUD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zztBqUPLK7rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaLZorDpdJu5" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zltTwPRuv1ok" title="Exercise Prices">6.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhuVdovBn5B2" style="width: 47%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z55dmao6Mka" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZLhk6etfMUg" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWDwDBwvcVfk" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zj7d2Ceu95nb" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqTRr9U7PTbc" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXl7zLlzOVyl" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHAi6xf6gxG" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdJKWyt0dQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930_zmjOH53BqWod" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zGyYbeFI2Gsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z489484kBsG5" title="Warrants exercisable">57.00</span> per share at September 30, 2023 consist of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBkrEpVs81be" title="Warrants outstanding">1,497,000</span> publicly-traded warrants pre-split <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbVyz21f5lj" title="Reverse stock split">1-for-10</span> that
were issued as part of the Company&#8217;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPSAPv0i5jQb" title="Exercise price">5.70</span> per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWPaUfIh7hyi" title="Warrants exercisable">5.70</span>, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVUsnkyJqHq3" title="Warrants and rights outstanding">57.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPRmAu3PPXRb" title="Fair market value of stock">2.45</span> per share on September 30, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091886384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcG6o54ltZs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82E_znXlPUB0QMfj">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_900_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zDbAcHtPNI17" title="Annual salary">250,000</span>.
During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_900_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zXPqF7A1AdE5" title="Compensation">62,500</span> and $<span id="xdx_902_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z8iBPG9CIJAc" title="Compensation">62,500</span>, respectively, to Dr. Kovach under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zPfT1WTQPjpg" title="Compensation">187,500</span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zbNLroryDWSe" title="Compensation">187,500</span>, respectively,
to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated
statements of operations for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zdaKYI1PoY31" title="Annual salary">150,000</span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90D_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zuvyMKcbPCgl" title="Increase in annual salary">175,000</span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the three months ended September
30, 2023 and 2022, the Company paid $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zxN7fTSCiw14" title="Compensation">43,750</span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zSoz4hzJ0UA4" title="Compensation">43,750</span>, respectively, to Dr. Miser under this employment agreement, and during the nine
months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z9b6JLkv58kj" title="Compensation">131,250</span> and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zuKSZw1hpzj7" title="Compensation">131,250</span>, respectively, to Dr. Miser under this employment agreement,
which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_909_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zqdi1K38Ksyg" title="Annual salary">120,000</span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_908_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zibRcudpDW5f" title="Increase in annual salary">175,000</span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zXML71QFoZF4" title="Compensation">200,000</span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zaEe2AYaTLxg" title="Paid office rent">7,323</span> and $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zy3QgP87tR43" title="Paid office rent">11,436</span>, respectively, for the three months and nine months ended September 30, 2023.
During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zRSlvxlNg0Wk" title="Compensation">50,000</span> and $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z0SAHQ7szDY6" title="Compensation">43,750</span>, respectively, to Mr. Forman under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_905_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zVJIRQaq9cA6" title="Compensation">150,000</span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zX8fpg3NeB1f" title="Compensation">131,250</span>, respectively,
to Mr. Forman under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated
statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_90D_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zyaTma7f9U9g" title="Annual salary">120,000</span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_906_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zQAIqIBugYI5" title="Increase in annual salary">175,000</span>. During the three months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zp2rOuZc1U8i" title="Compensation">43,750</span> and $<span id="xdx_903_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zLwH0TPHehtl" title="Compensation">43,750</span>, respectively, to Mr. Weingarten
under this employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zuckifzBeIjk" title="Compensation">131,250</span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIWsFe724u93" title="Compensation">131,250</span>,
respectively, to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the
Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023, to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_906_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zjTva8f2dUoi" title="Annual salary">150,000</span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors. During the three months and nine months ended
September 30, 2023, the Company paid $<span id="xdx_909_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zuozEEqOTYTb" title="Compensation"><span id="xdx_90C_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zwyeBzjuv9Pc" title="Compensation">1,667</span></span> to Mr. van der Baan under this employment agreement, which costs are included in general
and administrative costs in the Company&#8217;s consolidated statements of operations for such periods. Mr. Van der Baan was appointed
as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20220615_zcxdOmneoQV" title="Cash board fee payable">100,000</span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_90C_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zYGctzdEc7Gg" title="Cash board fee payable quarterly">40,000</span>, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
9).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for independent directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z0XMbmfM4Duj" title="Compensation">20,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_za0jGC4FmPf5" title="Compensation">10,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zymV2IUuxYLa" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zKGJG4vm0YCj" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zsGg1KTU8C26" title="Compensation">2,500</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for independent directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new independent directors &#8211; The Company grants options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zVk9HehVzio1" title="Options, grants in period, gross">25,000</span> shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zDtHCdx6uZQk" title="Share-based payment award, award vesting period">50</span>% on the grant date and the remaining <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z2P8VxCZH03" title="Share-based payment award, award vesting period">50</span>% vesting <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930_zmggabJEsw7a" title="Award vesting rights, percentage">12.5</span>% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $<span id="xdx_90B_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVtl8SY3syMe" title="One time cash">100,000</span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to independent directors &#8211; Effective on the last business day of the month of June, the Company grants options
to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zqqPa04kbGn4" title="Options, grants in period, gross">10,000</span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant,
vesting <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zzOMgNl9Xqvi" title="Share-based payment award, award vesting period">12.5</span>% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully
vested, subject to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount
of such stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors,
for a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_90F_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzuA9jzcekqg" title="Annual cash fee">40,000</span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to independent directors was $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zOFzv8FZiSX7" title="Stock based compensation">42,228</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zuD6DvrC7yxj" title="Stock based compensation">53,324</span>, respectively, for the three months ended September 30, 2023
and 2022. Total cash compensation paid to independent directors was $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zw3ZSfGYx9c" title="Stock based compensation">127,229</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zWEzLdl52pE" title="Stock based compensation">221,510</span>, respectively, for the nine months ended September
30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zkNzOsV5Ft1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zCumS3XlPEW4" style="display: none">Summary of Related Party Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230701__20230930_zXtPzbawr8W4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_zlkUFkvHMQc9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zF5Qrmn4YUg9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20220930_zhOyWuLBgWH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdTYXtsXSyPe" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">243,895</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">247,074</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">728,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">802,760</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockBasedMember_zHoTcCa8zH34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">396,883</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zzkQX8iRRvwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">643,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,398,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,963,409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_zlpCe759Ssqb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related
    party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">643,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,398,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,963,409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_z3eXZDt8Ten1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091892560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zMLTkSRADci2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_828_z1SR3qly2M88">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zafFpZ06Xlu5" title="Number of restricted stock issued">233,333</span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWW3D6bRNBYa" title="Common shares avaliable for issuable">180,000</span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvuD35rd3Xy8" title="Shares total">413,333</span> shares.
The Company has scheduled a meeting of stockholders for November 27, 2023 to consider and vote on, among other matters, a proposal to
increase the number of common shares issuable under the 2020 Plan by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBueXCOBE8k1" title="Common shares avaliable for issuable">336,667</span> shares, to a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRur1AcrIv0d" title="Shares total">750,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, there was a deficiency of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zQqh9H1LgZHe" title="Shares outstanding">136,980 </span>shares with respect to stock options issuable under the 2020 Plan. However,
subject to approval of the proposal to increase the number of common shares issuable under the 2020 Plan at the meeting of stockholders
scheduled for November 27, 2023, there will be unexpired stock options for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrb5AS9VMbk5" title="Shares outstanding">550,313</span> shares issued and outstanding under the 2020 Plan
and <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHwTsWEGS8O4" title="Shares were available for issuance">199,687 </span>shares available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXtUFyzGcPW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zfgpbDyRkv44" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930_zUwF11wlHIdl" title="Risk-free interest rate">4.843</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930_zlhGen2z87db" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930_zFXJ0JmdW6xf" title="Expected volatility">138.05</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zFiz9nGu1nl2" title="Expected life">4.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2022, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220930_zDSXZcdldCtg" title="Risk-free interest rate">3.03</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220930_zJe73ve7yIY1" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20220930_zNEfvh7lXCuk" title="Expected volatility">198.79</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zisZAepBOJa3" title="Expected life">3.6</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zmiAA6LFZr85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZdd8D2RIovg" title="Stock options description">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zntCbzqgH4c" title="Stock options granted to purchase common stock, issued">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zHVYt9PZNwJe" title="Stock option vested exercisable term">five years</span> at an exercise price of $71.40 per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6BYEEFZCfil" title="Fair value of stock options">400,855</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsyxzJ7KZZ0f" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEDe3qWKDIVc" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsSySPcPQJhj" title="Stock based compensation">11,806</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zak2DAJIjElg" title="Stock based compensation">25,259</span> for the three
months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z03N3qDbpWxi" title="Stock based compensation">61,501</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ9AngHtEaxe" title="Stock based compensation">74,954</span> for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVXDDGVQoN09" title="Stock options description">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zayzoJefj7s2" title="Stock options granted to purchase common stock, issued">8,333</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC8wwUoS4id3" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z32ckApiKyZ4" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5azDtUzV1b" title="Fair value of stock options">572,650</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz6fIZ5IXi01" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z604TJC65id2" title="Stock options fully vested amount, fair value">143,163</span> was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPKT2w5qb1wb" title="Stock based compensation">12,551</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zijr9z2osFZ7" title="Stock based compensation">36,085</span> for the three
months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zwstCNam4NX3" title="Stock based compensation">83,544</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg44xJV09jQ9" title="Stock based compensation">107,078</span> for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVtfYn5Ftfjb" title="Stock options description">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_z2ZAFYofQWF7" title="Number of fully vested option exercisable">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zULixY6fCiia" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrfqqs0IJ7og" title="Stock options are exercisable price per share">71.40 </span>per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg6sI8Zaw78d" title="Fair value of stock options">400,855</span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfRi0iQ7jO59" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc6YtvRxSS5e" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy9OQPYGJck3" title="Stock based compensation">11,806</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUQZ65pjCb2g" title="Stock based compensation">25,259</span> for the three months ended September 30,
2023 and 2022, respectively, and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb7pHndyTBz3" title="Stock based compensation">61,501</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpDnbGd2cENg" title="Stock based compensation">74,954</span> for the nine months ended September 30, 2023 and 2022, respectively, with respect
to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zE4CB3NANqbb" title="Stock options description">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zf3UrKskq6jb" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s
common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6hceGbq9JX9" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zxUrm8idk1i9" title="Stock options are exercisable price per share">32.00</span> per share (the closing market price on the grant
date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zebnferywMOg" title="Fair value of stock options">753,611</span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGphqam0SPLj" title="Stock price per share">30.144</span> per share), of which $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zS8DhB78F499" title="Stock options fully vested amount, fair value">376,800</span> was attributable to the portion of the stock options fully
vested on April 9, 2021 and was therefore charged to operations on that date. Although the remaining unvested portion of the fair value
of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options
terminated on October 30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zL15gULMTJdi" title="Stock based compensation">42,692</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_z55LmLvPPoU2" title="Stock based compensation">126,684</span> for the three months and nine months ended September
30, 2022, respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zF2Sg0krn8kk" title="Stock options description">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z8CDWItMgfCk" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzQgvlo0x3ab" title="Stock option vested exercisable term">five years</span>
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zc7usJl0J6md" title="Stock options are exercisable price per share">28.00 </span>per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zpdP8ZgvtVBd" title="Fair value of stock options">658,363</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zLMnU1NtXnAe" title="Stock price per share">26.335</span> per
share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zgoEsRRGDSi9" title="Stock options fully vested amount, fair value">329,188</span> was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. The Company recorded charges to general and administrative costs in the consolidated statement of
operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RjHoJIXps1" title="Stock based compensation">0</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3YHv9mP58Be" title="Stock based compensation">38,827</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zi6LEXwFAGj8" title="Stock based compensation">76,388</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6yu8ria5Kxa" title="Stock based compensation">115,215</span> for the nine
months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z63CABwuq9qd" title="Stock options description">the
Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of
Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zZAd6xHreXB6" title="Number of fully vested option exercisable">10,000</span>
shares (a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zLpF5EH1f5c5" title="Number of fully vested option exercisable">50,000</span>
shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zIUqEijouci8" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zoGHl33ELSIk" title="Stock options are exercisable price per share">30.30</span> per share (the
closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z1uJR4AbWvVc" title="Fair value of stock options">1,421,095</span>
($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOLEuSc8F2vc" title="Stock price per share">28.423</span>
per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zGVrOIk5WOvc" title="Stock based compensation">0</span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zLHY2ksXlIZ2" title="Stock based compensation">179,100</span>
for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zSTAKXjTrGCd" title="Stock based compensation">211,412</span>
and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zQMGyxVE3e42" title="Stock based compensation">531,455</span>
for the nine months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zF9o3zD8Xd4d" title="Stock options description">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z35yQNWzNBH" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zFB5DvmsXBdi" title="Stock option vested exercisable term">five years</span>
at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zS7bUOlhE7y9" title="Stock options are exercisable price per share">7.40</span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zDGMa68H381" title="Fair value of stock options">158,525</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zaNi0pl5i2Uj" title="Stock price per share">6.341</span> per share),
of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zu8FODcTNFV3" title="Stock options granted to purchase common stock, issued">79,263</span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zau6IIrvODac" title="Stock based compensation">9,801</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zm2C23awz7qh" title="Stock based compensation">9,801</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zV6axkm8eEgg" title="Stock based compensation">29,084</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zvjDjIncW6Z2" title="Stock based compensation">90,449</span> for the nine months
ended September 30, 2023 and 2022, respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zJv439dY2ry6" title="Stock options description">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zxDmx7T0PB7f" title="Fair value of stock options">10,000</span> shares (a total
of <span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuPBNQXbsxH9" title="Stock price per share">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220628__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_za4hwzANisQi" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zNnp58RRAcH4" title="Stock options are exercisable price per share">7.40</span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCa0QMcDoD61" title="Fair value of stock options">316,700</span> ($<span id="xdx_909_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuzadZHkiFfi" title="Stock price per share">6.334</span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzsxgBXB7W0l" title="Stock based compensation">23,916</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zke4roWdzh64" title="Stock based compensation">39,860</span> for
the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zXWAAyOPZg8j" title="Stock based compensation">70,965</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zSbe8u11wsNi" title="Stock based compensation">39,860</span> for the nine months ended September 30, 2023
and 2022, respectively, with respect to these stock options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPihBnic9Bo9" title="Number of fully vested option exercisable">20,000</span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zqjxrT3h4VTd" title="Number of fully vested option exercisable">80,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zGrJzjPAm3uk" title="Share price">20.00</span>
per share, vesting <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziYgSbIWrhG8" title="Share based compensation vesting rights, percentage">25</span>% on issuance and <span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhuANZxNViRk" title="Share based compensation issuance, percentage">25</span>% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zbEf27pdSkF7" title="Stock options granted to purchase common stock, issued">80,000</span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjeBHLeFG0Ql" title="Fair value of stock options">262,560</span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znubjJrHRfJ4" title="Stock price per share">3.282</span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zO8QjNuxlJ9c" title="Stock based compensation">16,528</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zCeBwECz9GZ6" title="Stock based compensation">49,053</span> for the
three months and nine months ended September 30, 2023, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zllxBBCI0gHa" title="Number of fully vested option exercisable">10,000</span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zkXsG0amN9t" title="Stock options are exercisable price per share">5.025</span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z4lUHoIe24Jg" title="Fair value of stock options">43,264</span> ($<span id="xdx_900_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCYTUjpjmx84" title="Stock price per share">4.326</span> per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zKRLVnat5Yv4" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230606__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmBtZoiDm0m5" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYgUXE994V9h" title="Share price">5.88 </span>per share
(the closing market price on the grant date), vesting <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zWtNoow6xrVi" title="Share based compensation vesting rights, percentage">12.5</span>% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zFpFXJXKdty1" title="Fair value of stock options">192,593</span> ($<span id="xdx_907_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_ztyjuq4LEC81" title="Stock price per share">4.8131</span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zf0co99NOIAh" title="Stock based compensation"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zXNmV1tZ4C12" title="Stock based compensation">24,232</span></span> for the
three months and nine months ended September 30, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bastiaan van der Baan, Mr. van der Baan was granted
stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3CcsLS8JTRl" title="Options, grants in period, gross">250,000</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc23SAZFWS9c" title="Stock options are exercisable price per share">1.95</span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3FsVuMj86Oa" title="Fair value of stock options">403,066</span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20230626__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBuY2A4lcYA8" title="Stock price per share">1.612</span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkIquRZ91PGl" title="Stock based compensation"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zXGG7paNdExg" title="Stock based compensation">1,466</span> </span>for the three months and nine months ended September 30, 2023 with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each of such persons ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each of such persons are contractually scheduled to expire one year from the respective dates that their service to the Company
terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zauCGEf9gBz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zs8KYHunmwUi" style="display: none">Summmary of Stock-based Compensation Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_zKvXYW25Doji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20220930_zkWi7ODwOsjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230930_zihVRu0M1BH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_zEeAqz8dy69g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zUsTG6NOBHNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">112,106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">396,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">669,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,160,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zIJ2IPZInf8k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zIGnguhXuLo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">396,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,160,649</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zKYjKEx00hJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuOnmgRxuN4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2023 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zmI7aGeU55G8" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230930_zdbiTnSA2AOa" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zv4loaOvqwRe" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.1826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230930_ztQZycVN4PJi" style="text-align: right" title="Number of shares, Granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zEN3kaotjXE7" style="text-align: right" title="Weighted average exercise price, granted">2.4920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zgMvMYCbSQwh" style="text-align: right" title="Number of shares, Exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zHiQcLuvFmxd" style="text-align: right" title="Weighted average exercise price, exercised">5.0250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20230930_z0fOeCCEjqId" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired">(3,333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zeZmYLVRqwHc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">16.800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230930_z5Cdd26ERkNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">674,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z8ZFkZGA4aMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">17.8197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zWo2Yt9dEkJ2" title="Weighted average remaining contractual life (in years), stock options outstanding">4.96</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCVOhAWDILi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">281,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_zRNdZtWFjbzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">32.8335</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230930_zQV7tfaxceda" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">313,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zCOZ3jvLSAq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">31.8997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z02bkROQC2Yh" title="Weighted average remaining contractual life (in years), stock options exercisable">1.93</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zvPmWfj8TBi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_900_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230930_ztT1f0Sd3Et9" title="Total deferred compensation expense for outstanding value of unvested stock options">808,000</span> at September 30, 2023, which
will be recognized subsequent to September 30, 2023 over a weighted-average period of approximately <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230930_zRMIk1w1bWRa" title="Stock option vested exercisable term">28</span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFHv7Nv5V2Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at September 30,
2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zc5BLjyk8Fm5" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BJvZTwvRMg" style="width: 30%; text-align: right" title="Exercise Prices">1.950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z4S0dDRoDK1g" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHlyPPzmVB49" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zW1Kv318YTAh" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znu0bafyQqw3" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1Y14Wvktsi9" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuOTbR14jGd9" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWArKZ3eUtzc" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFSENW3isqle" style="text-align: right" title="Options Exercisable (Shares)">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z049sE32KZX2" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3EzQLjoLWOh" style="text-align: right" title="Options Outstanding (Shares)">57,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zp4a3Cw0vm25" style="text-align: right" title="Options Exercisable (Shares)">41,563</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTNu4lOz3Elb" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zXo88duZ95B7" style="text-align: right" title="Options Outstanding (Shares)">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zznhSdtALEUa" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z2hJmRZJRvFj" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z5xoRZDMsLhb" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zG76ifye7pta" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zKangMbgi1x1" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNye65ckqlFe" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxIdreuF6F5k" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPjBV5zSIX7a" style="text-align: right" title="Exercise Prices">30.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zUoaqshFf6ka" style="text-align: right" title="Options Outstanding (Shares)">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNMHKGC96GY7" style="text-align: right" title="Options Exercisable (Shares)">66,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBgF0BrNcB9a" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLWvZvmQN0x7" style="text-align: right" title="Options Outstanding (Shares)">42,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEHI544hTjvc" style="text-align: right" title="Options Exercisable (Shares)">42,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMDm870ZUGb" style="text-align: right" title="Exercise Prices">32.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zd9Wnw0jSHT4" style="text-align: right" title="Options Outstanding (Shares)">20,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zg0WYkhCZHm2" style="text-align: right" title="Options Exercisable (Shares)">20,313</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrOOC4yPft16" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKfJ7QtIVlt4" style="text-align: right" title="Options Outstanding (Shares)">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRYHIY9mZlTl" style="text-align: right" title="Options Exercisable (Shares)">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zEN0rhxarIyk" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z9XPMuwqGXS9" style="text-align: right" title="Options Outstanding (Shares)">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zzEwYECZuTka" style="text-align: right" title="Options Exercisable (Shares)">16,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zYYI4ksHWSob" style="text-align: right" title="Exercise Prices">66.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwiJF2VE8qVh" style="text-align: right" title="Options Outstanding (Shares)">4,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRRzSGEUeHja" style="text-align: right" title="Options Exercisable (Shares)">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zYWnEYkDJsS5" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zEjNksFoRbIf" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zragodmNuVIl" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zy9cC17TEx4i" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgCKLz4dA9Xg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">8,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zt5zKAuuQKVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">8,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930_zlYWcK0ee0pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">674,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930_z3NySbFeQmuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">313,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zW3lKq54bZdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230930_zqZG0J7gcEog" title="Fair market value, per share">2.45</span> per share on September 30, 2023, there was <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20230930_zGrCkwTuXzJ9" title="Intrinsic value">no</span> intrinsic value attributed to exercisable but unexercised
common stock options at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230930_zwwGYT2LDaC8" title="Outstanding stock options to acquire shares of common stock not vested">360,938</span> shares of the Company&#8217;s common stock had not vested at September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734181476592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zu0TA8k3fzQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_824_zLNnUH0Vo63h">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2023 and 2022, the Company did not record any provision for income taxes, as the
Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091892560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ9Sw9RVjYUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82D_zver3TU4LCP">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2023 and
December 31, 2022, the Company was not subject to any pending or threatened legal claims or actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the Company&#8217;s remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements not yet incurred, as described below, aggregated $<span id="xdx_901_eus-gaap--ContractualObligation_iI_c20230930_zrb2O8bSHvak" title="Contractual commitment">6,262,000</span>, which, based on current estimates, are currently scheduled to
be incurred through approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is
subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation
of such funds to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures
will be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration
are not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can
frequently involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified,
suspended or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein
should be considered as estimates only based on current clinical assumptions and conditions, and are typically subject to significant
modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzoVUGimRbHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_z1xWwPGQoxDa" style="display: none">Schedule
of Contractual Clinical Trials</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Institution</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
                                            Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            End Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
                                            Objective</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Update</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NCT
                                            No.</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zMweHho9w3cb" title="Clinical trial, description">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Phase 1b</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: left">City of Hope and Sarah Cannon</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zkGYUKP3Zfqh" title="Estimated Start Date">March 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zbwDDMA9u5Z9" title="Estimated End Date">March 2026</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: center"><span id="xdx_90C_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zxabq7ZIrDjj" title="Number of Patients in Trial">14</span> to <span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zWO4jNr1shBd" title="Number of Patients in Trial">36</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Determine RP2D</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Three patients entered</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">NCT04560972</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90D_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z6UaZC3NQEje" title="Clinical trial, description">LB-100 combined with doxorubicin in sarcoma</span></td><td>&#160;</td>
    <td>Phase 1b</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zwtlNZQEM8ij" title="Estimated Start Date">June 2023</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zXCiV4a8eJff" title="Estimated End Date">June 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zq7hEVY7iX0k" title="Number of Patients in Trial">9</span> to <span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zYEZiX3WVhxf" title="Number of Patients in Trial">18</span></td><td>&#160;</td>
    <td style="text-align: left">Determine MTD and RP2D</td><td>&#160;</td>
    <td style="text-align: left">One patient entered</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zv0hojwaMeRj" title="Clinical trial, description">Doxorubicin with or without LB-100 in sarcoma</span></td><td>&#160;</td>
    <td style="text-align: left">Randomized Phase 2</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zXtpTMghuJG" title="Estimated Start Date">July 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zExmr02ZwFBj" title="Estimated End Date">June 2026</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zagZZ9zMCkSj" title="Number of Patients in Trial">150</span></td><td>&#160;</td>
    <td style="text-align: left">Determine efficacy: PFS</td><td>&#160;</td>
    <td style="text-align: left">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_908_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zzOUOeN7Pu8c" title="Description of Clinical Trial">LB-100 combined with dostarlimab in ovarian clear cell carcinoma</span></td><td>&#160;</td>
    <td>Phase 1b/2</td><td>&#160;</td>
    <td style="text-align: left">MD Anderson</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zJVMhpxLYtJ6" title="Estimated Start Date">March 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_z2sBINvnUAuc" title="Estimated End Date">December 2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zqj4ttmOLVN9" title="Number of Patients in Trial">21</span></td><td>&#160;</td>
    <td style="text-align: left">Determine the survival of patients with ovarian clear cell carcinoma</td><td>&#160;</td>
    <td style="text-align: left">No patients entered at September 30, 2023</td><td>&#160;</td>
    <td style="text-align: justify">NCT06065462</td></tr>
  </table>

<p id="xdx_8A2_z3IPntyM95le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a five-year Clinical Trial Research Agreement with the Moffitt Cancer Center
and Research Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;). Pursuant to the Clinical Trial Research Agreement, Moffitt
agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead
anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome
(MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2023, the Phase 1b/2 clinical trial at Moffitt evaluating LB-100 in patients with MDS was closed by the
principal investigator. In this clinical trial, single agent LB-100 was used on a new schedule of days 1, 3, and 5 every 3 weeks. The
Company is not employing this schedule in its other clinical trials. Although the Maximally Tolerated Dose (&#8220;MTD&#8221;) was not
achieved, there was no dose-limiting toxicity on this schedule at doses that were greater than the MTD in the Phase 1 clinical trial
of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zLlPogT4MNTj" title="Research and development process costs">0</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zyVwgf4xm8Je" title="Research and development process costs">9,218</span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. During the nine
months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zDIIUiL8ZRU6" title="Research and development process costs">0</span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zC4xI4jGu5pb" title="Research and development process costs">18,623</span>, respectively, pursuant to this agreement, which
have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30,
2023, total costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230130__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjKf7nJJL9d9" title="Research and development costs">131,074</span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(&#8220;PFS&#8221;, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative
median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zuRLIufGzrqj" title="Research and development costs">1,144,000</span>. Although the production of new inventory
has been completed, nominal trailing costs subsequent to September 30, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b section of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the
nine months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhpdwMTxcFak" title="Research and development costs">268,829</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zu15nqUCyOx6" title="Research and development costs">0</span>, respectively, pursuant to this agreement.
Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of operations.
Through September 30, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_905_ecustom--AmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zpXK2C9wMoi6" title="Amount related to milestone payment">684,652</span> for work done under this agreement through the fourth
milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_909_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfp1NkeOYKQ9" title="Aggregate commitments expected">3,423,000</span>
as of September 30, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously
untreated ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm
the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free-survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early July 2023, the Company was notified that one of three centers accruing patients to its Phase 1b clinical trial in small cell lung
cancer had a shortage of carboplatin and as a result the clinical trial was placed on a temporary enrollment hold. This matter was resolved
and the temporary enrollment hold was lifted in late July 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the nine months
ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zuqvNcSPWNY8" title="Research and development expense">69,001</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zP5pRYVBiWQl" title="Research and development expense">0</span>, respectively, pursuant to this agreement, which are
included in research and development costs in the Company&#8217;s consolidated statements of operations. As of September 30, 2023, total
costs of $<span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zdwWmlSCt5za" title="Total costs">447,512</span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zSeiWOnS6D5e" title="Aggregate commitments expected">2,433,000</span>
as of September 30, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zVeUW4sPPOsc" title="Aggregate commitments expected">800,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theradex.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to conduct a Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin
alone in first line of advanced soft tissue sarcomas. The study is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zFxPBycuLeg6" title="Work cost">153,000</span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z1AXKjoguBx8" title="Percentage of payment through services">72</span>% to Theradex for services and approximately <span id="xdx_90A_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVAsDydlzcRa" title="Percentage of payment through software">28</span>% for payments for pass-through software costs. During the three months and nine months
ended September 30, 2023, the Company incurred costs of $$<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSTHoEM8mpEj" title="Research and development costs">3,750</span> and <span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z3EdXnmm5Wne" title="Research and development costs">10,000</span>, respectively, pursuant to this work order. As of September
30, 2023, total costs of $<span id="xdx_906_eus-gaap--DeferredCosts_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLvm0N1ke9jl" title="Total costs">10,000</span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z5GGHCqJglzk" title="Aggregate commitments expected">144,000</span> as of September 30, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain has not been determined. Many
drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Five patients were entered into this study and analysis of the blood and tissue has been conducted. If there is clinical
evidence in at least two of the patients of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results
of this study are currently being reviewed by the NCI and a report is pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Trial</b>. On September 20, 2023, the Company announced a Phase 1b/2 collaborative clinical trial to assess whether
adding LB-100 to the programmed death receptor-1 (&#8220;PD-1&#8221;)-blocking monoclonal antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab,
may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). The clinical trial
is sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and will be conducted at MD Anderson, and
will also be open at Northwestern University&#8217;s Robert H. Lurie Comprehensive Cancer Center. The Company will provide LB-100 and
GSK will provide dostarlimab and financial support for the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex (&#8220;CRO&#8221;), to monitor the Phase 1b/2
clinical trial being managed and conducted by Moffitt. The clinical trial began in April 2019 and the first patient was entered into
the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the three months ended September 30, 2023 and 2022, the Company incurred costs of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zamaK1pgiNqb" title="Research and development costs">566</span> and
$<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zgmkdNclhHC4" title="Research and development costs">11,953</span>, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022, the Company incurred costs
of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zNpO5ArAhM6b" title="Research and development costs">20,850</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zZT29UYWdHCb" title="Research and development costs">19,792</span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zblboL8TZ3O4" title="Research and development costs">148,138</span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the three months ended June 30,
2023 (see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to September 30,
2023 are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAbOe1yyahA5" title="Research and development costs">335,000</span>. During the three months ended September 30, 2023 and 2022, the Company
incurred costs of $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zZhDZv4Ngnp2" title="Advance amount related to milestone payment">4,500</span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGeb3CpCF6qc" title="Advance amount related to milestone payment">7,731</span>, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022,
the Company incurred costs of $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zF1EKsYPpeB9" title="Advance amount related to milestone payment">15,740</span> and $<span id="xdx_909_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zqVqxKeecYJ6" title="Advance amount related to milestone payment">23,466</span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of
$<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zXDTi6qcrZyg" title="Aggregate commitments expected">74,181</span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zRbqECELYYBc" title="Aggregate commitments expected">262,000</span> as of September 30, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zAeIbBBkFJDf" title="Non refundable license issue fee">25,000 </span>after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $<span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zApRbs2byUd6" title="Maintenance fee">25,000</span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $<span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsw53rxZnWC" title="Payment on non refundable milestone">1,897,000</span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months and nine months ended September 30, 2023, the Company recorded credits to operations of $<span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20230701__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z1CxROS0EXG1" title="Operating costs and expenses">21,507</span> and $<span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zP6QYLuaYHFl" title="Operating costs and expenses">9,109</span>, respectively,
representing the reversal of obligations previously recorded with respect to the Exclusive License Agreement. During the three months
and nine months ended September 30, 2022, the Company recorded charges to operations of $<span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20220701__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zud92GBcb3ca" title="Operating costs and expenses">6,301</span> and $<span id="xdx_903_eus-gaap--OperatingCostsAndExpenses_c20220101__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zoM6ohs9lD89" title="Operating costs and expenses">18,699</span>, respectively, in connection
with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_z1iuid16g825" title="Salary and compensation">640,000</span>, payable monthly (see Note 6). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_z5wxTcgx982k" title="Annual compensation">775,000</span>, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zTmpyXfRFWP9" title="Compensation">200,000</span>. In addition,
Mr. Forman is being provided an office allowance of approximately $<span id="xdx_906_eus-gaap--PaymentsForRent_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zW91votLSB6g" title="Paid office rent">1,500</span> per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_90C_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_zvjgBCWu3xud" title="Annual salary">150,000</span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual may be
increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors. Mr. Van der Baan was appointed as Chairman of the Board
of Directors upon the death of Dr. Kovach on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers increased to $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20230925__20230926__srt--TitleOfIndividualAxis__srt--OfficerMember_zFZep8FiVpz" title="Compensation">950,000</span>, effective September 26, 2023, which has continued through
September 30, 2023. As a result of Dr. Kovach&#8217;s death on October 5, 2023, aggregate annual compensation of all officers will decrease
to $<span id="xdx_903_eus-gaap--OfficersCompensation_c20231004__20231005__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ9d6d04Dmy" title="Compensation">700,000</span> from that date forward.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOnWrw5qnBBj" title="Consulting and advisory fee">4,000</span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOh1FdiHtaK2" title="Consulting and advisory fee">4,000</span> and $<span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYjwLAVRMBZ5" title="Consulting and advisory fee">4,000</span> for the three months
ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYuWWjqVzzG" title="Consulting and advisory fee">12,000</span> and $<span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zPkFNR1YYQSb" title="Consulting and advisory fee">12,000</span> for the nine months ended September 30, 2023 and 2022, which
were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_904_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zX0iWnt9r0Q5" title="Consulting and advisory fee">10,000</span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90F_ecustom--ReimbursementExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zElbb42jkqIj" title="Reimbursed expense">30,000</span> and $<span id="xdx_901_ecustom--ReimbursementExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zFE5UtSib4Ph" title="Reimbursed expense">30,000</span> for the three months ended September 30, 2023 and
2022, respectively, and $<span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zRzAEDgcIQ75" title="Reimbursed expense">90,000</span> and $<span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zIzXnqSxRsCd" title="Reimbursed expense">90,000</span> for the nine months ended September 30, 2023 and 2022, respectively, which were included
in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 6), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zh6xad3tqnPj" title="Aggregate commitments expected">391,000</span> Euros and
provide a sufficient supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
<span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z15qYDfwSemf" title="Aggregate commitments expected">250,000</span> Euros (approximately $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxZ7PYRN9w49" title="Aggregate commitments expected">263,000</span> at October 3, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmXXu4Il4Az8" title="Advance amount related to milestone payment">51,568</span> and $<span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zA67BibNkONf" title="Advance amount related to milestone payment">46,068</span>, respectively,
with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements
of operations. During the nine months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_900_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zjSBsGbhW3qk" title="Advance amount related to milestone payment">156,949</span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYU2SzIExbQ5" title="Advance amount related to milestone payment">149,184</span>,
respectively, with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated
statements of operations. As of September 30, 2023, total costs of $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zyfriKm30zBf" title="Research and development costs">416,356</span> have been incurred pursuant to this agreement. The Company&#8217;s
aggregate commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlVPND6Qjsql" title="Aggregate commitments expected">316,000</span> as
of September 30, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid
for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zOw1s53Hvd3b" title="Contract price">273,980</span> for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$<span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zfE3rkYMt2O9" title="Contract price">326,274</span> for services to be rendered through April 30, 2024. During the three months ended September 30, 2023 and 2022, the Company incurred
costs of $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z13A7he1ZCD9" title="Advance amount related to milestone payment">19,845</span> and $<span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbUE2GqePu4b" title="Advance amount related to milestone payment">5,549</span>, respectively, pursuant to this contract. During the nine months ended September 30, 2023 and 2022, the Company
incurred costs of $<span id="xdx_906_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zhW026YHpQrd" title="Advance amount related to milestone payment">27,028</span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zt2JVOP8CER5" title="Advance amount related to milestone payment">25,902</span>, respectively, pursuant to this work order. As of September 30, 2023, total costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zQUxCCDjlkFf" title="Research and development costs">241,841</span> have
been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_c20230930_zTuGRcM6JdCd" title="Aggregate commitments expected">84,000</span> as
of September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising efforts in the future is uncertain and
cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091886384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zXAWZTrsJx8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82E_zlSvuJduLuj7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements
with the SEC. Other than those matters described elsewhere in the footnotes, there were no material subsequent events which affected,
or could affect, the amounts or disclosures in the condensed consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090090016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_z2eti3b7lHA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z1cYKXmAmo18">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zsUiVAlVqDP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zgeelSlJlfZc">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense denominated in a foreign currency. Such cost or expense is converted into United States
dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company
purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase
of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations. As of September 30,
2023 and December 31, 2022, the Company did not hold any currencies other than the United States dollar in its bank account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWzwfpwvFc43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zGhku7413rFf">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--UseOfEstimates_zYGhTCfb0Tx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zL3s4xHNvmGj">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSoAG8Iwlnka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmYUevFxr3g8">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230930_zzVrO5ZoyS68" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_905_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230930_zs0T6H0X5Owg" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2WDGaqCYUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zqpONPVFXKPi">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PrepaidInsurancePolicyTextBlock', window );">Prepaid Insurance</a></td>
<td class="text"><p id="xdx_843_ecustom--PrepaidInsurancePolicyTextBlock_zI8WxieDP9T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_znLMoh1EJMVc">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zajv7XUxgz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwxMXWdWwNmf">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230701__20230930_zLzVVea1Id54">178,012</span> and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220701__20220930_zzVJ8sD3ciy8">271,163</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20230101__20230930_zwRoGlqq5qKg">835,362 </span>and $<span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20220101__20220930_zGZuG1zKNcy8">944,789</span>
for the nine months ended September 30, 2023 and 2022, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6qs5gImq235" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zwN75KICZ743">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zSIu73Xo3yge" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgxsksCwncR2" title="Concentration of risk, percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE1JebAMNyQ7" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztsybRVNETe3" title="Concentration of risk, percentage">10</span></span></span></span>% or more of general and administrative costs or research and development costs for the three months and nine months
ended September 30, 2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended September 30, 2023 and 2022 included charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWabCorlhdT6" title="Concentration risk percentage">20.0</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEz1rVlkt6z1" title="Concentration of risk, percentage">22.5</span>% of
total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2023
and 2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z5BMLGPUFem" title="Concentration of risk, percentage">12.6</span>% and
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zpVWgiFEylqb" title="Concentration of risk, percentage">32.9</span>%, respectively, of total general and administrative costs. General and administrative costs for the three months ended September
30, 2023 also included charges from two vendors representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zVWHsjU8QUo8" title="Concentration of risk, percentage">11.9</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zWLC2BdhvGA2" title="Concentration of risk, percentage">10.6</span>%, respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended September 30, 2023 included charges from four vendors and consultants representing <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLh24gMc58ta" title="Concentration of risk, percentage">38.9</span>%,
<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgPU1rru6XKc" title="Concentration of risk, percentage">24.9</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zovs1r0vOTTh" title="Concentration of risk, percentage">15.9</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zbeSvniRKGf2" title="Concentration of risk, percentage">14.9</span>%, respectively, of total research and development costs. Research and development costs for the three months ended
September 30, 2022 include charges from four vendors and consultants representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4FV76f6LBx3" title="Concentration of risk, percentage">32.0</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5NlA7ZRYwlb" title="Concentration of risk, percentage">23.2</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze6F9qyZMwA6" title="Concentration of risk, percentage">16.9</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7foDi94gOH2" title="Concentration of risk, percentage">11.0</span>%, respectively, of total
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the nine months ended September 30, 2023 and 2022 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsFHITlsxmP7" title="Concentration risk percentage">25.2</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJhUDYmnON21" title="Concentration of risk, percentage">25.0</span>% of
total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2023 and
2022 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zxaPfYTaCZ2g" title="Concentration of risk, percentage">20.2</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zh85uOaSUJHc" title="Concentration of risk, percentage">30.7</span>%,
respectively, of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zANX9VkcZwbc" title="Concentration of risk, percentage">35.9</span>%,
<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1oh68qZT2Pj" title="Concentration of risk, percentage">21.0</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z90sPG8XIzll" title="Concentration of risk, percentage">12.4</span>%, respectively, of total research and development costs. Research and development costs for the nine months ended September
30, 2022 include charges from three vendors and consultants representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz5Uc8IabDkj" title="Concentration of risk, percentage">31.0</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zidbKL6e9gZh" title="Concentration of risk, percentage">16.7</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zMKkchs4NhHf" title="Concentration of risk, percentage">10.0</span>%, respectively, of total research and
development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zziQ71bS1YUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaEsmGGKefQ1">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of September 30, 2023 or
December 31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2023 or December
31, 2022. Subsequent to September 30, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7FnXFc6LX6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_znKG4J2eNzWl">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash
for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_841_ecustom--WarrantsPolicyTextBlock_zkM34u8aIrf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5AI7k5nQ0qb">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480,
Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 5)
meet the requirements for equity classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zK6hNr4oWbFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_ztxdQ1PgXS5g">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2XT2q3Vedm7" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,556,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">745,448</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z2KMGOqhgLY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zUuzLaadsK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z9fPxBAs9CCa">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zruReJoFaQ4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zOp60YNQ3pK">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting
Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212;
Stock Compensation (Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB
Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC
Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280
&#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new
guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03
immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial
statement presentation or related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PrepaidInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Insurance [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PrepaidInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091843072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2XT2q3Vedm7" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,556,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">745,448</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091851744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchDevelopmentTableTextBlock', window );">Schedule of Research and Development Costs</a></td>
<td class="text"><p id="xdx_894_ecustom--ResearchDevelopmentTableTextBlock_zrcsjMtV2fXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated
with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical
regions where such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zqLHcZFdzSM1" style="display: none">Schedule
of Research and Development Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20230930_zDf90xcyndd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220701__20220930_zyM03hvMlOoh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930_zgJohYyjc56h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220930_zZzDEHQsVGT9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_z4XvV3CYrPli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">161,744</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">291,846</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">316,565</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_z26fC9u1fpM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,850</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zCxObD6nrZf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,050</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zsPXl1vtkSM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Netherlands</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">156,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">149,184</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zglxOoL5IBL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">749,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">895,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_z3zd7m1rEQN8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expense</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">749,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">895,649</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and developement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091902192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhHFKCNEJo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the nine months ended September 30, 2023, excluding the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6kO1BxglUn3" title="Warrants to purchase shares">403,334</span> pre-funded warrants,
exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePO4syuM9ra" title="Common stock, par or stated value per share">0.0001</span> per common share, to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTPSlCjBRr9" title="Warrants to purchase shares">403,334</span> shares of common stock described above, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zC8PkhwyBa0i" style="display: none">Schedule of Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTWGXOVzX9ja" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb805odK5IS2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0ZP2vMYjG3j" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKfJ7FaYHen8" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLlRcrdfaY9h" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztbqlLNImt76" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5mOK4pPyyS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0kqxgwjAGn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0829">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwpfFTAA1YE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK3fWOMCO5ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN2ejtbtuaL8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">4.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7uclRtbEc5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance">190,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBrpG9xzXPT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">50.161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhcNZbWrYLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcHvkMxTNhee" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgTYyU7QM2G9" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">4.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zztBqUPLK7rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zaLZorDpdJu5" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zltTwPRuv1ok" title="Exercise Prices">6.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhuVdovBn5B2" style="width: 47%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z55dmao6Mka" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZLhk6etfMUg" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWDwDBwvcVfk" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zj7d2Ceu95nb" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqTRr9U7PTbc" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXl7zLlzOVyl" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHAi6xf6gxG" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdJKWyt0dQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930_zmjOH53BqWod" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091440288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Related Party Costs</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zkNzOsV5Ft1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zCumS3XlPEW4" style="display: none">Summary of Related Party Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230701__20230930_zXtPzbawr8W4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_zlkUFkvHMQc9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zF5Qrmn4YUg9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20220930_zhOyWuLBgWH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdTYXtsXSyPe" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">243,895</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">247,074</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">728,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">802,760</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockBasedMember_zHoTcCa8zH34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">396,883</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669,146</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zzkQX8iRRvwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">643,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,398,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,963,409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_zlpCe759Ssqb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related
    party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">643,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,398,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,963,409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090408928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Award Estimated Assumption</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXtUFyzGcPW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zfgpbDyRkv44" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930_zUwF11wlHIdl" title="Risk-free interest rate">4.843</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930_zlhGen2z87db" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930_zFXJ0JmdW6xf" title="Expected volatility">138.05</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zFiz9nGu1nl2" title="Expected life">4.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the nine months ended September 30, 2022, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220930_zDSXZcdldCtg" title="Risk-free interest rate">3.03</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220930_zJe73ve7yIY1" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20220930_zNEfvh7lXCuk" title="Expected volatility">198.79</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zisZAepBOJa3" title="Expected life">3.6</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summmary of Stock-based Compensation Costs</a></td>
<td class="text"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zauCGEf9gBz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zs8KYHunmwUi" style="display: none">Summmary of Stock-based Compensation Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_zKvXYW25Doji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20220930_zkWi7ODwOsjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230930_zihVRu0M1BH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_zEeAqz8dy69g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zUsTG6NOBHNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">112,106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">396,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">669,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,160,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zIJ2IPZInf8k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zIGnguhXuLo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">396,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,160,649</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuOnmgRxuN4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2023 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zmI7aGeU55G8" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230930_zdbiTnSA2AOa" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zv4loaOvqwRe" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.1826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230930_ztQZycVN4PJi" style="text-align: right" title="Number of shares, Granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zEN3kaotjXE7" style="text-align: right" title="Weighted average exercise price, granted">2.4920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zgMvMYCbSQwh" style="text-align: right" title="Number of shares, Exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zHiQcLuvFmxd" style="text-align: right" title="Weighted average exercise price, exercised">5.0250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20230930_z0fOeCCEjqId" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired">(3,333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zeZmYLVRqwHc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">16.800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230930_z5Cdd26ERkNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">674,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z8ZFkZGA4aMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">17.8197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zWo2Yt9dEkJ2" title="Weighted average remaining contractual life (in years), stock options outstanding">4.96</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCVOhAWDILi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">281,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_zRNdZtWFjbzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">32.8335</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230930_zQV7tfaxceda" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">313,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zCOZ3jvLSAq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">31.8997</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z02bkROQC2Yh" title="Weighted average remaining contractual life (in years), stock options exercisable">1.93</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFHv7Nv5V2Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at September 30,
2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zc5BLjyk8Fm5" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BJvZTwvRMg" style="width: 30%; text-align: right" title="Exercise Prices">1.950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z4S0dDRoDK1g" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHlyPPzmVB49" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zW1Kv318YTAh" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znu0bafyQqw3" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1Y14Wvktsi9" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuOTbR14jGd9" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWArKZ3eUtzc" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFSENW3isqle" style="text-align: right" title="Options Exercisable (Shares)">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z049sE32KZX2" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3EzQLjoLWOh" style="text-align: right" title="Options Outstanding (Shares)">57,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zp4a3Cw0vm25" style="text-align: right" title="Options Exercisable (Shares)">41,563</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTNu4lOz3Elb" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zXo88duZ95B7" style="text-align: right" title="Options Outstanding (Shares)">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zznhSdtALEUa" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z2hJmRZJRvFj" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z5xoRZDMsLhb" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zG76ifye7pta" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zKangMbgi1x1" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNye65ckqlFe" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxIdreuF6F5k" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPjBV5zSIX7a" style="text-align: right" title="Exercise Prices">30.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zUoaqshFf6ka" style="text-align: right" title="Options Outstanding (Shares)">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNMHKGC96GY7" style="text-align: right" title="Options Exercisable (Shares)">66,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBgF0BrNcB9a" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLWvZvmQN0x7" style="text-align: right" title="Options Outstanding (Shares)">42,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEHI544hTjvc" style="text-align: right" title="Options Exercisable (Shares)">42,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMDm870ZUGb" style="text-align: right" title="Exercise Prices">32.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zd9Wnw0jSHT4" style="text-align: right" title="Options Outstanding (Shares)">20,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zg0WYkhCZHm2" style="text-align: right" title="Options Exercisable (Shares)">20,313</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrOOC4yPft16" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKfJ7QtIVlt4" style="text-align: right" title="Options Outstanding (Shares)">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRYHIY9mZlTl" style="text-align: right" title="Options Exercisable (Shares)">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zEN0rhxarIyk" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z9XPMuwqGXS9" style="text-align: right" title="Options Outstanding (Shares)">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zzEwYECZuTka" style="text-align: right" title="Options Exercisable (Shares)">16,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zYYI4ksHWSob" style="text-align: right" title="Exercise Prices">66.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwiJF2VE8qVh" style="text-align: right" title="Options Outstanding (Shares)">4,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRRzSGEUeHja" style="text-align: right" title="Options Exercisable (Shares)">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zYWnEYkDJsS5" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zEjNksFoRbIf" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zragodmNuVIl" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zy9cC17TEx4i" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgCKLz4dA9Xg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">8,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zt5zKAuuQKVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">8,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930_zlYWcK0ee0pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">674,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930_z3NySbFeQmuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">313,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091815888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Clinical Trials</a></td>
<td class="text"><p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzoVUGimRbHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_z1xWwPGQoxDa" style="display: none">Schedule
of Contractual Clinical Trials</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Institution</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
                                            Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            End Date</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
                                            Objective</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
                                            Update</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NCT
                                            No.</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zMweHho9w3cb" title="Clinical trial, description">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Phase 1b</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: left">City of Hope and Sarah Cannon</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zkGYUKP3Zfqh" title="Estimated Start Date">March 2021</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zbwDDMA9u5Z9" title="Estimated End Date">March 2026</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%; text-align: center"><span id="xdx_90C_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zxabq7ZIrDjj" title="Number of Patients in Trial">14</span> to <span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zWO4jNr1shBd" title="Number of Patients in Trial">36</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Determine RP2D</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">Three patients entered</td><td style="width: 2%">&#160;</td>
    <td style="width: 9%">NCT04560972</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90D_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z6UaZC3NQEje" title="Clinical trial, description">LB-100 combined with doxorubicin in sarcoma</span></td><td>&#160;</td>
    <td>Phase 1b</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zwtlNZQEM8ij" title="Estimated Start Date">June 2023</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zXCiV4a8eJff" title="Estimated End Date">June 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zq7hEVY7iX0k" title="Number of Patients in Trial">9</span> to <span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zYEZiX3WVhxf" title="Number of Patients in Trial">18</span></td><td>&#160;</td>
    <td style="text-align: left">Determine MTD and RP2D</td><td>&#160;</td>
    <td style="text-align: left">One patient entered</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zv0hojwaMeRj" title="Clinical trial, description">Doxorubicin with or without LB-100 in sarcoma</span></td><td>&#160;</td>
    <td style="text-align: left">Randomized Phase 2</td><td>&#160;</td>
    <td>GEIS</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zXtpTMghuJG" title="Estimated Start Date">July 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zExmr02ZwFBj" title="Estimated End Date">June 2026</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zagZZ9zMCkSj" title="Number of Patients in Trial">150</span></td><td>&#160;</td>
    <td style="text-align: left">Determine efficacy: PFS</td><td>&#160;</td>
    <td style="text-align: left">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</td><td>&#160;</td>
    <td style="text-align: justify">NCT05809830</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_908_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zzOUOeN7Pu8c" title="Description of Clinical Trial">LB-100 combined with dostarlimab in ovarian clear cell carcinoma</span></td><td>&#160;</td>
    <td>Phase 1b/2</td><td>&#160;</td>
    <td style="text-align: left">MD Anderson</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zJVMhpxLYtJ6" title="Estimated Start Date">March 2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_z2sBINvnUAuc" title="Estimated End Date">December 2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zqj4ttmOLVN9" title="Number of Patients in Trial">21</span></td><td>&#160;</td>
    <td style="text-align: left">Determine the survival of patients with ovarian clear cell carcinoma</td><td>&#160;</td>
    <td style="text-align: left">No patients entered at September 30, 2023</td><td>&#160;</td>
    <td style="text-align: justify">NCT06065462</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091777808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative)<br></strong></div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734090539648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 1,018,760<span></span>
</td>
<td class="nump">$ 1,478,009<span></span>
</td>
<td class="nump">$ 4,054,774<span></span>
</td>
<td class="nump">$ 4,681,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,391,142<span></span>
</td>
<td class="nump">$ 3,403,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">5,105,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,105,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="nump">$ 6,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091279728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,556,178<span></span>
</td>
<td class="nump">745,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">340,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">674,896<span></span>
</td>
<td class="nump">332,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734085588864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashSIPCInsuredAmount', window );">Cash SIPC insurance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">$ 178,012<span></span>
</td>
<td class="nump">$ 271,163<span></span>
</td>
<td class="nump">$ 835,362<span></span>
</td>
<td class="nump">$ 944,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Vendor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Vendor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Stock Options Granted to Directors and Corporate Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">32.90%<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">30.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">35.90%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">23.20%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="nump">16.90%<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor and Consultant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash SIPC insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734085692560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 132,487<span></span>
</td>
<td class="nump">$ 272,388<span></span>
</td>
<td class="nump">$ 749,029<span></span>
</td>
<td class="nump">$ 895,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">68,315<span></span>
</td>
<td class="nump">161,744<span></span>
</td>
<td class="nump">291,846<span></span>
</td>
<td class="nump">316,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">9,496<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">283,035<span></span>
</td>
<td class="nump">348,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">3,108<span></span>
</td>
<td class="nump">63,330<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
<td class="nump">81,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 51,568<span></span>
</td>
<td class="nump">$ 46,068<span></span>
</td>
<td class="nump">$ 156,950<span></span>
</td>
<td class="nump">$ 149,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734085522400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding (Details) - Common Stock Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">190,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare', window );">Weighted Average Exercise Price, Warrants Outstanding, Beginning</a></td>
<td class="nump">$ 50.161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Issued</a></td>
<td class="nump">618,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">$ 6.034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Outstanding</a></td>
<td class="text">4 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants exercisable, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">190,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants exercisable, Beginning Balance</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 50.161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Exercisable</a></td>
<td class="text">4 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734085526928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">583,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 37.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">11,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 57.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">149,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734083738432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">96 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="nump">$ 5,141,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember', window );">Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable', window );">Warrant expires term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,141,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember', window );">Common Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend', window );">Principal cash obligations and commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares', window );">Annual net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net revenue divided by converted or redeemed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst term from which warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share tranche of the series a convertible preferred stock receive a per share dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734083643296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Related Party Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">$ 356,001<span></span>
</td>
<td class="nump">$ 643,957<span></span>
</td>
<td class="nump">$ 1,398,042<span></span>
</td>
<td class="nump">$ 1,963,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">243,895<span></span>
</td>
<td class="nump">247,074<span></span>
</td>
<td class="nump">728,896<span></span>
</td>
<td class="nump">802,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_StockBasedMember', window );">Stock Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">$ 112,106<span></span>
</td>
<td class="nump">$ 396,883<span></span>
</td>
<td class="nump">$ 669,146<span></span>
</td>
<td class="nump">$ 1,160,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_StockBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_StockBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734084295280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash board fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ManagementFeePayableQuarterly', window );">Cash board fee payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,001<span></span>
</td>
<td class="nump">$ 643,957<span></span>
</td>
<td class="nump">$ 1,398,042<span></span>
</td>
<td class="nump">$ 1,963,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,106<span></span>
</td>
<td class="nump">396,883<span></span>
</td>
<td class="nump">669,146<span></span>
</td>
<td class="nump">1,160,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,895<span></span>
</td>
<td class="nump">247,074<span></span>
</td>
<td class="nump">728,896<span></span>
</td>
<td class="nump">802,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember', window );">Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,228<span></span>
</td>
<td class="nump">53,324<span></span>
</td>
<td class="nump">$ 127,229<span></span>
</td>
<td class="nump">221,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FormanMember', window );">Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,916<span></span>
</td>
<td class="nump">39,860<span></span>
</td>
<td class="nump">70,965<span></span>
</td>
<td class="nump">39,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember', window );">Chairman of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember', window );">Chairman of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember', window );">Member of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember', window );">Member of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. James S. Miser, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">$ 43,750<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="nump">$ 131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Mr Vander Baan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ManagementFeePayableQuarterly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee payable quarterly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ManagementFeePayableQuarterly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee payable for management of fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrKovachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrKovachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MrVanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MrVanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734089644992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.843%<span></span>
</td>
<td class="nump">3.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">138.05%<span></span>
</td>
<td class="nump">198.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091192656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summmary of Stock-based Compensation Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 112,106<span></span>
</td>
<td class="nump">$ 396,883<span></span>
</td>
<td class="nump">$ 669,146<span></span>
</td>
<td class="nump">$ 1,160,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember', window );">Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="nump">112,106<span></span>
</td>
<td class="nump">396,883<span></span>
</td>
<td class="nump">669,146<span></span>
</td>
<td class="nump">1,160,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember', window );">Non Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734091311648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity Including Options Form of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the beginning</a></td>
<td class="nump">389,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the beginning</a></td>
<td class="nump">$ 29.1826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.4920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 5.0250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, Expired</a></td>
<td class="num">(3,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 16.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end</a></td>
<td class="nump">674,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the end</a></td>
<td class="nump">$ 17.8197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), stock options outstanding</a></td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, stock options exercisable, at the end</a></td>
<td class="nump">313,959<span></span>
</td>
<td class="nump">281,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable, at the end</a></td>
<td class="nump">$ 31.8997<span></span>
</td>
<td class="nump">$ 32.8335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">1 year 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734085485616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">674,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">313,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 7.400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">57,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">41,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 28.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 30.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">66,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">66,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 30.300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">42,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">42,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 32.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 32.100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 60.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember', window );">ExercisePriceThirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 66.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember', window );">Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 71.400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember', window );">Exercise Price Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 120.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734072119360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,106<span></span>
</td>
<td class="nump">$ 396,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669,146<span></span>
</td>
<td class="nump">$ 1,160,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Total deferred compensation expense for outstanding value of unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 808,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding stock options to acquire shares of common stock not vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $7.40 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($6.334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $23,916 and $39,860 for
the three months ended September 30, 2023 and 2022, respectively, and $70,965 and $39,860 for the nine months ended September 30, 2023
and 2022, respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 6.334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,916<span></span>
</td>
<td class="nump">39,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,965<span></span>
</td>
<td class="nump">39,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember', window );">Five Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of
Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000
shares (a total of 50,000
shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $30.30 per share (the
closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $1,421,095
($28.423
per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $0
and $179,100
for the three months ended September 30, 2023 and 2022, respectively, and $211,412
and $531,455
for the nine months ended September 30, 2023 and 2022, respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,700<span></span>
</td>
<td class="nump">$ 1,421,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,412<span></span>
</td>
<td class="nump">531,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember', window );">Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share),
of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $9,801 and $9,801 for the three months ended September 30, 2023 and 2022, respectively, and $29,084 and $90,449 for the nine months
ended September 30, 2023 and 2022, respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,801<span></span>
</td>
<td class="nump">9,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,084<span></span>
</td>
<td class="nump">90,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember', window );">Four Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage', window );">Share based compensation issuance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficersMember', window );">Four Non Officers[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase 5,833 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $11,806 and $25,259 for the three
months ended September 30, 2023 and 2022, respectively, and $61,501 and $74,954 for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,806<span></span>
</td>
<td class="nump">25,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501<span></span>
</td>
<td class="nump">74,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember', window );">Dr. James Miser [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase 8,333 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $572,650 ($68.718 per share), of which $143,163 was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $12,551 and $36,085 for the three
months ended September 30, 2023 and 2022, respectively, and $83,544 and $107,078 for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,551<span></span>
</td>
<td class="nump">36,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,544<span></span>
</td>
<td class="nump">107,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase 5,833 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $11,806 and $25,259 for the three months ended September 30,
2023 and 2022, respectively, and $61,501 and $74,954 for the nine months ended September 30, 2023 and 2022, respectively, with respect
to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,806<span></span>
</td>
<td class="nump">25,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501<span></span>
</td>
<td class="nump">74,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember', window );">Mr Schwartberg [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 25,000 shares of the Company&#8217;s
common stock, exercisable for a period of five years at an exercise price of $32.00 per share (the closing market price on the grant
date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $753,611 ($30.144 per share), of which $376,800 was attributable to the portion of the stock options fully
vested on April 9, 2021 and was therefore charged to operations on that date. Although the remaining unvested portion of the fair value
of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options
terminated on October 30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $42,692 and $126,684 for the three months and nine months ended September
30, 2022, respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 753,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember', window );">Ms.Regina Brown [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($26.335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. The Company recorded charges to general and administrative costs in the consolidated statement of
operations of $0 and $38,827 for the three months ended September 30, 2023 and 2022, respectively, and $76,388 and $115,215 for the nine
months ended September 30, 2023 and 2022, respectively, with respect to these stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 658,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 38,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,388<span></span>
</td>
<td class="nump">$ 115,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember', window );">Mr Vander Baan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares avaliable for issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares avaliable for issuable</a></td>
<td class="nump">336,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="nump">550,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were available for issuance</a></td>
<td class="nump">199,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_FairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_FairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734187792992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Contractual Clinical Trials (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>Integer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Description of Clinical Trial</a></td>
<td class="text">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">March 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">March 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Description of Clinical Trial</a></td>
<td class="text">LB-100 combined with doxorubicin in sarcoma<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">June 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">June 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember', window );">Randomized Phase 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Description of Clinical Trial</a></td>
<td class="text">Doxorubicin with or without LB-100 in sarcoma<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">July 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">June 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1b2Member', window );">Clinical Trial Phase 1b 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Description of Clinical Trial</a></td>
<td class="text">LB-100 combined with dostarlimab in ovarian clear cell carcinoma<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">March 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClinicalTrialDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClinicalTrialDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period end date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfPatientInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patient in trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfPatientInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139734070352656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,262,000<span></span>
</td>
<td class="nump">$ 6,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,487<span></span>
</td>
<td class="nump">$ 272,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,029<span></span>
</td>
<td class="nump">$ 895,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FormanMember', window );">Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member] | Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember', window );">City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,181<span></span>
</td>
<td class="nump">74,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember', window );">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember', window );">GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AmountRelatedToMilestonePayment', window );">Amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember', window );">NDA Consulting Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember', window );">Clinical Trial Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development process costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember', window );">Other Clinical Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,423,000<span></span>
</td>
<td class="nump">3,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ReimbursementExpense', window );">Reimbursed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,000<span></span>
</td>
<td class="nump">2,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,512<span></span>
</td>
<td class="nump">447,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">7,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,740<span></span>
</td>
<td class="nump">23,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EstimatedWorkCost', window );">Work cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentinServices', window );">Percentage of payment through services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentThroughSoftware', window );">Percentage of payment through software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">11,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,850<span></span>
</td>
<td class="nump">19,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NonRefundableLicenseIssueFee', window );">Non refundable license issue fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualLicenseMaintenanceFee', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PaymentsOnNonrefundableMilestone', window );">Payment on non refundable milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,507<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,109<span></span>
</td>
<td class="nump">18,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Bastiaan van der Baan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,000<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 391,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,568<span></span>
</td>
<td class="nump">46,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,949<span></span>
</td>
<td class="nump">149,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="nump">&#8364; 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember', window );">MRI Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,845<span></span>
</td>
<td class="nump">$ 5,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,028<span></span>
</td>
<td class="nump">$ 25,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractPrice', window );">Contract price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvanceAmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvanceAmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConsultingAndAdvisoryCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory quarterly cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConsultingAndAdvisoryCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EstimatedWorkCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated work cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EstimatedWorkCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentThroughSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected paymen through software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentThroughSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentinServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected payment in services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentinServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NonRefundableLicenseIssueFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay non refundable license issue fee..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NonRefundableLicenseIssueFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PaymentsOnNonrefundableMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PaymentsOnNonrefundableMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20230930"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lixt-20230930.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorOneMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorTwoMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-17</instant>
        </period>
    </context>
    <context id="From2015-03-162023-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-16</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="AsOf2022-04-12_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_NewIndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-27</instant>
        </period>
    </context>
    <context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-26</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-07_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_NonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-06-282022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-28</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_srt_DirectorMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2022-11-06_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="From2023-06-292023-06-30_custom_FourNonOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_FourNonOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_FourNonOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_FourNonOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="AsOf2023-06-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-302023-09-30_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_OtherClinicalAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:OtherClinicalAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_WorkOrderAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-18</startDate>
            <endDate>2018-08-20</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:Dr.JamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BastiaanVanDerBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-10-042023-10-05_srt_OfficerMember_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-23</startDate>
            <endDate>2013-12-24</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-12</startDate>
            <endDate>2015-09-14</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-10</endDate>
        </period>
    </context>
    <context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-15</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Integer">
        <measure>LIXT:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-09-30">0001335105</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      id="xdx2ixbrl0823"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      id="xdx2ixbrl0825"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      id="xdx2ixbrl0827"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      id="xdx2ixbrl0829"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl1274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl1275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl1277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember"
      id="xdx2ixbrl1328"
      unitRef="Shares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-09-30">001-39717</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-09-30">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-09-30">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-09-30">680 East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-09-30">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-09-30">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-09-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-09-30">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-09-30">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30">830-7092</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-09-30_custom_CommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-06" decimals="INF" unitRef="Shares">2249290</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5105611</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5353392</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">78015</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">147017</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:PrepaidInsurance contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">23230</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">49224</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">27840</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10380</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5234696</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5234696</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">43895</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">46982</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">221171</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">229764</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">90565</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">165022</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">311736</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">394786</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1664706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1664706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">225</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">166</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">48872208</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">45059760</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-47449473</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-43394699</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4922960</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5234696</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">112106</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">396883</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">669146</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1160649</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">356001</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">643957</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1398042</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1963409</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">178012</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">271163</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">835362</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">944789</us-gaap:LegalFees>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">357681</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">290993</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1081893</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">875016</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">132487</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">272388</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">749029</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">895649</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">1024181</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">1478501</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">4064326</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">4678863</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1024181</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-1478501</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-4064326</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4678863</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">5809</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">3911</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">13538</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">4211</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">279</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">2119</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6088</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">5240</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-109</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-1300</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">2102</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-1339</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1018760</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-1478009</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-4054774</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4681231</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-2.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-2.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-3.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-3.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">2074938</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">2074938</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">1664659</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">1664659</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1803466</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1803466</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">1554183</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">1554183</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1665956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45623081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-46430713</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">2692534</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3137021</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">3137039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">112106</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">112106</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1018760</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1018760</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">48872208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-47449473</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4922960</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1664706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45059760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-43394699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3137021</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">3137039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">669146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">669146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4054774</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-4054774</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">48872208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-47449473</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4922960</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1664593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">44277486</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-40285386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7492266</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">396883</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">396883</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1478009</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-1478009</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1664593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">44674369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-41763395</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6411140</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1374593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38372365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37082164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4790338</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1374593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38372365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37082164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4790338</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">29</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5141355</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">5141384</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1160649</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1160649</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4681231</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4681231</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1664593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">44674369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-41763395</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6411140</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1664593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">44674369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-41763395</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6411140</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-4054774</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4681231</us-gaap:NetIncomeLoss>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">669146</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1160649</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-69002</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-3224</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-25994</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-22375</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">17460</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">13708</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-8593</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">81433</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-74457</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">23969</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-3391142</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-3403289</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">3137039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">5141384</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">41</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6281</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">3143361</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">5141384</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-247781</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1738095</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5353392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4823745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5105611</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6561840</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6088</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">5240</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zoUNYkcAGija" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_827_zYhBMmcl4Du5"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#x201c;Company&#x201d;), at September 30, 2023, and for the three months
and nine months ended September 30, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including
normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of September
30, 2023, and the results of its operations for the three months and nine months ended September 30, 2023 and 2022, and its cash flows
for the nine months ended September 30, 2023 and 2022. Operating results for the interim periods presented are not necessarily indicative
of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#x2019;s
audited consolidated financial statements at such date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;President
and Chief Executive Officer&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 26, 2023, Bas van der Baan was appointed as the Company&#x2019;s President and Chief Executive Officer, at which time he replaced
Dr. John S. Kovach as the Company&#x2019;s President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE1TzfK1NL9i" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Listing &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#x201c;LIXT&#x201d; and &#x201c;LIXTW&#x201d;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to achieve compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market, the Company held a special
meeting of stockholders on May 26, 2023 to seek approval for an amendment to the Company&#x2019;s Certificate of Incorporation to effect
a reverse stock split of its issued and outstanding shares of common stock. As a result of the approval of this amendment, the Company
effected a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z02S4g9t2jY3" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. Commencing with
the opening of trading on the Nasdaq Capital Market on Monday, June 5, 2023, the Company&#x2019;s common stock began trading on a post-split
basis under the same symbol LIXT. The Company subsequently received confirmation from Nasdaq that it had regained compliance with the
minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria
for continued listing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum bid price requirement over time,
or that it will be successful in maintaining compliance with any of the other Nasdaq continued listing requirements.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80B_eus-gaap--NatureOfOperations_z9OGZ05Ow1c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_82E_zyfvEivLRqCd"&gt;Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a drug research company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#x2019;s corporate office is located in Pasadena, California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
reflected in the accompanying financial statements, for the nine months ended September 30, 2023, the Company recorded a net loss of
$&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930_zp7FFVQsogdk"&gt;4,054,774&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
used cash in operations of $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230930_zbOVMBwcis9"&gt;3,391,142&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
At September 30, 2023, the Company had cash of $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230930_zcCr2UZflSJk"&gt;5,105,611
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;available to fund its operations. Because the
Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time and
resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#x2019;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At September 30, 2023, the Company&#x2019;s
remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated
approximately $&lt;span id="xdx_903_eus-gaap--ContractualObligation_iI_pp0p0_c20230930_zsauRVl4oQ5g"&gt;6,262,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(see
Note 9), which are currently scheduled to be incurred through approximately December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#x2019;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#x2019;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on current operating plans, the Company estimates that its existing cash resources at September 30, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#x2019;s lead anti-cancer clinical compound
LB-100 through at least September 30, 2024. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#x2019;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able
to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#x2019;s operating
plans may change as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional
funds may be needed sooner than planned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
market conditions present uncertainty as to the Company&#x2019;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
cash resources are insufficient to satisfy the Company&#x2019;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-4054774</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-3391142</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">5105611</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ContractualObligation contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">6262000</us-gaap:ContractualObligation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zhCCLzEw3wsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82B_ztDvgeDNAQcd"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_z2eti3b7lHA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z1cYKXmAmo18"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zsUiVAlVqDP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zgeelSlJlfZc"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense denominated in a foreign currency. Such cost or expense is converted into United States
dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company
purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase
of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations. As of September 30,
2023 and December 31, 2022, the Company did not hold any currencies other than the United States dollar in its bank account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWzwfpwvFc43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zGhku7413rFf"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#x2019;s Chief Operating Decision Maker, which is the Company&#x2019;s
President and Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zYGhTCfb0Tx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zL3s4xHNvmGj"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSoAG8Iwlnka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zmYUevFxr3g8"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230930_zzVrO5ZoyS68" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230930_zs0T6H0X5Owg" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2WDGaqCYUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zqpONPVFXKPi"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--PrepaidInsurancePolicyTextBlock_zI8WxieDP9T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_znLMoh1EJMVc"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zajv7XUxgz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwxMXWdWwNmf"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230701__20230930_zLzVVea1Id54"&gt;178,012&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220701__20220930_zzVJ8sD3ciy8"&gt;271,163&lt;/span&gt; for the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20230101__20230930_zwRoGlqq5qKg"&gt;835,362 &lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20220101__20220930_zGZuG1zKNcy8"&gt;944,789&lt;/span&gt;
for the nine months ended September 30, 2023 and 2022, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6qs5gImq235" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zwN75KICZ743"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zSIu73Xo3yge" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgxsksCwncR2" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE1JebAMNyQ7" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztsybRVNETe3" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months and nine months
ended September 30, 2023 and 2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended September 30, 2023 and 2022 included charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWabCorlhdT6" title="Concentration risk percentage"&gt;20.0&lt;/span&gt;% and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEz1rVlkt6z1" title="Concentration of risk, percentage"&gt;22.5&lt;/span&gt;% of
total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2023
and 2022 also included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z5BMLGPUFem" title="Concentration of risk, percentage"&gt;12.6&lt;/span&gt;% and
&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zpVWgiFEylqb" title="Concentration of risk, percentage"&gt;32.9&lt;/span&gt;%, respectively, of total general and administrative costs. General and administrative costs for the three months ended September
30, 2023 also included charges from two vendors representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zVWHsjU8QUo8" title="Concentration of risk, percentage"&gt;11.9&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zWLC2BdhvGA2" title="Concentration of risk, percentage"&gt;10.6&lt;/span&gt;%, respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended September 30, 2023 included charges from four vendors and consultants representing &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLh24gMc58ta" title="Concentration of risk, percentage"&gt;38.9&lt;/span&gt;%,
&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgPU1rru6XKc" title="Concentration of risk, percentage"&gt;24.9&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zovs1r0vOTTh" title="Concentration of risk, percentage"&gt;15.9&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zbeSvniRKGf2" title="Concentration of risk, percentage"&gt;14.9&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the three months ended
September 30, 2022 include charges from four vendors and consultants representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4FV76f6LBx3" title="Concentration of risk, percentage"&gt;32.0&lt;/span&gt;%, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5NlA7ZRYwlb" title="Concentration of risk, percentage"&gt;23.2&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze6F9qyZMwA6" title="Concentration of risk, percentage"&gt;16.9&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7foDi94gOH2" title="Concentration of risk, percentage"&gt;11.0&lt;/span&gt;%, respectively, of total
research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the nine months ended September 30, 2023 and 2022 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsFHITlsxmP7" title="Concentration risk percentage"&gt;25.2&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJhUDYmnON21" title="Concentration of risk, percentage"&gt;25.0&lt;/span&gt;% of
total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2023 and
2022 also included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zxaPfYTaCZ2g" title="Concentration of risk, percentage"&gt;20.2&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zh85uOaSUJHc" title="Concentration of risk, percentage"&gt;30.7&lt;/span&gt;%,
respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zANX9VkcZwbc" title="Concentration of risk, percentage"&gt;35.9&lt;/span&gt;%,
&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1oh68qZT2Pj" title="Concentration of risk, percentage"&gt;21.0&lt;/span&gt;% and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z90sPG8XIzll" title="Concentration of risk, percentage"&gt;12.4&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the nine months ended September
30, 2022 include charges from three vendors and consultants representing &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz5Uc8IabDkj" title="Concentration of risk, percentage"&gt;31.0&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zidbKL6e9gZh" title="Concentration of risk, percentage"&gt;16.7&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zMKkchs4NhHf" title="Concentration of risk, percentage"&gt;10.0&lt;/span&gt;%, respectively, of total research and
development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zziQ71bS1YUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaEsmGGKefQ1"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of September 30, 2023 or
December 31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2023 or December
31, 2022. Subsequent to September 30, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7FnXFc6LX6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_znKG4J2eNzWl"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting period
of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash
for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--WarrantsPolicyTextBlock_zkM34u8aIrf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z5AI7k5nQ0qb"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480,
Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 5)
meet the requirements for equity classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zK6hNr4oWbFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_ztxdQ1PgXS5g"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z2XT2q3Vedm7" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,556,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;745,448&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z2KMGOqhgLY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zUuzLaadsK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z9fPxBAs9CCa"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zruReJoFaQ4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zOp60YNQ3pK"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statement presentation or related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting
Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014;
Stock Compensation (Topic 718) Presentation of Financial Statements (&#x201c;ASU 2023-03&#x201d;). ASU 2023-03 amends the FASB
Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC
Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280
&#x2014; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new
guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03
immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company&#x2019;s consolidated financial
statement presentation or related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85E_zAgxAESh4uPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_z2eti3b7lHA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z1cYKXmAmo18"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zsUiVAlVqDP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zgeelSlJlfZc"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense denominated in a foreign currency. Such cost or expense is converted into United States
dollars for financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company
purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase
of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations. As of September 30,
2023 and December 31, 2022, the Company did not hold any currencies other than the United States dollar in its bank account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWzwfpwvFc43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zGhku7413rFf"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#x2019;s Chief Operating Decision Maker, which is the Company&#x2019;s
President and Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zYGhTCfb0Tx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zL3s4xHNvmGj"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSoAG8Iwlnka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zmYUevFxr3g8"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230930_zzVrO5ZoyS68" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230930_zs0T6H0X5Owg" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <LIXT:CashSIPCInsuredAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">500000</LIXT:CashSIPCInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2WDGaqCYUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zqpONPVFXKPi"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <LIXT:PrepaidInsurancePolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_843_ecustom--PrepaidInsurancePolicyTextBlock_zI8WxieDP9T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_znLMoh1EJMVc"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</LIXT:PrepaidInsurancePolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zajv7XUxgz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwxMXWdWwNmf"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230701__20230930_zLzVVea1Id54"&gt;178,012&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220701__20220930_zzVJ8sD3ciy8"&gt;271,163&lt;/span&gt; for the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20230101__20230930_zwRoGlqq5qKg"&gt;835,362 &lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--LegalFees_pp0p0_c20220101__20220930_zGZuG1zKNcy8"&gt;944,789&lt;/span&gt;
for the nine months ended September 30, 2023 and 2022, respectively. Patent and licensing legal and filing fees and costs are included
in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LegalFees
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">178012</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">271163</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">835362</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">944789</us-gaap:LegalFees>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6qs5gImq235" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zwN75KICZ743"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zSIu73Xo3yge" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgxsksCwncR2" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE1JebAMNyQ7" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztsybRVNETe3" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months and nine months
ended September 30, 2023 and 2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended September 30, 2023 and 2022 included charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWabCorlhdT6" title="Concentration risk percentage"&gt;20.0&lt;/span&gt;% and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEz1rVlkt6z1" title="Concentration of risk, percentage"&gt;22.5&lt;/span&gt;% of
total general and administrative costs, respectively. General and administrative costs for the three months ended September 30, 2023
and 2022 also included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_z5BMLGPUFem" title="Concentration of risk, percentage"&gt;12.6&lt;/span&gt;% and
&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zpVWgiFEylqb" title="Concentration of risk, percentage"&gt;32.9&lt;/span&gt;%, respectively, of total general and administrative costs. General and administrative costs for the three months ended September
30, 2023 also included charges from two vendors representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zVWHsjU8QUo8" title="Concentration of risk, percentage"&gt;11.9&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zWLC2BdhvGA2" title="Concentration of risk, percentage"&gt;10.6&lt;/span&gt;%, respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended September 30, 2023 included charges from four vendors and consultants representing &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLh24gMc58ta" title="Concentration of risk, percentage"&gt;38.9&lt;/span&gt;%,
&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgPU1rru6XKc" title="Concentration of risk, percentage"&gt;24.9&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zovs1r0vOTTh" title="Concentration of risk, percentage"&gt;15.9&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zbeSvniRKGf2" title="Concentration of risk, percentage"&gt;14.9&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the three months ended
September 30, 2022 include charges from four vendors and consultants representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4FV76f6LBx3" title="Concentration of risk, percentage"&gt;32.0&lt;/span&gt;%, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z5NlA7ZRYwlb" title="Concentration of risk, percentage"&gt;23.2&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze6F9qyZMwA6" title="Concentration of risk, percentage"&gt;16.9&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7foDi94gOH2" title="Concentration of risk, percentage"&gt;11.0&lt;/span&gt;%, respectively, of total
research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the nine months ended September 30, 2023 and 2022 include charges from legal firms and other vendors for
general licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsFHITlsxmP7" title="Concentration risk percentage"&gt;25.2&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJhUDYmnON21" title="Concentration of risk, percentage"&gt;25.0&lt;/span&gt;% of
total general and administrative costs, respectively. General and administrative costs for the nine months ended September 30, 2023 and
2022 also included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zxaPfYTaCZ2g" title="Concentration of risk, percentage"&gt;20.2&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zh85uOaSUJHc" title="Concentration of risk, percentage"&gt;30.7&lt;/span&gt;%,
respectively, of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the nine months ended September 30, 2023 include charges from three vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zANX9VkcZwbc" title="Concentration of risk, percentage"&gt;35.9&lt;/span&gt;%,
&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1oh68qZT2Pj" title="Concentration of risk, percentage"&gt;21.0&lt;/span&gt;% and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z90sPG8XIzll" title="Concentration of risk, percentage"&gt;12.4&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the nine months ended September
30, 2022 include charges from three vendors and consultants representing &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz5Uc8IabDkj" title="Concentration of risk, percentage"&gt;31.0&lt;/span&gt;%, &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zidbKL6e9gZh" title="Concentration of risk, percentage"&gt;16.7&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zMKkchs4NhHf" title="Concentration of risk, percentage"&gt;10.0&lt;/span&gt;%, respectively, of total research and
development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.200</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.225</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.329</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorOneMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorTwoMember_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.106</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.389</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.159</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.149</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.320</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.232</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.169</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_custom_VendorAndConsultantFourMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.252</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.250</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.202</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.307</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.359</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.310</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zziQ71bS1YUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaEsmGGKefQ1"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of September 30, 2023 or
December 31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2023 or December
31, 2022. Subsequent to September 30, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7FnXFc6LX6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_znKG4J2eNzWl"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting period
of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash
for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <LIXT:WarrantsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_841_ecustom--WarrantsPolicyTextBlock_zkM34u8aIrf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z5AI7k5nQ0qb"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480,
Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for
equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued
and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of
the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are
required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at
each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on
the statements of operations. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 5)
meet the requirements for equity classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:WarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zK6hNr4oWbFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_ztxdQ1PgXS5g"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z2XT2q3Vedm7" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,556,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;745,448&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z2KMGOqhgLY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zJd7b8fo46Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z2XT2q3Vedm7" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930_zRVHhz445US7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220930_zxamEhE61n83" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zR170SFajs3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zpjHxcyy02o" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zRMBHzPAlk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zvLl8ArdNzX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,556,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;745,448&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">808365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">340031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      unitRef="Shares">674896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      unitRef="Shares">332500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1556178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">745448</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zUuzLaadsK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z9fPxBAs9CCa"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zruReJoFaQ4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zOp60YNQ3pK"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statement presentation or related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting
Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014;
Stock Compensation (Topic 718) Presentation of Financial Statements (&#x201c;ASU 2023-03&#x201d;). ASU 2023-03 amends the FASB
Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC
Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280
&#x2014; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new
guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03
immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company&#x2019;s consolidated financial
statement presentation or related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80E_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zav7OskLkOUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_823_zuqL31HSGgy8"&gt;Research and Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ResearchDevelopmentTableTextBlock_zrcsjMtV2fXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated
with clinical trials involving the Company&#x2019;s lead clinical compound LB-100, are summarized below based on the respective geographical
regions where such costs have been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zqLHcZFdzSM1" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230701__20230930_zDf90xcyndd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220701__20220930_zyM03hvMlOoh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930_zgJohYyjc56h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220930_zZzDEHQsVGT9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_z4XvV3CYrPli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;68,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;161,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;291,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;316,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_z26fC9u1fpM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,246&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;348,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zCxObD6nrZf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zsPXl1vtkSM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Netherlands&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;156,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;149,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zglxOoL5IBL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;132,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;272,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;749,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;895,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_z3zd7m1rEQN8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;132,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;272,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;749,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;895,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_zXuSXx688aw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <LIXT:ResearchDevelopmentTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_894_ecustom--ResearchDevelopmentTableTextBlock_zrcsjMtV2fXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated
with clinical trials involving the Company&#x2019;s lead clinical compound LB-100, are summarized below based on the respective geographical
regions where such costs have been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zqLHcZFdzSM1" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230701__20230930_zDf90xcyndd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220701__20220930_zyM03hvMlOoh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930_zgJohYyjc56h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220930_zZzDEHQsVGT9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_z4XvV3CYrPli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;68,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;161,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;291,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;316,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_z26fC9u1fpM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,246&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;348,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zCxObD6nrZf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zsPXl1vtkSM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Netherlands&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;156,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;149,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zglxOoL5IBL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;132,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;272,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;749,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;895,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_z3zd7m1rEQN8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;132,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;272,388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;749,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;895,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</LIXT:ResearchDevelopmentTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_country_US"
      decimals="0"
      unitRef="USD">68315</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30_country_US"
      decimals="0"
      unitRef="USD">161744</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_country_US"
      decimals="0"
      unitRef="USD">291846</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_country_US"
      decimals="0"
      unitRef="USD">316565</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_country_ES"
      decimals="0"
      unitRef="USD">9496</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30_country_ES"
      decimals="0"
      unitRef="USD">1246</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_country_ES"
      decimals="0"
      unitRef="USD">283035</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_country_ES"
      decimals="0"
      unitRef="USD">348850</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_country_CN"
      decimals="0"
      unitRef="USD">3108</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30_country_CN"
      decimals="0"
      unitRef="USD">63330</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_country_CN"
      decimals="0"
      unitRef="USD">17198</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_country_CN"
      decimals="0"
      unitRef="USD">81050</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_country_NL"
      decimals="0"
      unitRef="USD">51568</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30_country_NL"
      decimals="0"
      unitRef="USD">46068</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_country_NL"
      decimals="0"
      unitRef="USD">156950</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_country_NL"
      decimals="0"
      unitRef="USD">149184</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">132487</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">272388</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">749029</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">895649</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">132487</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">272388</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">749029</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">895649</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFi765UO65il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_823_zfu8SkSLRn2a"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930_zVOvVYqk9H17" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930_zdgCSf0uwmi8" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total of &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLf9Y3SMfuIa" title="Preferred stock, shares authorized"&gt;350,000&lt;/span&gt; shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of &lt;span id="xdx_90F_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpVwzFi0nyj5" title="Principal cash obligations and commitments"&gt;175,000&lt;/span&gt; shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to &lt;span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20230317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNljoFshXUYb" title="Preferred stock dividend, percentage"&gt;1&lt;/span&gt;% of the annual net revenue of the Company divided by &lt;span id="xdx_908_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpUeHq1XHSdb" title="Annual net revenue"&gt;175,000&lt;/span&gt;, until converted or redeemed. As of September 30, 2023 and December
31, 2022, the Company had &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zlNIZJ2fGsNl" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_z86k5TX1qdDj" title="Preferred stock, shares authorized"&gt;9,650,000&lt;/span&gt;&lt;/span&gt; shares of undesignated preferred stock which may be issued with such rights and powers as the Board
of Directors may designate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockConversionBasis_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPuSIA5glSH8" title="Preferred stock, conversion description"&gt;Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY3kHZF7Q5ah" title="Preferred stock convertible into common stock"&gt;0.20833&lt;/span&gt; shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOilYgJeMsxh" title="Gross proceeds from sale of transaction"&gt;21,875,000&lt;/span&gt;.&lt;/span&gt; The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the &lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znbcJ1IsMZx9" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAgGmKMPaGpa" title="Preferred stock, shares outstanding"&gt;350,000&lt;/span&gt;&lt;/span&gt; outstanding shares
of Series A Convertible Preferred Stock would convert into &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zZx7AkhOApz7" title="Preferred stock convertible into common stock"&gt;&lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zx8mj8rfHaZh" title="Preferred stock convertible into common stock"&gt;72,917&lt;/span&gt;&lt;/span&gt; shares of common stock at September 30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zDMiMyDvqmck" title="Common stock, shares authorized"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zmTuNU4F7F2k" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zje6so0n6zP4" title="Common Stock, Par or Stated Value Per Share"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zXAmlxuUq3ta" title="Common Stock, Par or Stated Value Per Share"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of September 30, 2023 and
December 31, 2022, the Company had &lt;span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_zNQcDkJi7dWe" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_z1HVGKzPq8T" title="Common stock, shares outstanding"&gt;2,249,290&lt;/span&gt;&lt;/span&gt; shares and &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zhRNheIEPIl7" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zSc4285ahqmd" title="Common stock, shares outstanding"&gt;1,664,706&lt;/span&gt;&lt;/span&gt; shares, respectively, of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBCKEusXGYIk" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock. No fractional shares were issued
in connection with the reverse split, with any fractional shares resulting from the reverse split being rounded up to the nearest whole
share. All share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock
split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 10, 2023, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOCcJDLGXmI6" title="Stock issued new issue shares"&gt;1,250&lt;/span&gt; shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwUEtA7CkeOi" title="Stock issued new issue shares"&gt;1,250&lt;/span&gt; shares exercisable at $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxIBCYzLaWv9" title="Warrant exercise price"&gt;5.025&lt;/span&gt; per share for total cash proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT0IowCaph3f" title="Proceeds from warrant exercises"&gt;6,281&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;April
12, 2022 Sale of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 12, 2022, the Company completed the sale of &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDeecwPVTVb" title="Number of common stock shares issued during period"&gt;290,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztBLVJqBgMdk" title="Sale of stock price per share"&gt;20.00&lt;/span&gt; per share in a registered direct
offering, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjHFMs0JNXX8" title="Proceeds from issuance initial public offering"&gt;5,800,000&lt;/span&gt;. The total cash costs of this offering were $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaZIGzFEQDS8" title="Costs of public offering"&gt;658,616&lt;/span&gt;, resulting in net proceeds of
$&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9XzJ6DEShb" title="Net proceeds from issuance of stock"&gt;5,141,384&lt;/span&gt;. Pursuant to the placement agents&#x2019; agreement, the Company granted warrants to the placement agents to purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zsT3UBdm5KOb" title="Warrants to purchase shares"&gt;29,000&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zpmApYfQ69k9" title="Warrant exercise price"&gt;20.00&lt;/span&gt; per share exercisable through April 14, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;July
20, 2023 Sale of Common Stock and Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 20, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM5B4ifsL0x4" title="Number of common stock shares issued during period"&gt;180,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znlNev8VOTVh" title="Sale of stock price per share"&gt;6.00&lt;/span&gt; per share and pre-funded warrants to purchase &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zohoH8AhPbh7" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt;
shares of common stock at a price of $&lt;span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeNMvMvR4K81" title="Common Stock, Par or Stated Value Per Share"&gt;5.9999&lt;/span&gt; per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ2sH5F1OJLd" title="Warrant exercise price"&gt;0.0001&lt;/span&gt; per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full. As of August 7, 2023, all pre-funded warrants had been exercised in full. The pre-funded
warrants were determined to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLRTMyMZnBp6" title="Warrants to purchase shares"&gt;583,334&lt;/span&gt; shares of common stock.
Each common warrant had an initial exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYY2Ha97JPo4" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share, was immediately exercisable upon issuance, and expires &lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable_dc_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zompdFE1Cmci" title="Warrant expires term"&gt;five years&lt;/span&gt;
thereafter on &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zl3jqtrpUpC8" title="Warrant expires date"&gt;July 20, 2028&lt;/span&gt;. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
registered direct offering and the concurrent private placement generated gross proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zW72K4rRfD7e" title="Proceeds from issuance initial public offering"&gt;3,499,964&lt;/span&gt;. The total cash costs of the registered
direct offering and the private placement were $&lt;span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCUYrMqlYixg" title="Costs of public offering"&gt;362,925&lt;/span&gt;, resulting in net proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIO5Kc5WkjRf" title="Net proceeds from issuance of stock"&gt;3,137,039&lt;/span&gt;. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zTP1n2U2wBcg" title="Warrants to purchase shares"&gt; 35,000&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zLZ2nMjb2Yvj" title="Warrant exercise price"&gt;6.60&lt;/span&gt; per share and
expiring on &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zRn4KhYvCkd3" title="Warrant expires date"&gt;July 20, 2028&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from July 24, 2023 through August 7, 2023, the &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8C2hmOT7cYb" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; pre-funded warrants, exercisable at $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGvERjmtHQ8" title="Common Stock, Par or Stated Value Per Share"&gt;0.0001&lt;/span&gt; per common share, were
exercised for total cash proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5YPkzyOgLjb" title="Exercise of common stock options"&gt;41&lt;/span&gt;, resulting in the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfmliIOR7mej" title="Issuance of common stock"&gt;403,334&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of the warrants issued to the institutional investor (exercisable at $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_znoHxzeoS0f" title="Common Stock, Par or Stated Value Per Share"&gt;6.00&lt;/span&gt;
per share) and to the placement agent (exercisable at $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3qc6XEbZfh8" title="Common Stock, Par or Stated Value Per Share"&gt;6.60&lt;/span&gt;
per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications,
reorganizations or similar events affecting the Company&#x2019;s common stock. In addition, the warrants issued to the institutional
investor contain a &#x201c;fundamental transaction&#x201d; provision whereby in the event of a fundamental transaction (a sale or
transfer of assets or ownership of the Company as defined in the warrant agreement) within the Company&#x2019;s control, the holder
of the unexercised common stock warrants will be entitled to receive cash consideration equal to a Black-Scholes valuation, as
defined in the warrant agreement. If such fundamental transaction is not within the Company&#x2019;s control, the warrant holder
would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#x2019;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash
payment for a warrant redemption as a distribution from stockholders&#x2019; equity, as and when such cash payment is
made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhHFKCNEJo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity during the nine months ended September 30, 2023, excluding the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6kO1BxglUn3" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; pre-funded warrants,
exercisable at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePO4syuM9ra" title="Common stock, par or stated value per share"&gt;0.0001&lt;/span&gt; per common share, to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTPSlCjBRr9" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; shares of common stock described above, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zC8PkhwyBa0i" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTWGXOVzX9ja" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb805odK5IS2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0ZP2vMYjG3j" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKfJ7FaYHen8" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLlRcrdfaY9h" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztbqlLNImt76" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5mOK4pPyyS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0kqxgwjAGn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwpfFTAA1YE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK3fWOMCO5ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN2ejtbtuaL8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7uclRtbEc5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBrpG9xzXPT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;50.161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhcNZbWrYLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcHvkMxTNhee" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgTYyU7QM2G9" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z1K878rCBUD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zztBqUPLK7rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zaLZorDpdJu5" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zltTwPRuv1ok" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhuVdovBn5B2" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z55dmao6Mka" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZLhk6etfMUg" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWDwDBwvcVfk" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zj7d2Ceu95nb" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqTRr9U7PTbc" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXl7zLlzOVyl" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHAi6xf6gxG" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdJKWyt0dQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930_zmjOH53BqWod" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zGyYbeFI2Gsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants exercisable at $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z489484kBsG5" title="Warrants exercisable"&gt;57.00&lt;/span&gt; per share at September 30, 2023 consist of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBkrEpVs81be" title="Warrants outstanding"&gt;1,497,000&lt;/span&gt; publicly-traded warrants pre-split &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbVyz21f5lj" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; that
were issued as part of the Company&#x2019;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#x2019;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPSAPv0i5jQb" title="Exercise price"&gt;5.70&lt;/span&gt; per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWPaUfIh7hyi" title="Warrants exercisable"&gt;5.70&lt;/span&gt;, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVUsnkyJqHq3" title="Warrants and rights outstanding"&gt;57.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on a fair market value of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPRmAu3PPXRb" title="Fair market value of stock"&gt;2.45&lt;/span&gt; per share on September 30, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesAuthorized>
    <LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">175000</LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2015-03-162023-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:PreferredStockDividendRatePercentage>
    <LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">175000</LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockConversionBasis contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">0.20833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234"
      decimals="0"
      unitRef="USD">21875000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-09-30_custom_SeriesAConvertiblePreferredStockMember34360234"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72917</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1664706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1664706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">6281</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">290000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">658616</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5141384</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-12_custom_PlacementAgentsMember"
      decimals="INF"
      unitRef="Shares">29000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-12_custom_PlacementAgentsMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">5.9999</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember"
      decimals="INF"
      unitRef="Shares">583334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <LIXT:ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">P5Y</LIXT:ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">2028-07-20</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">3499964</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">362925</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">3137039</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="0"
      unitRef="Shares">35000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="INF"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-07-192023-07-20_custom_PlacementAgentsMember">2028-07-20</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">41</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-07_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-07_us-gaap_PrivatePlacementMember"
      decimals="INF"
      unitRef="USDPShares">6.60</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhHFKCNEJo5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity during the nine months ended September 30, 2023, excluding the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6kO1BxglUn3" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; pre-funded warrants,
exercisable at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePO4syuM9ra" title="Common stock, par or stated value per share"&gt;0.0001&lt;/span&gt; per common share, to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NraG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTPSlCjBRr9" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; shares of common stock described above, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zC8PkhwyBa0i" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTWGXOVzX9ja" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb805odK5IS2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0ZP2vMYjG3j" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKfJ7FaYHen8" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLlRcrdfaY9h" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztbqlLNImt76" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5mOK4pPyyS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0kqxgwjAGn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwpfFTAA1YE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK3fWOMCO5ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN2ejtbtuaL8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7uclRtbEc5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBrpG9xzXPT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;50.161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhcNZbWrYLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcHvkMxTNhee" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgTYyU7QM2G9" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">190031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">50.161</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      decimals="INF"
      unitRef="Shares">618334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937"
      decimals="INF"
      unitRef="USDPShares">6.034</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare
      contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937">P4Y2M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">190031</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">50.161</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">808365</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-09-30_custom_CommonStockWarrantsMember34360937">P4Y2M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zztBqUPLK7rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zaLZorDpdJu5" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zltTwPRuv1ok" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhuVdovBn5B2" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z55dmao6Mka" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZLhk6etfMUg" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWDwDBwvcVfk" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zj7d2Ceu95nb" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqTRr9U7PTbc" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXl7zLlzOVyl" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHAi6xf6gxG" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZdJKWyt0dQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930_zmjOH53BqWod" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">6.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">583334</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">6.600</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">35000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">20.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">29000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">37.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">11331</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">57.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">149700</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">808365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">57.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1497000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.70</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">57.00</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_custom_CommonStockWarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.45</us-gaap:SharePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcG6o54ltZs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82E_znXlPUB0QMfj"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
party transactions include transactions with the Company&#x2019;s officers, directors and affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#x2019;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $&lt;span id="xdx_900_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zDbAcHtPNI17" title="Annual salary"&gt;250,000&lt;/span&gt;.
During the three months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_900_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zXPqF7A1AdE5" title="Compensation"&gt;62,500&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z8iBPG9CIJAc" title="Compensation"&gt;62,500&lt;/span&gt;, respectively, to Dr. Kovach under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zPfT1WTQPjpg" title="Compensation"&gt;187,500&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zbNLroryDWSe" title="Compensation"&gt;187,500&lt;/span&gt;, respectively,
to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated
statements of operations for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#x2019;s Chief
Medical Officer, with an annual salary of $&lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zdaKYI1PoY31" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective May 1, 2021, Dr. Miser&#x2019;s annual salary was increased to $&lt;span id="xdx_90D_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zuvyMKcbPCgl" title="Increase in annual salary"&gt;175,000&lt;/span&gt;.
Dr. Miser is required to devote at least 50% of his business time to the Company&#x2019;s activities. During the three months ended September
30, 2023 and 2022, the Company paid $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zxN7fTSCiw14" title="Compensation"&gt;43,750&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zSoz4hzJ0UA4" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Dr. Miser under this employment agreement, and during the nine
months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z9b6JLkv58kj" title="Compensation"&gt;131,250&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zuKSZw1hpzj7" title="Compensation"&gt;131,250&lt;/span&gt;, respectively, to Dr. Miser under this employment agreement,
which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#x2019;s Chief Administrative Officer, with an annual salary of $&lt;span id="xdx_909_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zqdi1K38Ksyg" title="Annual salary"&gt;120,000&lt;/span&gt;. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#x2019;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#x2019;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#x2019;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#x2019;s
annual salary was increased to $&lt;span id="xdx_908_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zibRcudpDW5f" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $&lt;span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zXML71QFoZF4" title="Compensation"&gt;200,000&lt;/span&gt;. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zaEe2AYaTLxg" title="Paid office rent"&gt;7,323&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--PaymentsForRent_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FormanMember_zy3QgP87tR43" title="Paid office rent"&gt;11,436&lt;/span&gt;, respectively, for the three months and nine months ended September 30, 2023.
During the three months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zRSlvxlNg0Wk" title="Compensation"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z0SAHQ7szDY6" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Mr. Forman under this
employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zVJIRQaq9cA6" title="Compensation"&gt;150,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zX8fpg3NeB1f" title="Compensation"&gt;131,250&lt;/span&gt;, respectively,
to Mr. Forman under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated
statements of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#x2019;s Vice President
and Chief Financial Officer, with an annual salary of $&lt;span id="xdx_90D_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zyaTma7f9U9g" title="Annual salary"&gt;120,000&lt;/span&gt;. Effective May 1, 2021, Mr. Weingarten&#x2019;s annual salary was increased
to $&lt;span id="xdx_906_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zQAIqIBugYI5" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. During the three months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zp2rOuZc1U8i" title="Compensation"&gt;43,750&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zLwH0TPHehtl" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Mr. Weingarten
under this employment agreement, and during the nine months ended September 30, 2023 and 2022, the Company paid $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zuckifzBeIjk" title="Compensation"&gt;131,250&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIWsFe724u93" title="Compensation"&gt;131,250&lt;/span&gt;,
respectively, to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the
Company&#x2019;s consolidated statements of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023, to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zjTva8f2dUoi" title="Annual salary"&gt;150,000&lt;/span&gt;. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#x2019;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined in the sole discretion of the Board of Directors. During the three months and nine months ended
September 30, 2023, the Company paid $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zuozEEqOTYTb" title="Compensation"&gt;&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrvanderBaanMember_zwyeBzjuv9Pc" title="Compensation"&gt;1,667&lt;/span&gt;&lt;/span&gt; to Mr. van der Baan under this employment agreement, which costs are included in general
and administrative costs in the Company&#x2019;s consolidated statements of operations for such periods. Mr. Van der Baan was appointed
as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Appointment
of Dr. Ren&#xe9; Bernards to the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
as of June 15, 2022, Dr. Ren&#xe9; Bernards was appointed to the Company&#x2019;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $&lt;span id="xdx_90F_eus-gaap--ManagementFeePayable_iI_c20220615_zcxdOmneoQV" title="Cash board fee payable"&gt;100,000&lt;/span&gt;, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $&lt;span id="xdx_90C_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zYGctzdEc7Gg" title="Cash board fee payable quarterly"&gt;40,000&lt;/span&gt;, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensatory
Arrangements for Members of the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
compensation for independent directors, payable quarterly, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Base
director compensation - $&lt;span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_z0XMbmfM4Duj" title="Compensation"&gt;20,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of audit committee &#x2013; additional $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_za0jGC4FmPf5" title="Compensation"&gt;10,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of any other committees &#x2013; additional $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zymV2IUuxYLa" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of audit committee &#x2013; additional $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zKGJG4vm0YCj" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of any other committees &#x2013; additional $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zsGg1KTU8C26" title="Compensation"&gt;2,500&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
compensation for independent directors is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Appointment
of new independent directors &#x2013; The Company grants options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zVk9HehVzio1" title="Options, grants in period, gross"&gt;25,000&lt;/span&gt; shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zDtHCdx6uZQk" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% on the grant date and the remaining &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z2P8VxCZH03" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% vesting &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930_zmggabJEsw7a" title="Award vesting rights, percentage"&gt;12.5&lt;/span&gt;% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $&lt;span id="xdx_90B_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVtl8SY3syMe" title="One time cash"&gt;100,000&lt;/span&gt; to such director, payable upfront.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
grant of options to independent directors &#x2013; Effective on the last business day of the month of June, the Company grants options
to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zqqPa04kbGn4" title="Options, grants in period, gross"&gt;10,000&lt;/span&gt; shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant,
vesting &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zzOMgNl9Xqvi" title="Share-based payment award, award vesting period"&gt;12.5&lt;/span&gt;% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully
vested, subject to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount
of such stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors,
for a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $&lt;span id="xdx_90F_eus-gaap--CostOfRevenue_c20230101__20230930__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzuA9jzcekqg" title="Annual cash fee"&gt;40,000&lt;/span&gt; to such director, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash compensation paid to independent directors was $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zOFzv8FZiSX7" title="Stock based compensation"&gt;42,228&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zuD6DvrC7yxj" title="Stock based compensation"&gt;53,324&lt;/span&gt;, respectively, for the three months ended September 30, 2023
and 2022. Total cash compensation paid to independent directors was $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zw3ZSfGYx9c" title="Stock based compensation"&gt;127,229&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zWEzLdl52pE" title="Stock based compensation"&gt;221,510&lt;/span&gt;, respectively, for the nine months ended September
30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation granted to members of the Company&#x2019;s Board of Directors, officers and affiliates is described at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zkNzOsV5Ft1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2023 and 2022, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zCumS3XlPEW4" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230701__20230930_zXtPzbawr8W4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220701__20220930_zlkUFkvHMQc9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zF5Qrmn4YUg9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20220930_zhOyWuLBgWH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdTYXtsXSyPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;243,895&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;247,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;728,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;802,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockBasedMember_zHoTcCa8zH34" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zzkQX8iRRvwb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;643,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,398,042&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,963,409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_zlpCe759Ssqb" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Related
    party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;643,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,398,042&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,963,409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_z3eXZDt8Ten1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">187500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">187500</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2023-07-012023-09-30_custom_FormanMember"
      decimals="0"
      unitRef="USD">7323</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-09-30_custom_FormanMember"
      decimals="0"
      unitRef="USD">11436</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-07-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-09-30_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">131250</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-07-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember"
      decimals="0"
      unitRef="USD">1667</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-09-30_custom_EmploymentAgreementMember_custom_MrVanderBaanMember"
      decimals="0"
      unitRef="USD">1667</us-gaap:OfficersCompensation>
    <us-gaap:ManagementFeePayable contextRef="AsOf2022-06-15" decimals="0" unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <LIXT:ManagementFeePayableQuarterly contextRef="AsOf2022-06-15" decimals="0" unitRef="USD">40000</LIXT:ManagementFeePayableQuarterly>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="0"
      unitRef="USD">20000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember"
      decimals="0"
      unitRef="USD">2500</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-09-30_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-09-30_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">40000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">42228</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">53324</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">127229</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">221510</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zkNzOsV5Ft1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months and nine months ended September 30, 2023 and 2022, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zCumS3XlPEW4" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230701__20230930_zXtPzbawr8W4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220701__20220930_zlkUFkvHMQc9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zF5Qrmn4YUg9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20220930_zhOyWuLBgWH" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdTYXtsXSyPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;243,895&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;247,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;728,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;802,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockBasedMember_zHoTcCa8zH34" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zzkQX8iRRvwb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;643,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,398,042&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,963,409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_zlpCe759Ssqb" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Related
    party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;643,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,398,042&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,963,409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">243895</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">247074</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">728896</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">802760</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">112106</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">396883</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-09-30_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">669146</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">1160649</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">356001</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">643957</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1398042</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1963409</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">356001</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">643957</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1398042</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1963409</us-gaap:CostOfRevenue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zMLTkSRADci2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_828_z1SR3qly2M88"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zafFpZ06Xlu5" title="Number of restricted stock issued"&gt;233,333&lt;/span&gt; shares of the Company&#x2019;s common stock, under terms
and conditions as determined by the Company&#x2019;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWW3D6bRNBYa" title="Common shares avaliable for issuable"&gt;180,000&lt;/span&gt; shares, to a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zvuD35rd3Xy8" title="Shares total"&gt;413,333&lt;/span&gt; shares.
The Company has scheduled a meeting of stockholders for November 27, 2023 to consider and vote on, among other matters, a proposal to
increase the number of common shares issuable under the 2020 Plan by &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBueXCOBE8k1" title="Common shares avaliable for issuable"&gt;336,667&lt;/span&gt; shares, to a total of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRur1AcrIv0d" title="Shares total"&gt;750,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, there was a deficiency of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230930__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zQqh9H1LgZHe" title="Shares outstanding"&gt;136,980 &lt;/span&gt;shares with respect to stock options issuable under the 2020 Plan. However,
subject to approval of the proposal to increase the number of common shares issuable under the 2020 Plan at the meeting of stockholders
scheduled for November 27, 2023, there will be unexpired stock options for &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrb5AS9VMbk5" title="Shares outstanding"&gt;550,313&lt;/span&gt; shares issued and outstanding under the 2020 Plan
and &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHwTsWEGS8O4" title="Shares were available for issuance"&gt;199,687 &lt;/span&gt;shares available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#x2019;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXtUFyzGcPW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zfgpbDyRkv44" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930_zUwF11wlHIdl" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930_zlhGen2z87db" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930_zFXJ0JmdW6xf" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zFiz9nGu1nl2" title="Expected life"&gt;4.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2022, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220930_zDSXZcdldCtg" title="Risk-free interest rate"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220930_zJe73ve7yIY1" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20220930_zNEfvh7lXCuk" title="Expected volatility"&gt;198.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zisZAepBOJa3" title="Expected life"&gt;3.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zmiAA6LFZr85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZdd8D2RIovg" title="Stock options description"&gt;On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zntCbzqgH4c" title="Stock options granted to purchase common stock, issued"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zHVYt9PZNwJe" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $71.40 per share, which was equal to the closing market
price of the Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6BYEEFZCfil" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsyxzJ7KZZ0f" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEDe3qWKDIVc" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsSySPcPQJhj" title="Stock based compensation"&gt;11,806&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zak2DAJIjElg" title="Stock based compensation"&gt;25,259&lt;/span&gt; for the three
months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z03N3qDbpWxi" title="Stock based compensation"&gt;61,501&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ9AngHtEaxe" title="Stock based compensation"&gt;74,954&lt;/span&gt; for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2020, in connection with an employment agreement entered into with &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVXDDGVQoN09" title="Stock options description"&gt;Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zayzoJefj7s2" title="Stock options granted to purchase common stock, issued"&gt;8,333&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC8wwUoS4id3" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z32ckApiKyZ4" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5azDtUzV1b" title="Fair value of stock options"&gt;572,650&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz6fIZ5IXi01" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z604TJC65id2" title="Stock options fully vested amount, fair value"&gt;143,163&lt;/span&gt; was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPKT2w5qb1wb" title="Stock based compensation"&gt;12,551&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zijr9z2osFZ7" title="Stock based compensation"&gt;36,085&lt;/span&gt; for the three
months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zwstCNam4NX3" title="Stock based compensation"&gt;83,544&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg44xJV09jQ9" title="Stock based compensation"&gt;107,078&lt;/span&gt; for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVtfYn5Ftfjb" title="Stock options description"&gt;On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_z2ZAFYofQWF7" title="Number of fully vested option exercisable"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zULixY6fCiia" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrfqqs0IJ7og" title="Stock options are exercisable price per share"&gt;71.40 &lt;/span&gt;per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zg6sI8Zaw78d" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfRi0iQ7jO59" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc6YtvRxSS5e" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy9OQPYGJck3" title="Stock based compensation"&gt;11,806&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zUQZ65pjCb2g" title="Stock based compensation"&gt;25,259&lt;/span&gt; for the three months ended September 30,
2023 and 2022, respectively, and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb7pHndyTBz3" title="Stock based compensation"&gt;61,501&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpDnbGd2cENg" title="Stock based compensation"&gt;74,954&lt;/span&gt; for the nine months ended September 30, 2023 and 2022, respectively, with respect
to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zE4CB3NANqbb" title="Stock options description"&gt;On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#x2019;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zf3UrKskq6jb" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6hceGbq9JX9" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zxUrm8idk1i9" title="Stock options are exercisable price per share"&gt;32.00&lt;/span&gt; per share (the closing market price on the grant
date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zebnferywMOg" title="Fair value of stock options"&gt;753,611&lt;/span&gt; ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGphqam0SPLj" title="Stock price per share"&gt;30.144&lt;/span&gt; per share), of which $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zS8DhB78F499" title="Stock options fully vested amount, fair value"&gt;376,800&lt;/span&gt; was attributable to the portion of the stock options fully
vested on April 9, 2021 and was therefore charged to operations on that date. Although the remaining unvested portion of the fair value
of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options
terminated on October 30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zL15gULMTJdi" title="Stock based compensation"&gt;42,692&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_z55LmLvPPoU2" title="Stock based compensation"&gt;126,684&lt;/span&gt; for the three months and nine months ended September
30, 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 11, 2021, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zF2Sg0krn8kk" title="Stock options description"&gt;the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z8CDWItMgfCk" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzQgvlo0x3ab" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt;
at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zc7usJl0J6md" title="Stock options are exercisable price per share"&gt;28.00 &lt;/span&gt;per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zpdP8ZgvtVBd" title="Fair value of stock options"&gt;658,363&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zLMnU1NtXnAe" title="Stock price per share"&gt;26.335&lt;/span&gt; per
share), of which $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zgoEsRRGDSi9" title="Stock options fully vested amount, fair value"&gt;329,188&lt;/span&gt; was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. The Company recorded charges to general and administrative costs in the consolidated statement of
operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z4RjHoJIXps1" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3YHv9mP58Be" title="Stock based compensation"&gt;38,827&lt;/span&gt; for the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zi6LEXwFAGj8" title="Stock based compensation"&gt;76,388&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6yu8ria5Kxa" title="Stock based compensation"&gt;115,215&lt;/span&gt; for the nine
months ended September 30, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2021, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z63CABwuq9qd" title="Stock options description"&gt;the
Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of
Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zZAd6xHreXB6" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt;
shares (a total of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zLpF5EH1f5c5" title="Number of fully vested option exercisable"&gt;50,000&lt;/span&gt;
shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zIUqEijouci8" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zoGHl33ELSIk" title="Stock options are exercisable price per share"&gt;30.30&lt;/span&gt; per share (the
closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z1uJR4AbWvVc" title="Fair value of stock options"&gt;1,421,095&lt;/span&gt;
($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOLEuSc8F2vc" title="Stock price per share"&gt;28.423&lt;/span&gt;
per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zGVrOIk5WOvc" title="Stock based compensation"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zLHY2ksXlIZ2" title="Stock based compensation"&gt;179,100&lt;/span&gt;
for the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zSTAKXjTrGCd" title="Stock based compensation"&gt;211,412&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zQMGyxVE3e42" title="Stock based compensation"&gt;531,455&lt;/span&gt;
for the nine months ended September 30, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2022, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zF9o3zD8Xd4d" title="Stock options description"&gt;the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z35yQNWzNBH" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zFB5DvmsXBdi" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt;
at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zS7bUOlhE7y9" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zDGMa68H381" title="Fair value of stock options"&gt;158,525&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zaNi0pl5i2Uj" title="Stock price per share"&gt;6.341&lt;/span&gt; per share),
of which $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zu8FODcTNFV3" title="Stock options granted to purchase common stock, issued"&gt;79,263&lt;/span&gt; was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zau6IIrvODac" title="Stock based compensation"&gt;9,801&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zm2C23awz7qh" title="Stock based compensation"&gt;9,801&lt;/span&gt; for the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zV6axkm8eEgg" title="Stock based compensation"&gt;29,084&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zvjDjIncW6Z2" title="Stock based compensation"&gt;90,449&lt;/span&gt; for the nine months
ended September 30, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2022, &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zJv439dY2ry6" title="Stock options description"&gt;the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_902_ecustom--FairValueOfStockOptions_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zxDmx7T0PB7f" title="Fair value of stock options"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuPBNQXbsxH9" title="Stock price per share"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220628__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_za4hwzANisQi" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zNnp58RRAcH4" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCa0QMcDoD61" title="Fair value of stock options"&gt;316,700&lt;/span&gt; ($&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zuzadZHkiFfi" title="Stock price per share"&gt;6.334&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zzsxgBXB7W0l" title="Stock based compensation"&gt;23,916&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zke4roWdzh64" title="Stock based compensation"&gt;39,860&lt;/span&gt; for
the three months ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__srt--DirectorMember_zXWAAyOPZg8j" title="Stock based compensation"&gt;70,965&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__srt--TitleOfIndividualAxis__srt--DirectorMember_zSbe8u11wsNi" title="Stock based compensation"&gt;39,860&lt;/span&gt; for the nine months ended September 30, 2023
and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPihBnic9Bo9" title="Number of fully vested option exercisable"&gt;20,000&lt;/span&gt; shares
(a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zqjxrT3h4VTd" title="Number of fully vested option exercisable"&gt;80,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zGrJzjPAm3uk" title="Share price"&gt;20.00&lt;/span&gt;
per share, vesting &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziYgSbIWrhG8" title="Share based compensation vesting rights, percentage"&gt;25&lt;/span&gt;% on issuance and &lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhuANZxNViRk" title="Share based compensation issuance, percentage"&gt;25&lt;/span&gt;% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zbEf27pdSkF7" title="Stock options granted to purchase common stock, issued"&gt;80,000&lt;/span&gt; stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zjeBHLeFG0Ql" title="Fair value of stock options"&gt;262,560&lt;/span&gt; ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znubjJrHRfJ4" title="Stock price per share"&gt;3.282&lt;/span&gt; per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zO8QjNuxlJ9c" title="Stock based compensation"&gt;16,528&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zCeBwECz9GZ6" title="Stock based compensation"&gt;49,053&lt;/span&gt; for the
three months and nine months ended September 30, 2023, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zllxBBCI0gHa" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zkXsG0amN9t" title="Stock options are exercisable price per share"&gt;5.025&lt;/span&gt; per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $&lt;span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z4lUHoIe24Jg" title="Fair value of stock options"&gt;43,264&lt;/span&gt; ($&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zCYTUjpjmx84" title="Stock price per share"&gt;4.326&lt;/span&gt; per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2023, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zKRLVnat5Yv4" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230606__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmBtZoiDm0m5" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zYgUXE994V9h" title="Share price"&gt;5.88 &lt;/span&gt;per share
(the closing market price on the grant date), vesting &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zWtNoow6xrVi" title="Share based compensation vesting rights, percentage"&gt;12.5&lt;/span&gt;% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20230629__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zFpFXJXKdty1" title="Fair value of stock options"&gt;192,593&lt;/span&gt; ($&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_ztyjuq4LEC81" title="Stock price per share"&gt;4.8131&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zf0co99NOIAh" title="Stock based compensation"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__srt--TitleOfIndividualAxis__custom--FourNonOfficersMember_zXNmV1tZ4C12" title="Stock based compensation"&gt;24,232&lt;/span&gt;&lt;/span&gt; for the
three months and nine months ended September 30, 2023 with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, in connection with the employment agreement entered into with Bastiaan van der Baan, Mr. van der Baan was granted
stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3CcsLS8JTRl" title="Options, grants in period, gross"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zc23SAZFWS9c" title="Stock options are exercisable price per share"&gt;1.95&lt;/span&gt; per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3FsVuMj86Oa" title="Fair value of stock options"&gt;403,066&lt;/span&gt; ($&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20230626__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBuY2A4lcYA8" title="Stock price per share"&gt;1.612&lt;/span&gt; per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkIquRZ91PGl" title="Stock based compensation"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zXGG7paNdExg" title="Stock based compensation"&gt;1,466&lt;/span&gt; &lt;/span&gt;for the three months and nine months ended September 30, 2023 with respect
to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#x2019;s Board of Directors at the
Company&#x2019;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#x2019;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each of such persons ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each of such persons are contractually scheduled to expire one year from the respective dates that their service to the Company
terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zauCGEf9gBz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zs8KYHunmwUi" style="display: none"&gt;Summmary of Stock-based Compensation Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230701__20230930_zKvXYW25Doji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220701__20220930_zkWi7ODwOsjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230930_zihVRu0M1BH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220930_zEeAqz8dy69g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zUsTG6NOBHNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zIJ2IPZInf8k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zIGnguhXuLo2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zKYjKEx00hJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuOnmgRxuN4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2023 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zmI7aGeU55G8" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average Remaining Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230930_zdbiTnSA2AOa" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zv4loaOvqwRe" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.1826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230930_ztQZycVN4PJi" style="text-align: right" title="Number of shares, Granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zEN3kaotjXE7" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.4920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zgMvMYCbSQwh" style="text-align: right" title="Number of shares, Exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zHiQcLuvFmxd" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.0250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20230930_z0fOeCCEjqId" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;(3,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zeZmYLVRqwHc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;16.800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230930_z5Cdd26ERkNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z8ZFkZGA4aMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;17.8197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zWo2Yt9dEkJ2" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;4.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCVOhAWDILi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;281,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_zRNdZtWFjbzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;32.8335&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230930_zQV7tfaxceda" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;313,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zCOZ3jvLSAq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;31.8997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z02bkROQC2Yh" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zvPmWfj8TBi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $&lt;span id="xdx_900_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230930_ztT1f0Sd3Et9" title="Total deferred compensation expense for outstanding value of unvested stock options"&gt;808,000&lt;/span&gt; at September 30, 2023, which
will be recognized subsequent to September 30, 2023 over a weighted-average period of approximately &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230930_zRMIk1w1bWRa" title="Stock option vested exercisable term"&gt;28&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFHv7Nv5V2Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at September 30,
2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zc5BLjyk8Fm5" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BJvZTwvRMg" style="width: 30%; text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z4S0dDRoDK1g" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHlyPPzmVB49" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zW1Kv318YTAh" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znu0bafyQqw3" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1Y14Wvktsi9" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuOTbR14jGd9" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWArKZ3eUtzc" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFSENW3isqle" style="text-align: right" title="Options Exercisable (Shares)"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z049sE32KZX2" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3EzQLjoLWOh" style="text-align: right" title="Options Outstanding (Shares)"&gt;57,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zp4a3Cw0vm25" style="text-align: right" title="Options Exercisable (Shares)"&gt;41,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTNu4lOz3Elb" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zXo88duZ95B7" style="text-align: right" title="Options Outstanding (Shares)"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zznhSdtALEUa" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z2hJmRZJRvFj" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z5xoRZDMsLhb" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zG76ifye7pta" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zKangMbgi1x1" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNye65ckqlFe" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxIdreuF6F5k" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPjBV5zSIX7a" style="text-align: right" title="Exercise Prices"&gt;30.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zUoaqshFf6ka" style="text-align: right" title="Options Outstanding (Shares)"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNMHKGC96GY7" style="text-align: right" title="Options Exercisable (Shares)"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBgF0BrNcB9a" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLWvZvmQN0x7" style="text-align: right" title="Options Outstanding (Shares)"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEHI544hTjvc" style="text-align: right" title="Options Exercisable (Shares)"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMDm870ZUGb" style="text-align: right" title="Exercise Prices"&gt;32.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zd9Wnw0jSHT4" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zg0WYkhCZHm2" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrOOC4yPft16" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKfJ7QtIVlt4" style="text-align: right" title="Options Outstanding (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRYHIY9mZlTl" style="text-align: right" title="Options Exercisable (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zEN0rhxarIyk" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z9XPMuwqGXS9" style="text-align: right" title="Options Outstanding (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zzEwYECZuTka" style="text-align: right" title="Options Exercisable (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zYYI4ksHWSob" style="text-align: right" title="Exercise Prices"&gt;66.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwiJF2VE8qVh" style="text-align: right" title="Options Outstanding (Shares)"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRRzSGEUeHja" style="text-align: right" title="Options Exercisable (Shares)"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zYWnEYkDJsS5" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zEjNksFoRbIf" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zragodmNuVIl" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zy9cC17TEx4i" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgCKLz4dA9Xg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zt5zKAuuQKVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930_zlYWcK0ee0pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930_z3NySbFeQmuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;313,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zW3lKq54bZdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on a fair market value of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230930_zqZG0J7gcEog" title="Fair market value, per share"&gt;2.45&lt;/span&gt; per share on September 30, 2023, there was &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20230930_zGrCkwTuXzJ9" title="Intrinsic value"&gt;no&lt;/span&gt; intrinsic value attributed to exercisable but unexercised
common stock options at September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
stock options to acquire &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230930_zwwGYT2LDaC8" title="Outstanding stock options to acquire shares of common stock not vested"&gt;360,938&lt;/span&gt; shares of the Company&#x2019;s common stock had not vested at September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">233333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">413333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">336667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">136980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">550313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">199687</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXtUFyzGcPW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zfgpbDyRkv44" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930_zUwF11wlHIdl" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930_zlhGen2z87db" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930_zFXJ0JmdW6xf" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zFiz9nGu1nl2" title="Expected life"&gt;4.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the nine months ended September 30, 2022, the fair value of each stock option award
was estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220930_zDSXZcdldCtg" title="Risk-free interest rate"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220930_zJe73ve7yIY1" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20220930_zNEfvh7lXCuk" title="Expected volatility"&gt;198.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zisZAepBOJa3" title="Expected life"&gt;3.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.04843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">1.3805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-09-30">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Pure">0.0303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Pure">1.9879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase 5,833 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market
price of the Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $11,806 and $25,259 for the three
months ended September 30, 2023 and 2022, respectively, and $61,501 and $74,954 for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">11806</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">25259</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">74954</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase 8,333 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $572,650 ($68.718 per share), of which $143,163 was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company
recorded charges to general and administrative costs in the consolidated statement of operations of $12,551 and $36,085 for the three
months ended September 30, 2023 and 2022, respectively, and $83,544 and $107,078 for the nine months ended September 30, 2023 and 2022,
respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-07-302020-08-07_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="2"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">572650</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">143163</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">12551</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">36085</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">83544</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">107078</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase 5,833 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of five years at an exercise price of $71.40 per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $11,806 and $25,259 for the three months ended September 30,
2023 and 2022, respectively, and $61,501 and $74,954 for the nine months ended September 30, 2023 and 2022, respectively, with respect
to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember"
      decimals="INF"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="2"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">11806</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">25259</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">74954</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#x2019;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 25,000 shares of the Company&#x2019;s
common stock, exercisable for a period of five years at an exercise price of $32.00 per share (the closing market price on the grant
date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $753,611 ($30.144 per share), of which $376,800 was attributable to the portion of the stock options fully
vested on April 9, 2021 and was therefore charged to operations on that date. Although the remaining unvested portion of the fair value
of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options
terminated on October 30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $42,692 and $126,684 for the three months and nine months ended September
30, 2022, respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="2"
      unitRef="USDPShares">32.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">753611</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="4"
      unitRef="USDPShares">30.144</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-04-012021-04-09_custom_MrSchwartbergMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">376800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="0"
      unitRef="USD">42692</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="0"
      unitRef="USD">126684</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 25,000 shares of the Company&#x2019;s common stock, exercisable for a period of five years
at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($26.335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. The Company recorded charges to general and administrative costs in the consolidated statement of
operations of $0 and $38,827 for the three months ended September 30, 2023 and 2022, respectively, and $76,388 and $115,215 for the nine
months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="2"
      unitRef="USDPShares">28.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">658363</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="4"
      unitRef="USDPShares">26.335</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">329188</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">38827</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">76388</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">115215</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">the
Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of
Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000
shares (a total of 50,000
shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $30.30 per share (the
closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $1,421,095
($28.423
per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $0
and $179,100
for the three months ended September 30, 2023 and 2022, respectively, and $211,412
and $531,455
for the nine months ended September 30, 2023 and 2022, respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember"
      decimals="INF"
      unitRef="USDPShares">30.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">1421095</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      unitRef="USDPShares">28.423</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">179100</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">211412</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">531455</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 25,000 shares of the Company&#x2019;s common stock, exercisable for a period of five years
at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share),
of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $9,801 and $9,801 for the three months ended September 30, 2023 and 2022, respectively, and $29,084 and $90,449 for the nine months
ended September 30, 2023 and 2022, respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-06-162022-06-17_srt_DirectorMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="2"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">158525</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="4"
      unitRef="USDPShares">6.341</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">79263</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">9801</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">9801</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">29084</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">90449</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-06-30_srt_DirectorMember">the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $7.40 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($6.334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $23,916 and $39,860 for
the three months ended September 30, 2023 and 2022, respectively, and $70,965 and $39,860 for the nine months ended September 30, 2023
and 2022, respectively, with respect to these stock options.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-06-012021-06-30_srt_DirectorMember"
      decimals="0"
      unitRef="USD">10000</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-30_srt_DirectorMember"
      decimals="5"
      unitRef="USDPShares">50000</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-06-282022-06-30_srt_DirectorMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_srt_DirectorMember"
      decimals="2"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">316700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_srt_DirectorMember"
      decimals="5"
      unitRef="USDPShares">6.334</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_srt_DirectorMember"
      decimals="0"
      unitRef="USD">23916</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_srt_DirectorMember"
      decimals="0"
      unitRef="USD">39860</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_srt_DirectorMember"
      decimals="0"
      unitRef="USD">70965</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_srt_DirectorMember"
      decimals="0"
      unitRef="USD">39860</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_srt_DirectorMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Pure">0.25</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="0"
      unitRef="USD">262560</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="4"
      unitRef="USDPShares">3.282</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_FourOfficersMember"
      decimals="0"
      unitRef="USD">16528</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_FourOfficersMember"
      decimals="0"
      unitRef="USD">49053</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">43264</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      unitRef="USDPShares">4.326</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-06-30_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-06-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">5.88</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-06-292023-06-30_custom_FourNonOfficersMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-06-292023-06-30_custom_FourNonOfficersMember"
      decimals="0"
      unitRef="USD">192593</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficersMember"
      decimals="4"
      unitRef="USDPShares">4.8131</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_FourNonOfficersMember"
      decimals="0"
      unitRef="USD">24232</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_FourNonOfficersMember"
      decimals="0"
      unitRef="USD">24232</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.95</us-gaap:SharePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">403066</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">1.612</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">1466</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">1466</us-gaap:ShareBasedCompensation>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zauCGEf9gBz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months and nine months ended September 30, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zs8KYHunmwUi" style="display: none"&gt;Summmary of Stock-based Compensation Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230701__20230930_zKvXYW25Doji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220701__20220930_zkWi7ODwOsjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230930_zihVRu0M1BH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220930_zEeAqz8dy69g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zUsTG6NOBHNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zIJ2IPZInf8k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zIGnguhXuLo2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;112,106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;396,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;669,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,160,649&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">112106</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">396883</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">669146</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">1160649</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">112106</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">396883</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">669146</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1160649</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuOnmgRxuN4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2023 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zmI7aGeU55G8" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average Remaining Contractual Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230930_zdbiTnSA2AOa" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zv4loaOvqwRe" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.1826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230930_ztQZycVN4PJi" style="text-align: right" title="Number of shares, Granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zEN3kaotjXE7" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.4920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zgMvMYCbSQwh" style="text-align: right" title="Number of shares, Exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zHiQcLuvFmxd" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.0250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20230930_z0fOeCCEjqId" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;(3,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zeZmYLVRqwHc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;16.800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230930_z5Cdd26ERkNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z8ZFkZGA4aMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;17.8197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zWo2Yt9dEkJ2" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;4.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCVOhAWDILi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;281,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_zRNdZtWFjbzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;32.8335&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230930_zQV7tfaxceda" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;313,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zCOZ3jvLSAq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;31.8997&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z02bkROQC2Yh" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">389479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">29.1826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">2.4920</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">5.0250</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">3333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">16.800</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">674896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">17.8197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-09-30">P4Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">281979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">32.8335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">313959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">31.8997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-09-30">P1Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">808000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-09-30">P28M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFHv7Nv5V2Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at September 30,
2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zc5BLjyk8Fm5" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BJvZTwvRMg" style="width: 30%; text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z4S0dDRoDK1g" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHlyPPzmVB49" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zW1Kv318YTAh" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znu0bafyQqw3" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1Y14Wvktsi9" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuOTbR14jGd9" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWArKZ3eUtzc" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFSENW3isqle" style="text-align: right" title="Options Exercisable (Shares)"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z049sE32KZX2" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3EzQLjoLWOh" style="text-align: right" title="Options Outstanding (Shares)"&gt;57,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zp4a3Cw0vm25" style="text-align: right" title="Options Exercisable (Shares)"&gt;41,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTNu4lOz3Elb" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zXo88duZ95B7" style="text-align: right" title="Options Outstanding (Shares)"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zznhSdtALEUa" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z2hJmRZJRvFj" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z5xoRZDMsLhb" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zG76ifye7pta" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zKangMbgi1x1" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNye65ckqlFe" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxIdreuF6F5k" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zPjBV5zSIX7a" style="text-align: right" title="Exercise Prices"&gt;30.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zUoaqshFf6ka" style="text-align: right" title="Options Outstanding (Shares)"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNMHKGC96GY7" style="text-align: right" title="Options Exercisable (Shares)"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBgF0BrNcB9a" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLWvZvmQN0x7" style="text-align: right" title="Options Outstanding (Shares)"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEHI544hTjvc" style="text-align: right" title="Options Exercisable (Shares)"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMDm870ZUGb" style="text-align: right" title="Exercise Prices"&gt;32.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zd9Wnw0jSHT4" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zg0WYkhCZHm2" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrOOC4yPft16" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKfJ7QtIVlt4" style="text-align: right" title="Options Outstanding (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRYHIY9mZlTl" style="text-align: right" title="Options Exercisable (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zEN0rhxarIyk" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z9XPMuwqGXS9" style="text-align: right" title="Options Outstanding (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zzEwYECZuTka" style="text-align: right" title="Options Exercisable (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zYYI4ksHWSob" style="text-align: right" title="Exercise Prices"&gt;66.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwiJF2VE8qVh" style="text-align: right" title="Options Outstanding (Shares)"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRRzSGEUeHja" style="text-align: right" title="Options Exercisable (Shares)"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zYWnEYkDJsS5" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zEjNksFoRbIf" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zragodmNuVIl" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zy9cC17TEx4i" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgCKLz4dA9Xg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zt5zKAuuQKVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230930_zlYWcK0ee0pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;674,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230930_z3NySbFeQmuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;313,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">1.950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">5.880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">7.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">57500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">41563</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">20.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">20.600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">28.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">30.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">66667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">66667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="USDPShares">30.300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">42500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">42500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="USDPShares">32.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">20313</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">20313</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="USDPShares">32.100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="USDPShares">60.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="USDPShares">66.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">4167</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">4167</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="USDPShares">71.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="USDPShares">120.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">8332</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">8332</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">674896</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">313959</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-09-30"
      decimals="2"
      unitRef="USDPShares">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">360938</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zu0TA8k3fzQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_824_zLNnUH0Vo63h"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months and nine months ended September 30, 2023 and 2022, the Company did not record any provision for income taxes, as the
Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences
between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented as the Company currently
believes it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ9Sw9RVjYUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_82D_zver3TU4LCP"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2023 and
December 31, 2022, the Company was not subject to any pending or threatened legal claims or actions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2023, the Company&#x2019;s remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements not yet incurred, as described below, aggregated $&lt;span id="xdx_901_eus-gaap--ContractualObligation_iI_c20230930_zrb2O8bSHvak" title="Contractual commitment"&gt;6,262,000&lt;/span&gt;, which, based on current estimates, are currently scheduled to
be incurred through approximately December 31, 2027. The Company&#x2019;s ability to conduct and fund these contractual commitments is
subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation
of such funds to the Company&#x2019;s current or future clinical trial programs. The Company expects that the full amount of these expenditures
will be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration
are not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can
frequently involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified,
suspended or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein
should be considered as estimates only based on current clinical assumptions and conditions, and are typically subject to significant
modifications and revisions over time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzoVUGimRbHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_z1xWwPGQoxDa" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Institution&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Start
                                            Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
                                            End Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;in
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Study
                                            Objective&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Update&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NCT
                                            No.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: left"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zMweHho9w3cb" title="Clinical trial, description"&gt;LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Phase 1b&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: left"&gt;City of Hope and Sarah Cannon&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zkGYUKP3Zfqh" title="Estimated Start Date"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zbwDDMA9u5Z9" title="Estimated End Date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span id="xdx_90C_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zxabq7ZIrDjj" title="Number of Patients in Trial"&gt;14&lt;/span&gt; to &lt;span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zWO4jNr1shBd" title="Number of Patients in Trial"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Determine RP2D&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Three patients entered&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;NCT04560972&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_90D_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z6UaZC3NQEje" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in sarcoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Phase 1b&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;GEIS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zwtlNZQEM8ij" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zXCiV4a8eJff" title="Estimated End Date"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zq7hEVY7iX0k" title="Number of Patients in Trial"&gt;9&lt;/span&gt; to &lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zYEZiX3WVhxf" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine MTD and RP2D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;One patient entered&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT05809830&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zv0hojwaMeRj" title="Clinical trial, description"&gt;Doxorubicin with or without LB-100 in sarcoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Randomized Phase 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;GEIS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zXtpTMghuJG" title="Estimated Start Date"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zExmr02ZwFBj" title="Estimated End Date"&gt;June 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zagZZ9zMCkSj" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine efficacy: PFS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT05809830&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_908_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zzOUOeN7Pu8c" title="Description of Clinical Trial"&gt;LB-100 combined with dostarlimab in ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Phase 1b/2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;MD Anderson&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zJVMhpxLYtJ6" title="Estimated Start Date"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_z2sBINvnUAuc" title="Estimated End Date"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zqj4ttmOLVN9" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine the survival of patients with ovarian clear cell carcinoma&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No patients entered at September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT06065462&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z3IPntyM95le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into a five-year Clinical Trial Research Agreement with the Moffitt Cancer Center
and Research Institute Hospital Inc., Tampa, Florida (&#x201c;Moffitt&#x201d;). Pursuant to the Clinical Trial Research Agreement, Moffitt
agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#x2019;s lead
anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome
(MDS).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended June 30, 2023, the Phase 1b/2 clinical trial at Moffitt evaluating LB-100 in patients with MDS was closed by the
principal investigator. In this clinical trial, single agent LB-100 was used on a new schedule of days 1, 3, and 5 every 3 weeks. The
Company is not employing this schedule in its other clinical trials. Although the Maximally Tolerated Dose (&#x201c;MTD&#x201d;) was not
achieved, there was no dose-limiting toxicity on this schedule at doses that were greater than the MTD in the Phase 1 clinical trial
of LB-100 on the Monday, Tuesday, Wednesday schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zLlPogT4MNTj" title="Research and development process costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zyVwgf4xm8Je" title="Research and development process costs"&gt;9,218&lt;/span&gt;, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#x2019;s consolidated statements of operations. During the nine
months ended September 30, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zDIIUiL8ZRU6" title="Research and development process costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zC4xI4jGu5pb" title="Research and development process costs"&gt;18,623&lt;/span&gt;, respectively, pursuant to this agreement, which
have been included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of September 30,
2023, total costs of $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230130__20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjKf7nJJL9d9" title="Research and development costs"&gt;131,074&lt;/span&gt; have been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#x201c;Patent and License
Agreements - Moffitt&#x201d; below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas or &#x201c;GEIS&#x201d;), Madrid, Spain, to carry out a
study entitled &#x201c;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#x201d;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#x201c;ASTS&#x201d;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(&#x201c;PFS&#x201d;, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative
median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#x2019;s existing LB-100 inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zuRLIufGzrqj" title="Research and development costs"&gt;1,144,000&lt;/span&gt;. Although the production of new inventory
has been completed, nominal trailing costs subsequent to September 30, 2023 may be incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#xf1;ola de Medicamentos
y Productos Sanitarios or &#x201c;AEMPS&#x201d;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#x2019;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b section of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the
nine months ended September 30, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zhpdwMTxcFak" title="Research and development costs"&gt;268,829&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zu15nqUCyOx6" title="Research and development costs"&gt;0&lt;/span&gt;, respectively, pursuant to this agreement.
Such costs, when incurred, are included in research and development costs in the Company&#x2019;s consolidated statements of operations.
Through September 30, 2023, the Company has paid GEIS an aggregate of $&lt;span id="xdx_905_ecustom--AmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zpXK2C9wMoi6" title="Amount related to milestone payment"&gt;684,652&lt;/span&gt; for work done under this agreement through the fourth
milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfp1NkeOYKQ9" title="Aggregate commitments expected"&gt;3,423,000&lt;/span&gt;
as of September 30, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#x201c;City of Hope&#x201d;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#x2019;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#x201c;ED-SCLC&#x201d;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously
untreated ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#x201c;RP2D&#x201d;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm
the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free-survival and overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#x201c;SCRI&#x201d;), Nashville, Tennessee, joined the City of Hope&#x2019;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
early July 2023, the Company was notified that one of three centers accruing patients to its Phase 1b clinical trial in small cell lung
cancer had a shortage of carboplatin and as a result the clinical trial was placed on a temporary enrollment hold. This matter was resolved
and the temporary enrollment hold was lifted in late July 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. During the nine months
ended September 30, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zuqvNcSPWNY8" title="Research and development expense"&gt;69,001&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zP5pRYVBiWQl" title="Research and development expense"&gt;0&lt;/span&gt;, respectively, pursuant to this agreement, which are
included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of September 30, 2023, total
costs of $&lt;span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zdwWmlSCt5za" title="Total costs"&gt;447,512&lt;/span&gt; have been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zSeiWOnS6D5e" title="Aggregate commitments expected"&gt;2,433,000&lt;/span&gt;
as of September 30, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zVeUW4sPPOsc" title="Aggregate commitments expected"&gt;800,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Theradex.
&lt;/b&gt;On June 22, 2023, the Company finalized a work order agreement with Theradex Systems, Inc. (&#x201c;Theradex&#x201d;), an international
contract research organization (&#x201c;CRO&#x201d;), to conduct a Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin
alone in first line of advanced soft tissue sarcomas. The study is expected to be completed by June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zFxPBycuLeg6" title="Work cost"&gt;153,000&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z1AXKjoguBx8" title="Percentage of payment through services"&gt;72&lt;/span&gt;% to Theradex for services and approximately &lt;span id="xdx_90A_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVAsDydlzcRa" title="Percentage of payment through software"&gt;28&lt;/span&gt;% for payments for pass-through software costs. During the three months and nine months
ended September 30, 2023, the Company incurred costs of $$&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSTHoEM8mpEj" title="Research and development costs"&gt;3,750&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z3EdXnmm5Wne" title="Research and development costs"&gt;10,000&lt;/span&gt;, respectively, pursuant to this work order. As of September
30, 2023, total costs of $&lt;span id="xdx_906_eus-gaap--DeferredCosts_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLvm0N1ke9jl" title="Total costs"&gt;10,000&lt;/span&gt; have been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z5GGHCqJglzk" title="Aggregate commitments expected"&gt;144,000&lt;/span&gt; as of September 30, 2023, which is expected to be incurred through June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Cancer Institute Pharmacologic Clinical Trial. &lt;/b&gt;In May 2019, the National Cancer Institute (&#x201c;NCI&#x201d;) initiated a glioblastoma
(&#x201c;GBM&#x201d;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#x2019;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain has not been determined. Many
drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Five patients were entered into this study and analysis of the blood and tissue has been conducted. If there is clinical
evidence in at least two of the patients of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results
of this study are currently being reviewed by the NCI and a report is pending.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Trial&lt;/b&gt;. On September 20, 2023, the Company announced a Phase 1b/2 collaborative clinical trial to assess whether
adding LB-100 to the programmed death receptor-1 (&#x201c;PD-1&#x201d;)-blocking monoclonal antibody of GSK plc (&#x201c;GSK&#x201d;), dostarlimab,
may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#x201c;OCCC&#x201d;). The clinical trial
is sponsored by The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;) and will be conducted at MD Anderson, and
will also be open at Northwestern University&#x2019;s Robert H. Lurie Comprehensive Cancer Center. The Company will provide LB-100 and
GSK will provide dostarlimab and financial support for the clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Monitoring Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;On September 12, 2018, the Company finalized a work order agreement with Theradex (&#x201c;CRO&#x201d;), to monitor the Phase 1b/2
clinical trial being managed and conducted by Moffitt. The clinical trial began in April 2019 and the first patient was entered into
the clinical trial in July 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the three months ended September 30, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zamaK1pgiNqb" title="Research and development costs"&gt;566&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zgmkdNclhHC4" title="Research and development costs"&gt;11,953&lt;/span&gt;, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022, the Company incurred costs
of $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zNpO5ArAhM6b" title="Research and development costs"&gt;20,850&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zZT29UYWdHCb" title="Research and development costs"&gt;19,792&lt;/span&gt;, respectively, pursuant to this work order. As of September 30, 2023, total costs of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zblboL8TZ3O4" title="Research and development costs"&gt;148,138&lt;/span&gt; have been incurred
pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the closure of the Company&#x2019;s Clinical Trial Research Agreement with Moffitt during the three months ended June 30,
2023 (see &#x201c;Clinical Trial Agreements &#x2013; Moffitt&#x201d; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to September 30,
2023 are expected to be incurred relating to the closure of the Moffitt study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAbOe1yyahA5" title="Research and development costs"&gt;335,000&lt;/span&gt;. During the three months ended September 30, 2023 and 2022, the Company
incurred costs of $&lt;span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zZhDZv4Ngnp2" title="Advance amount related to milestone payment"&gt;4,500&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGeb3CpCF6qc" title="Advance amount related to milestone payment"&gt;7,731&lt;/span&gt;, respectively, pursuant to this work order. During the nine months ended September 30, 2023 and 2022,
the Company incurred costs of $&lt;span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zF1EKsYPpeB9" title="Advance amount related to milestone payment"&gt;15,740&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zqVqxKeecYJ6" title="Advance amount related to milestone payment"&gt;23,466&lt;/span&gt;, respectively, pursuant to this work order. As of September 30, 2023, total costs of
$&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_c20230930__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zXDTi6qcrZyg" title="Aggregate commitments expected"&gt;74,181&lt;/span&gt; have been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zRbqECELYYBc" title="Aggregate commitments expected"&gt;262,000&lt;/span&gt; as of September 30, 2023, which is expected to be incurred through March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#x201c;Licensed Patents&#x201d;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $&lt;span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zAeIbBBkFJDf" title="Non refundable license issue fee"&gt;25,000 &lt;/span&gt;after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $&lt;span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zApRbs2byUd6" title="Maintenance fee"&gt;25,000&lt;/span&gt; commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $&lt;span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsw53rxZnWC" title="Payment on non refundable milestone"&gt;1,897,000&lt;/span&gt;, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months and nine months ended September 30, 2023, the Company recorded credits to operations of $&lt;span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20230701__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z1CxROS0EXG1" title="Operating costs and expenses"&gt;21,507&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_c20230101__20230930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zP6QYLuaYHFl" title="Operating costs and expenses"&gt;9,109&lt;/span&gt;, respectively,
representing the reversal of obligations previously recorded with respect to the Exclusive License Agreement. During the three months
and nine months ended September 30, 2022, the Company recorded charges to operations of $&lt;span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20220701__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zud92GBcb3ca" title="Operating costs and expenses"&gt;6,301&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OperatingCostsAndExpenses_c20220101__20220930__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zoM6ohs9lD89" title="Operating costs and expenses"&gt;18,699&lt;/span&gt;, respectively, in connection
with its obligations under the Exclusive License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $&lt;span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_z1iuid16g825" title="Salary and compensation"&gt;640,000&lt;/span&gt;, payable monthly (see Note 6). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $&lt;span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_z5wxTcgx982k" title="Annual compensation"&gt;775,000&lt;/span&gt;, effective May 1,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zTmpyXfRFWP9" title="Compensation"&gt;200,000&lt;/span&gt;. In addition,
Mr. Forman is being provided an office allowance of approximately $&lt;span id="xdx_906_eus-gaap--PaymentsForRent_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zW91votLSB6g" title="Paid office rent"&gt;1,500&lt;/span&gt; per month through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $&lt;span id="xdx_90C_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_zvjgBCWu3xud" title="Annual salary"&gt;150,000&lt;/span&gt;. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#x2019;s annual may be
increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors. Mr. Van der Baan was appointed as Chairman of the Board
of Directors upon the death of Dr. Kovach on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate annual cash compensation for all officers increased to $&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20230925__20230926__srt--TitleOfIndividualAxis__srt--OfficerMember_zFZep8FiVpz" title="Compensation"&gt;950,000&lt;/span&gt;, effective September 26, 2023, which has continued through
September 30, 2023. As a result of Dr. Kovach&#x2019;s death on October 5, 2023, aggregate annual compensation of all officers will decrease
to $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20231004__20231005__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ9d6d04Dmy" title="Compensation"&gt;700,000&lt;/span&gt; from that date forward.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NDA
Consulting Corp.&lt;/b&gt; On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#x2019;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $&lt;span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOnWrw5qnBBj" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt;. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $&lt;span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOh1FdiHtaK2" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_c20220701__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYjwLAVRMBZ5" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt; for the three months
ended September 30, 2023 and 2022, respectively, and $&lt;span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYuWWjqVzzG" title="Consulting and advisory fee"&gt;12,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zPkFNR1YYQSb" title="Consulting and advisory fee"&gt;12,000&lt;/span&gt; for the nine months ended September 30, 2023 and 2022, which
were included in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioPharmaWorks&lt;/b&gt;.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#x2019;s
product pipeline; assisting in preparing technical presentations concerning the Company&#x2019;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $&lt;span id="xdx_904_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zX0iWnt9r0Q5" title="Consulting and advisory fee"&gt;10,000&lt;/span&gt;, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $&lt;span id="xdx_90F_ecustom--ReimbursementExpense_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zElbb42jkqIj" title="Reimbursed expense"&gt;30,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--ReimbursementExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zFE5UtSib4Ph" title="Reimbursed expense"&gt;30,000&lt;/span&gt; for the three months ended September 30, 2023 and
2022, respectively, and $&lt;span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zRzAEDgcIQ75" title="Reimbursed expense"&gt;90,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zIzXnqSxRsCd" title="Reimbursed expense"&gt;90,000&lt;/span&gt; for the nine months ended September 30, 2023 and 2022, respectively, which were included
in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute&lt;/b&gt;. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#x201c;NKI&#x201d;) (see Note 6), one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of &lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zh6xad3tqnPj" title="Aggregate commitments expected"&gt;391,000&lt;/span&gt; Euros and
provide a sufficient supply of LB-100 to conduct the study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
&lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z15qYDfwSemf" title="Aggregate commitments expected"&gt;250,000&lt;/span&gt; Euros (approximately $&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxZ7PYRN9w49" title="Aggregate commitments expected"&gt;263,000&lt;/span&gt; at October 3, 2023) to the operating budget being funded by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmXXu4Il4Az8" title="Advance amount related to milestone payment"&gt;51,568&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zA67BibNkONf" title="Advance amount related to milestone payment"&gt;46,068&lt;/span&gt;, respectively,
with respect to this agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated statements
of operations. During the nine months ended September 30, 2023 and 2022, the Company incurred charges in the amount of $&lt;span id="xdx_900_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zjSBsGbhW3qk" title="Advance amount related to milestone payment"&gt;156,949&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zYU2SzIExbQ5" title="Advance amount related to milestone payment"&gt;149,184&lt;/span&gt;,
respectively, with respect to this agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated
statements of operations. As of September 30, 2023, total costs of $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zyfriKm30zBf" title="Research and development costs"&gt;416,356&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s
aggregate commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlVPND6Qjsql" title="Aggregate commitments expected"&gt;316,000&lt;/span&gt; as
of September 30, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid
for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MRI
Global. &lt;/b&gt;The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $&lt;span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zOw1s53Hvd3b" title="Contract price"&gt;273,980&lt;/span&gt; for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$&lt;span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zfE3rkYMt2O9" title="Contract price"&gt;326,274&lt;/span&gt; for services to be rendered through April 30, 2024. During the three months ended September 30, 2023 and 2022, the Company incurred
costs of $&lt;span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z13A7he1ZCD9" title="Advance amount related to milestone payment"&gt;19,845&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbUE2GqePu4b" title="Advance amount related to milestone payment"&gt;5,549&lt;/span&gt;, respectively, pursuant to this contract. During the nine months ended September 30, 2023 and 2022, the Company
incurred costs of $&lt;span id="xdx_906_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zhW026YHpQrd" title="Advance amount related to milestone payment"&gt;27,028&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zt2JVOP8CER5" title="Advance amount related to milestone payment"&gt;25,902&lt;/span&gt;, respectively, pursuant to this work order. As of September 30, 2023, total costs of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zQUxCCDjlkFf" title="Research and development costs"&gt;241,841&lt;/span&gt; have
been incurred pursuant to this contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_902_eus-gaap--OtherCommitment_iI_c20230930_zTuGRcM6JdCd" title="Aggregate commitments expected"&gt;84,000&lt;/span&gt; as
of September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;External
Risks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Covid-19
Virus&lt;/b&gt;. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may reappear and impact the Company&#x2019;s clinical trial programs and capital raising efforts in the future is uncertain and
cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflation
Risk. &lt;/b&gt;The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#x2019;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#x2019;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#x2019;s working capital resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supply
Chain Issues. &lt;/b&gt;The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Potential
Recession. &lt;/b&gt;There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">6262000</us-gaap:ContractualObligation>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzoVUGimRbHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the contractual clinical trials discussed below as of September 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_z1xWwPGQoxDa" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Institution&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Start
                                            Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
                                            End Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;in
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Study
                                            Objective&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
                                            Update&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NCT
                                            No.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: left"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zMweHho9w3cb" title="Clinical trial, description"&gt;LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Phase 1b&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: left"&gt;City of Hope and Sarah Cannon&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zkGYUKP3Zfqh" title="Estimated Start Date"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zbwDDMA9u5Z9" title="Estimated End Date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span id="xdx_90C_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zxabq7ZIrDjj" title="Number of Patients in Trial"&gt;14&lt;/span&gt; to &lt;span id="xdx_90E_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zWO4jNr1shBd" title="Number of Patients in Trial"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Determine RP2D&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;Three patients entered&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;NCT04560972&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_90D_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z6UaZC3NQEje" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in sarcoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Phase 1b&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;GEIS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zwtlNZQEM8ij" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zXCiV4a8eJff" title="Estimated End Date"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zq7hEVY7iX0k" title="Number of Patients in Trial"&gt;9&lt;/span&gt; to &lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zYEZiX3WVhxf" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine MTD and RP2D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;One patient entered&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT05809830&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zv0hojwaMeRj" title="Clinical trial, description"&gt;Doxorubicin with or without LB-100 in sarcoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Randomized Phase 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;GEIS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zXtpTMghuJG" title="Estimated Start Date"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zExmr02ZwFBj" title="Estimated End Date"&gt;June 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zagZZ9zMCkSj" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine efficacy: PFS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT05809830&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_908_ecustom--ClinicalTrialDescription_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zzOUOeN7Pu8c" title="Description of Clinical Trial"&gt;LB-100 combined with dostarlimab in ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Phase 1b/2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;MD Anderson&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zJVMhpxLYtJ6" title="Estimated Start Date"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_z2sBINvnUAuc" title="Estimated End Date"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20230930__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1b2Member_zqj4ttmOLVN9" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Determine the survival of patients with ovarian clear cell carcinoma&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No patients entered at September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NCT06065462&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <LIXT:ClinicalTrialDescription contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember">LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember">March 2021</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember">March 2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Integer">14</LIXT:NumberOfPatientInTrial>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Integer">36</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember">LB-100 combined with doxorubicin in sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember">June 2023</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember">June 2024</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Integer">9</LIXT:NumberOfPatientInTrial>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Integer">18</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember">Doxorubicin with or without LB-100 in sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember">July 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember">June 2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialRandomizedPhaseTwoMember"
      decimals="INF"
      unitRef="Integer">150</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member">LB-100 combined with dostarlimab in ovarian clear cell carcinoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member">March 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member">December 2025</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialPhase1b2Member"
      decimals="INF"
      unitRef="Integer">21</LIXT:NumberOfPatientInTrial>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-07-012023-09-30_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-07-012022-09-30_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">9218</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-012023-09-30_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-01-012022-09-30_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">18623</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-302023-09-30_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">131074</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_OtherClinicalAgreementsMember"
      decimals="0"
      unitRef="USD">1144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      unitRef="USD">268829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-09-30_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      unitRef="USD">684652</LIXT:AmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      unitRef="USD">3423000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">69001</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">447512</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">2433000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:OtherCommitment>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">153000</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      unitRef="Pure">0.72</LIXT:ExpectedPaymentinServices>
    <LIXT:ExpectedPaymentThroughSoftware
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      unitRef="Pure">0.28</LIXT:ExpectedPaymentThroughSoftware>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">3750</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">144000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      unitRef="USD">566</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      unitRef="USD">11953</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      unitRef="USD">20850</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      unitRef="USD">19792</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      unitRef="USD">148138</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">335000</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-07-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">4500</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-07-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">7731</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">15740</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-09-30_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">23466</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_CityOfHopeNationalMedicalCenterMember"
      decimals="0"
      unitRef="USD">74181</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_WorkOrderAgreementMember_custom_CityOfHopeNationalMedicalCenterMember"
      decimals="0"
      unitRef="USD">262000</us-gaap:OtherCommitment>
    <LIXT:NonRefundableLicenseIssueFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">25000</LIXT:NonRefundableLicenseIssueFee>
    <LIXT:AnnualLicenseMaintenanceFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">25000</LIXT:AnnualLicenseMaintenanceFee>
    <LIXT:PaymentsOnNonrefundableMilestone
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">1897000</LIXT:PaymentsOnNonrefundableMilestone>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-07-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">21507</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">9109</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-07-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">6301</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-09-30_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">18699</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember"
      decimals="0"
      unitRef="USD">640000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember"
      decimals="0"
      unitRef="USD">775000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_FormanMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2022-11-052022-11-06_custom_FormanMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:PaymentsForRent>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-09-252023-09-26_srt_OfficerMember"
      decimals="0"
      unitRef="USD">950000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-10-042023-10-05_srt_OfficerMember_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">700000</us-gaap:OfficersCompensation>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2023-07-012023-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2022-07-012022-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2023-01-012023-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">12000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2022-01-012022-09-30_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">12000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">10000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ReimbursementExpense
      contextRef="From2023-07-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">30000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2022-07-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">30000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2023-01-012023-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">90000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2022-01-012022-09-30_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">90000</LIXT:ReimbursementExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="EUR">391000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="EUR">250000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">263000</us-gaap:OtherCommitment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-07-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">51568</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-07-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">46068</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">156949</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">149184</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">416356</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-09-30_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">316000</us-gaap:OtherCommitment>
    <LIXT:ContractPrice
      contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">273980</LIXT:ContractPrice>
    <LIXT:ContractPrice
      contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">326274</LIXT:ContractPrice>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-07-012023-09-30_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">19845</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-07-012022-09-30_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">5549</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-09-30_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">27028</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-09-30_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">25902</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">241841</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">84000</us-gaap:OtherCommitment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zXAWZTrsJx8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_82E_zlSvuJduLuj7"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements
with the SEC. Other than those matters described elsewhere in the footnotes, there were no material subsequent events which affected,
or could affect, the amounts or disclosures in the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2023-07-012023-09-30">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2023-07-012023-09-30">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2023-07-012023-09-30">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2023-07-012023-09-30">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,,;4[H&2W8:6Z^R9C >IM0RSERO!/:'2'>#SA91ZOY%^0?%8S^ _4$L#!!0
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MJ0 *ZRJ P# %$-B  H<VC@WW<9_+DTOH]N-[*&<;<:*")G)OM(%";_O;_I1
M.C<*;4E[EYXC0.;[KN]U1$& (75<OU/H$*#G097MJW.'/H\--WK_0YBA7$':
M.EP:I$W$I4& N#0($)5F<G1:FPNU*8_)-?#=%Z8ZHVN>-D?Q;\H#Z-;S:W8Y
M9\CSA3VZ+T^'#^ZK<__WL=JDA89WJ34,12\"V.I4=91>W1BY*\^*[Z0Q,B\O
MMR).A+( ^'XMI7FZL0,T/VC,_@-02P,$%     @ "(II5PI@6;JV @  ^@<
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MZU:&KMG@,N8SEW;G(M5R?1+B.WV.:IL-9'2SX;S#!C8;-'*$B''[2H*"-AM
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MC.V(GT0331CW\QU_>\"G1N;4JIV3-HUC!1Z,@?M^@G$PW)-6R\#S23R%OA<
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M//'$H@OA:ZK0J7PVB/Y3DG*Z3L8!N\'J09 R03K5$#8H6_H!+ B,.-HP8JF
MG3*E*@33+>OQ&N0!YY4D>=>"C3)12E#5(:J5\@6 OI?"Y9QJAPFV$AJ1 -]C
MLT?XWD!=<F,1W5@BR#[%N(2-&Q;N;+,?+";YXMO7X&RBWA-2&(I\5]3$6_(_
M70 86(=,Y0V 2/H](@+ %M"5U';.=P*\ S01J4[+X>BZTSU7>AAOF-P@HDR)
M]_:NJ(591P\;Y>.P\4V?V3=OKX:LSNFB0&GA+.'T+Z0+F'@0I307#56OLC:P
MF50B%-KZ#D&CE%4QIIQH,!@G1V^S/6]'CQ3/*ZPO1FRK0DUK:< L%H,OS, R
M;NE,)%N+="U4JP\ LHT*X0$^,19' <HS!,='TCPY/+ZVG2Z9CSP1LMDX\VMG
MTL@5[3XL @]":_'5': X8)0I<XQX=&$,"A)]EJCRJ&V&>#BCQ?S9CV.B[:5!
MG[&_8_J4JTZE-+Z-1B+:>>Q6"NZ'2(ZK6LD*% %E.!/INJH40D]OJRJU@FQ7
M"Y8OA[*%UD<;$9,(SWC8XH5H6ZM2MONCCHV:Z1'-L;EL:X48!LS&%,M"J]&/
MT="0]#_8VM!-3C_:C<">OZ(J)Q;8"VJ%9T*@8=XSYM=%L.SSB^1RCG!LI/.
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MJG3@]&8UF?O.B*\5J3[(C![$H2G0@I8:(P:@"^'&!M-V\V$-3V,<4 @SF%I
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MB3^LD!;D%))&+IB\OSJ9 -\S@PEP:)0\2M 3<"'EX6#24%:[KY)*- ^_>#.
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MKZ6AI\"9+9UB5!9 ZQLIS6E@ YQ?\\574$L#!!0    (  B*:5>/#)94*@8
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M%=WJM9^Q_,*JSLTUM\K2E.1>*QI+43,!?=\I CHL6,$TZ%[\!5!+ P04
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M0N5;^%T)PJS7EJEFU  [2)TQI2Y2^<:$NIEC^4@:9JX9!O9(H^^93NB14(+
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M0IG^,"9[F![.?#.*E3K,$.CC&>)]'&Z!Z>\BZ/)A/T%NY)BQ(LASK0B5Z\,
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M5T@\08)9\L@&ZQ-XW[_"G>,/Z'\"LR=02P,$%     @ "(II5S:[\,+*'P
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MQB-0*UFKU&\+F5$=:!6 %H4+>J2KD0?\=\1!9,]&R7VUEBF0BW_O\B5#AA
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MN3G(-^;4CG-0>CBMD"1WV?6HT<6F#8C=<R8\EJ_ 43_!$Y+9QF!K#R\_L0Z
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M:7@5GN<!1G)P^Z[*\HKNN0YG]53[>U9V>(F[ZSK%H31$=$HXS%U)RZG'G3M
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MPYE!$;Y@$!\,8L=[=.18ON6&SZ=*[D%9;4*S@@O561,YT=NBK(RB4T%V9OZ
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MT%<;:KZXRA#$#AZYE+S0"GZOM-*\B--BW\?W+&(_W_6@:4;C)Q)Y3GVB3$7
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MX])MRLIJFN5D9V=S513<4I2M 28SF"MIN=RB3#D:>+=FB4#S?A):\N4LPO2
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MGY_N=-!Q:^%=C><_@:?$[D/KVV\2&%T*2/GO-I5+%FX["_61..$YCF!BR*\
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M$U/%NY2K(&17+2UIDHEGUAK]](/7=7]M<C8DC$#"*!#,"$N[#$O;1A^- [E
MM^1NC*)$KD60A*PI$CFDFT'21\7S"'=<_6_H/&_[V%K7J3X^KDX*5*?AO4[I
MO<YA[TWN[@]X+X>TMUJ2-:3N/6M=IWKON#HI4)V&][JE][I6[[UE\R!&MXS)
M)J=U=\+O]?JNAVM.VS7#/<_K^J89V37K^QV_6Z/17;-!N]WK#THSHZ&]LJ$]
M>S?A4F4/Q"#6C[U/[]CRD8G/Z!_TP)Y9LF;HAB7A0C\VG[8OOBCFF.MNE2B1
M:^9#)"NK)K]9;^54T82$$4@8!8(9\>R7\>R#/\OZD&&!A!%(& 6"&6$9E&$9
M'!AFVP-%CS>AQ\IKM&(B/:VSE*:XY,C!UHAW+[R:QAQA0XZPH78;H\V>6\VW
M76NKW["$":VC03)%UU,]HX^DRF?3B'[1Z9]D_[?BV&_PU+X-2B.@- I%,T.]
ME5IYX+I3(*&" TDCH#0*13.#@ZO@8'CU*9BF)-2G.(51VOFVK7"G)D%[[#KU
M24YSI9T]0E0E>)XU4?G*0J2M/K)DR@5ZGS"[/(&FD: T DJC4#2S U2II->&
MER?(E'$,2B.@- I%,X-39:K>@53U+'GJ-"F*YPWJ"@6:NH+2*!3-]'N5XWKV
M)/=;J>(?&VY71>MMGSSP(&D$E$:A:&8'J')_KP>OBJ!)/"B-@-(H%,T,3I7(
M>]:$]$Q5[#>JHMNMJR)HF@Y*HU TT^]5IN[94_6OKHH3Q<,G]'Z57I3HC0@2
MQ:9(<40BP4+%A<SN9<S%BFL$0^]GLRAD0MI%U-K*D\<I)(V TB@4S7R15BUR
M8!=<1#'HL@0HC8#2*!3-#$ZU+(&MF?5Y(EHPZR**ZR+:;.?CVA24--MAMY[\
M[N&YO>;T%U?Y/[;G_P_:LX$(%YF.$*U8,5\M=?M/%K1Q]I*>B>/F>=>9:B5R
M':OT/?NA9-C>B),'!22-@-(H%,WL#M5J"(9_WXU!5RI :0241J%H9G"JE0I\
MX*WW68K5;E2.?CT9+NP&-<&JZU4SK3.HZU4C;<]; UPM!V#[<L#WH5:'DE1[
M(TX>$*"K%* T"D4SNT.U2H&[\&H%NH( 2B.@- I%,X-3K2#@0Y\/G*-6O<;Y
M4'M'K9KM=O6JU_32H/Z&LYGF=??-KJI$'=L3]>]$KQ:"'9A?@;[G!Z414!J%
MHID=HEI!P -XQ0)-UT%I!)1&H6CFIYY5NN[;OTDX2[$*9ET[ZC.B\1Z[;CTC
MW&.'VS7-*NR.^BS#KY)BWYX4?R/!"DS!NN5K8=4K>RM._L86]/, 4!J%HIG]
MH5H>\#&X7OF@R3HHC8#2*!3-#,[6M^GV3Q?.TRN_45]V9EB%74U?ZM^/V>_P
M9'^"YM?.UG80K43S;!^.1-F.CGP'0'FVW.MSG>UPJ9V_\2['7L-YXEW2?"=/
MA<\W%KT+Q#Q*)(K93%?E7O3T^!+Y7IW\0/%5MAGED2LMD]G/!0NF3*0&^OJ,
M<_5RD%90[I@:_0M02P,$%     @ "(II5U]ST,N5 P  01   !D   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULK5AM;Z,X&/PK%K<Z[4JW!6->>TFD-+!J
MI6M4->WN9S<X"5K G.TDO7]_-E#*6U&[RY<&FYFQYV%D>#H[4_:3'P@1X#E-
M,C[7#D+DE[K.MP>28GY!<Y+).SO*4BSDD.UUGC."HX*4)KII&(Z>XCC3%K-B
M[HXM9O0HDC@C=PSP8YIB]M\52>AYKD'M9>(^WA^$FM 7LQSOR8:(Q_R.R9%>
MJT1Q2C(>TPPPLIMK2W@9PH)0(+['Y,P;UT!9>:+TIQK<1'/-4#LB"=D*)8'E
MSXFL2)(H);F/?RM1K5Y3$9O7+^K?"O/2S!/F9$63'W$D#G/-TT!$=OB8B'MZ
MOB:5(5OI;6G"B[_@7&(=I('MD0N:5F2Y@S3.RE_\7!6B09 ZPP2S(IA=@O4&
M 54$]-X5K(I@O7<%NR(4UO72>U&X  N\F#%Z!DRAI9JZ**I?L&6]XDP%92.8
MO!M+GEAL9/*B8T( W8%[P@EFVP/ 600"<I(IRF4F!%A1+CCX'!"!XX1_ 5_!
MXR8 GS]]F>E"[D$IZ=MJO:MR/?.-]1"XI9DX<!!F$8D&^,$XWQ_AZ])[70#S
MI0!7YJC@AN07 !E_ =,PT<!^5N^GFT-V?F_U\)=7;Q4#U6E A1YZ0Z^5@*B1
M /(L3R9.AIYWJ>@4BNI8.BT@,BW/G>FG9AG[,-,UD>>U84$?YEJ^8?IM6-B'
M>;[M6*^PEGVKMF^-VG]<WSR$ =@\+!_"S9#74;HZTR]YCK=DKLE#FQ-V(MKB
MSS^@8_P]%*PIQ8(IQ<*)Q%K/P*Z?@3UY!$M%JY$&QT/0[B2PCX(.="VKD\ ^
MS/2A9SF=!/9A"#JV8P\GT*G=.Z/N-W?+F_60Q5':1Y,WI5@PI5@XD5BK]FY=
M>W?RY+F]%/B6WXG*J@^"9C=/01]D>LA G1"'?1BR/,\VAF/GU=:]4>NKZYOU
M<LC?*.VCL9M2+)A2+)Q(K%5[OZZ]/WGL_('#Q^B\2E=]D(,0,CJYZZ.@"_V.
M5MA'>=!X*W70>/WX-$:]K\.'Z_#^G^4Z&'S=CK,_&K])U8))U<*IU-K/H=$$
MP,DS6$DVO\%L:#O=% [ +,?HPH(!F!3S[4Y<PR&<I=[/G2CJC98H)6Q?]*(<
M;.DQ$^7W<#U;][O+HLOKS%_!RQ4<F ]4?URT8*_R97-]B]D^SCA(R$XN95RX
M\E.!E?UJ.1 T+QJR)RID>U=<'F2/3Y@"R/L[2L7+0"U0_]=@\3]02P,$%
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MD6L?M?MT_2*R(GE8"NU3)AY%EHE%A^MIJ_W>V4/[.ZAFHYJ#:BZJ>:CFHUJ
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M-0?57%3S4,U'M0#50E2+*$W.>-,>&J/7^AFC72%4LU#-1C4'U5Q4\U#-1[4
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M!<I_?TS3XO6+:H*O:?9EM]IW_P=02P,$%     @ "(II5[/0*<A> P  "A
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M(H\":QK/9B!HK3NK:RIDGZ8O=[)9!Z8,Y/T-I>)NH!QT[?_\%U!+ P04
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MEJ):AFHYJAE*L^N[2:@-W0FU?=?33.7]M9A=EY7WJ=CS,13W2)VK'PVSH9I
M-8EJ":HI5-.HEJ):AFHYJAE*L^>()F8W#(YT)6V(9NY0+48U@6H2U1)44ZBF
M42U%M0S5<E0SE&9/"4TR;^@,\^P]ZW9W[USXI!:CFD UB6H)JBE4TQO-.A^+
MHN'623<Z9G;0F#DZIJ&TIT(]6]R591T7=7'Q?EI6M^5E.9DLO*OYPZQ>#?+B
M4:\J;Y:%[+_[&)R<[3RN_7>IW_)XYK_+UX^?-?S%^_OBMC1%=3N>+;Q)>;,<
MJG<Z7"X7JO'MW?,W]?S^P\ERI?)M7M?SZ?K+N[)8GCJL&BS__F8^KW]^LQK@
M<5[]OCZ<B_\ 4$L#!!0    (  B*:5>G4GHHWP(  .,'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;*U5WV_:,!#^5ZQ,FC9I)2'A9P>1@%)U#]50
MT;J':0\FOA"KCIW9!LI_/]L)*;" ^K 7\-GW??[N?+D;[81\41F 1J\YXVKL
M95H7M[ZOD@QRK%JB &Y.4B%SK(TIU[XJ)&#B0#GSPR#H^3FFW(M';F\AXY'8
M:$8Y+"12FSS'<C\%)G9CK^T=-I[H.M-VPX]'!5[#$O2/8B&-Y=<LA.; %14<
M24C'WJ1].^M;?^?P3&&GCM;(1K(2XL4:W\C8"ZP@8)!HRX#-WQ9FP)@E,C+^
M5)Q>?:4%'J\/[/<N=A/+"BN8"?:3$IV-O8&'"*1XP_23V#U %4_7\B6"*?>+
M=J5OO^NA9*.TR"NP49!37O[CURH/1X#V)4!8 <(S0-BY (@J0.0"+96YL.ZP
MQO%(BAV2UMNPV87+C4.;:"BWK[C4TIQ2@]/QTI0%V3! (D7WF$KTC-G&67.<
M9.A[X9(]V6%)T%QI:A('!$V4>?7RZ-,=:$R9^CSRM=%C6?VDNGM:WAU>N'N(
M'@77F4)S3H"<XGT31QU,> AF&EXE7$+10E'P!85!&#7HF;T?'EZ1$]6YC1Q?
M]Q)?AB7<3$V1$;3 >U/[&DVDQ'P-;OUKLE):FD+^W92[DCMJYK8?]ZTJ< )C
MSWR]"N06O/CCAW8O^-H4^'\B.TE#ITY#YQI[_$35RTTJ 1#E&@R_1M)445/,
M)5&[XYAL ]K&02OH##KF-;?'\52.P:EC%+SYG4CMUE*[5Z7.7PO37LQS$;JE
M!#A!>PJ,-$DMB8;' LXT7O,X4=>KU?7>IVXK&-:44;UO4M;[-S?M5C0(NF?Z
M&OV&@_ZP666_5ME_GTI&T\9'O@[OH#U@J9J*^#HP*H&HC_*RJ_00P7O55,#^
M4;_,0:[=&%$H$1NNRVY3[]:3:N(:]-G^U$RP<N"\T93C[Q'+->4*,4@-9="R
M T.6(Z4TM"A<5UX);7J\6V9F"H.T#N8\%4(?#'M!/=?COU!+ P04    "  (
MBFE7KR&P\U<#  #H$   &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU
MF%]OVC 0P+^*E4U3)ZW-/TB!0:1",JW2.J&R;@_5'DQR0-0D9K:![MO/=D)*
MVC1K-_-";.?N=[X[^^ 8[@B]8RL CNZS-&<C8\7Y>F":+%I!AMD964,NWBP(
MS3 74[HTV9H"CI52EIJ.97EFAI/<\(=J;4K](=GP-,EA2A';9!FFO\>0DMW(
ML(W]PG6R7'&Y8/K#-5["#/C->DK%S*PH<9)!SA*2(PJ+D7%A#T+;D@I*XGL"
M.W8P1M*5.2%W<G(9CPQ+[@A2B+A$8/'8P@325)+$/GZ54*.R*14/QWOZ)^6\
M<&:.&4Q(^B.)^6ID] P4PP)O4GY-=I^A=*@K>1%)F?I$NT+6<PT4;1@G6:DL
M=I E>?'$]V4@#A0$IUG!*16<QPJ=9Q3<4L%]J85.J=!YJ85NJ:!<-PO?5> "
MS+$_I&2'J)06-#E0T5?:(EY)+@_*C%/Q-A%ZW)^) R)/""(+-.,DNCN588_1
MA&3B+#*LLCDAC#-T$@#'2<K>HU-T,PO0R=OW0Y.+/4B2&97VQH4]YQE[+KHB
M.5\Q%.8QQ WZ0;M^OT7?%+Y7 7#V 1@[K< 9K,^0:WU CN6X#?N9O%S=:7+G
M_ZR'_VR]%@RW.@VNXG6?X06P$"LQ&D,N1AQ-4YRC(&%12MB& KK](EZC2PX9
M^]F4^X+N-M-ES1NP-8Y@9(BBQH!NP?#?O;$]ZV-3X'7" IVP4!.LEJ).E:).
M&]W_1CA.$3NXJM'A58WD56U*34'U%%5^>VQ]VW9LRQN:V\.@/Q5S^UZOY];%
M@J=BGM>W.X]H89-1S_(Z_4JN%H-N%8-N:PRN(<5<>#[%E"? T.T59'.@C4>R
ME?3:(ZD3%NB$A9I@M71X53J\HU8-3V>*=,("G;!0$ZR6HO,J1>='J1H%M?.W
MJO%4K+%J/!5KK!I-1ENJ1J^*0:\U!E^%HZ^I'*VTUQY+G;! )RS4!*NEI%^E
MI'_4RM'7F2*=L$ G+-0$JZ7(MAXZ!.LHM:,=V[QMU)087:! %RC4 "J281YT
M;AG0I6J9F8CI)N?%S_9JM6K++U0S^FA]; \F=L-Z(-MXU2D^X(O_ *XP728Y
M0RDLA"GK[%Q<4EJTU<6$D[7J&^>$BRY4#5> 8Z!20+Q?$,+W$VF@^G/#_P-0
M2P,$%     @ "(II5\NM/Z@H!   (A(  !D   !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&ULM9C?<Z,V$,?_%0WM=.YF$H.$L2&U/>,DU_8>[BYSGC8/G3[(
ML+:9 **2'"?_?25!L(.Q;DQ2'FQ^:%?[^>X*%B8[QA_$!D"BISPKQ-392%E>
MN:Z(-Y!3,6 E%.K*BO&<2G7(UZXH.=#$&.692SQOY.8T+9S9Q)R[X[,)V\HL
M+>".(['-<\J?KR%CNZF#G9<3W]/U1NH3[FQ2TC4L0/Y9WG%UY#9>DC2'0J2L
M0!Q64V>.KV[P6!N8$7^EL!,'^TBC+!E[T >?DZGCZ8@@@UAJ%U3]/<(-9)GV
MI.+XMW;J-'-JP\/]%^^_&7@%LZ0";EAVGR9R,W5"!R6PHMM,?F>[/Z &"K2_
MF&7"_*)=/=9S4+P5DN6UL8H@3XOJGS[50AP8D-$) U(;D)8!'IXP\&L#WX!6
MD1FL6RKI;,+9#G$]6GG3.T8;8ZUHTD*G<2&YNIHJ.SE;5.E#;(46DL4/Z%MI
MY)UK>5/YC#X7<;9-TF)=7Q%(RZ?'WU/.:2$%^G +DJ:9^(@NT<_(16)#.8B)
M*U5\>A8WKF.YKF(A)V*)T!=6R(U GXH$DM?VKN)JX,@+W#6Q.EQ .4"^=X&(
M1_R.>&[LYK<0*W-LS(DE'+_1VC?^@E/A:%TNKU71)>B./JO%(-%<:[@&L__W
M?"DD5X7]3Y=VE6^_V[=>[5>BI#%,';6<!?!'<&:__(1'WJ]=X._D[)4,PT:&
MH<W[[.LV7P+7%505R@42IO)875_J9B,D+73-72 JD=P 6L(Z+0IUIDN9:KJA
MF4[?MAYG?A@-Q]'$?3QDMD;5DSEHF ,K\[VYG:B\TT?@ZO:(X EXG I )4]C
M>+,$U>SC PE(-, A&;4TL$;94X-1H\'HS+S_KN\?[95> 8V.<DHB3VTM'NN,
M/7G&#<_X;3E=G\8;'^=K,(Q(B\XZ?T^ZL*$+S\S6IQJO$R@\RM<E)D$[7=8I
M>P)%#5#TMG2!C2\Z2E@P\$C0XK-&T),/>_M'N7=VRLJ4=P/5OEYES%=;B\@^
M95^D@^X$OS5IIPGKS@<?(.+1(&P36B/H2TCVA.3=GX90= .3HY2.QL,P:C\$
M[!'U)=YW0=C:7;S'L_"4 /[1*L7C08BC<5N!_Z/_P?L&"-L[H",%..@W+MUD
MQZH#UBW@EF8H2U> /J0%>@;*Q4>+,)UBV&,85EX1QBBONFX<H(0^=_7M-W9?
M??7:-T_8WCW]:(W4!427&?RP1(+C9A'[4=!N%CO&$5U(^W&O6?9-$+9W06=6
M_SEHHZ/J]_$@C(ZKOV,@&82^'YR VW=$^,R6J%=A'S!W<MICP,;K05T/3Y?U
MNS98[L%;> Y\;3Y." 6^+63U0MZ<;3Z S,UKO[L?7GT]^4*Y:O8%RF"E3+W!
M6%4CKSY(5 >2E>:=?LFD9+G9W0!-@.L!ZOJ*,?ERH"=H/@O-_@-02P,$%
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M#C4<*$-Q/.Q-R6UZ*T"L":E-_:\K1Q8$W8F3-"")[HHDG)-;9#Y5ZOLV*-$
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M8NPW>O/\T%RI_9N29P+&N>#OC3S:,V,!XXH9M5@TO?G!B"ZX=\&;&LK[G\U
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MU0LOMB1C57[.5^*Y,:%R=9$@-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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M.QNF#3RP.!#I]W*-KS9>(;OK %O3716"S12O1&RF>*X!L><-/*+(OMI8'/#
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MK<KFZ,^Z/T?S3U!+ 0(4 Q0    (  B*:5<'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "(II5XWG
MMAGO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ "(II5YE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (BFE7,Y9'S$T&  #B
M(P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ "(II5YQ0 C)1!0  H!,  !@              ("!D0X
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  B*:5<%AZW)
MB@,  #<-   8              " @1@4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  (BFE7?A*L(.@%  #<&   &
M@('8%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "(II
M5PI@6;JV @  ^@<  !@              ("!]AT  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    (  B*:5=%#)1=)0@  -L\   8
M      " @>(@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  (BFE7WFZV)+<%  "A%P  &               @($]*0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ "(II5TF(VV&7 @  VP<  !@
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M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "(II5X(
M*)R%'@  F5T  !D              ("!G48  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    "  (BFE71+0#;WD#  #9!P  &0
M    @(%990  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M  B*:5>/#)94*@8  /0.   9              " @0EI  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ "(II5X_PWOLD"0  "QD  !D
M             ("!:F\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  (BFE7VL1:&P@-  !F)P  &0              @('%>   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  B*:5<]ZYGE)P,
M "$'   9              " @02&  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ "(II5V\)X:L6&@  ]T8  !D              ("!
M8HD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  (BFE7
M+-I0/*@"   0!@  &0              @(&OHP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    (  B*:5<VN_#"RA\  #9F   9
M      " @8ZF  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ "(II5Y+-,]1- P  20<  !D              ("!C\8  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  (BFE7S>7AFH(#  #,!P
M&0              @($3R@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    (  B*:5<)>S<K>@,  -L(   9              " @<S-  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "(II5RU4BHLQ
M P  3@<  !D              ("!?=$  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  (BFE7@!.MP+D%  !_$0  &0
M@('EU   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  B*
M:5>EU?<&$@0  "8)   9              " @=7:  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ "(II5QZ<YE3X 0  + 0  !D
M         ("!'M\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  (BFE7S< I^*D#  #(#0  &0              @(%-X0  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  B*:5>4](;[6@,  &,.
M   9              " @2WE  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ "(II5_]$RE6 !@  /34  !D              ("!ON@
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  (BFE77W/0
MRY4#  !!$   &0              @(%U[P  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    (  B*:5>44KF_%@0  ((2   9
M  " @4'S  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M"(II5P7MF4IX P  41$  !D              ("!CO<  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  (BFE7*ZCAINP1  ". @$ &0
M            @($]^P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    (  B*:5>ST"G(7@,   H0   9              " @6 - 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "(II5U&3B);G$
MQ!T! !D              ("!]1 ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  (BFE7IU)Z*-\"  #C!P  &0              @($3
M(@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  B*:5>O
M(;#S5P,  .@0   9              " @2DE 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ "(II5\NM/Z@H!   (A(  !D
M     ("!MR@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B*:5?!\*\-= ,  +H6   -              "
M ;J2 0!X;"]S='EL97,N>&UL4$L! A0#%     @ "(II5Y>*NQS     $P(
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9>&UL4$L%!@     S #, W T  #R? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>380</ContextCount>
  <ElementCount>235</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995514 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995516 - Disclosure - Research and Development Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCosts</Role>
      <ShortName>Research and Development Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995518 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995519 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995520 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995521 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995522 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995524 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Research and Development Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCostsTables</Role>
      <ShortName>Research and Development Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/ResearchAndDevelopmentCosts</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995526 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995528 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995529 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995531 - Disclosure - Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BusinessDetailsNarrative</Role>
      <ShortName>Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Business</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995534 - Disclosure - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails</Role>
      <ShortName>Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995538 - Disclosure - Summary of Related Party Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfRelatedPartyCostsDetails</Role>
      <ShortName>Summary of Related Party Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995539 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails</Role>
      <ShortName>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails</Role>
      <ShortName>Summmary of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Summary of Stock Option Activity Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995544 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails</Role>
      <ShortName>Schedule of Contractual Clinical Trials (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995546 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>lixt-20230930.xsd</File>
    <File>lixt-20230930_cal.xml</File>
    <File>lixt-20230930_def.xml</File>
    <File>lixt-20230930_lab.xml</File>
    <File>lixt-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="770">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "lixt-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lixt-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 194,
   "keyCustom": 41,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 78,
   "hidden": {
    "total": 64,
    "http://fasb.org/us-gaap/2023": 56,
    "http://lixte.com/20230930": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 380,
   "entityCount": 1,
   "segmentCount": 107,
   "elementCount": 533,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 770,
    "http://xbrl.sec.gov/dei/2023": 33,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://lixte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lixte.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "LIXT:AdvancesOnResearchAndDevelopmentContractServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lixte.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lixte.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://lixte.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://lixte.com/role/StatementsOfStockholdersEquity",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://lixte.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentation",
     "longName": "995513 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lixte.com/role/Business",
     "longName": "995514 - Disclosure - Business",
     "shortName": "Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995515 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lixte.com/role/ResearchAndDevelopmentCosts",
     "longName": "995516 - Disclosure - Research and Development Costs",
     "shortName": "Research and Development Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lixte.com/role/StockholdersEquity",
     "longName": "995517 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lixte.com/role/RelatedPartyTransactions",
     "longName": "995518 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lixte.com/role/Stock-basedCompensation",
     "longName": "995519 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lixte.com/role/IncomeTaxes",
     "longName": "995520 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lixte.com/role/CommitmentsAndContingencies",
     "longName": "995521 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lixte.com/role/SubsequentEvents",
     "longName": "995522 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995523 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995524 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lixte.com/role/ResearchAndDevelopmentCostsTables",
     "longName": "995525 - Disclosure - Research and Development Costs (Tables)",
     "shortName": "Research and Development Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "LIXT:ResearchDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "LIXT:ResearchDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lixte.com/role/StockholdersEquityTables",
     "longName": "995526 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsTables",
     "longName": "995527 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lixte.com/role/Stock-basedCompensationTables",
     "longName": "995528 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesTables",
     "longName": "995529 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "longName": "995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-06-022023-06-02_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://lixte.com/role/BusinessDetailsNarrative",
     "longName": "995531 - Disclosure - Business (Details Narrative)",
     "shortName": "Business (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "995532 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995533 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
     "longName": "995534 - Disclosure - Schedule of Research and Development Costs (Details)",
     "shortName": "Schedule of Research and Development Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_country_US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ResearchDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "995535 - Disclosure - Schedule of Warrants Outstanding (Details)",
     "shortName": "Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "995536 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_ExercisePriceOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://lixte.com/role/StockholdersEquityDetailsNarrative",
     "longName": "995537 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-07_us-gaap_InvestorMember",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
     "longName": "995538 - Disclosure - Summary of Related Party Costs (Details)",
     "shortName": "Summary of Related Party Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_custom_StockBasedMember",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995539 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2022-06-15",
      "name": "us-gaap:ManagementFeePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-15",
      "name": "us-gaap:ManagementFeePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
     "longName": "995540 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "shortName": "Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails",
     "longName": "995541 - Disclosure - Summmary of Stock-based Compensation Costs (Details)",
     "shortName": "Summmary of Stock-based Compensation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_custom_RelatedPartiesMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
     "longName": "995542 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "shortName": "Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
     "longName": "995543 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "shortName": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "995544 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
     "longName": "995545 - Disclosure - Schedule of Contractual Clinical Trials (Details)",
     "shortName": "Schedule of Contractual Clinical Trials (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember",
      "name": "LIXT:ClinicalTrialDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-09-30_custom_ClinicalTrialPhase1bMember",
      "name": "LIXT:ClinicalTrialDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995546 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-09-252023-09-26_srt_OfficerMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AnnualNetRevenueDividedByConvertedOrRedeemedShares",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual net revenue",
        "documentation": "Annual net revenue divided by converted or redeemed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r714"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "LIXT_ConsultingAndAdvisoryCashFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ConsultingAndAdvisoryCashFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and advisory fee",
        "documentation": "Consulting and advisory quarterly cash fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value, per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "LIXT_ReimbursementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ReimbursementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursed expense",
        "documentation": "Reimbursement expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, stock options outstanding, at the beginning",
        "periodEndLabel": "Number of shares, stock options outstanding, at the end",
        "label": "Shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, stock options outstanding, at the beginning",
        "periodEndLabel": "Weighted average exercise price, stock options outstanding, at the end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299"
     ]
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share",
        "documentation": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, stock options exercisable, at the end",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, stock options exercisable, at the end",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal cash obligations and commitments",
        "documentation": "Number of share tranche of the series a convertible preferred stock receive a per share dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClassOfWarrantOrRighstTermFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expires term",
        "documentation": "Class of warrant or righst term from which warrants or rights exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "LIXT_ManagementFeePayableQuarterly": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ManagementFeePayableQuarterly",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash board fee payable quarterly",
        "documentation": "Management fee payable quarterly."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Warrants Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "LIXT_FairValueOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "FairValueOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock options",
        "documentation": "Fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r338",
      "r341",
      "r342",
      "r345",
      "r349",
      "r350",
      "r351",
      "r352",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted to purchase common stock, issued",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r247",
      "r248",
      "r573",
      "r734"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardIssuancePercentage",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation issuance, percentage",
        "documentation": "Share based compensation arrangement by share based payment award issuance percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "LIXT_ClinicalTrialDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialDescription",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Clinical Trial",
        "documentation": "Clinical trial description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate commitments expected",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r464"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodStartDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ContractualClinicalTrialPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Start Date",
        "documentation": "Contractual clinical trial period start date."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodEndDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ContractualClinicalTrialPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated End Date",
        "documentation": "Contractual clinical trial period end date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "LIXT_NumberOfPatientInTrial": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NumberOfPatientInTrial",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Patients in Trial",
        "documentation": "Number of patient in trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "LIXT_VendorAndConsultantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorAndConsultantThreeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant Three [Member]",
        "documentation": "Vendor And Consultant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r393"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r683"
     ]
    },
    "LIXT_AmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AmountRelatedToMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount related to milestone payment",
        "documentation": "Amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other costs and expenses",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r453"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r722",
      "r723",
      "r746",
      "r763",
      "r767"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted to purchase common stock, issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r202",
      "r572"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_EstimatedWorkCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "EstimatedWorkCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work cost",
        "documentation": "Estimated work cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r393"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r598",
      "r741",
      "r761",
      "r762"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r291"
     ]
    },
    "LIXT_ExpectedPaymentinServices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExpectedPaymentinServices",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through services",
        "documentation": "Expected payment in services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value of stock",
        "verboseLabel": "Stock price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PaymentsOnNonrefundableMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "PaymentsOnNonrefundableMilestone",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment on non refundable milestone",
        "documentation": "Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share",
        "documentation": "Warrants to Purchase Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "LIXT_ExpectedPaymentThroughSoftware": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExpectedPaymentThroughSoftware",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through software",
        "documentation": "Percentage of expected paymen through software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r130",
      "r586"
     ]
    },
    "LIXT_VendorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorOneMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor One [Member]",
        "documentation": "Vendor One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "LIXT_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "StockOptionsGrantedtoDirectorsAndCorporateOfficersMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Granted to Directors and Corporate Officers [Member]",
        "documentation": "Stock Options Granted to Directors and Corporate Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvanceAmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AdvanceAmountRelatedToMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance amount related to milestone payment",
        "documentation": "Advance amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares avaliable for issuable",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "LIXT_NonRefundableLicenseIssueFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NonRefundableLicenseIssueFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable license issue fee",
        "documentation": "Company is obligated to pay non refundable license issue fee.."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorAndConsultantTwoMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant Two [Member]",
        "documentation": "Vendor And Consultant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "LIXT_VendorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorTwoMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Two [Member]",
        "documentation": "Vendor Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r264",
      "r279",
      "r364",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r451",
      "r594",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "LIXT_AnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AnnualLicenseMaintenanceFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintenance fee",
        "documentation": "Company is obligated to pay annual license maintenance fee."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorAndConsultantOneMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant One [Member]",
        "documentation": "Vendor And Consultant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BastiaanVanDerBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "BastiaanVanDerBaanMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bastiaan van der Baan [Member]",
        "documentation": "Bastiaan van der Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_Dr.JamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "Dr.JamesMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr.James [Member]",
        "documentation": "Dr.James [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r175"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding Shares",
        "verboseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r202"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceElevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eleven [Member]",
        "documentation": "Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidInsurance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid insurance",
        "label": "Increase (Decrease) in Prepaid Insurance",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r293",
      "r324",
      "r325",
      "r326",
      "r600"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded common stock warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of common stock in direct equity offering, net of offering costs, shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceTwelveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Twelve [Member]",
        "documentation": "Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r648",
      "r658",
      "r675",
      "r683",
      "r687",
      "r695"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "LIXT_ExercisePriceThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceThirteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceThirteen [Member]",
        "documentation": "Exercise PriceThirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r150",
      "r265",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r280",
      "r283",
      "r365",
      "r547",
      "r549",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lixte.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r394"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "LIXT_ExercisePriceFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceFourteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fourteen [Member]",
        "documentation": "Exercise Price Fourteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "LIXT_ExercisePriceFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceFifteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fifteen [Member]",
        "documentation": "Exercise Price Fifteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/BusinessDetailsNarrative",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "verboseLabel": "Contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "LIXT_ClinicalTrialResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialResearchAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research Agreement [Member]",
        "documentation": "Clinical Trial Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_OtherClinicalAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "OtherClinicalAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Clinical Agreements [Member]",
        "documentation": "Other Clinical Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "GrupoEspanolDeInvestigacionEnSarcomasMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEIS [Member]",
        "documentation": "GEIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "LIXT_CityOfHopeNationalMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CityOfHopeNationalMedicalCenterMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City of Hope [Member]",
        "documentation": "City of Hope [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "LIXT_ClinicalResearchSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalResearchSupportAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Research Support Agreement [Member]",
        "documentation": "Clinical Research Support Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "LIXT_WorkOrderAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "WorkOrderAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work Order Agreement [Member]",
        "documentation": "Work Order Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r286",
      "r288",
      "r319",
      "r320",
      "r321",
      "r401",
      "r425",
      "r454",
      "r489",
      "r490",
      "r552",
      "r555",
      "r559",
      "r560",
      "r562",
      "r583",
      "r584",
      "r593",
      "r596",
      "r599",
      "r602",
      "r605",
      "r733",
      "r739",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "LIXT_TheradexSystemsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "TheradexSystemsIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theradex Systems, Inc. [Member]",
        "documentation": "Theradex Systems, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r135",
      "r151",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r354",
      "r356",
      "r369",
      "r601",
      "r737",
      "r738",
      "r752"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MoffittCancerCenterandResearchInstituteHospitalIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]",
        "documentation": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r179",
      "r266",
      "r267",
      "r268",
      "r270",
      "r273",
      "r279",
      "r281",
      "r465",
      "r466",
      "r467",
      "r468",
      "r596",
      "r704",
      "r718"
     ]
    },
    "LIXT_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "LIXT_ExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExecutiveOfficersMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officers [Member]",
        "documentation": "Executive Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r96",
      "r448",
      "r458",
      "r459",
      "r469",
      "r500",
      "r601"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r387",
      "r388",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r516",
      "r518",
      "r551",
      "r751"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r254",
      "r735",
      "r736"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs and expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r337"
     ]
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, conversion description",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r73"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r254",
      "r735",
      "r736"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation to related parties, including stock-based compensation expense of $112,106 and $396,883 for the three months ended September 30, 2023 and 2022, respectively, and $669,146 and $1,160,649 for the nine months ended September 30, 2023 and 2022, respectively",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r522"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r132",
      "r133",
      "r134",
      "r151",
      "r170",
      "r171",
      "r173",
      "r175",
      "r179",
      "r180",
      "r234",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r266",
      "r267",
      "r270",
      "r273",
      "r281",
      "r369",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r499",
      "r520",
      "r544",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r704",
      "r718",
      "r725"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Information [Table]",
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BusinessDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net Cash Provided by (Used in) Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r90",
      "r501",
      "r517",
      "r545",
      "r546",
      "r601",
      "r613",
      "r719",
      "r731",
      "r747",
      "r767"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development process costs",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expires date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses and current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r764"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r607",
      "r608",
      "r609",
      "r610",
      "r763",
      "r767"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r641",
      "r651",
      "r676"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r643",
      "r653",
      "r678"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "documentation": "Person with designation of chief operating officer."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r750"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r629",
      "r641",
      "r651",
      "r676"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of common stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r15"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding stock options to acquire shares of common stock not vested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r642",
      "r652",
      "r677"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r684"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrJamesSMiserMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "DrJamesSMiserMDMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. James S. Miser, M.D [Member]",
        "documentation": "Dr. James S. Miser, M.D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r93",
      "r95",
      "r96",
      "r132",
      "r133",
      "r134",
      "r179",
      "r266",
      "r267",
      "r268",
      "r270",
      "r273",
      "r279",
      "r281",
      "r465",
      "r466",
      "r467",
      "r468",
      "r596",
      "r704",
      "r718"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16"
     ]
    },
    "LIXT_DrKovachMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "DrKovachMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Kovach [Member]",
        "documentation": "Dr. Kovach [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value; authorized \u2013 10,000,000 shares; issued and outstanding \u2013 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares \u2013 72,917 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r446",
      "r601"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r129",
      "r151",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r355",
      "r356",
      "r357",
      "r369",
      "r601",
      "r737",
      "r752",
      "r753"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "LIXT_VendorAndConsultantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "VendorAndConsultantFourMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Four [Member]",
        "documentation": "Vendor and Consultant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Licensing Legal and Filing Fees and Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r426",
      "r427",
      "r428",
      "r430",
      "r589"
     ]
    },
    "LIXT_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares were available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "LIXT_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r178",
      "r429",
      "r463",
      "r485",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r521",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r544",
      "r606"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r750"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of common stock in direct equity offering, net of offering costs, shares",
        "negatedLabel": "Number of shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r96",
      "r303"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r334"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r131",
      "r151",
      "r181",
      "r193",
      "r197",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r354",
      "r356",
      "r369",
      "r444",
      "r511",
      "r601",
      "r613",
      "r737",
      "r738",
      "r752"
     ]
    },
    "LIXT_PlacementAgentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "PlacementAgentsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents [Member]",
        "documentation": "Placement Agents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issuable upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r44",
      "r73",
      "r94",
      "r276"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CommonStockWarrantMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrant [Member]",
        "documentation": "Common Stock Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r627",
      "r640"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option vested exercisable term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and licensing legal and filing fees and costs",
        "verboseLabel": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r69",
      "r445",
      "r498"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense included in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Total stock-based compensation costs",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Related Party Costs",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "LIXT_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r104",
      "r449",
      "r601",
      "r719",
      "r731",
      "r747"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r106",
      "r142",
      "r184",
      "r382",
      "r528",
      "r611",
      "r766"
     ]
    },
    "LIXT_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r202",
      "r572"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r541"
     ]
    },
    "LIXT_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r202",
      "r460",
      "r572"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r705"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "LIXT_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r175"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r149"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "LIXT_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award, award vesting period",
        "verboseLabel": "Share based compensation vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options fully vested amount, fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "LIXT_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Ten [Member]",
        "documentation": "Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "country_ES": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "ES",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MsReginaBrownMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MsReginaBrownMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms.Regina Brown [Member]",
        "documentation": "Ms.Regina Brown [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for -",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "LIXT_FiveNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "FiveNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non Officer Directors [Member]",
        "documentation": "Five Non Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r683"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r170",
      "r173",
      "r174",
      "r175",
      "r177",
      "r367",
      "r368",
      "r443",
      "r452",
      "r590"
     ]
    },
    "LIXT_NonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Officer Directors [Member]",
        "documentation": "Non Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r125",
      "r200",
      "r201",
      "r486",
      "r487",
      "r488",
      "r554",
      "r557",
      "r561",
      "r564",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r597",
      "r605",
      "r741",
      "r761"
     ]
    },
    "LIXT_BasvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "BasvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasvanderBaan [Member]",
        "documentation": "BasvanderBaan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs of public offering",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r192",
      "r196",
      "r198",
      "r591"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "LIXT_FourOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "FourOfficersMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Officers [Member]",
        "documentation": "Four Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "LIXT_FourNonOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "FourNonOfficersMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non Officers[Member]",
        "documentation": "Four Non Officers[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r527"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r147"
     ]
    },
    "LIXT_RelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "RelatedPartiesMember",
     "presentation": [
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r527"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r393"
     ]
    },
    "LIXT_NonRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NonRelatedPartiesMember",
     "presentation": [
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Related Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r200",
      "r201",
      "r486",
      "r487",
      "r488",
      "r554",
      "r557",
      "r561",
      "r564",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r597",
      "r605",
      "r741",
      "r761"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock Option Activity Including Options Form of Warrants",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r56"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party costs",
        "verboseLabel": "Annual cash fee",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r151",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r369",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Each Option Award Estimated Assumption",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "LIXT_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "documentation": "Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties accounts payable and accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r601"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r588"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses, including $43,895 and $46,982 to related parties at September 30, 2023 and December 31, 2022, respectively",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "LIXT_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seven [Member]",
        "documentation": "Exercise Price Seven [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r297",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r330",
      "r331",
      "r332",
      "r333"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r101",
      "r461",
      "r462"
     ]
    },
    "LIXT_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eight [Member]",
        "documentation": "Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r73",
      "r718",
      "r740"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Nine [Member]",
        "documentation": "Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Warrants exercisable, Beginning Balance",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r553",
      "r556",
      "r558",
      "r563"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants exercisable, Ending Balance",
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r699"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://lixte.com/role/Business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r114"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of pre-funded common stock warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r601",
      "r765"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r474",
      "r722",
      "r723",
      "r724",
      "r746",
      "r767"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r699"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23",
      "r126",
      "r139",
      "r140",
      "r141",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r167",
      "r178",
      "r235",
      "r236",
      "r283",
      "r327",
      "r328",
      "r329",
      "r347",
      "r348",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r455",
      "r456",
      "r457",
      "r474",
      "r544"
     ]
    },
    "LIXT_NDAConsultingCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NDAConsultingCorpMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NDA Consulting Corp [Member]",
        "documentation": "NDA Consulting Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r167",
      "r235",
      "r236",
      "r327",
      "r328",
      "r329",
      "r347",
      "r348",
      "r358",
      "r360",
      "r361",
      "r363",
      "r366",
      "r455",
      "r457",
      "r474",
      "r767"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r699"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BioPharmaWorksLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "BioPharmaWorksLLCMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Pharma Works LLC [Member]",
        "documentation": "Bio Pharma Works LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DevelopmentCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "DevelopmentCollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Collaboration Agreement [Member]",
        "documentation": "Development Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r598",
      "r741",
      "r761",
      "r762"
     ]
    },
    "LIXT_NetherlandsCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NetherlandsCancerInstituteMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands Cancer Institute [Member]",
        "documentation": "Netherlands Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other prepaid expenses and current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r595",
      "r732"
     ]
    },
    "LIXT_MRIGlobalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MRIGlobalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MRI Global [Member]",
        "documentation": "MRI Global [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialPhase1bMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b [Member]",
        "documentation": "Phase 1b [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r126",
      "r139",
      "r140",
      "r141",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r167",
      "r178",
      "r235",
      "r236",
      "r283",
      "r327",
      "r328",
      "r329",
      "r347",
      "r348",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r455",
      "r456",
      "r457",
      "r474",
      "r544"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of securities in registered direct offering, net of offering costs",
        "label": "Proceeds from issuance initial public offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r387",
      "r388",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r516",
      "r518",
      "r551"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of transaction",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "LIXT_ClinicalTrialPhase1bTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialPhase1bTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b Two [Member]",
        "documentation": "Phase 1b\tTwo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development costs",
        "documentation": "Stock based compensation expense included in general and administrative costs.",
        "label": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r200",
      "r592"
     ]
    },
    "LIXT_ClinicalTrialRandomizedPhaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialRandomizedPhaseTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Randomized Phase 2 [Member]",
        "documentation": "Randomized Phase 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "LIXT_ClinicalTrialPhase1b2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ClinicalTrialPhase1b2Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Phase 1b 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r646",
      "r656",
      "r681"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summmary of Stock-based Compensation Costs",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r54"
     ]
    },
    "LIXT_AdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on research and development contract services",
        "documentation": "Advances on research and development contract services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r109",
      "r110",
      "r112",
      "r113"
     ]
    },
    "LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ResearchAndDevelopmentContractLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contract liabilities",
        "documentation": "Research and development contract liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs",
        "documentation": "Stock based compensation expense included in research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances on research and development contract services",
        "documentation": "Increase decrease in advances on research and development contract services",
        "label": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development contract liabilities",
        "documentation": "Increase decrease in research and development contract liabilities",
        "label": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PrepaidInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "PrepaidInsurancePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "documentation": "Prepaid Insurance [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ResearchDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ResearchDevelopmentTableTextBlock",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Costs",
        "documentation": "Tabular disclosure of research and developement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r202"
     ]
    },
    "LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Tabular disclosure of warrants outstanding and exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "LIXT_CashSIPCInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "CashSIPCInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash SIPC insurance",
        "documentation": "Cash SIPC insured amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r684"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.",
        "label": "Share based compensation arrangement by share based payment award non option outstanding weighted average number of share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock convertible into common stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease)",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86"
     ]
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred compensation expense for outstanding value of unvested stock options",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r98"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r647",
      "r657",
      "r682"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r191",
      "r194",
      "r195",
      "r199",
      "r200",
      "r202",
      "r284",
      "r285",
      "r429"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r86",
      "r148"
     ]
    },
    "LIXT_ContractPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ContractPrice",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract price",
        "documentation": "Contract price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r178",
      "r429",
      "r463",
      "r485",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r521",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r544",
      "r606"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r264",
      "r279",
      "r364",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r451",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares issued during period",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r266"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r639",
      "r648",
      "r658",
      "r675",
      "r683",
      "r687",
      "r695"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, grants in period, gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r132",
      "r133",
      "r134",
      "r151",
      "r170",
      "r171",
      "r173",
      "r175",
      "r179",
      "r180",
      "r234",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r266",
      "r267",
      "r270",
      "r273",
      "r281",
      "r369",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r499",
      "r520",
      "r544",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r704",
      "r718",
      "r725"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r660",
      "r685"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r499"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r499",
      "r517",
      "r767",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://lixte.com/role/SummmaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r50",
      "r51"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r683"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r202",
      "r572",
      "r706"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r266"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid office rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options are exercisable price per share",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r663"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r288",
      "r425",
      "r454",
      "r489",
      "r490",
      "r552",
      "r555",
      "r559",
      "r560",
      "r562",
      "r583",
      "r584",
      "r593",
      "r596",
      "r599",
      "r602",
      "r739",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r286",
      "r288",
      "r319",
      "r320",
      "r321",
      "r401",
      "r425",
      "r454",
      "r489",
      "r490",
      "r552",
      "r555",
      "r559",
      "r560",
      "r562",
      "r583",
      "r584",
      "r593",
      "r596",
      "r599",
      "r602",
      "r605",
      "r733",
      "r739",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r168",
      "r170",
      "r173",
      "r174",
      "r175",
      "r177",
      "r367",
      "r368",
      "r443",
      "r452",
      "r590"
     ]
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficerMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "documentation": "Person with designation of officer."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r764"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r288",
      "r425",
      "r454",
      "r489",
      "r490",
      "r552",
      "r555",
      "r559",
      "r560",
      "r562",
      "r583",
      "r584",
      "r593",
      "r596",
      "r599",
      "r602",
      "r739",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "LIXT_EricJFormanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "EricJFormanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric J. Forman [Member]",
        "documentation": "Eric J. Forman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r387",
      "r388",
      "r389",
      "r390",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r516",
      "r518",
      "r551"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BusinessDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88",
      "r105",
      "r127",
      "r136",
      "r137",
      "r141",
      "r151",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r172",
      "r181",
      "r192",
      "r196",
      "r198",
      "r234",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r368",
      "r369",
      "r450",
      "r519",
      "r542",
      "r543",
      "r591",
      "r611",
      "r737"
     ]
    },
    "LIXT_RobertNWeingartenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "RobertNWeingartenMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert N. Weingarten [Member]",
        "documentation": "Robert N. Weingarten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "LIXT_FormanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "FormanMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forman [Member]",
        "documentation": "Forman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r523",
      "r524",
      "r527"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r388",
      "r391",
      "r471",
      "r472",
      "r473",
      "r525",
      "r526",
      "r527",
      "r548",
      "r550"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r645",
      "r655",
      "r680"
     ]
    },
    "LIXT_MrVanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MrVanderBaanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Vander Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insurance",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; authorized \u2013 100,000,000 shares; issued and outstanding \u2013 2,249,290 shares and 1,664,706 shares at September 30, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r447",
      "r601"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r527"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r499"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r74",
      "r499",
      "r517",
      "r767",
      "r768"
     ]
    },
    "LIXT_ChairmanOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ChairmanOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Audit Committee [Member]",
        "documentation": "Chairman of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash board fee payable",
        "documentation": "Amount of fee payable for management of fund or trust."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "LIXT_ChairmanOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "ChairmanOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Other Committees [Member]",
        "documentation": "Chairman of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r111"
     ]
    },
    "LIXT_MemberOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MemberOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Audit Committee [Member]",
        "documentation": "Member of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MemberOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MemberOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Other Committees [Member]",
        "documentation": "Member of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "NL",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r644",
      "r654",
      "r679"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r336",
      "r760"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contractual Clinical Trials",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in annual salary",
        "verboseLabel": "Salary and compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_NewIndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "NewIndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Independent Director [Member]",
        "documentation": "New Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct offering, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r96",
      "r474",
      "r544",
      "r566",
      "r612"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AnnualGrantOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "AnnualGrantOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Grant of Options [Member]",
        "documentation": "Annual Grant of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_IndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "IndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Independent Director [Member]",
        "documentation": "Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r644",
      "r654",
      "r679"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r683"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23",
      "r96"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r683"
     ]
    },
    "LIXT_StockBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "StockBasedMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MrSchwartbergMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "MrSchwartbergMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Schwartberg [Member]",
        "documentation": "Mr Schwartberg [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock in direct equity offering, net of offering costs, shares",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r96",
      "r465",
      "r544",
      "r566"
     ]
    },
    "LIXT_DrJamesMiserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "DrJamesMiserMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. James Miser [Member]",
        "documentation": "Dr. James Miser [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20230930",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001493152-23-040115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-040115-xbrl.zip
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M-!*!F"S)G0@\L"!HL!>YY_7\&,"?T:%,_#L:V$'/]DNLW^NL7!;$_MI4,L_
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M4C.7&^T#IWD<:[<P1Q) !B 8 02@VY0:E$OEE/B!6,B,?6(VX5+%%%JC^-"
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M&4(]\%7\)A_SU3[X#4"_ U!+ P04    "  (BFE7RH2_L:X$  "'&P  "@
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M.F.#[8[H[8+F7.1,Z%5<G'R==E:WJI8W6T+U0DV]2,O>K*D7<'\"4$L#!!0
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M/X@\^,^'5T$;P7^KY<J_1#KM]V$,TT/#[MG#[5G##?"03,VXBR*I?6[/%GL
M(AD2#_]7&@.)A_]I-9$=]@:LJ((@CZ)6'E6>*@IZD*!RK/@$6*4J\156 SWC
MY[L.^78OD(O[A__^VY?:BLQ-Q_8[6D 19+X&OU-[#TR09Q96GEF5()[F9?A4
MA17K$@_>?H!YCX3VGF&R%)D-\-P\V?M=^=U#IH@BX:-?/L*O ]R?NX%0J_2H
MGFE[#0+A5T&>0?<Z(U8!:H_NZ:[&>(BJ?Q?D.15$2\M\%K-%TF$/+_9:4P7T
M,JM/F<!O@CPCVZL^MGOD.F7PJR#/H'IU:".&0('/,3^9M_=E?DZHVEP$_UT-
MH"&Y)BARHA%=80Q'V@"O1%L>LU+*^"(%7Z$( ]UD\<+,NH\7U(G(SJ\)29:
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M2=F%CB&!(Y?-R 5# L<2SE:B>NZ0J)[<2B0MEL"0B-Q*)"V6P)"(W$HD+9;
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M76"<I'ZZ&,88QBXPCM]:@=<)S1C&&,9.UCAF?8OM*1YT$PQI?"H$F^)]9\=
M[=S#:;%R7\%HCAS-#OP^\81/QT[0"9\.LTA!3:$]\G31^)1= ;4C#ST1GU10
M1X2H&.A3A* VL1,,U";,8IO%P);ZLBWU6>8T,*@O&]1GF>' H+YL4)]EO@.#
M^K)!'>?L1\'HB&E\HGV#NJH(W/>:K(Q9"0,Z8D!O\?K468]"X"Z=)KQ.D_7
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MEXYS$TY[S#\C/M1K$^=YC'.,\Y/@/-K%/FS%,;KW0?=ZTGO5'$=4BN&2#L2
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MD?G2N%V V+<&>^K($<DE<.08>6D%ALF)87(L5^ G_X EC[,0@;(0&# X%^$
MF&*:SMJ?[+#S7OFYL=,&GWJX??[*)H_"78A-WH&')ISVP#D=;<H$HQNC^_"
M;Q6FT<W],4PQ3 ^<ET0%4\^#7S!@,6#] #;ATRF,<XSSO7 >VUF@LSU?$:T
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M3T4P8Q7>Q?NZ9Y+=WD.[K!;2L^8B4Z__R(27)W%X^=77SE30 )RBDV<XIW7
M'.TDCC+\V%2Z\JOD+(SOXVI=RU-R_B5TQ"U???6UQ:HL-&.L&[:V5Y_+3J/1
M(Z"FTH(S%>B(7"9(PEA]XU] HRR%LJSH;X+D3.#5US)$ 'R8)+@-W9]6M61(
M@?A'F+C/"[N93JES=_/GZ688MB37WG[UM4A1J)KT['3J@SG<]^_D 3%1H "%
M"2L2X UP4TV8H=P1.O </@'^)$Y1TH2 3"$05\XL6Y04ZAW,8-74'V1^2@I@
MW36F?W__FZE^H^8/F1 T9O5]$$LYAOK7=4EID^:L2?.=S*'*<5G:N= @W#WR
M;UFVWA?_AD#WYCNOOA88,ITGB_0YJO@R(_Y__[= 4_G/4-LU((()8H"Y$+2J
MWRR4*&0J5O!3K3)WH/%5!$T 4%!&XAXH@"<F4T6=H@R^)L-;C?0'17_H_XL2
M_*C&H\1IU^<ELG/)X&ORQ"'!L5'IW=^L]#;8%"S=2D:>;NT*FFBEY 8$8+D1
MP8FLJIYAMCM4 8W@S"R-8 PID.17A9TL@5B(7FIPP@OUQ1AB9S[NR^('-:R\
MU27*C(E>9F@!>UW1P!LW0MN "6CZ(7'PFZ5_B"Y#ZVR]_#XOROHK:\9L>LPY
M1?=U\^081%I'1L'+T915;_R,#%=ST-%D[AGM:NR9NSEA*"V/QVC9#_[08I6?
MK#@%Y$>TZ;(%%'T7G+G1?<%F^Z,?CZ7?_1LQ0&3JL'_4WPM7P]C-45]]-1YB
M*CEZ5(J8L HQ0T\C_H_Q/%0 2NA[WER#W1",0FP3UXXZ'?&,;0.UI(E:TR8;
MUOB(D)W+S$AJ<K5??X*4W80"V;4A&\4Y&(7'06%W9#H3MR)6RYQ432?C6K<5
M#2J_#>]KO^=BNS4)DIHX )6;"4_D7+=SG4Y<0:Y9Y=D7M_RF_G+BGE6>@4;<
MW94OT357(G/-OUC4>%13NW)KJG"HYX!OC+5+;V2A?7]'YH.LPVQC;&\2=KMO
MZ[&&0.$TWWHZ83P>^_386%.W2#1DGWX UN_YUYHLY%LWU2#+7!%AW<'O_\)0
M/;'C+T3J^ ^ ;J4 BHL2],>SXJF@>^K@(.J"E@C2U@G/NM<E'M4;05WISPEN
M!*"0("'/4&/U$YKT#/M*&?T'ZE\"(HI NVEX@A5%^"/:7*7"?U^F DK80P?>
M!^8%\)EVSIY!]6/&MBDS<[_,^!,6E-Z_*W$:^AWMFR)X^+,TU*^=*( #^D(-
M11/Z1DF5^  ?"!%+J%-N!., &17S6QL]M1&K;1+_RJZ3J6\)TF\V!_%OBF E
MGOA __O^'1IE'P(?7M#_"\> ;M"OA7<A,LP'Z:VA="IT*E&A39$D>':N?CRO
M18FD4+]I[DMK51;EJ:+ 5QH[ I%KAA;=;2MLOWC#R/<@>]\*KV+&^?U77Y]0
M*R:7-61S]SK1D E[!V,R97-9MA)9$&@\QH*F07L#1&A$%%GO&R?."0#GM',"
M]8E26$ZO.:FP&DN@;8";IG3YC-6U4-3OZ/V[#)E%UK(-AE.1U>UL)]TE/B!&
MYS_3#/W1O$ ;"?I^IPG:[Q2R77W_;M.P&A3;YA*H_V)C& MCF-O8DV2C#X'/
MM$TNI2C=3BO_O?JMO0BC%&77^[$Q/$=C",T/2XB04D"P' >-H<(BBX:L@X*B
M+L=OX5112CO^H(ZA%85O42Q'^OX=)X_AV.8I%&;"Y\'(#+%E2 P5^54;$>;/
M'^& @$X<#P:"I/<'4)&%1%5"-/G9A43]5^ISRKK,]0*$4/V*+0HM"NQ'H5#3
MO-B%6/-2M%\5F7MHHOMIVHJ>K9 9%<"<F7D][P*8X.4MV7_"Y/D=@KA!U1:,
MMXQJ*"42V7 '4%I2;=#F2OJE+#MDMOI7*&7(GJ&LS)W=>8[\K@W[8NTU0X=6
M.F\T+M9EP9DO=RJ@7Z/NZFMCW<2O"-0ME61W\XI9QK1C6'R#EBVS[YJ'-+BB
MWWPS504)J"[ST<%OYM??^O=\.[]_:R8?7=0<Z/'JH'8)*A=B/CQ,LJIFY& 0
MLQX^;$&.68.<=>NM?E/9N,<9>DS^_G;0?GI^[.R_/=Q/[Z8=A'FU;\([).,Q
M+1B\?^<>?:.">V/:0*S/&H2!4_9$SYG T$22]93'5#4B=S@"HX^?9K?XLM(3
M*&V!WB7.=9UX%>"[D29(<  R"L9G@JK'.A(K<0(KH@@(];= I*H:C,A9A5<)
MM/]+X-V*SYD/[+^.03B>D29N1JJ.X*3"MI<?(.;T::'1(VCWG OGM$Y#_1/:
M(&)JVI:'JZT'54BZ.QV;*O[Z(71GOQK?\D=P;*OTH,C7;X2;, DEW(Z4C'VA
M#7EF]%;-I0@D[I1N 4SI0?>TW49V8ZEIN>AN'"#2G&JZBX&^IB?4#3Q2%)GK
M+8K436/1^#-7GD97A(:JHOZ[,AZR40)E/(A8>9*-VIJ>2867;BTY[:#C:@WD
M);4YT(%-09#GUH$M3<>\K/& $^#$X(HP/ZC_7=4;M2L"'66A/\(Z*H5.T9EB
MBB[:._(M\FR,&^>/(,/*&4-4C2':M5U6M1>,&51UBE:;)9Z0E[1C\WN:)84-
MND,^(F1KSXKG(2'VH2+Q.R(D6LBL,Q^-ZS-\P,L42*C*BC(&J4]1MSGN>LZ*
M-4!#)B3BNOF%=4M.1\$R1;N:DMU,V:Z_=#O7NI&3W0;;,H?@D!E8Y[H(!OH=
MO"/J+ Y:LT-K9FB=K;/%)P6PS^D^@#804C/1F;O*F9P#9PR2;4RM(&7U8)VU
M-Z["\PC(3'C]4R1M!7RU2DWN1G@XPE(#G9KS>-.I5^JE]E.21Y-XM'5+-W<0
M;<T:46XVNM5&-ZD'&9W=\MU!*W6>WBEZRQOUMF#G#H:V6,B/^:P@K?J_F&,7
M*B/RN%OJI[,P08,PFKEL#./@I9ASU(;#L7[L??Z'+:;UH;8/%7DJ\<A.RLHU
M\;_E<K5:JX4MW+ ;/;'$2$'9A/_M3'LD25U];97:7:).P%BYWB@URO72'8S+
MT&%FI:Y^4!Z[U3(X<<)GHI2[OO\FSE+'VGLFVKNNNO35U[H&QC#D(,JRQ ,)
M+;[!3WKPH5<=U>R5.'MSE6KH<X*A@'49Z_+9Z3*#&JTXZO -*T(=!D1G!("F
MZC6M%(5RD:NGTZ&%!>+#H\1.>8A?_E\]G5\!G'D%I5]!8]7'JH]5_^1RW%#]
MC*OJ+YTV6LEK3H!Q7H"ZINF60>C"9P+B7M8W&2'U;PB2_7=5K^AQL!GHPK,P
M#1EL&K!I.#?3D/5I&O3Z@Y$L\D!1S8:\1/5EBDH<L*G88G(6FPIL*L[-5.1\
MFHHRJXZ(FBB_.D<1EV4)\M@28$MP;I8@CXI?-?@$30Z2%\21PC9G"]@^8/MP
M*OM@:S5K+-.%N)<#K1K0'XE[5F*'NO9;IW@0%4'EIOJA[KH6ER16G*N"'CDL
MC0:R*L;&('1-&ZA3<3-%8;.<32AR&)Q0P+H?#]VG0]=]YB/Q@';>"=#[H^Y(
M2(WA%Z+U-[("HJQ.T1Z"4E^>:E9OP;:@/I](M;,TUD2LB:?51"9T3<SH:_>:
M(HM&?-U29 [P2/$2[T&1PF(/BO4V!GJ;";NT5:^80R5SS>ZW:GN]7&ZE5"ZQ
MJHL7VK'JQD-ULZ&[7.HC<0>&<!JK^UJ]/><9.%L\7<4:&P^-S86OL:6/^LR3
MJ+&<)BM86[&VGEJ"9Z.M^2@2RX_2RAG#'58$>G;8K$A9.9@ S7@?570BO.6,
ML6YCW3ZU!,]&MPM1)(XK8,#JZSV/$]0Z!TB"K*SH--9?K+]8?\/1WV(4Z>9[
M5,'180< NN*5=1ZLMUAOL=Z&HK<4&;K>9C\23;W-9ETR^L8)LH0U%FLLUMAP
M-#;\\JK<1Z+Z-A+Z@G8&KA7OF,"*&@]%#;46JE._;92ZC^UJ)_DJFCOO,U]W
MM^.D/Q/-B5YW>HU>9#:3_TSHA_'"GP_LUIFXYIS;6%M[W=5:YU:+C9^)[GP"
MWU]2V+[ ?2;0P<,&JQLR8B"]UD_3NDOO1AMFX\]D<#AX^]/(FY'B3I K%3K+
M[N%6ERMS,*ATY_V['=VNSJU?9&+L_K;4:%MJ]6[U_OT[U.BHV:A4&YUJ!7WJ
M-._JE5(7_K&49:<+O[@_S]:?2:%^6Y*,+4G<$#A!HTD\#&US\?[=FKVX*=U!
M>U$E.M^JU7.T%/XB*.MP#8:\Z5$4U5N\_7WZU?DQZN3:%(ROIF,XHKE^R?5R
MHRCTG+XZ5>W1@]A?*+?5@]AYQN4P$W62Q&KLMKS2Y)H=^>NS@K6+EP^'1"+F
M_W=%+SF:*197SQ8$=6W<>)G^_)[9#%MW3#X<<9,46$+=6]L8O*%BB>H!C 3I
MV $X"%Y"!5<.@8NF: ;JK-1N]C7U%@Q+P@6!:[6W7<*Q11^.+8=<GJ=1W "G
M-_QV&-&5U@%.S]OW\8HP'&UI42P&[DW9489L6P2RV@-3-3UDV4DZ75)5Z']+
M?704'Z?UA)NKW;QQ2N<JP_X'FLRD:*:0HK/9?U?Y5^IT]*!IUS =AF;D4)Q-
MHB<+_#XP3M0X2XK>DE1YJBA0D98"(ZE]1/;+91UEFTCSA02KO_XZCKR+%S7.
MDBRN2!*U52I)//H'E;G.6!'U5"EI9591T&FI>B8:2I:N]R83<D+VQFRIO'B3
M7WN+I^\T]?2C^?:G ,)5U(U<90Z%SHC S;&;O]/_N,0@&RG/?YQ2H__'Y:%4
M;N-R4PK.Y^J9[+SVQ4V7X_4<SHUT/5X/99$AEX'^R3YF[[%3N?J:35%D-I6C
M*(<S]IQ'ZL@79[2=$\?I-$6G&2H,CC-9)L44Z? X[JRW9 ]P4Q7J$S3 _ Q-
M6=6FU 8J8!4.,:$"9D"4)VBRJ^_-AE3 "&XFP.N<-5B8_:PV.TTP_YN)U&Y;
MU!)0?(I)KUY#SR\IUD6$2"94D^:H#:HSL%">[SHH>Z-5Z7PA15)93W2=RC%%
MS<?0%)7*Y"$C\P<RTEDW:RL^M:6 "2OP=4F=*FCXSLKW\C*>M93Q+^HE(O>Y
M/0R3,$*P*#L--"S;O<FG:+6(9B"SG$Z>C;,6!6)5:(J"#NFE,Y'H27E;3ZIO
M$Y24A99!+Q5=FUNX1)ZWXEB8ODW>7HH1^JW/A$L&PZAHG9C*! SRC4UAW-H,
MY9 $VEX9L5V8"_:D(*C<)<"(=3J?*F2\==J1[_XYA\46MB,F4TPA(K&YAL[.
MR0MD8+JVA=%,"P--S8(L?NLM.H^Y_HLXK+R\#(_CI%V-3E?66/'"[,L1+4D6
M"BF3RA5SV)B$+:,0)]K9' DC>.:8EB._93E0GG/59!B6XEG+-@8/VJU&[F,I
M]H])Z%7SX,\LT'M"3K^/X.5I7P2^,CL!GQ( ;W$U!O1AQN!<)1,#$^!+,KZ7
MY8(N/<5WB2!>U'A/&N\$MB^(^I9]&+FN'B!CM.DX;/G0?T[SKEZZJ=_5N_5J
MAR@U*D2GVRS_0/6 U7;'/LKFX;'>?8HCG^-%C?<RU8K40UIUW"N!9BU BDMR
M\"ID"!G3$L=!V6AJBYVC D"HV/ ;90KX;;FO9X3NR@M1R_<6]^W60WM>>WM;
M4-&N9)B$PC!,IU1/^K &K78F*$4($B=.D?LA_L^RH!@-N[AKV/8(ZSW.+L+K
MV5>W@8C*%5NLHLV["BNIAN=3;^:KOY3>!-7EIGN]\JBW*-]0WX4.W[W[W;\B
M-$%#0S6O@^-2C Y'?@;J&1$XCF]7[&81WMNFVW_PL)',9%*%HM/JB5ZXI(]K
M2TBD;R$9Q6P1"*DSX>IRL_ @5C.Q$9(9QD4AI%RJ6'!:0#6$I,F$LCEVC7 Y
MP67K^-@46G2<H+UU,R#.][206R%T\/C8OY&+.&M*4RDJ[UT@$+*/.3T'0YN&
MT'0QE<]%LT)26Z[R[UXT]>L;%]J"_?FRR->R@Q/G,-N>:_\K@=6Y)L[TA?&@
MDHW6(!1).*WV+C# F<^0!1C>@DHNF](+LH^7%V5VSLXVEE5,4P1M4JE372A"
MN;<8=>KLE 9_)C1]BC7<]>64"S [E@\]MFUA*"J59_"R2C1B"LV",,5,*E^(
M2$PXK1K+#$QIM0Y<'H\%33]0$Y730J1!*0.)$_3:46HEJK0M>.:&?50?VG2G
MP$5;];\DS:BQ624N\K*LU4U3O*!.1'9^34 - >:^J+WW4*T^.*T"+BV\I4<"
MSP/X<B@?6GCK*R))%@I77]/V+JN55CFG1^+I>5,\D#?8,,72,*UN-=JUPA/U
M?J/5=UMK.D"G 6?]0\CZMQ0P #"V,5;Q5G8:C5GH8QI ZRW8$;CEO_WF[K[O
MXV/V+9(VJ")TLE*[4_CK8VBQ2E/1.P[P^G!:0.F,6 6@;/%$X%?2^HOGVD/]
MD<O^_:X5[?SN\M6J\>H)JQ S?0?+UTTB\@<18>[!'H[N\MP/^F'4%?P1X557
MZ(.,$*8;]49M/7YMZ4_V3'4?0&"P0-N=0/(C29).J5?GS+>5 +=E\)E@I]I(
M5J"WY.W3SC>Q47'%AD%&R7[$^EK30AN^_%; Z^BM^.R.!U5_Q@H=V^ L!";
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M#R')&GR"7DIEG<;*K9[&.A D5N($/4PSJW_4CTD=?F(/-7=$'1S _Z331$T
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MRZO1IWV)OA6H.0&*OD= )598?16<K?Z<YM5F,Y*-IBJ>1T2[QR-N4UE=%J\
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MA&C X4=KG"]\;HHS!.<HA2AG\1<3JR39MX<\N\8R3P#M(4]^L<P30'NT4]S
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M:95!)L:K-A.M;9J)ABRW@&:BM4TST9#"FV:B*ZP31YN)UC;-1-=Q-6O/AF?
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M ;:I:8Z&7UZ6@=:<619_NI^IKJ;^S69.#)=4PN9D7ST1IJ!0W,B.H R*6*W
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MX:7=A)LYD?;"EL:NS4(3'U:-KC6ONPI(%5K^L"<3%4NX.^P:D-W*680\C:R
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M9&S3&<7K&C!PA[WG\=5D\3NZ,#B"%]##;'2I0I#6EA@E@O^%.8+Q_H!G$HZ
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MB7H;V;82)A0+8@<)B8\ZWO7BB'B_U0E#]3QR&)H$0:HG3W]0]MDTLQD^.=<
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M:CL@R49L!_Q0 0<, _B"U!$W(066%U2+N$MHX--!5ZVK@SWE0G74CJ/VNU%
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MOF2XM.A\L3.5T^?-L*)0G=@-3N/+H:4N5IP+E7RI4+N]E8P6GI5"J,;G;1J
M9Z5P7!M&I(9$HNCK6 OQV^%)>^=WZ>JT[1^KKZHB"I6M?&D+5LF;GD\W_^>U
M0*],I4T0KW8:EI,[L6&+IP>;$ ]%MR9$57/]YAWO[@G<Y! $(C*J[3/(Q0##
M&;@=H548(K)ZA]!K T)AP5]Q.TV@,$\E#@@[ZS+0MT?#Q?YJA!J,T(4,%V<*
M^2.>SV:DUQ/F, (EMKIZ$K<?ACA+8/?#?@&K(E&OV2/P+YI[ZB8CFK[Q$.B[
M?0.1&ZV7$HW^CT>P^?/6X*XBB09LG-%'["'5Q6YX8$M(J.O4MHLPF=TT$2'
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M8>J5_413+[;2_,PKE0"\ER?83_7>7=UI?U'_O"6C=L93>QZQGV]=<OKR2ZN
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M?)%7W=!?B]BXD^:/P;!8:%?,L.<!?[W"6I'2 J8LGZENY8OA7^,V)":;DTD
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MOGF@A%]>;-=\IY8MHOL^AB&SF:^^.2"):O@=>#,%*W.R*"I48 H:&8Q8&V,
M6QB(5/1@WQ4UMNT4M $+QF!1D99/,44AR2R\A_^!">;$Q0/-!9[9=[:5KW87
M;.IMY9O] "/EE ,\J;]N*X=H/,'*Z#<J+A=^= IFLI.C%5S:8 V#;;.M_-1A
M/% ].ORZKP[(L@9CRNN:@QR&;34XS\$ AT4U==-^W%:NN[JK2VO*9N1%H26/
M  !HNK54DZ*<EOX8AFHUS4 ]IIHA?5CPU@5CWM1=%S;3Z1D6G6Q-(*F![H'"
MM"/%OZIY15,'\"['\&#:X#3 JW10H#"*(\Q#W=)$(%?M]TV8"\X@]LJ< @_
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M<0^'<2_%!F]*9>$QM(59 @YSL,ASF\X"EQQ/<C1Q?>0:XL65L+\K[^8":09
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MMU?L2]BO)'U_=\<F>9<M.MV.=?))3(V.,&A[^J/)J6E>;Y\6H6&]BS<WVFL
M$^8::0$'E,#T6< 4FN3AEVWS5?8PF_<K/IM_:Q[W\U_'_HW>\$K6[XR8XQ+6
M+[.2\;N[$Z52UCY7I8P)-R>7YYT+N?+X/I2^L%$2#[*NIL<RB:NQ 166(J]+
MAV7"5=@&#>[8R3PX;8,D\PF$F&A/BRY@/\N1!SLK-YLG!"Q[RNOYGF*8WM&
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M8BZ3SRXN/^<ZH'#Y68J6G_+@4"P5*C?:>S,\*S(JE3 I<6I:[?09KK#)-T?
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M-\12/_H\2STP5ZMV\_C<$F3A4.]LIJ6^;.>%&5I>;C^[-=.7MF02P_#99GH
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M:ZT>"UW-DYQ@4MAZDQ/"4'S2SMVIO[6W]Z(K;6;#$A,L2HY.3 C9^4I)"6!
M9+/1E613LQ*\,:#,0LW-BZG.*4BC "EV6^)Q\[UR^AC>H&65[(&59<FWSQ6(
M,QDLQER!]'#GCSNU5Y:$-U:*ZB_T];("DF3G43D .6Y_"C^WH<G\C [XNV+Y
MNSOHB?XK8X?<"]G_!H/]1/G1;<^\ "^QKF>Y_8)]A\QK>,/8&=QM-#4RH$O'
M<#L8BKS*O!MHT:I[.$K5Z.N@''I""9L6X"\L$N!/H]P1F_VVJ(Y'YY>=M8;R
MXY1)R[DZ"KE,D8UV@ 4#]X&F1L' ?7K.]7C0?>=[V9NK,W_'XWA#]$DRP:B
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M"Z?CPL/GJE#\.%'%QX/B!@=H%\#W%>*R;'9:7-9T7VG,3QZ01 >[=YYVZ"G
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M1QF8XE!7'('X@Q%!7 VP<E#%F91>45N3-'1C&"J:A+/<DUJ4?_(6EG$@ XH
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ME>]I'G@Y<1[+YB;> ,<]06'EWLGN#C'!W2>E] $ZDKG*B-?28Z='03T$0(3
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MR"Q<L=]%B%$XDPP-W>@IF+Z"5&QVTQ-\U6\$RP<#7J6AH!: 0C/',YONX*W
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M)N_!?-!76HJ<V=V!1UC8;.W>>1O U6AC60.0%,;.,0[?)ZMT>+Z!Q4 ,<3D
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M6H,:+$$+%>U&&NP!6XYW4J=M<"!*X*0'>FHZH&N?VK\$V-&P)J^U?\'W(X!
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M':/?^"'SZ'>/U3YOM:Z05)]V&#Y,9C '47^53ZQW]#)%F,L)7DZJK2D002:
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M4A>FH)H".<#2J#\VY?Q1KA9>=CFU4> G$6^%;.@J]V*#J>#7_\A\'3/6E\O
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M3A20O(L *)4ABB('E9)8(OD2T[,G.$MB78)=:FP.'L(\-W],,,">[5/#UD5
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MI5"L<7'1/A395E.7'9:H"H64KY2V@O4PYTJMU/6O,*MT9LLH*65(^<YU?C?
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M(@B(_;6D[X1"@]Z-CK$"TTE\#_TK7+5.-;;BMC<;L [T_O@R?"CJYX26)<=
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M4,EWXMBBWKX+1/;\/9J7<3#^LB?@D_'(04+4F;P[2&J93%Z]X(>Y@,JEC?!
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MU:A8ENK#J:T+K($P $7#0 8.TAVK:N1$349#LR/C)QM^<$+%>,43)H,N"ZV
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MU-+@%.LU"Q?Z)1C9L2]X.K;A)2G*MO\-&$D+DEJOW:5I^-TAJ>WMW<9N>T^
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M]"S$G<OF57%(!C,$] E5?:L?,>^Q<.HH\;R/4MX+E"DC335VQ^< 8F30]CQ
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M:+L:]$/(; BG>.V)<X"+*#94%GA0!>]?([T.TJ"30;WV)HB&NM%FD39#4%'
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MBQ3'H423H9Z]V-!3.UX;[@L$HLYU6&ICK'^>-SAMVY>AS A+T0='"B,_SDL
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M8BLW0K,0/Q546.+ET!)F=" %YXXQ2U932C46(#HY&[(S"]R0,2G3B-F,<SH
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MR*]0MJ<+(2:(W%\B(IU@-+^45VX'>]A>=JZLQ3)+E9&WQ#P6,KOFJ$4S09E
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M;UMIXIJ@5E )#.6-1<QD1G5()BCRD?MK=BW6B#)W@(=T@X'. ME YYI.P #
M**-6LR8F*-EG4@@6\"ESOFH<(]0@WFXT_XFM\;UBA=P[[$C?Z@-:MC2DBVR$
M8F&,1#$_\=?R?'S-,%&+;8)JGQG_,N*P\B]1I@)N@OA3&,&0@[>3G0!,,:1V
MII1:#C=!_#LVGQ//Z\N7L'C@^(@ZD>,,:4 5_\3$FGC(S:GWA/8FJ*]NO!5D
M@V\A.Z "EQT7J44S0QELJSM]BPL_Y6 3A!_PPZ!2GRG?9YZ:(.H5@G8(T5\0
M'934,LO@)HA_/[@,#TP3NI!O;F2J5:5@$X2_(FR\1'R%Y+0@;F_[F:XO!9L@
M?.I"W_J$2Q_=!.7NL4SF71C]13 ;Q(-_=HN]%L\$=>X>AA]=-I-)86J^RSTV
M0=C4NG LW[T[F56L'+,8IJJ0.ZU<AV2<(@_@YFQ%_L".DK9:H0IDXQ0+._^T
MWCZG1BEQZ6SDH"-&M.RB]> RGPGF&WEO5WRFIGF[6G6#RP^\" 2#BF0!:N,9
M\:(^"& K1K&'^.Y9]MBJY+\E:$9<]3F(OL\YEN)%^V^-V[7N 9O#2OSEND"]
M?'R5O>@KN&T-.T/Z$5-8QKB@Z:6S H\67G#=C[PQ,C[J\S0:#6+AJWI'G5KE
MGR?0[9A*"J9V"XC/,>@TP,'_A[3M0/(LE-IWTPM'5EX[[6&CO(.:D##5@<8<
MKQ$!]Q? '_BI;ZKLIGCK7;G,_A(I7X_VA$G4B\@\1]4N?%>U1(]RL"'R1SZ5
M<"CUE;J<)CJ(ANC4X ,5Q;H^A8 A?=!'8CD9COLJ@K!SN9(WV\3I:0G0T$RM
M>":]E)99*-2KW1YEC(+7V>0]YO)XESKVG3#?9RP/D(#2&TA+%OC>#P[L*P+5
M4_?+,-3O\ZR[K,/;8XSH877*7@SI6$F>T3FU]_Q\G=R(YQ/BTJB.CO1ROFY?
M-V7[O]+=-XS/,;!Q1OQZNR;\:_=[:_X&&2!WE72^ V:E'2#*A]('+(LAJCH?
MWSP\Q7R5ZOUOP+QQUP<8T5,C_#[X-I,L27-?G45)Y#S!%/:,8XL.KZ;S9( @
M)&=A1(^6N](+#1WZ#,W)09X6K0F_^?I#12OFWWZH2.6C\GM0L/:!O]2U?J6W
M^CU@&\OWWZ(/\I(-<3!UXJVMYZ7YC4,_>(WT'GL/\@2Q'TKF7.U"5>3<_( =
MN17I*-'WQ?(V+;^QMGT7"1$O?$$^<&7A27>5WV7^O"3V,EX4*V!JN-YO@#R1
MRK</C#M$41#[-QA#R$MQ_N7+FQJXNXNW06N03*W\)[XZEKRR+'XWJA1L;,6U
M]7R9S_2"_#I;?U7]\>39N2DW4^NXK2?,H1"^JNA"M,,SB)XGS\&%))^V_I%T
MGGNK>("%S<DZX%FP3YR&MQP (8<&GWJ6D]#%GXL)W'4";N0-D+<?\+71S5;L
MFCKZ:NV1O[524<8U!B;2=:F2,IN/Y: MQ2;4PPO,GR.W4J7G\*W0*;LC+A8>
MC%)A>,>)5"V:J>-D_"5->1 ON3U<!#!6B>T:VUX\Z!*:W<RM0C!B(,X(.%U"
MX\5RPN;>8Z+N7XMEA"[A/KENZ.AB&YO9J=?&YSYUI'CAP7,YY6-(N>,1KAK'
MU, *%HBAO'=(CJM4\DUH5HUBJF*A6XD1!<OPV#*QV\7[_/5XQOKE_G2X.MRT
M(8+QG=Q:35BO!L=4\SU@LIKY7*C'<E2D(E:I!&:J*E$&ERJN9A\:*WSN'&GM
M0=-O=<ST_5'PX1GX^5]02P,$%     @ "(II5\8B?;7F"P  $X4  !4   !L
M:7AT+3(P,C,P.3,P7V-A;"YX;6SM7=UOVS@2?S_@_@>>%SAT'QSGHVF;M-E%
MZB0+ [G&2-+=?2L8B8Z)RI*7E!QG__H;4I)-61\D;<E2@>U#D]B<X<S\AC-#
M4A0__;J<>6A!&*>!?]$[.CCL(>([@4O]YXO>UX?^Y<-P-.HA'F+?Q5[@DXN>
M'_1^_>7?_T+P[]-_^GUT0XGGGJ.KP.F/_$GP$7W!,W*.?B,^83@,V$?T._8B
M\4EP0SW"T#"8S3T2$O@B[O@<G1X<'SZA?M^ [^_$=P/V]7ZTXCL-PSD_'PQ>
M7EX._&"!7P+VG1\XP<R,X4.(PXBON!TN#Y-_,?DGC_K?S\5_3Y@3!/;R^?F2
MTXN>Z#?I]N7D(&#/@^/#PZ/!G_^[?7"F9(;[U!=V<T@OI1)<BNB.SL[.!O+;
MM&FNY?*)>6D?)X-4G!5G^)96M%<DX?2<2_%N P>'$G9M-ZBTA?BKGS;KBX_Z
M1\?]DZ.#)7=[J?&E!5G@D7LR0>(GH+?JU:/+D BT!N*;P3  ;P0Q)<V4D<E%
M3[0 UL<GAV<GAX+Q3YE&X>L<O))3X50]--BFT\_8$]9YF!(2<EWGA8WK%F*,
M&?'#*0FI@STKB0HI:Q!/#!,R ];\;G(W%T,;?$=KK&JJQL2R,I\%BYH%?@@#
MY_LT\%R(@]=_131\M9&UG+IF,8>83V^\X,4*[1Q1#4+=L6?LT[\E0)>^^QES
M"CV-&>'0I_Q4)Z$YASI&=,2I3[@^HFRTJP.^:#;#[!6<A#[[= (^[(>7CA-$
M?@BI?1QXU*%$CZ<5EQK$O@<<,'.F ,T561 OF MO&@9<'Y8-2&L9%O8CML%1
M>D\\&'$NQ*KP]9%AGV/'*"SKZ.JR5%^4!:XH^ CT83) -60U"#:"^G9&'O%2
M[_\%36L0 /2:T5"&27#682 '$U3=!@/2@+26X/'$R5\1]'*]$%WIPT1Q^[W%
ML7KC60-QS:SC1_SDU:5$EE>SH=E,;F,&C81I0]MJZ!H,V:9&-*%N+GQ;F%%'
MW&PD-1/4F,%>BM<K$F+J\2^8B3G(@NQ>S)9QK+&XM15:1U>'[SI3XD8>N9M<
M J!]EWJ1Z.&!.!&C(6![O72\R"7N#0MFPD&CV%IWDVO,?/  /B;L80H3P$1(
MK;\WU>'>4H\MBKMQK17CBKQB#9\YKUI5^$,82,R:HU"NM(()K477\VA:9##:
M]9(PAW(1.NM0H))C(V6"]3@PYE#G4%:K "M'-V708)UC:V%;/K5Z^0VF3.X+
MB$CM3._F,M6^8.9>\Y#.A&"7G$>SN9)LS3U^%^XUN5,2Q(OK-5O7LF96:WH3
MW28F! ]9P%"$Z3MD78@C\<?\)F"S=9RQ'3.[=E"K8R9AD8P9=8A8;85"-O 5
M$<O#:#U6V;LDS<UIMHKYYFQJQ5U,41A$P A[0^ @]B8>&<6>/6ZFG)J=IMG:
M?@M650J TD[D2?ANX>\,!0$=?*C94SY"%:-=RY"&HF6RBWR$^F++.1(RPZ])
MRV;$*-Z:S(AS##*LMFFD/,#<!U<6OW&HVUV1=E#""26L$FE3>;W R<CHB:WD
M8&/;-MV6EQO&$\R?Y*YQQ/O/&,\' M4!\4*>?B)QEA@G'WR#W =]#R,F-N)2
MWAY^(I[L\5O2;J/9H!59Q6Z7<$CX(<K !?:DBX9#\,97<%&9YLMU,"3?U$WQ
MFTOFH(!!&7K1.TK[@9E,QEORV_=)BP$724ZPZ5/PC)1^ K/5*E,G9@VV446%
M!*3HH1="GZ>AE'XK"/.QXG;TY^.W2W<A')G?^65SNS@,/A"V$ FL "/!QYZ-
M&5;'[6"UG4JU8[;SL!LS,L?4'?D\8LGS+24C+-_2#*"35@=3F7X=Q.!Z*2HA
M CYT%TX),PS>1L1F2+WM E(F5N@2>+& NN3:E<Q38OO.6_F6XB?JR95@[8@H
M:MN2;\3KN7R,7\5L#7P:/F$1<6W4L6+2MI>5*[;I<?:F:;[4J4[C1J )/O9L
MVBYU]+!MIU?W DGYPT3YD5?4MK4*84+ IJX423,5*FS<=F"H>(@K5P:4J=HE
M/U(6Z70STUS+MD>[,19E2G8)B$O7I4)E[(UEG3_$<QJNGS<NR*=E!&U/9XQA
MT:C<)73NQ9*B3]QTEQZ2?#2+Y'[4%9E0AU84/B:T;4]LC#$S-T27X%-R.B1]
MF]RIIVP[(YGJM@'DCU'F&#SF6IRI2HG:3EI;PF7\O*\.MWUG@RWUU3TL7Z;F
MI\&FEK?P=_-[+,6'A#(;+B?;;+B@-QG./S>U8:0YGI51Y*V9(FN6*)B@-5/T
MYJN/(TC]Q/VYG?VD1!;_.5FDJX@E!4W;B83Q*5I/+#"X,^I3'L:;FXE<Y1IH
M"=M.8*5H;(0$0PMT*7W=DF?LW9 J!U.:M)V:3('(:=4ED\O5=O&(D7S"1.JQ
MTJMBF%=2M9U#38$QT;U+6!4OQ&DCFH:L[;F4*5I&VG<)KI5B\6FXVX";)$ZU
M<5MNMB!^1.)'[N-%WC]H.!U&/ 3)6/Q(OG@FC0-84,8\XF65\VW!K#,I-H]<
MSBFWMM4N\X\])#6MZN7C-J]8O[5!^(6$)L-OHUG;#E@H=9G]"UIV* J._ 7A
M<B8>R_DE\ -]@5%-U?8@,8''1.]NX102!A)KRXE<P[;+/3,T"K7K5*BZ"1C(
MX,?+BXYZ9N,W3'VAW&<R@3:5^=:*2=NEGPER6UBE,TM>-B_(R2P9G=:W9-3&
MBEC%:F1&S7?;J*DR_R^>!_PCBOO(+)3M0<O\BWHRRKW?1CG!$TFF[2_[P>@4
MXHQ9L*!@GL^O7T'XD;^J.Y+#/)5["S8\_BD0K2*G)38;8;4X]#;^J)4\J_UY
M\P10?)Y)*%"V:"E6:4H>N]J-90=*R2V!W%WWKH!>?GA\2\BK&':@6FT0<+TI
MFX<;I&$$1+PB\<^17]-9DCH8=Z#DW0'^^DS;J9E/7BWS\RDFM&:@GW80= LE
M?R1<KY*'/0M/?6R!M8:?&?[O?D#\C0S9<9\P.1-@XQ-F_,Q\XOV/Y!,VAFRC
M## ^2&"<_RTXFN']H8-X[ZQZ]Q:;2XQQ0WW(9;LM+13R:.OX1N 0XG*Q.SCB
M/!)Y.O.>CW+E#$@[N@11@6'NR(>A>;KDN<5"IZ]>L05T3=?1=8A=T=PT3%>A
M5%^[D[Z8QS5#LX2TH^L,VP%::9XN82I4WGB#!B3*D%$G)&[RAHWL!TK+,6$T
M</.I-GF&XWKI3+'_3.YQ2*XG$^)4'&+9MQQM)X-V[)Y?T[8ML3KY#$Z7C5D5
M/[JR[6IQ5T6\8W=V=GIZ),X;7%'N> &/&($_5#8(^^*H 3 2NW195@V]DFKS
M;@M%U+>;HJX;-[3M:7>?A2+JZ::H"2NYD[MFAM;<T)I=,\J87'BA:/!N4X.4
M7OJ$P@$E+)K:>=;LJ4MAW^?,K>Z6__3A^.A]NEW>G'DU5V0HXG[(VU82(TF-
MLN0-VK7BW@Q%VK-"X_;E=@S*$C<C:]&U&FOYC@\WY8O;HX2@J3?XZ4_:*3(>
M;<JHT,L!57+^L.YX5G+QAB+I<3YRI40HI6HSVE9$W>-<+C./NNA-^EMS#]%L
M<Q&'HETN_=EH%[-M3#?SRSH4A7))LCK%-*Z$]C8/1?9<>BS/.'LPOM$E'XKT
MN7Q9GH#V8W7MY1^*\+GL69:/&A?=_#H01?Q<.JU,!8WKL,.E(&NE3G(YV&P6
M@=XDS-&*>V.*:B\24=3)I>N4>)\"-W=+B*)I/MTGO0JH,OVB=<<H[1F)23Q2
M^A94:>\(ND>R_Y756LZM)M#O5$.TX1P6=Y H:N:+"05W71YN'$V;6TH4I?*S
M;D6IE!52>+6L2O5])8IB^6I#IYA 3N&]!T7-;S91%+.8N.]U=!E??*+HDJ]+
MUI$C6U_M:1A97X6B*).K4JHJQ#;"WDZ7H:P5?9NK7-2A)3J)+WJ/$QN$Q+@C
M)'M"JZ[0NJ_])#O[NU,4G7/E3<IQ== DYIFMIO<5_&N[0$71N&!5(ZOP"M>D
M)[3J*OF&(]%9)M[N,7GL[=84Q6;Y2D@9&:E *)9('N*1,F7,69V3.F%BR\M9
M%/OD2ZC2>6@; =+XPA9%I<H"2F&(4HXH9MD\3MM<Y*(HEBN@-)/N,L"2[3SQ
MG_ 9^.3_4$L#!!0    (  B*:5>MQYWP%C8  %5W P 5    ;&EX="TR,#(S
M,#DS,%]D968N>&UL[7W=<^,XDN?[1=S_H*V)V)A]<%79KL^>Z=N0OVH]4V5Y
M;7?5WKTH:!*R.$T1:I"4[?[K#R IB1*1 $B! .C2//24;0#,S%\"2"02F7__
MSZ=9-%@@DH0X_O75X>NWKP8H]G$0Q@^_OOKM]F!X>WIY^6J0I%X<>!&.T:^O
M8OSJ/__/__Y? _J_O__;P<'@(D11\,O@#/L'E_$$_VUPY<W0+X,O*$;$2S'Y
MV^"[%V7L-_@BC! 9G.+9/$(IHG\H/OS+X/WKH[?W@X,#A7&_HSC Y+>;R]6X
MTS2=)[^\>?/X^/@ZQ@OO$9/?D]<^GJD->)MZ:9:L1GO[]+;\7]'][U$8__X+
M^\^]EZ !E5><_/*4A+^^8M\M/_MX_!J3AS=';]\>OOF?;U]O_2F:>0=AS.3F
MHU?+7FP47K_#SY\_O\G_NFQ::_ET3Z+E-X[?+,E9C4S_&J2K#M7&[]\4?ZPV
M#05#5XA.PE^2G).OV/?27$.D% W %NRG@V6S _:K@\.C@^/#UT])\&J)4RYL
M@B-T@R8#]O\4Z-57H_ I10S8-^PO;TXQ55Q*9MYG2M#DUU>L!1WZZ/CMY^.W
M;."_;#1*G^=4@9.0Z=^KP9LV'SWQ(B:=VRE":2+[.+>Q;B*N/8+B=(K2T/>B
M1A1Q>VH@C\TH-*-#)Z/):,Y6 :H[4F&)>W5&5B/Q-1A",\&W*?9_G^(HH$OF
M^1]9F#XWH17NK9G,4R^97D3XL1':M4X:B!J1!R\._\P!&L;!B9>$]$O7!"7T
MF_EO912JCZ!C1F=)&*-$OJ)LM=,!7S:;>>29*DGX$(<3JL-Q.O1]G,4IM0*N
M<13Z(9+CV6@4#63?4!P\XD\I-&=H@2(\9]ITBA/YLJS05<NT:#YC.YRE-RBB
M,RZ@:U7Z?$>\./%\I659UD^7I Z861 PVQ#1;ZA,4$DW#81=4E-XANZ\)[G^
M<YIJ((#R-0O3?)FDRGJ*\\E$#72%":G05<OB<9^@/S+ZE?,%^Y1\F>"W-[:.
MZ5W/.EC7U#Y\Y]U'NIC8'*O;I5F-;N4!.EFF%64KZ=?ADJTJ1)7>W2W?#<0H
MZ]SM2JI&J/( 1HS7,Y1Z891<>82=019H=V,6&E&C<=N4:%D_';KK3U&016@T
M&5) #X(PRM@7;I&?D3"EV)X_^5$6H.""X!E3T*R0UFAR[I&8:D!RC<CME!X
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MY "20@'GX 27#YN[UWL*F<>>0!2HAJR]@">/,397QM[0$T<^P:48"D>:.C2
M#7-'#MJKT,!SS1YY<+]B_H1S[^R]0^%8J=]5P*;L[QM)@/30P'/F@.<:@=/
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MLV*DZT6.BACN%QFT #+) 55)[=:)(TFN#S$LT(=I]N<#".OS88+M^0"6+UJ
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MG ::#52/9$P**OD]/E$ XB5$8=PLRUA#5<T_+DB!WQOKKY4-RRX+W"&G-(*
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M2KQ]6=Z5N2'[E%8J% DL$%L>:$1 4,&,2\G&7Z)&%$G9&-FI!F UU1G]'HH
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M/JL[=,(NJCW@#Y?/%@4P#/-!.2';"P@S-EZB^2[E(B^,O1;$L"YPF. 9,KO
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MRJBZ<9<!\GZ6IN6ZJ*OKY(4_#<JW8]*4KEGK;;QZ[S;T*RPN[Z=4V,Y[GY(
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M,DGE_RR;,(S7"A(4]KI&N+Z!#A<."&8E<I!JN2=DH89?P9E*-:G^AYAP]XD
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M*<0=^RZ%]!S3I9[IH5$ 9'VD)E!";\9$I:U^M[O+S_AJ5H)X_II!>-/P70R
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MK&[>L1;*O019')+E(5F@2,3;.7E=F:@ME!O.V-'Q-WBQ+C*>;>2"N3=%A7G
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MCS@T).[_Z8+]&_MS^R?V/]QQ9G_Y_P%02P,$%     @ "(II5U<Y[EU^20
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MF^@0K#WTB[CA=<@$R-%6(NI94DVQ> 8V:!']HF[@Q8<QF$>]RX2?LPYQ2^1
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M1:3IH&S(,3**6D>I3NY1%F+&2%?G- ?<I)+X(U.$JB,7)/5I6!PWZ_RD /7
MC%C9U&K<H\!RCVZ/MX]L__#N9+-7(^WME;8:F XK>]EN P2,AB,!?)>4\IE'
M&<3W0RN(CS]ZQ1:TS_R=3-9"$I,D3Z/GR>E7CW'"G]7<OY$R1DS?MC_3>4N>
M%EF':@BK.<I=8_G];8<4$7[BDOCNXR8LU"\0A>*,'?K'<U=4&0PNV)]RGWUA
M07SP5>I3 UO8^Y$# (\S] P(\&L8VK<0AE8?1B0C=!7&!41\3.G-1KL&;J!*
M1\,- 6'LQ>ABD54RR(\'&F5PPU1 (";2SJ.@O.T 6^4^IV&J<X"2EL8-3)%
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M%NC<8Z>G@P"=IMTE!GA5(J^!%B#=?32IA3_JM8?XA8'INO+XORYTDQD._H9
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M#4E9LSI#V"P'-8#6$LO(=:J!NEA"=$-W>#C7O!)7S4CJ>LB.'\I[NM94!('
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M-3!8 O\3_>SQ1VO//(UZBPKB>6(- [E<>!1;?Q%2XJLR6+-"S3+0-)TN:KU
M'*NZ?K[T0F[5IO/3/ @S'O079AE1/U*OJP0EP-7E#@P4ZXQ,LR6ANX^KGQG1
MUL)[,&EH3I2PV)H22!F=93!(U%6@=+BXZM1+-PH7)L-#4P?*AJLK4Q DZ#X7
M5V'LQ7[H1==QFM%<?\<DK?""CEAUHJ(_/E;(,R>4'_,_$+H)_6*?*>APRJ]D
M4O&O= Y]PW[%#?W0Z'OSGG%0!.R<[/(L6FQSL.9>/K%DH=I\8T%9!6IXK46.
MV=#N@[<6 (A93;__L8BDFE=QBDJJ5!6@1%E+:&*;*#U:Z//GJS\\@C_\Z[MJ
MK_[P6/[P'ZR%:[KK$&^ZONB_N/@!,>Q (X$C$\^#%WG\<2@V]7[Q%LK$LJV2
MQ^DR+Y,8G8KJ@B_E#X\3)HTZA9:X-+;O6$=.5**C\[)5F$);F-:8\02KC?W
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M]<7AMM$MW56HI+@C7$+TM,&/1"!LKY':FR&Z(S%!4>@49"WUBE*K&@Q(177
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M!NXHFV+DZEPO P75D1V]4$(!FO)$ZM5O^'_XV[GL)_\?4$L! A0#%     @
M"(II5Y-%ML4L @  3A4   H              ( !     &5X,3 M,RYH=&U0
M2P$"% ,4    "  (BFE70&J!*\D!  "]!@  "@              @ %4 @
M97@Q,"TU+FAT;5!+ 0(4 Q0    (  B*:5>G1[OK/ @   A%   *
M      "  44$  !E>#,Q+3$N:'1M4$L! A0#%     @ "(II5V##:<!7"
M"$@   H              ( !J0P  &5X,S$M,BYH=&U02P$"% ,4    "  (
MBFE7RH2_L:X$  "'&P  "@              @ $H%0  97@S,BTQ+FAT;5!+
M 0(4 Q0    (  B*:5?I61$IL00  '$<   *              "  ?X9  !E
M>#,R+3(N:'1M4$L! A0#%     @ "(II5S( X4R)Z $ (',4  P
M     ( !UQX  &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    (  B*:5=.UB!?T1
M !2\   1              "  8H' @!L:7AT+3(P,C,P.3,P+GAS9%!+ 0(4
M Q0    (  B*:5?&(GVUY@L  !.%   5              "  8H8 @!L:7AT
M+3(P,C,P.3,P7V-A;"YX;6Q02P$"% ,4    "  (BFE7K<>=\!8V  !5=P,
M%0              @ &C) ( ;&EX="TR,#(S,#DS,%]D968N>&UL4$L! A0#
M%     @ "(II5_UK XJU;    S8& !4              ( ![%H" &QI>'0M
M,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0    (  B*:5=7.>Y=?DD  "O6!  5
M              "  =3' @!L:7AT+3(P,C,P.3,P7W!R92YX;6Q02P4&
/  P # #5 @  A1$#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
